Gene "Gene synonym" Ensembl "Gene description" Uniprot Chromosome Position "Protein class" "Biological process" "Molecular function" "Disease involvement" Evidence "HPA evidence" "UniProt evidence" "NeXtProt evidence" "MS evidence" "RNA tissue specificity" "RNA tissue distribution" "RNA tissue specificity score" "RNA tissue specific NX" "RNA single cell type specificity" "RNA single cell type distribution" "RNA single cell type specificity score" "RNA single cell type specific NX" "RNA cancer specificity" "RNA cancer distribution" "RNA cancer specificity score" "RNA cancer specific FPKM" "RNA brain regional specificity" "RNA brain regional distribution" "RNA brain regional specificity score" "RNA brain regional specific NX" "RNA blood cell specificity" "RNA blood cell distribution" "RNA blood cell specificity score" "RNA blood cell specific NX" "RNA blood lineage specificity" "RNA blood lineage distribution" "RNA blood lineage specificity score" "RNA blood lineage specific NX" "RNA cell line specificity" "RNA cell line distribution" "RNA cell line specificity score" "RNA cell line specific NX" "RNA mouse brain regional specificity" "RNA mouse brain regional distribution" "RNA mouse brain regional specificity score" "RNA mouse brain regional specific pTPM" "RNA pig brain regional specificity" "RNA pig brain regional distribution" "RNA pig brain regional specificity score" "RNA pig brain regional specific pTPM" Antibody "Reliability (IH)" "Reliability (Mouse Brain)" "Reliability (IF)" "Subcellular location" "Secretome location" "CCD Protein" "CCD Transcript" "Blood concentration - Conc. blood IM [pg/L]" "Blood concentration - Conc. blood MS [pg/L]" "Subcellular main location" "Subcellular additional location" "Antibody RRID" "Pathology prognostics - Breast cancer" "Pathology prognostics - Cervical cancer" "Pathology prognostics - Colorectal cancer" "Pathology prognostics - Endometrial cancer" "Pathology prognostics - Glioma" "Pathology prognostics - Head and neck cancer" "Pathology prognostics - Liver cancer" "Pathology prognostics - Lung cancer" "Pathology prognostics - Melanoma" "Pathology prognostics - Ovarian cancer" "Pathology prognostics - Pancreatic cancer" "Pathology prognostics - Prostate cancer" "Pathology prognostics - Renal cancer" "Pathology prognostics - Stomach cancer" "Pathology prognostics - Testis cancer" "Pathology prognostics - Thyroid cancer" "Pathology prognostics - Urothelial cancer" "Tissue RNA - adipose tissue [NX]" "Tissue RNA - adrenal gland [NX]" "Tissue RNA - amygdala [NX]" "Tissue RNA - appendix [NX]" "Tissue RNA - basal ganglia [NX]" "Tissue RNA - bone marrow [NX]" "Tissue RNA - breast [NX]" "Tissue RNA - cerebellum [NX]" "Tissue RNA - cerebral cortex [NX]" "Tissue RNA - cervix, uterine [NX]" "Tissue RNA - colon [NX]" "Tissue RNA - corpus callosum [NX]" "Tissue RNA - ductus deferens [NX]" "Tissue RNA - duodenum [NX]" "Tissue RNA - endometrium 1 [NX]" "Tissue RNA - epididymis [NX]" "Tissue RNA - esophagus [NX]" "Tissue RNA - fallopian tube [NX]" "Tissue RNA - gallbladder [NX]" "Tissue RNA - heart muscle [NX]" "Tissue RNA - hippocampal formation [NX]" "Tissue RNA - hypothalamus [NX]" "Tissue RNA - kidney [NX]" "Tissue RNA - liver [NX]" "Tissue RNA - lung [NX]" "Tissue RNA - lymph node [NX]" "Tissue RNA - midbrain [NX]" "Tissue RNA - olfactory region [NX]" "Tissue RNA - ovary [NX]" "Tissue RNA - pancreas [NX]" "Tissue RNA - parathyroid gland [NX]" "Tissue RNA - pituitary gland [NX]" "Tissue RNA - placenta [NX]" "Tissue RNA - pons and medulla [NX]" "Tissue RNA - prostate [NX]" "Tissue RNA - rectum [NX]" "Tissue RNA - retina [NX]" "Tissue RNA - salivary gland [NX]" "Tissue RNA - seminal vesicle [NX]" "Tissue RNA - skeletal muscle [NX]" "Tissue RNA - skin 1 [NX]" "Tissue RNA - small intestine [NX]" "Tissue RNA - smooth muscle [NX]" "Tissue RNA - spinal cord [NX]" "Tissue RNA - spleen [NX]" "Tissue RNA - stomach 1 [NX]" "Tissue RNA - testis [NX]" "Tissue RNA - thalamus [NX]" "Tissue RNA - thymus [NX]" "Tissue RNA - thyroid gland [NX]" "Tissue RNA - tongue [NX]" "Tissue RNA - tonsil [NX]" "Tissue RNA - urinary bladder [NX]" "Tissue RNA - vagina [NX]" "Tissue RNA - B-cells [NX]" "Tissue RNA - dendritic cells [NX]" "Tissue RNA - granulocytes [NX]" "Tissue RNA - monocytes [NX]" "Tissue RNA - NK-cells [NX]" "Tissue RNA - T-cells [NX]" "Tissue RNA - total PBMC [NX]" "Cell RNA - A-431 [NX]" "Cell RNA - A549 [NX]" "Cell RNA - AF22 [NX]" "Cell RNA - AN3-CA [NX]" "Cell RNA - ASC diff [NX]" "Cell RNA - ASC TERT1 [NX]" "Cell RNA - BEWO [NX]" "Cell RNA - BJ [NX]" "Cell RNA - BJ hTERT+ [NX]" "Cell RNA - BJ hTERT+ SV40 Large T+ [NX]" "Cell RNA - BJ hTERT+ SV40 Large T+ RasG12V [NX]" "Cell RNA - CACO-2 [NX]" "Cell RNA - CAPAN-2 [NX]" "Cell RNA - Daudi [NX]" "Cell RNA - EFO-21 [NX]" "Cell RNA - fHDF/TERT166 [NX]" "Cell RNA - GAMG [NX]" "Cell RNA - HaCaT [NX]" "Cell RNA - HAP1 [NX]" "Cell RNA - HBEC3-KT [NX]" "Cell RNA - HBF TERT88 [NX]" "Cell RNA - HDLM-2 [NX]" "Cell RNA - HEK 293 [NX]" "Cell RNA - HEL [NX]" "Cell RNA - HeLa [NX]" "Cell RNA - Hep G2 [NX]" "Cell RNA - HHSteC [NX]" "Cell RNA - HL-60 [NX]" "Cell RNA - HMC-1 [NX]" "Cell RNA - HSkMC [NX]" "Cell RNA - hTCEpi [NX]" "Cell RNA - hTEC/SVTERT24-B [NX]" "Cell RNA - hTERT-HME1 [NX]" "Cell RNA - hTERT-RPE1 [NX]" "Cell RNA - HUVEC TERT2 [NX]" "Cell RNA - JURKAT [NX]" "Cell RNA - K-562 [NX]" "Cell RNA - Karpas-707 [NX]" "Cell RNA - LHCN-M2 [NX]" "Cell RNA - MCF7 [NX]" "Cell RNA - MOLT-4 [NX]" "Cell RNA - NB-4 [NX]" "Cell RNA - NTERA-2 [NX]" "Cell RNA - OE19 [NX]" "Cell RNA - PC-3 [NX]" "Cell RNA - REH [NX]" "Cell RNA - RH-30 [NX]" "Cell RNA - RPMI-8226 [NX]" "Cell RNA - RPTEC TERT1 [NX]" "Cell RNA - RT4 [NX]" "Cell RNA - SCLC-21H [NX]" "Cell RNA - SH-SY5Y [NX]" "Cell RNA - SiHa [NX]" "Cell RNA - SK-BR-3 [NX]" "Cell RNA - SK-MEL-30 [NX]" "Cell RNA - SuSa [NX]" "Cell RNA - T-47d [NX]" "Cell RNA - THP-1 [NX]" "Cell RNA - TIME [NX]" "Cell RNA - U-138 MG [NX]" "Cell RNA - U-2 OS [NX]" "Cell RNA - U-2197 [NX]" "Cell RNA - U-251 MG [NX]" "Cell RNA - U-266/70 [NX]" "Cell RNA - U-266/84 [NX]" "Cell RNA - U-698 [NX]" "Cell RNA - U-87 MG [NX]" "Cell RNA - U-937 [NX]" "Cell RNA - WM-115 [NX]" "Blood RNA - basophil [NX]" "Blood RNA - classical monocyte [NX]" "Blood RNA - eosinophil [NX]" "Blood RNA - gdT-cell [NX]" "Blood RNA - intermediate monocyte [NX]" "Blood RNA - MAIT T-cell [NX]" "Blood RNA - memory B-cell [NX]" "Blood RNA - memory CD4 T-cell [NX]" "Blood RNA - memory CD8 T-cell [NX]" "Blood RNA - myeloid DC [NX]" "Blood RNA - naive B-cell [NX]" "Blood RNA - naive CD4 T-cell [NX]" "Blood RNA - naive CD8 T-cell [NX]" "Blood RNA - neutrophil [NX]" "Blood RNA - NK-cell [NX]" "Blood RNA - non-classical monocyte [NX]" "Blood RNA - plasmacytoid DC [NX]" "Blood RNA - T-reg [NX]" "Blood RNA - total PBMC [NX]" "Brain RNA - amygdala [NX]" "Brain RNA - basal ganglia [NX]" "Brain RNA - cerebellum [NX]" "Brain RNA - cerebral cortex [NX]" "Brain RNA - hippocampal formation [NX]" "Brain RNA - hypothalamus [NX]" "Brain RNA - midbrain [NX]" "Brain RNA - olfactory region [NX]" "Brain RNA - pons and medulla [NX]" "Brain RNA - thalamus [NX]" "Single Cell Type RNA - Alveolar cells type 1 [NX]" "Single Cell Type RNA - Alveolar cells type 2 [NX]" "Single Cell Type RNA - B-cells [NX]" "Single Cell Type RNA - Basal glandular cells [NX]" "Single Cell Type RNA - Basal keratinocytes [NX]" "Single Cell Type RNA - Bipolar cells [NX]" "Single Cell Type RNA - Cardiomyocytes [NX]" "Single Cell Type RNA - Cholangiocytes [NX]" "Single Cell Type RNA - Ciliated cells [NX]" "Single Cell Type RNA - Club cells [NX]" "Single Cell Type RNA - Collecting duct cells [NX]" "Single Cell Type RNA - Cone photoreceptor cells [NX]" "Single Cell Type RNA - Cytotrophoblasts [NX]" "Single Cell Type RNA - Distal tubular cells [NX]" "Single Cell Type RNA - Ductal cells [NX]" "Single Cell Type RNA - Early spermatids [NX]" "Single Cell Type RNA - Endothelial cells [NX]" "Single Cell Type RNA - Enterocytes [NX]" "Single Cell Type RNA - Erythroid cells [NX]" "Single Cell Type RNA - Exocrine glandular cells [NX]" "Single Cell Type RNA - Extravillous trophoblasts [NX]" "Single Cell Type RNA - Fibroblasts [NX]" "Single Cell Type RNA - Glandular cells [NX]" "Single Cell Type RNA - granulocytes [NX]" "Single Cell Type RNA - Hepatocytes [NX]" "Single Cell Type RNA - Hofbauer cells [NX]" "Single Cell Type RNA - Horizontal cells [NX]" "Single Cell Type RNA - Intestinal endocrine cells [NX]" "Single Cell Type RNA - Ito cells [NX]" "Single Cell Type RNA - Kupffer cells [NX]" "Single Cell Type RNA - Late spermatids [NX]" "Single Cell Type RNA - Leydig cells [NX]" "Single Cell Type RNA - Macrophages [NX]" "Single Cell Type RNA - Melanocytes [NX]" "Single Cell Type RNA - monocytes [NX]" "Single Cell Type RNA - Mucus-secreting cells [NX]" "Single Cell Type RNA - Muller glia cells [NX]" "Single Cell Type RNA - Pancreatic endocrine cells [NX]" "Single Cell Type RNA - Paneth cells [NX]" "Single Cell Type RNA - Peritubular cells [NX]" "Single Cell Type RNA - Proximal tubular cells [NX]" "Single Cell Type RNA - Rod photoreceptor cells [NX]" "Single Cell Type RNA - Sertoli cells [NX]" "Single Cell Type RNA - Smooth muscle cells [NX]" "Single Cell Type RNA - Spermatocytes [NX]" "Single Cell Type RNA - Spermatogonia [NX]" "Single Cell Type RNA - Suprabasal keratinocytes [NX]" "Single Cell Type RNA - Syncytiotrophoblasts [NX]" "Single Cell Type RNA - T-cells [NX]" "Single Cell Type RNA - Undifferentiated cells [NX]" "Single Cell Type RNA - Urothelial cells [NX]" ABL1 "ABL, c-ABL, JTK7, p150" ENSG00000097007 "ABL proto-oncogene 1, non-receptor tyrosine kinase" P00519 9 130713946-130887675 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins" "Apoptosis, Autophagy, Cell adhesion, DNA damage, DNA repair, Endocytosis" "DNA-binding, Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002686, HPA027251, HPA027280, HPA028409" Supported Enhanced "Nucleoplasm,Nuclear bodies" Yes No Nucleoplasm "Nuclear bodies" "CAB002686: , HPA027251: AB_1844453, HPA027280: AB_1844454, HPA028409: AB_10601011" "unprognostic (4.82e-2)" "unprognostic (3.99e-2)" "unprognostic (5.55e-2)" "unprognostic (4.72e-2)" "unprognostic (1.16e-1)" "unprognostic (1.46e-1)" "unprognostic (3.75e-3)" "unprognostic (1.89e-3)" "unprognostic (2.34e-1)" "unprognostic (2.54e-2)" "unprognostic (1.09e-2)" "unprognostic (1.48e-1)" "unprognostic (3.96e-3)" "unprognostic (1.10e-2)" "unprognostic (1.47e-1)" "unprognostic (1.22e-1)" "unprognostic (1.06e-1)" 20.1 11.6 12.4 15.0 18.1 10.7 22.0 6.7 16.0 28.9 34.3 29.1 12.1 11.9 26.6 16.9 21.4 20.8 30.9 14.2 10.3 8.4 9.9 6.7 13.8 8.7 24.1 9.4 24.2 12.2 27.7 14.5 13.6 17.1 27.3 15.8 19.4 14.6 18.0 10.8 14.2 17.0 66.6 14.3 10.8 21.9 9.8 21.2 5.8 19.5 11.4 9.1 35.8 31.9 3.1 3.1 1.1 5.0 2.4 2.6 1.6 7.2 16.1 17.2 20.8 25.3 30.9 6.3 12.7 19.9 14.9 12.6 12.6 9.4 11.9 7.3 16.8 15.3 14.0 8.7 11.7 11.0 7.4 5.4 7.8 27.4 10.7 17.3 11.9 10.9 22.5 12.9 26.6 16.5 20.8 20.6 15.4 43.5 9.5 18.1 13.7 15.1 9.8 19.1 11.3 11.9 17.5 22.3 12.8 15.1 8.5 16.1 20.1 21.3 8.3 10.2 10.5 16.2 11.0 23.6 57.2 14.8 21.8 19.9 2.9 6.8 15.9 23.5 9.9 18.1 0.2 2.1 1.1 2.0 1.2 2.6 3.1 2.0 1.9 2.0 1.4 1.9 1.7 0.2 2.4 5.0 3.1 0.9 1.6 12.4 18.1 6.7 16.0 10.3 8.4 24.1 9.4 17.1 21.2 8.9 9.9 4.2 6.4 8.1 6.2 5.8 12.7 5.3 5.7 14.0 11.8 11.3 1.7 12.6 3.1 14.3 15.4 0.0 9.5 3.5 27.8 8.1 2.3 13.4 13.7 9.5 21.2 20.3 13.7 7.4 25.9 6.5 5.0 3.6 15.7 15.7 14.3 20.3 24.1 8.4 9.7 19.4 21.0 11.9 13.6 5.9 12.7 7.9 19.1 6.4 ACVR1 "ACVR1A, ACVRLK2, ALK2, SKR1" ENSG00000115170 "Activin A receptor type 1" Q04771 2 157736444-157875862 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Kinase, Receptor, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA007505, HPA046514" Approved Uncertain Nucleoli,Cytosol NA NA Nucleoli Cytosol "HPA007505: AB_1844752, HPA046514: AB_2732526" "unprognostic (6.99e-2)" "unprognostic (3.32e-2)" "unprognostic (3.02e-1)" "unprognostic (1.19e-2)" "unprognostic (2.73e-1)" "unprognostic (6.09e-2)" "unprognostic (3.66e-3)" "unprognostic (1.08e-1)" "unprognostic (3.99e-1)" "unprognostic (3.20e-1)" "unprognostic (2.65e-2)" "unprognostic (4.29e-2)" "unprognostic (2.42e-1)" "unprognostic (3.43e-3)" "unprognostic (3.17e-1)" "unprognostic (1.76e-2)" "prognostic unfavorable (5.17e-4)" 18.9 9.2 18.0 10.0 12.7 1.6 38.7 15.3 12.2 25.2 14.4 7.4 8.4 8.9 24.8 26.8 11.0 16.6 20.5 18.8 18.7 8.6 21.7 18.9 22.5 15.1 10.4 7.9 18.5 12.3 11.3 17.0 14.2 12.3 16.8 10.5 14.3 18.1 13.6 15.6 12.8 11.5 29.2 12.3 9.2 11.8 8.8 10.9 7.5 34.0 14.6 6.9 16.1 32.5 1.4 2.4 3.8 2.6 1.9 10.0 1.6 2.1 4.3 5.0 6.5 25.4 26.5 7.0 15.4 25.6 12.4 13.2 3.4 4.8 0.0 7.1 16.6 12.0 6.0 3.6 8.3 13.3 14.7 3.1 8.7 2.5 4.9 20.1 0.6 10.4 33.2 15.8 25.3 32.3 16.2 13.4 2.4 3.2 2.4 15.5 3.8 0.1 0.2 7.5 3.0 7.8 1.4 6.7 1.8 16.0 8.1 4.4 5.5 5.9 3.4 21.1 8.2 1.8 2.3 19.3 18.8 6.2 9.2 5.8 1.6 1.2 0.1 19.3 0.5 20.2 3.8 2.6 0.2 1.1 1.7 1.2 1.4 7.8 2.5 1.8 0.8 3.1 1.5 0.8 1.9 2.3 2.4 10.0 1.6 18.0 12.7 15.3 12.2 18.7 8.6 10.4 7.9 12.3 10.9 8.9 7.0 0.8 6.8 8.8 7.5 9.2 12.7 6.7 9.1 7.0 0.0 7.0 5.0 8.4 0.5 13.5 3.1 0.0 15.5 4.4 11.6 8.9 4.7 12.1 6.5 3.2 4.1 17.2 11.6 1.1 18.7 7.7 3.3 3.6 5.2 6.1 14.7 3.5 14.9 15.3 1.5 12.9 15.5 0.5 2.5 6.6 8.8 1.0 3.5 7.6 ACVR2A "ACTRII, ACVR2" ENSG00000121989 "Activin A receptor type 2A" P27037 2 147844517-147930826 "Cancer-related genes, Enzymes, Predicted membrane proteins" "Kinase, Receptor, Serine/threonine-protein kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "HHSteC: 21.0;RH-30: 17.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA046997 Approved Approved Cytosol NA NA Cytosol "HPA046997: AB_10970077" "unprognostic (4.55e-2)" "unprognostic (2.26e-2)" "unprognostic (2.09e-1)" "unprognostic (7.34e-3)" "unprognostic (2.75e-1)" "unprognostic (1.17e-1)" "unprognostic (4.41e-3)" "unprognostic (8.73e-3)" "unprognostic (1.30e-2)" "unprognostic (3.61e-1)" "unprognostic (1.34e-2)" "unprognostic (1.52e-1)" "prognostic favorable (1.62e-4)" "unprognostic (1.16e-1)" "unprognostic (1.40e-1)" "unprognostic (3.95e-1)" "unprognostic (3.99e-2)" 12.0 6.0 13.6 8.2 9.9 3.8 10.7 14.5 14.2 10.2 14.1 4.7 9.7 10.4 9.3 9.9 13.6 7.6 17.7 5.6 10.0 9.0 9.0 10.3 7.5 4.7 5.9 10.6 7.6 9.8 8.6 15.9 10.6 7.3 12.2 9.1 7.6 12.2 12.0 19.6 29.5 17.8 13.8 5.4 6.5 9.3 11.0 6.4 1.5 9.5 6.9 6.8 13.5 11.8 0.7 3.0 0.5 3.6 7.7 4.6 1.4 1.3 1.6 10.0 3.7 5.9 3.8 4.1 3.1 3.7 5.3 9.3 4.3 6.0 0.0 2.8 4.9 1.9 4.7 9.1 4.5 6.8 1.0 5.5 0.6 2.8 7.4 21.0 0.6 0.7 6.3 5.7 3.4 6.8 4.1 4.0 1.2 1.4 2.6 3.6 3.5 0.3 0.5 11.3 4.0 2.6 0.1 17.5 0.9 4.2 8.5 9.9 5.6 2.6 3.1 3.8 4.5 1.9 1.0 3.1 4.9 5.8 4.6 2.1 0.7 0.2 1.8 3.0 0.3 3.9 0.4 3.0 0.5 1.2 3.6 0.5 0.3 4.6 2.1 2.3 0.7 3.0 0.7 0.1 7.7 3.1 3.0 0.4 1.4 13.6 9.9 14.5 14.2 10.0 9.0 5.9 10.6 7.3 6.4 6.0 6.5 0.5 6.7 26.4 15.8 7.8 10.2 8.1 11.4 7.0 13.7 3.9 1.7 5.0 4.1 9.8 13.2 0.0 5.6 2.1 13.5 6.7 0.0 8.6 4.7 11.1 8.6 12.9 9.4 0.8 9.2 7.6 10.1 8.2 13.8 3.7 6.3 8.6 10.6 5.0 8.5 32.3 14.4 13.8 12.8 26.1 4.5 5.1 8.5 7.1 AKT1 "AKT, PKB, PRKBA, RAC" ENSG00000142208 "AKT serine/threonine kinase 1" P31749 14 104769349-104795751 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins" "Apoptosis, Carbohydrate metabolism, Glucose metabolism, Glycogen biosynthesis, Glycogen metabolism, Neurogenesis, Sugar transport, Translation regulation, Transport" "Developmental protein, Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "eosinophil: 30.7" "Lineage enriched" "Detected in all" 5 "granulocytes: 30.7" "Cell line enhanced" "Detected in all" "MCF7: 115.3" "Low region specificity" "Detected in all" "HPA002891, CAB003765" Supported Supported Nucleoplasm,Microtubules NA NA Nucleoplasm Microtubules "CAB003765: AB_562035, HPA002891: AB_1078123" "unprognostic (3.30e-2)" "unprognostic (4.27e-2)" "unprognostic (1.98e-1)" "unprognostic (1.84e-1)" "unprognostic (3.70e-1)" "unprognostic (9.17e-3)" "unprognostic (1.55e-3)" "unprognostic (1.21e-1)" "unprognostic (1.47e-1)" "prognostic favorable (4.83e-4)" "unprognostic (3.58e-2)" "unprognostic (1.90e-2)" "prognostic favorable (2.12e-4)" "unprognostic (7.14e-2)" "unprognostic (1.28e-1)" "unprognostic (1.06e-1)" "unprognostic (2.41e-1)" 31.7 45.4 22.9 24.2 23.6 20.3 40.0 20.9 29.5 24.7 32.6 20.0 30.8 22.5 27.0 21.5 33.0 25.5 30.3 47.7 22.9 19.1 26.3 49.2 31.3 21.0 22.1 14.7 25.9 43.0 20.3 16.7 28.4 21.5 31.1 18.2 25.3 30.4 36.1 23.8 20.4 24.0 40.5 17.5 35.4 32.6 16.2 18.8 26.3 32.7 22.4 29.3 36.7 35.9 3.2 5.2 30.7 5.8 5.7 6.2 3.0 15.4 30.8 25.5 37.9 19.7 20.5 28.5 28.4 34.6 42.0 33.7 20.2 18.7 18.7 21.9 38.9 21.4 20.1 18.0 26.4 18.3 42.6 7.3 14.1 18.4 21.7 21.9 23.0 36.9 29.3 22.3 21.0 14.0 20.2 31.4 18.4 12.3 20.8 26.9 115.3 28.9 29.4 6.6 30.3 22.1 27.3 23.6 12.7 19.4 38.4 29.3 24.3 23.7 31.0 17.8 11.9 40.6 34.3 25.0 28.2 13.5 40.1 28.5 22.6 10.9 16.1 23.8 19.5 33.9 3.3 5.3 30.7 5.4 5.2 4.0 2.9 4.8 6.2 3.6 3.2 2.5 5.7 11.8 5.7 5.8 5.2 4.7 3.0 22.9 23.6 20.9 29.5 22.9 19.1 22.1 14.7 21.5 18.8 14.9 24.3 13.4 13.8 11.0 24.3 13.8 40.8 5.3 11.4 21.0 11.8 15.1 11.6 21.0 1.2 19.6 22.2 0.0 30.3 25.7 18.8 34.2 2.3 38.4 20.2 39.7 28.8 24.5 23.7 3.1 26.4 18.1 10.1 17.2 36.1 35.8 43.4 17.3 29.0 13.9 24.0 25.8 11.8 0.9 5.1 12.2 19.6 18.1 26.9 30.8 AL035425.2 ENSG00000260548 X 108722070-108732687 "Cancer-related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at transcript level" "Evidence at transcript level" "Tissue enhanced" "Detected in some" "ovary: 13.0;pituitary gland: 7.4;thyroid gland: 8.9" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "HEK 293: 19.0;NTERA-2: 2.7;RT4: 4.9;WM-115: 5.0" NA NA 0.0 0.0 0.1 0.0 0.3 0.0 0.0 0.0 0.6 2.9 0.0 0.0 3.9 0.9 0.0 0.5 0.0 0.0 0.1 5.1 0.0 0.0 0.0 0.0 0.5 13.0 0.9 0.0 7.4 0.0 0.1 0.0 0.0 0.7 0.0 1.1 0.0 1.5 0.1 0.0 0.4 0.0 8.9 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 19.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.7 0.0 0.0 0.0 0.0 0.0 0.0 4.9 0.0 0.0 0.1 0.0 0.1 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 5.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 ALK CD246 ENSG00000171094 "ALK receptor tyrosine kinase" Q9UM73 2 29192774-29921566 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 8.1;pituitary gland: 17.9" "Group enriched" "Detected in some" 12 "Early spermatids: 36.6;Late spermatids: 30.9" "Group enriched" "Detected in some" 5 "glioma: 1.0;melanoma: 1.5;ovarian cancer: 0.7;thyroid cancer: 1.3" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 6 "SH-SY5Y: 27.0" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA010694 Approved Supported "Plasma membrane" NA NA "Plasma membrane" "HPA010694: AB_1078133" "unprognostic (4.96e-2)" "unprognostic (1.11e-2)" "unprognostic (1.45e-1)" "unprognostic (4.56e-7)" "unprognostic (7.17e-2)" "unprognostic (1.71e-1)" "unprognostic (9.07e-3)" "unprognostic (6.29e-3)" "unprognostic (1.18e-1)" "unprognostic (1.01e-1)" "unprognostic (2.67e-4)" "unprognostic (3.70e-2)" "unprognostic (2.06e-2)" "unprognostic (7.15e-2)" "unprognostic (1.98e-1)" "unprognostic (1.38e-1)" "unprognostic (3.61e-2)" 1.8 3.1 3.6 1.2 4.4 0.3 1.1 0.5 8.1 0.7 2.1 2.0 0.0 0.7 0.5 0.5 0.6 0.5 1.2 0.4 3.4 4.9 0.4 0.5 1.1 0.5 2.7 4.2 0.6 0.4 0.4 17.9 0.5 5.5 0.5 1.2 2.4 0.9 0.8 0.3 0.9 1.5 0.9 2.1 0.5 0.8 4.9 0.9 0.0 1.6 0.0 0.3 0.6 1.2 0.0 0.0 0.0 0.2 0.0 0.7 0.0 0.0 0.0 0.4 0.0 0.4 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.5 0.0 3.6 0.0 0.0 0.1 0.3 27.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 3.2 0.0 4.1 0.0 0.1 0.0 0.7 0.0 0.2 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 3.6 4.4 0.5 5.9 3.4 4.9 2.7 4.2 5.5 0.9 0.0 0.0 0.0 0.0 0.0 1.5 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 36.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.7 0.0 0.0 0.0 0.0 30.9 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.9 0.2 0.0 0.0 0.0 0.0 0.0 AMER1 "FAM123B, FLJ39827, RP11-403E24.2, WTX" ENSG00000184675 "APC membrane recruitment protein 1" Q5JTC6 X 64185117-64205744 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Wnt signaling pathway" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 6 "Bipolar cells: 4.5;Cholangiocytes: 5.1;Sertoli cells: 6.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "NK-cell: 2.0" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "NTERA-2: 15.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA065214, HPA065265" Approved Supported "Nuclear bodies,Vesicles,Plasma membrane" NA NA "Nuclear bodies" "Vesicles, Plasma membrane" "HPA065214: AB_2685435, HPA065265: AB_2685450" "unprognostic (1.56e-2)" "unprognostic (8.85e-2)" "unprognostic (6.86e-2)" "unprognostic (2.74e-1)" "unprognostic (2.12e-2)" "unprognostic (1.86e-1)" "unprognostic (3.57e-2)" "unprognostic (1.48e-1)" "unprognostic (8.02e-2)" "unprognostic (1.75e-1)" "unprognostic (6.31e-2)" "unprognostic (3.43e-1)" "unprognostic (4.69e-4)" "unprognostic (1.26e-1)" "unprognostic (1.13e-1)" "unprognostic (6.19e-2)" "unprognostic (2.89e-1)" 3.0 3.4 3.0 2.8 5.6 2.3 3.0 8.8 4.9 6.8 4.7 3.1 7.8 3.3 9.8 11.3 6.9 5.2 2.4 3.5 3.0 3.4 4.2 7.1 2.8 2.6 4.5 1.6 15.5 8.1 5.1 3.9 2.0 6.3 4.5 3.2 6.8 7.0 5.3 9.0 4.8 3.7 6.6 2.9 3.7 5.1 1.4 4.3 2.4 3.4 6.5 3.4 4.3 5.7 0.4 0.2 0.0 0.3 2.0 1.0 0.1 3.0 2.2 5.8 4.6 2.2 2.2 4.6 1.4 1.2 2.1 1.3 7.2 1.0 5.7 1.9 2.9 1.6 4.2 12.2 4.0 2.0 2.6 2.4 3.5 4.5 4.6 1.6 7.4 0.9 3.0 5.3 1.6 3.2 1.7 1.2 4.5 5.3 5.8 1.1 3.5 4.8 4.0 15.4 3.8 4.3 11.5 9.4 4.1 1.0 0.9 2.6 3.9 3.6 4.9 1.9 5.0 1.6 2.1 0.8 2.6 5.9 6.6 1.9 3.0 2.0 4.4 1.2 8.4 0.0 0.0 0.3 0.0 0.4 0.1 0.0 0.4 0.0 0.4 0.0 0.3 1.0 0.0 0.0 2.0 0.0 0.2 0.9 0.1 3.0 5.6 8.8 4.9 3.0 3.4 4.5 1.6 6.3 4.3 0.0 0.0 0.0 0.6 1.9 4.5 2.3 5.1 0.0 0.0 0.0 2.0 0.8 0.0 1.0 0.0 1.0 0.5 0.0 1.4 0.6 0.8 0.4 0.0 1.9 0.3 0.0 1.2 2.5 1.5 0.0 2.3 0.1 1.7 0.0 0.9 0.2 0.5 0.0 3.9 0.6 0.7 6.5 1.2 0.0 0.2 2.3 0.6 0.5 1.3 0.7 APC "DP2, DP2.5, DP3, PPP1R46" ENSG00000134982 "APC, WNT signaling pathway regulator" P25054 5 112707498-112846239 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Wnt signaling pathway" "Cancer-related genes, Disease mutation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 40.9" "Cell type enhanced" "Detected in many" 8 "Bipolar cells: 169.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA013349, HPA013362" Supported Approved "Nucleoplasm,Golgi apparatus,Plasma membrane" NA NA "Plasma membrane" "Nucleoplasm, Golgi apparatus" "HPA013349: AB_1844913, HPA013362: " "unprognostic (4.80e-2)" "unprognostic (1.19e-1)" "unprognostic (3.72e-2)" "unprognostic (1.14e-1)" "unprognostic (1.10e-1)" "unprognostic (7.09e-3)" "unprognostic (1.62e-1)" "unprognostic (8.10e-3)" "unprognostic (2.35e-1)" "unprognostic (4.85e-3)" "unprognostic (1.27e-1)" "unprognostic (4.18e-2)" "unprognostic (1.02e-2)" "unprognostic (1.07e-1)" "unprognostic (3.35e-1)" "unprognostic (2.23e-2)" "unprognostic (1.96e-1)" 7.2 5.4 40.9 6.4 21.7 8.5 6.3 19.1 39.7 6.8 7.1 10.3 2.0 6.6 6.3 3.9 8.4 5.0 5.5 7.4 37.9 12.9 6.9 6.2 6.7 5.6 23.6 20.7 7.6 4.6 13.8 7.2 5.5 39.1 5.9 6.9 4.0 4.0 4.9 7.0 6.1 8.8 8.1 19.1 6.2 5.4 5.3 20.6 3.6 6.5 2.7 6.2 6.2 3.9 3.8 3.0 12.9 2.9 3.0 3.4 1.1 8.3 7.7 12.9 9.4 10.6 8.9 5.3 13.6 6.5 7.6 9.0 6.1 6.8 16.2 13.2 17.3 11.7 6.9 13.2 11.1 12.5 9.7 9.0 12.3 11.2 4.7 5.2 6.2 6.7 7.4 7.7 12.8 8.5 5.3 10.5 7.8 15.1 5.6 10.9 5.8 7.1 3.1 4.6 4.6 2.8 6.0 16.0 7.9 7.0 10.7 13.1 7.9 12.9 5.0 5.5 5.5 7.0 5.1 16.7 15.4 7.4 15.1 10.3 4.4 6.6 6.4 8.5 11.5 8.6 10.4 2.9 5.0 3.4 1.4 2.9 3.1 1.8 2.1 2.3 3.8 2.9 2.8 12.9 3.0 2.5 3.0 1.6 1.1 40.9 21.7 19.1 31.4 37.9 12.9 23.6 20.7 39.1 20.6 47.6 17.6 10.8 8.3 10.0 169.9 48.4 12.7 20.1 26.1 0.0 62.8 4.4 0.0 16.7 6.3 21.0 24.6 0.0 17.0 5.3 10.2 10.3 18.5 12.1 13.8 74.7 26.4 28.8 14.9 4.4 16.4 14.8 16.9 19.0 15.5 21.8 16.3 25.9 18.4 4.2 37.9 38.8 14.3 14.9 26.7 10.2 2.4 10.7 14.2 7.6 AR "AIS, DHTR, HUMARA, NR3C4, SBMA, SMAX1" ENSG00000169083 "Androgen receptor" P10275 X 67544032-67730619 "Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding, Receptor" "Cancer-related genes, Disease mutation, FDA approved drug targets, Neurodegeneration, Pseudohermaphroditism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "liver: 49.0" "Cell type enhanced" "Detected in many" 14 "Hepatocytes: 189.5;Leydig cells: 72.2;Peritubular cells: 81.3;Sertoli cells: 64.7" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in single" 16 "plasmacytoid DC: 5.4" "Lineage enriched" "Detected in single" 16 "dendritic cells: 5.4" "Cell line enhanced" "Detected in some" "AF22: 11.3;BJ hTERT+: 9.8;HAP1: 14.4;LHCN-M2: 12.6;RH-30: 20.9;T-47d: 8.8" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB000001, HPA004733, CAB065764" Enhanced Supported Cytosol NA NA Cytosol "CAB000001: AB_2060174, CAB065764: AB_10620739, HPA004733: " "unprognostic (1.34e-1)" "unprognostic (8.10e-3)" "unprognostic (2.49e-2)" "unprognostic (5.95e-2)" "unprognostic (1.04e-2)" "unprognostic (3.35e-2)" "prognostic favorable (8.77e-4)" "unprognostic (4.99e-2)" "unprognostic (1.72e-1)" "unprognostic (7.79e-2)" "unprognostic (2.30e-1)" "unprognostic (2.29e-1)" "prognostic favorable (1.03e-8)" "unprognostic (8.23e-3)" "unprognostic (8.90e-2)" "unprognostic (4.23e-2)" "unprognostic (7.97e-2)" 10.1 1.2 0.9 1.6 0.9 0.1 10.7 0.4 1.6 34.4 1.9 2.4 25.4 0.2 20.5 20.5 2.2 17.5 4.3 5.7 0.9 1.5 6.3 49.0 1.5 0.2 1.2 0.7 14.4 1.0 0.1 2.3 0.3 1.9 28.0 0.5 3.8 1.6 36.1 8.1 3.9 1.1 7.6 1.9 0.9 1.6 9.3 1.2 5.4 3.1 2.0 1.2 6.3 13.1 0.0 5.4 0.3 0.0 0.1 0.0 0.1 0.0 4.7 11.3 0.0 0.0 0.1 0.0 6.0 9.8 0.4 0.1 0.2 0.0 0.0 0.0 0.7 0.0 0.0 14.4 0.0 0.1 0.0 1.9 0.0 1.1 0.0 0.7 0.0 0.0 4.6 0.0 1.7 0.0 0.0 3.5 0.1 4.1 1.9 12.6 1.2 0.0 0.0 4.5 0.0 0.0 0.0 20.9 0.0 0.3 0.0 0.0 0.0 0.0 0.2 0.0 3.2 8.8 5.3 0.2 0.2 2.0 0.1 3.0 0.0 0.0 0.0 4.3 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.3 0.1 0.0 5.4 0.0 0.1 0.9 0.9 0.4 1.6 0.9 1.5 1.2 0.7 1.9 1.2 0.0 5.3 0.0 18.1 8.7 0.6 31.3 12.7 6.7 19.4 3.5 0.0 1.9 1.7 7.5 0.9 4.9 0.0 0.0 0.0 0.1 9.4 31.9 1.1 189.5 0.7 0.0 0.0 14.7 1.6 1.6 72.2 2.1 10.1 2.8 0.0 0.2 1.0 0.0 81.3 22.3 0.3 64.7 12.3 0.5 1.0 14.1 0.8 0.0 0.0 15.9 ARID1A "B120, BAF250, BAF250a, C10rf4, C1orf4, P270, SMARCF1" ENSG00000117713 "AT-rich interaction domain 1A" O14497 1 26693236-26782110 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Neurogenesis, Transcription, Transcription regulation" "Chromatin regulator, DNA-binding" "Cancer-related genes, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA005456, CAB016334" Supported Enhanced Nucleoplasm NA Yes Nucleoplasm "CAB016334: AB_673396, HPA005456: AB_1078205" "unprognostic (2.83e-1)" "unprognostic (1.81e-1)" "unprognostic (7.48e-2)" "unprognostic (1.41e-1)" "unprognostic (2.44e-1)" "unprognostic (1.89e-2)" "prognostic unfavorable (4.18e-4)" "unprognostic (3.02e-1)" "unprognostic (3.66e-2)" "unprognostic (1.34e-1)" "unprognostic (9.69e-2)" "unprognostic (7.76e-2)" "unprognostic (1.01e-2)" "unprognostic (1.62e-2)" "unprognostic (6.05e-2)" "unprognostic (2.66e-1)" "unprognostic (6.54e-2)" 18.6 18.4 17.4 24.9 17.0 33.8 27.8 23.6 19.1 20.3 23.7 21.7 23.9 15.8 24.1 17.3 23.2 20.6 21.9 15.5 14.8 12.8 13.7 15.9 18.8 35.6 20.3 19.2 24.1 23.9 27.5 15.8 19.3 17.2 16.5 16.4 18.9 21.4 23.1 22.6 20.6 20.7 18.4 15.4 25.9 19.5 16.5 19.8 57.3 24.8 14.2 24.5 24.4 20.4 4.3 5.3 7.4 3.3 4.7 5.1 3.5 19.2 18.3 25.9 27.0 7.5 7.2 12.2 9.0 7.9 12.4 8.8 13.3 13.0 27.2 7.9 11.7 7.8 11.7 22.5 10.0 14.5 33.6 8.8 23.1 11.9 8.9 6.2 34.2 7.4 8.3 7.1 14.6 10.5 6.9 10.6 19.7 27.6 30.5 8.0 9.1 28.8 13.3 27.4 12.5 8.5 30.1 17.1 15.4 7.7 13.0 24.3 20.0 15.8 13.4 10.9 15.0 3.9 19.4 18.7 13.3 12.9 12.4 14.6 14.5 19.1 12.5 8.1 21.9 11.7 0.4 3.3 2.9 4.0 2.9 5.1 4.3 3.2 4.9 3.1 4.3 4.0 4.4 7.4 4.7 2.8 5.3 1.5 3.5 17.4 17.0 23.6 19.1 14.8 12.8 20.3 19.2 17.2 19.8 56.6 36.8 33.6 18.1 65.3 60.2 31.1 28.1 25.4 28.4 36.6 49.1 31.8 1.7 31.8 14.2 37.2 28.4 0.0 32.5 32.1 42.6 39.3 56.9 53.9 43.0 69.9 45.7 51.0 93.5 7.5 35.6 45.4 38.8 34.3 56.1 31.2 40.3 31.6 39.3 14.5 37.1 51.8 27.2 46.0 55.3 82.4 30.7 41.2 46.0 27.7 ARID1B "6A3-5, BAF250b, DAN15, ELD/OSA1, KIAA1235, p250R" ENSG00000049618 "AT-rich interaction domain 1B" Q8NFD5 6 156777374-157210779 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Neurogenesis, Transcription, Transcription regulation" "Chromatin regulator, DNA-binding" "Cancer-related genes, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA016511, HPA075291" Approved Supported Nucleoplasm NA NA Nucleoplasm "HPA016511: AB_1845008, HPA075291: AB_2686743" "prognostic unfavorable (1.04e-4)" "unprognostic (9.82e-2)" "unprognostic (1.73e-1)" "unprognostic (5.42e-2)" "unprognostic (7.47e-2)" "unprognostic (1.40e-2)" "unprognostic (2.73e-2)" "unprognostic (2.89e-1)" "unprognostic (1.18e-1)" "prognostic unfavorable (4.16e-4)" "unprognostic (2.53e-1)" "unprognostic (5.33e-2)" "unprognostic (1.07e-3)" "unprognostic (2.46e-1)" "unprognostic (1.80e-1)" "unprognostic (3.53e-1)" "unprognostic (1.16e-1)" 18.3 15.0 20.2 18.8 20.9 25.8 19.3 42.1 32.8 20.0 17.4 26.3 21.7 15.3 23.0 14.2 18.6 20.7 15.9 16.8 20.4 11.3 14.2 10.6 17.0 18.3 19.4 16.7 30.2 18.5 47.4 29.2 12.2 17.7 17.7 13.3 24.0 20.0 20.2 30.6 27.3 17.8 21.7 14.9 21.1 15.0 10.7 24.6 24.0 23.8 13.3 26.3 23.5 21.0 9.5 11.9 5.6 3.0 2.7 5.6 1.6 7.2 11.1 16.4 22.3 13.5 12.4 11.2 7.7 10.1 10.0 10.0 9.8 10.5 22.8 4.8 13.0 12.3 9.2 14.0 12.5 9.9 22.9 9.8 16.5 11.2 11.6 9.5 13.7 12.1 14.0 10.1 15.2 13.6 10.9 13.8 14.9 19.4 17.8 7.1 8.5 15.9 15.5 8.3 9.6 5.9 36.3 7.0 12.3 6.9 13.4 15.0 19.2 15.4 16.2 9.0 9.0 10.9 21.6 14.2 12.6 13.4 11.6 15.0 12.3 11.0 29.2 11.0 16.5 16.9 5.6 3.0 2.5 5.4 2.4 5.0 6.8 4.7 3.8 2.3 9.5 4.0 5.6 5.5 2.7 2.6 11.9 4.6 1.6 20.2 20.9 42.1 32.8 20.4 11.3 19.4 16.7 17.7 24.6 44.7 46.7 59.6 18.3 42.2 35.6 27.8 28.1 28.1 36.4 120.4 27.5 10.8 6.6 33.6 12.1 27.8 19.2 0.0 29.8 6.4 27.7 23.2 38.1 23.3 12.3 44.5 39.2 37.4 29.2 13.0 52.6 28.8 28.7 72.1 38.0 23.8 39.9 21.0 59.1 12.2 30.1 45.3 28.2 6.3 14.9 48.7 14.6 23.2 34.9 20.2 ASXL1 KIAA0978 ENSG00000171456 "Additional sex combs like 1, transcriptional regulator" Q8IXJ9 20 32358330-32439319 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation, Ubl conjugation pathway" "Chromatin regulator, Repressor" "Cancer-related genes, Craniosynostosis" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA064156 Approved Nucleoplasm,Nucleoli NA NA "Nucleoplasm, Nucleoli" "HPA064156: AB_2685200" "unprognostic (1.49e-1)" "unprognostic (5.97e-2)" "unprognostic (8.36e-2)" "prognostic unfavorable (2.86e-4)" "unprognostic (6.69e-2)" "prognostic favorable (9.16e-4)" "unprognostic (2.01e-3)" "unprognostic (2.89e-1)" "unprognostic (1.49e-1)" "unprognostic (1.38e-1)" "unprognostic (4.32e-2)" "unprognostic (3.21e-2)" "unprognostic (1.84e-3)" "unprognostic (5.47e-2)" "unprognostic (1.90e-1)" "unprognostic (4.82e-2)" "unprognostic (1.06e-1)" 24.3 19.6 19.0 35.0 18.2 39.0 24.7 28.3 23.8 32.4 22.7 17.7 16.9 15.6 32.4 22.2 14.3 20.5 21.6 17.9 19.7 10.7 21.2 25.2 27.3 26.7 20.3 14.7 28.1 27.1 21.2 16.3 19.8 18.2 20.6 16.4 16.6 17.4 23.3 25.5 18.2 21.8 21.8 12.2 28.2 19.7 32.1 23.0 47.4 26.8 15.8 29.0 23.2 35.3 9.8 3.1 1.3 0.8 1.7 14.6 1.9 22.9 13.3 20.9 11.6 9.6 12.0 18.2 15.4 13.2 26.9 19.9 39.6 14.8 21.7 9.9 19.0 25.6 16.0 17.6 14.8 22.0 32.5 9.6 34.6 21.1 21.6 8.6 14.4 14.4 13.3 9.9 18.7 14.1 13.3 14.8 17.9 16.7 11.8 12.5 7.0 19.7 11.6 5.0 10.7 15.4 11.5 25.1 9.4 11.0 11.1 9.6 15.1 27.9 9.3 12.2 11.6 13.3 10.2 15.3 28.6 25.0 13.2 17.1 13.8 14.7 16.0 14.5 38.4 10.9 0.0 0.8 1.3 4.4 0.7 3.5 9.8 5.2 5.6 0.7 5.8 5.8 5.9 0.9 1.7 0.7 3.1 14.6 1.9 19.0 18.2 28.3 23.8 19.7 10.7 20.3 14.7 18.2 23.0 47.6 38.1 41.7 41.8 35.5 18.7 18.5 15.3 21.4 25.0 26.2 49.1 16.2 21.6 12.4 73.4 61.8 21.2 0.0 10.8 12.8 37.0 40.7 17.4 29.3 18.3 17.5 6.9 34.4 16.8 61.5 23.6 23.6 74.2 10.0 12.1 12.6 14.1 11.5 13.8 22.1 30.4 6.5 44.0 25.6 13.5 26.7 4.9 41.5 15.5 32.6 ATM "ATA, ATC, ATD, ATDC, TEL1, TELO1" ENSG00000149311 "ATM serine/threonine kinase" Q13315 11 108222484-108369102 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Cell cycle, DNA damage" "DNA-binding, Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease mutation, Neurodegeneration, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 6 "Cone photoreceptor cells: 198.3;Rod photoreceptor cells: 196.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "U-698: 48.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000102, HPA067142" Supported Enhanced Nucleoplasm,Vesicles NA NA Nucleoplasm Vesicles "CAB000102: , HPA067142: AB_2685789" "unprognostic (9.77e-2)" "unprognostic (1.47e-1)" "unprognostic (3.04e-1)" "unprognostic (2.36e-1)" "unprognostic (5.70e-2)" "unprognostic (2.86e-2)" "unprognostic (6.32e-3)" "unprognostic (1.05e-1)" "unprognostic (8.19e-2)" "unprognostic (1.63e-1)" "unprognostic (7.68e-2)" "unprognostic (6.16e-2)" "unprognostic (2.17e-3)" "unprognostic (3.10e-1)" "unprognostic (7.87e-2)" "unprognostic (1.21e-1)" "unprognostic (2.81e-1)" 8.3 10.9 12.7 26.5 19.3 16.8 9.4 17.7 14.4 10.9 8.5 10.9 8.8 6.0 11.2 11.4 6.9 9.5 9.2 9.6 12.4 8.5 7.7 9.5 10.1 33.4 19.6 6.7 20.5 20.7 15.7 29.2 8.8 14.5 9.1 7.9 7.2 15.1 9.8 6.2 8.4 16.5 10.6 23.4 22.6 8.9 6.1 17.9 19.5 10.7 5.1 26.9 10.7 10.7 13.7 6.1 13.5 12.5 7.6 18.5 4.4 2.7 3.9 7.7 4.1 10.0 14.6 2.0 6.1 6.8 3.5 5.9 4.8 6.5 9.6 9.1 4.9 5.6 4.1 5.8 5.1 5.5 7.7 3.4 8.7 4.8 4.8 5.3 10.5 9.4 9.4 3.2 5.4 10.4 7.7 7.4 8.2 8.4 6.6 6.9 2.0 7.1 9.7 6.3 4.1 3.9 5.6 5.3 15.1 4.0 5.5 5.2 6.4 7.1 3.3 10.5 7.1 5.0 5.9 11.5 8.8 4.9 5.0 5.7 4.4 4.6 48.5 5.8 11.5 9.8 13.5 5.7 3.8 14.9 5.3 10.4 11.1 10.5 11.3 2.7 13.7 18.5 17.9 10.8 7.6 12.5 6.1 5.3 4.4 12.7 19.3 17.7 14.4 12.4 8.5 19.6 6.7 14.5 17.9 35.7 21.0 122.7 17.4 11.2 101.7 35.4 10.2 13.4 19.4 21.0 198.3 14.8 5.0 7.7 12.8 18.8 4.9 0.0 10.6 10.5 26.4 9.5 12.7 21.2 26.0 57.2 19.5 36.8 82.2 2.7 36.5 48.1 25.3 9.0 15.9 35.9 7.6 10.5 26.2 10.3 196.6 25.8 17.3 18.7 33.6 10.8 3.5 111.7 11.7 9.9 ATP1A1 ENSG00000163399 "ATPase Na+/K+ transporting subunit alpha 1" P05023 1 116372668-116410261 "Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters" "Ion transport, Potassium transport, Sodium transport, Sodium/potassium transport, Transport" Translocase "Cancer-related genes, Charcot-Marie-Tooth disease, Epilepsy, FDA approved drug targets, Mental retardation, Neurodegeneration, Neuropathy, Primary hypomagnesemia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "intestine: 195.4;parathyroid gland: 194.4" "Cell type enhanced" "Detected in all" 5 "Enterocytes: 917.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "SK-MEL-30: 254.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB018702, CAB069993" Enhanced NA NA 380000 "CAB018702: AB_626713, CAB069993: AB_2060979" "unprognostic (6.18e-2)" "unprognostic (2.18e-1)" "unprognostic (6.91e-2)" "unprognostic (1.42e-2)" "unprognostic (6.80e-2)" "unprognostic (2.15e-1)" "prognostic unfavorable (1.42e-4)" "unprognostic (1.80e-1)" "unprognostic (1.21e-2)" "unprognostic (6.32e-2)" "unprognostic (1.61e-2)" "unprognostic (1.65e-1)" "prognostic favorable (8.98e-8)" "unprognostic (4.75e-2)" "unprognostic (1.17e-1)" "unprognostic (3.11e-2)" "prognostic unfavorable (4.01e-4)" 17.4 25.6 22.4 16.2 40.3 10.5 26.9 74.2 67.4 17.8 121.9 14.2 56.1 92.3 13.1 38.3 34.9 17.7 65.8 41.1 26.1 18.7 162.7 34.6 35.1 9.6 19.2 27.6 17.4 78.6 194.4 25.0 19.2 34.1 22.1 65.7 24.1 84.4 53.7 19.0 40.5 195.4 17.7 20.7 13.7 25.0 17.0 13.9 9.1 101.2 13.7 16.2 14.2 23.1 10.3 22.0 6.4 29.7 10.4 30.2 17.2 33.7 12.4 12.9 6.5 26.0 25.3 66.6 20.2 40.3 24.9 35.4 49.8 24.2 26.7 28.6 23.9 25.3 44.1 25.5 42.6 36.3 9.8 28.3 15.5 23.5 42.0 19.9 38.9 21.9 28.1 71.5 29.0 38.3 35.2 30.5 16.3 25.6 25.8 22.0 67.0 15.7 14.1 30.4 53.6 25.0 15.2 30.3 23.6 90.1 34.8 12.7 11.2 31.4 59.6 254.2 33.2 15.7 22.6 26.9 14.2 19.9 36.7 40.9 12.5 9.7 20.5 43.6 22.5 83.4 6.4 13.3 6.1 23.2 20.9 24.8 10.3 26.4 24.9 22.0 5.3 30.2 22.0 1.6 10.4 29.7 11.1 20.3 17.2 22.4 40.3 74.2 67.4 26.1 18.7 19.2 27.6 34.1 13.9 256.1 246.7 58.7 265.3 245.9 76.0 62.7 540.1 113.8 203.6 731.0 375.0 70.1 316.7 432.8 25.0 117.9 917.6 93.5 278.3 130.8 110.9 297.5 43.8 66.4 114.8 96.9 169.4 90.9 77.6 11.5 109.0 130.5 197.4 47.7 304.0 513.0 192.4 264.8 94.7 289.6 141.6 32.3 179.2 17.9 27.5 235.0 56.5 95.6 365.5 236.0 ATR "FRP1, MEC1, SCKL, SCKL1" ENSG00000175054 "ATR serine/threonine kinase" Q13535 3 142449235-142578826 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins" "DNA damage, DNA repair" "DNA-binding, Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease mutation, Dwarfism, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 5 "Cone photoreceptor cells: 35.3;Spermatocytes: 42.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA054320 Supported "Nucleoplasm,Golgi apparatus" No No Nucleoplasm "Golgi apparatus" "HPA054320: AB_2682448" "unprognostic (1.47e-1)" "unprognostic (8.90e-2)" "unprognostic (2.90e-1)" "unprognostic (4.23e-2)" "unprognostic (2.25e-2)" "unprognostic (6.42e-2)" "prognostic unfavorable (8.39e-5)" "unprognostic (3.44e-1)" "unprognostic (1.67e-1)" "unprognostic (3.02e-1)" "prognostic unfavorable (1.23e-5)" "unprognostic (1.94e-1)" "unprognostic (5.61e-2)" "unprognostic (1.06e-1)" "unprognostic (3.55e-1)" "unprognostic (1.69e-2)" "unprognostic (1.43e-1)" 10.5 24.3 7.7 11.4 15.9 10.1 14.8 11.3 14.6 10.1 8.5 10.0 10.4 6.0 14.7 16.8 9.4 12.1 9.3 8.8 9.8 7.1 9.6 12.0 10.3 16.0 10.0 8.1 12.3 13.6 18.0 22.5 8.8 12.5 11.0 11.2 9.5 12.5 10.8 7.7 11.2 10.9 9.8 8.8 14.2 9.0 15.3 9.7 19.0 13.8 7.7 15.1 10.9 10.6 5.8 2.8 2.2 4.0 6.7 6.0 0.8 22.7 11.2 7.5 8.5 10.7 11.8 8.9 12.6 7.1 9.4 9.7 5.2 7.3 18.6 13.0 8.9 12.3 14.8 11.0 11.6 14.2 5.9 7.2 10.2 8.5 5.1 4.7 17.1 5.7 9.2 6.4 8.9 10.6 6.4 9.7 9.7 7.1 8.4 9.6 10.0 12.9 7.1 7.2 14.9 8.0 10.7 10.9 13.5 9.5 10.6 5.3 5.4 23.2 8.4 8.2 7.1 12.2 6.9 12.5 9.6 4.8 12.4 13.5 11.0 6.5 17.3 12.5 6.7 7.6 0.7 2.7 2.2 4.4 4.0 6.0 3.1 3.2 4.2 2.8 5.8 4.1 4.0 1.7 6.7 2.5 2.5 2.4 0.8 7.7 15.9 11.3 14.6 9.8 7.1 10.0 8.1 12.5 9.7 6.0 8.8 13.4 6.5 3.5 14.7 7.1 7.6 18.7 6.8 3.5 35.3 6.6 0.0 5.3 12.0 7.1 2.1 0.0 4.3 3.3 4.8 6.7 1.1 6.0 5.7 7.9 7.5 8.6 9.1 6.9 6.1 6.9 10.1 4.6 5.4 4.8 6.2 0.0 6.7 4.1 23.4 0.0 6.4 42.3 15.8 4.0 4.2 5.1 7.0 5.2 ATRX "JMS, MRX52, RAD54, XH2, XNP" ENSG00000085224 "ATRX, chromatin remodeler" P46100 X 77504878-77786269 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors" "DNA damage, DNA repair, Transcription, Transcription regulation" "Chromatin regulator, DNA-binding, Helicase, Hydrolase" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001906, CAB009372, HPA064684, CAB068176" Supported Supported "Nuclear bodies" NA NA "Nuclear bodies" "CAB009372: AB_2061023, CAB068176: AB_2665665, HPA001906: AB_1078249, HPA064684: AB_2685321" "unprognostic (1.77e-2)" "unprognostic (1.55e-1)" "unprognostic (6.65e-2)" "unprognostic (4.37e-2)" "unprognostic (1.67e-1)" "unprognostic (9.69e-2)" "unprognostic (8.11e-2)" "unprognostic (1.15e-2)" "unprognostic (6.04e-2)" "unprognostic (2.35e-2)" "unprognostic (1.09e-1)" "unprognostic (5.80e-2)" "unprognostic (5.14e-3)" "unprognostic (1.50e-1)" "unprognostic (6.19e-2)" "unprognostic (1.76e-2)" "unprognostic (2.24e-1)" 16.4 16.6 24.5 18.9 29.3 24.3 16.3 48.2 26.4 20.6 15.4 7.1 18.9 10.2 20.2 17.1 13.5 13.8 13.4 15.1 22.9 15.8 16.6 12.2 15.9 18.6 21.1 21.3 25.4 18.3 35.7 28.1 15.9 20.2 18.4 12.6 7.1 15.8 16.5 20.1 14.1 13.5 22.3 15.3 20.1 15.6 6.5 22.4 23.7 19.8 12.7 16.5 19.9 21.1 21.9 12.8 21.5 11.5 14.6 17.7 5.7 15.3 24.7 25.4 17.1 12.7 17.1 9.0 13.3 12.3 9.9 11.7 8.4 13.5 21.4 13.7 14.1 18.6 13.7 20.4 7.9 16.8 12.0 13.3 12.9 29.4 6.2 6.9 16.7 4.4 11.2 7.8 14.5 13.9 12.3 17.4 13.5 15.1 24.6 12.3 12.1 12.9 8.7 18.4 7.1 19.2 21.0 35.2 10.9 9.6 20.6 14.5 25.1 26.8 10.5 8.8 17.2 8.5 8.6 24.0 14.0 21.6 15.6 9.3 7.3 22.7 19.2 10.2 13.3 12.3 21.3 6.9 13.8 17.7 8.7 17.1 19.2 16.3 13.7 5.1 21.9 16.8 13.5 21.5 14.6 11.5 12.8 12.8 5.7 24.5 29.3 48.2 26.4 22.9 15.8 21.1 21.3 20.2 22.4 148.9 213.6 88.0 96.7 82.1 217.2 263.3 58.6 120.5 117.2 68.0 200.3 58.0 19.9 72.8 3.1 123.5 43.3 23.3 72.0 39.7 90.3 99.7 106.6 45.6 60.7 149.4 121.7 91.4 84.5 4.9 150.4 86.3 59.1 120.0 68.3 114.7 80.3 40.3 195.6 28.6 231.4 90.5 113.3 13.6 49.5 73.8 50.0 94.4 62.6 104.6 AXIN1 PPP1R49 ENSG00000103126 "Axin 1" O15169 16 287440-352673 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Apoptosis, Wnt signaling pathway" "Developmental protein" "Cancer-related genes, Disease mutation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB012987 Approved Supported Nucleoli,Vesicles NA NA "Nucleoli, Vesicles" "CAB012987: AB_2533178" "unprognostic (3.81e-2)" "unprognostic (1.56e-1)" "unprognostic (1.90e-1)" "unprognostic (7.64e-2)" "unprognostic (1.90e-1)" "unprognostic (1.06e-1)" "prognostic unfavorable (3.38e-5)" "unprognostic (1.23e-1)" "unprognostic (3.58e-1)" "unprognostic (1.56e-1)" "unprognostic (4.58e-2)" "unprognostic (2.02e-2)" "unprognostic (1.57e-1)" "unprognostic (4.41e-2)" "unprognostic (1.94e-1)" "unprognostic (1.23e-2)" "unprognostic (1.03e-1)" 10.8 8.3 13.7 18.9 17.1 28.1 21.0 26.4 13.6 10.4 15.8 12.7 9.4 17.3 12.6 8.5 14.1 10.7 12.7 11.0 11.5 7.7 9.8 9.6 13.6 13.4 15.6 10.6 13.3 17.7 11.1 11.9 8.4 13.9 11.4 10.2 9.6 13.9 9.5 17.7 16.9 17.6 18.9 9.6 15.1 15.2 9.6 14.6 17.5 12.7 7.5 14.5 11.9 22.9 1.8 1.4 5.5 1.1 3.6 10.4 2.4 9.6 14.0 7.5 13.2 5.6 5.2 15.8 6.5 6.0 9.1 7.8 20.6 11.3 15.0 10.1 6.7 10.9 13.9 11.7 10.2 4.1 14.7 19.2 9.7 11.8 14.9 9.6 11.1 10.8 5.1 17.8 9.3 11.5 8.0 6.0 11.0 24.1 8.3 4.1 25.8 12.0 7.7 17.1 11.7 8.6 22.7 6.8 20.8 6.8 5.7 17.1 10.5 12.4 13.9 20.5 5.9 9.2 14.2 6.7 9.0 9.7 10.3 9.4 9.6 9.3 18.3 4.3 7.4 8.8 1.4 1.1 5.5 10.4 0.9 9.5 1.8 3.0 7.0 0.8 1.6 3.2 4.3 3.2 3.6 0.7 1.4 3.0 2.4 13.7 17.1 26.4 13.6 11.5 7.7 15.6 10.6 13.9 14.6 3.0 11.3 5.2 5.3 16.4 4.9 5.0 5.1 6.7 6.8 3.5 0.0 3.1 0.0 6.1 1.0 6.7 18.6 0.0 6.1 20.3 5.9 9.4 10.4 4.7 6.5 4.8 10.4 4.3 7.5 1.3 4.9 5.9 10.1 3.6 14.5 3.7 8.8 11.9 4.6 2.1 5.4 12.9 5.3 4.4 7.6 13.2 3.1 7.7 11.8 8.7 AXIN2 "DKFZp781B0869, MGC126582" ENSG00000168646 "Axin 2" Q9Y2T1 17 65528563-65561647 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Wnt signaling pathway" "Developmental protein" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" 12 "Extravillous trophoblasts: 87.1" "Cancer enhanced" "Detected in all" "colorectal cancer: 33.4" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "naive CD4 T-cell: 5.1" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "AF22: 11.8;CACO-2: 22.1;Hep G2: 32.9;OE19: 36.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB012283, CAB017783" Approved Uncertain "Nucleoplasm,Plasma membrane,Cytosol" NA NA "Nucleoplasm, Plasma membrane" Cytosol "CAB012283: AB_2290204, CAB017783: " "unprognostic (1.31e-2)" "unprognostic (1.29e-1)" "unprognostic (1.05e-2)" "unprognostic (3.45e-3)" "unprognostic (4.48e-1)" "unprognostic (9.81e-2)" "unprognostic (1.12e-2)" "unprognostic (1.82e-1)" "unprognostic (4.57e-2)" "unprognostic (8.84e-3)" "prognostic favorable (6.58e-4)" "unprognostic (1.98e-1)" "unprognostic (1.42e-1)" "unprognostic (3.45e-2)" "unprognostic (2.10e-1)" "unprognostic (2.74e-1)" "unprognostic (1.25e-1)" 7.4 10.1 9.0 7.0 8.9 0.9 5.2 8.2 13.1 16.5 12.2 8.7 10.5 7.2 29.0 7.7 6.5 18.6 6.9 7.3 7.9 5.7 3.5 2.5 15.2 3.4 5.3 10.3 14.7 3.9 3.2 5.8 18.2 10.6 14.8 15.2 7.8 4.6 9.8 12.4 14.9 7.5 18.0 4.8 6.9 14.6 6.8 9.0 27.6 11.3 3.6 3.8 11.8 8.7 4.1 0.0 4.4 0.0 1.9 5.1 0.8 0.0 5.9 11.8 0.2 4.3 1.8 5.2 0.1 0.5 0.4 0.7 22.1 2.1 0.4 0.7 3.4 0.4 0.1 2.4 0.0 0.8 1.0 1.3 0.0 1.0 32.9 0.4 0.0 0.0 1.0 0.9 0.9 0.2 0.7 1.0 2.2 0.0 0.5 0.6 0.1 5.7 0.0 2.3 36.5 0.2 4.1 0.6 0.0 1.1 0.1 3.7 2.4 0.2 0.1 2.0 9.1 0.4 0.1 2.6 2.3 4.3 3.3 0.7 0.0 1.2 1.5 1.1 0.2 1.1 4.4 0.0 0.0 0.3 0.0 0.8 1.0 2.3 0.4 0.0 4.1 5.1 0.8 0.0 1.9 0.0 0.0 0.0 0.8 9.0 8.9 8.2 13.1 7.9 5.7 5.3 10.3 10.6 9.0 0.0 7.0 0.0 1.2 10.0 3.8 8.1 2.5 1.4 10.3 0.0 3.9 14.3 0.0 1.0 27.8 3.8 2.8 0.0 0.7 87.1 17.5 4.1 0.0 1.9 3.3 1.6 5.2 1.3 0.0 11.2 6.1 0.3 16.9 1.8 18.7 3.5 0.7 3.5 10.3 0.6 1.9 12.9 5.9 5.4 12.6 4.8 11.9 0.0 16.8 1.1 B2M ENSG00000166710 Beta-2-microglobulin P61769 15 44711477-44718877 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" Immunity "Amyloidosis, Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" 9 "monocytes: 43079.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "THP-1: 178.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002572, HPA006361" Enhanced Enhanced "Golgi apparatus,Plasma membrane,Cytosol" "Intracellular and membrane" NA NA 1790000000 3200000000 "Golgi apparatus, Plasma membrane" Cytosol "CAB002572: AB_563434, HPA006361: AB_1078278" "unprognostic (9.45e-2)" "unprognostic (5.63e-2)" "unprognostic (3.02e-1)" "unprognostic (8.14e-2)" "unprognostic (1.18e-1)" "unprognostic (4.82e-2)" "unprognostic (1.81e-2)" "unprognostic (1.25e-1)" "unprognostic (2.69e-2)" "unprognostic (1.12e-1)" "unprognostic (2.44e-3)" "unprognostic (2.02e-2)" "unprognostic (4.77e-2)" "unprognostic (2.39e-1)" "unprognostic (5.25e-2)" "unprognostic (1.97e-2)" "unprognostic (2.17e-2)" 127.2 50.9 24.2 109.2 29.8 131.1 85.2 11.8 23.1 70.5 111.4 29.1 43.3 79.1 72.7 74.7 80.5 36.8 112.8 73.6 26.0 23.1 109.7 140.3 191.2 172.1 42.2 18.8 54.8 42.7 7.8 40.5 91.9 33.1 78.7 128.9 53.5 121.5 40.9 45.7 94.1 178.5 55.1 56.7 272.8 52.5 30.0 29.5 108.0 97.7 71.5 131.6 135.9 73.5 138.9 74.9 341.3 132.8 128.8 215.8 323.7 33.7 14.9 1.4 8.4 55.5 74.8 52.9 22.3 45.6 36.4 61.8 19.4 78.7 16.1 31.6 21.7 34.6 29.7 5.6 9.9 17.5 112.5 13.2 61.2 90.6 22.5 42.2 34.2 36.7 37.8 9.3 11.1 12.0 49.2 24.8 9.3 15.5 2.2 40.2 18.0 14.0 90.3 2.5 9.7 31.9 17.1 36.6 101.9 31.7 139.7 5.9 2.1 23.3 18.9 26.3 8.0 6.3 178.1 49.3 71.4 7.9 94.1 43.6 41.7 95.3 29.9 69.6 113.1 34.1 221.2 90.4 210.9 126.8 132.8 125.9 138.9 171.7 141.1 58.9 109.4 137.0 167.5 341.3 128.8 106.5 74.9 215.8 323.7 24.2 29.8 11.8 23.1 26.0 23.1 42.2 18.8 33.1 29.5 3147.5 4324.0 5959.3 2738.0 6967.5 30.8 1001.8 3658.6 2584.4 1819.9 1992.5 25.5 1178.5 880.3 10047.2 36.4 7847.2 5137.6 1074.6 7941.0 3388.9 4495.5 5043.9 2851.5 3441.9 11377.9 4.8 2180.6 6477.0 10376.7 71.4 2794.5 10340.1 6397.4 43079.4 4753.5 280.0 9393.5 5334.1 1587.5 2212.2 49.3 3951.7 5055.6 55.6 68.2 7534.8 673.0 11479.7 3001.5 5867.1 BAP1 "hucep-6, KIAA0272, UCHL2" ENSG00000163930 "BRCA1 associated protein 1" Q92560 3 52401013-52410350 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Ubl conjugation pathway" "Chromatin regulator, Hydrolase, Protease, Thiol protease" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 5 "Early spermatids: 81.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004322, HPA028814, HPA028815, HPA055560" Approved Enhanced Nucleoplasm,Cytosol NA NA Nucleoplasm Cytosol "CAB004322: AB_626723, HPA028814: AB_10602393, HPA028815: AB_2672785, HPA055560: AB_2682850" "unprognostic (1.52e-1)" "unprognostic (7.96e-2)" "unprognostic (1.96e-2)" "unprognostic (6.04e-2)" "unprognostic (1.74e-1)" "unprognostic (2.55e-2)" "unprognostic (9.41e-3)" "unprognostic (8.53e-3)" "unprognostic (1.33e-1)" "unprognostic (3.15e-1)" "unprognostic (4.64e-3)" "unprognostic (3.30e-3)" "prognostic favorable (3.29e-7)" "unprognostic (6.37e-2)" "unprognostic (1.91e-1)" "unprognostic (5.54e-2)" "unprognostic (2.92e-1)" 13.8 17.6 35.6 14.7 33.3 37.3 13.5 21.8 50.4 12.5 17.0 16.3 11.5 12.4 14.7 14.6 21.2 12.1 15.7 16.4 41.5 15.5 16.6 19.0 14.9 15.2 19.4 27.6 16.9 16.3 30.0 11.1 14.8 19.6 14.4 14.9 15.6 17.9 14.6 24.8 40.5 13.9 14.5 10.0 16.1 13.3 37.3 14.7 18.6 15.3 12.9 16.0 14.1 11.7 5.5 8.4 11.3 5.0 3.0 8.5 3.9 14.8 16.9 20.6 17.4 19.9 12.8 23.2 14.7 19.1 24.0 18.6 20.5 13.9 21.4 7.4 20.5 27.1 12.1 21.6 23.8 15.3 21.1 20.5 26.4 35.8 21.2 18.5 24.8 23.5 19.1 31.9 26.5 14.2 13.2 19.1 41.2 22.6 18.9 18.0 12.9 29.4 34.0 23.2 11.8 20.6 12.7 16.7 21.1 14.8 24.1 7.8 25.3 18.1 5.3 21.5 12.1 14.8 34.3 20.4 21.7 20.0 26.0 27.3 28.7 37.7 30.6 23.7 26.2 25.6 3.4 5.0 7.4 8.5 3.9 4.0 5.0 6.8 6.9 3.3 5.5 4.9 6.4 11.3 3.0 3.1 8.4 6.0 3.9 35.6 33.3 21.8 50.4 41.5 15.5 19.4 27.6 19.6 14.7 0.0 13.6 15.0 8.8 28.0 15.3 19.3 10.2 5.3 9.1 24.4 0.0 12.2 10.0 12.0 81.1 12.4 17.6 0.0 14.3 13.1 11.8 9.7 20.7 25.8 11.0 9.5 10.4 15.4 19.3 32.6 9.5 10.2 11.8 11.8 12.9 9.9 12.6 15.3 11.0 14.6 11.3 19.4 13.2 30.9 12.4 20.6 10.1 11.3 16.4 8.5 BARD1 ENSG00000138376 "BRCA1 associated RING domain 1" Q99728 2 214725646-214809711 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" "DNA damage, DNA repair, Ubl conjugation pathway" Transferase "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 5 "Basal glandular cells: 54.9;Basal keratinocytes: 60.9;Spermatogonia: 54.9;Suprabasal keratinocytes: 65.1;Urothelial cells: 57.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in single" "Low region specificity" "Detected in all" "CAB034106, HPA035354, HPA044864" Enhanced Supported "Nuclear speckles,Cytoplasmic bodies" No No "Nuclear speckles" "Cytoplasmic bodies" "CAB034106: AB_2061237, HPA035354: AB_2674585, HPA044864: AB_2679119" "unprognostic (4.85e-2)" "unprognostic (1.87e-2)" "unprognostic (1.74e-2)" "unprognostic (8.37e-3)" "unprognostic (2.57e-2)" "unprognostic (1.03e-2)" "unprognostic (6.25e-4)" "unprognostic (1.99e-1)" "unprognostic (2.16e-2)" "unprognostic (3.92e-3)" "unprognostic (2.80e-2)" "unprognostic (7.41e-2)" "unprognostic (1.94e-8)" "unprognostic (3.94e-2)" "unprognostic (2.28e-1)" "unprognostic (1.57e-1)" "unprognostic (1.08e-1)" 4.4 1.9 3.2 11.8 4.8 16.1 4.9 1.2 5.8 7.3 5.4 5.4 3.6 3.7 6.8 5.0 10.0 4.1 3.9 3.6 3.4 2.8 2.2 2.1 5.3 8.2 5.1 1.9 5.8 3.7 3.6 6.3 3.8 4.5 5.7 6.1 1.9 4.7 6.5 12.4 16.3 4.5 7.5 5.3 4.7 3.8 9.5 3.9 25.8 4.0 8.0 9.9 8.3 7.8 9.7 6.6 6.0 3.4 6.1 16.0 2.0 7.8 4.3 11.9 6.1 1.6 2.0 8.2 9.6 5.6 9.4 10.9 5.5 7.8 8.5 4.6 3.9 5.8 8.6 8.5 5.6 13.5 6.7 4.4 8.4 8.0 5.8 0.6 9.4 8.5 2.7 0.8 8.3 4.6 3.2 3.2 9.4 4.7 23.9 9.1 6.5 16.8 9.8 9.4 4.9 2.2 14.5 12.0 7.7 2.8 6.6 3.7 6.0 8.8 10.1 3.5 7.1 10.3 9.4 2.7 12.2 8.6 7.1 8.6 7.2 8.0 17.2 4.9 7.2 8.1 2.9 1.7 6.0 4.8 3.4 3.1 8.9 5.3 5.2 3.0 9.7 2.5 3.6 0.5 6.1 2.9 6.6 16.0 2.0 3.2 4.8 1.2 5.8 3.4 2.8 5.1 1.9 4.5 3.9 6.0 2.1 9.5 54.9 60.9 3.3 12.5 15.3 12.0 9.1 8.7 0.0 9.4 3.3 6.8 8.1 7.5 3.4 23.3 6.0 13.6 7.7 21.0 15.0 3.6 10.6 1.6 1.2 12.3 8.8 3.6 5.8 8.8 3.3 17.2 11.3 3.3 5.6 5.8 9.6 0.6 6.8 19.4 15.5 19.7 54.9 65.1 4.2 8.6 11.0 57.3 BAX BCL2L4 ENSG00000087088 "BCL2 associated X, apoptosis regulator" Q07812 19 48954815-48961798 "Cancer-related genes, Predicted intracellular proteins, Transporters" "Apoptosis, Host-virus interaction" "Cancer-related genes, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 5 "monocytes: 382.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004206, HPA027878" Approved NA NA 1300000 "CAB004206: AB_626729, HPA027878: AB_10601687" "unprognostic (4.11e-2)" "unprognostic (4.70e-2)" "unprognostic (1.50e-1)" "unprognostic (6.23e-2)" "unprognostic (1.70e-1)" "unprognostic (2.82e-1)" "prognostic unfavorable (1.63e-5)" "unprognostic (4.92e-2)" "unprognostic (1.09e-1)" "unprognostic (4.71e-2)" "unprognostic (3.66e-2)" "unprognostic (8.10e-2)" "unprognostic (1.19e-2)" "unprognostic (7.83e-2)" "unprognostic (1.08e-1)" "unprognostic (4.47e-3)" "unprognostic (6.22e-2)" 15.2 20.0 12.3 26.0 13.2 25.3 20.2 7.6 13.6 14.9 33.3 15.1 13.5 30.7 19.3 11.2 21.4 15.5 40.4 14.9 11.3 10.2 19.5 26.1 26.6 25.9 18.7 12.5 16.4 16.2 8.8 10.0 21.5 14.9 16.6 27.8 10.3 16.5 13.3 11.6 17.1 28.7 16.3 15.1 37.8 19.6 10.7 13.2 37.8 17.7 16.3 26.5 19.1 19.5 6.6 10.6 11.1 16.5 9.1 6.4 6.6 34.3 57.2 34.6 30.3 34.6 33.9 57.1 23.5 47.2 31.0 43.4 15.1 33.7 42.1 11.0 35.9 28.9 18.7 15.7 45.8 25.8 32.4 36.2 17.9 11.6 56.0 55.6 18.6 57.5 46.4 32.9 25.7 15.5 37.7 71.3 16.7 17.5 17.3 53.1 24.3 30.1 29.2 26.8 33.6 16.4 21.2 23.0 16.1 32.5 33.5 19.9 23.5 19.8 14.1 10.8 51.5 11.3 33.6 41.7 40.0 43.4 24.4 32.2 20.0 25.4 27.3 24.2 25.3 55.2 4.3 10.4 10.5 6.0 15.3 4.3 6.6 3.4 6.4 10.4 5.8 2.3 5.3 11.1 9.1 16.5 10.6 6.3 6.6 12.3 13.2 7.6 13.6 11.3 10.2 18.7 12.5 14.9 13.2 3.0 4.5 117.5 48.9 48.7 17.5 7.3 79.0 5.3 3.4 57.6 9.8 113.9 63.0 111.1 0.9 69.9 164.3 0.0 84.3 129.6 73.3 76.7 44.8 26.7 232.2 28.6 109.5 54.0 114.6 1.6 44.5 121.4 79.2 382.3 86.5 32.3 116.8 161.4 36.0 172.3 13.7 45.3 56.6 12.6 35.8 49.3 85.2 119.3 131.1 73.4 BCL6 "BCL5, BCL6A, LAZ3, ZBTB27, ZNF51" ENSG00000113916 "B cell CLL/lymphoma 6" P41182 3 187721377-187745727 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Immunity, Inflammatory response, Transcription, Transcription regulation" "Activator, DNA-binding, Repressor" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skeletal muscle: 114.3" "Cell type enhanced" "Detected in many" 5 "Smooth muscle cells: 96.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in many" 4 "neutrophil: 63.4" "Lineage enriched" "Detected in many" 4 "granulocytes: 63.4" "Cell line enhanced" "Detected in many" "ASC diff: 27.3;Daudi: 42.9;HSkMC: 31.1;U-698: 59.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000307, HPA004899, HPA050645" Enhanced Supported Nucleoplasm NA NA Nucleoplasm "CAB000307: AB_2063451, HPA004899: AB_1078273, HPA050645: AB_2681199" "unprognostic (5.36e-2)" "unprognostic (3.29e-2)" "unprognostic (1.63e-3)" "unprognostic (2.49e-1)" "unprognostic (2.85e-1)" "unprognostic (6.34e-3)" "unprognostic (2.62e-2)" "unprognostic (3.33e-3)" "unprognostic (8.75e-2)" "unprognostic (2.04e-2)" "unprognostic (1.63e-3)" "unprognostic (1.29e-1)" "prognostic unfavorable (1.27e-9)" "unprognostic (5.22e-2)" "unprognostic (7.82e-2)" "unprognostic (5.67e-2)" "unprognostic (2.58e-2)" 47.1 14.3 21.8 23.2 25.9 50.6 48.0 58.7 23.7 21.2 21.2 19.2 11.5 4.1 17.7 8.8 20.9 28.3 22.3 18.6 21.5 8.0 10.1 20.1 26.3 24.5 31.6 9.3 20.2 15.6 9.1 23.3 7.5 28.5 17.3 5.8 15.9 19.1 11.8 114.3 36.4 8.1 24.4 50.1 27.2 16.1 10.2 26.6 18.9 14.8 10.4 22.4 24.9 20.0 3.9 5.6 63.4 15.4 0.9 1.3 5.2 1.2 3.6 3.6 0.8 27.3 21.8 3.9 4.3 10.5 5.0 5.3 2.6 2.0 42.9 3.1 5.4 3.1 2.1 1.2 2.8 4.3 9.0 1.4 0.0 1.8 6.1 14.2 0.5 0.2 31.1 18.2 6.1 9.4 16.3 2.8 1.1 0.4 7.4 4.8 1.4 1.4 0.3 0.3 0.7 2.7 11.9 1.8 0.2 3.5 6.3 0.8 0.0 5.0 2.1 2.8 8.3 9.4 1.5 5.6 12.1 1.9 4.4 2.0 5.5 1.8 59.6 6.6 1.6 8.5 1.6 6.9 4.1 1.3 8.7 1.3 1.4 0.8 1.2 5.6 3.9 0.5 0.6 63.4 0.9 15.4 0.9 0.6 5.2 21.8 25.9 58.7 23.7 21.5 8.0 31.6 9.3 28.5 26.6 17.9 76.9 6.5 13.3 42.0 11.0 60.5 17.8 25.4 22.7 15.7 19.6 1.1 0.0 9.2 12.3 27.7 1.6 0.0 10.6 2.0 36.2 28.7 10.5 44.4 11.2 0.0 4.6 9.8 56.3 6.2 26.7 26.7 33.7 3.6 1.1 40.1 8.7 0.0 17.7 1.1 9.6 32.3 96.4 0.4 0.7 53.8 3.4 10.7 1.9 21.9 BCL9L DLNB11 ENSG00000186174 "B cell CLL/lymphoma 9 like" Q86UU0 11 118893875-118925608 "Cancer-related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" Activator "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA049370, HPA053421" Uncertain Enhanced Nucleoplasm NA NA Nucleoplasm "HPA049370: AB_2680732, HPA053421: AB_2682145" "unprognostic (1.67e-2)" "unprognostic (1.48e-2)" "unprognostic (1.20e-1)" "unprognostic (2.71e-1)" "unprognostic (2.87e-1)" "unprognostic (1.90e-1)" "unprognostic (6.61e-3)" "unprognostic (1.17e-3)" "unprognostic (1.03e-1)" "unprognostic (4.61e-2)" "unprognostic (4.66e-3)" "unprognostic (1.39e-1)" "unprognostic (2.83e-3)" "unprognostic (4.85e-3)" "unprognostic (2.24e-2)" "unprognostic (2.14e-1)" "unprognostic (2.90e-3)" 18.4 18.9 10.2 17.2 10.0 13.3 23.8 31.7 9.9 27.4 16.4 6.7 15.8 13.2 22.3 12.8 18.9 22.2 21.2 15.6 9.0 4.1 10.9 9.0 17.1 13.8 9.5 7.7 22.2 16.4 9.0 6.5 31.9 9.1 16.1 4.1 14.5 21.5 14.7 19.1 19.9 14.6 22.8 7.9 13.9 14.0 9.0 8.6 13.0 12.2 11.9 16.7 21.9 25.6 0.6 0.6 1.1 0.5 0.7 2.2 0.8 12.3 22.5 3.2 5.9 10.5 10.2 20.7 17.1 13.2 5.4 3.2 23.9 24.7 3.4 22.9 17.9 22.2 24.0 1.5 31.4 1.4 4.1 0.8 3.3 12.6 8.2 11.9 1.1 3.2 12.9 19.6 6.5 13.1 10.5 4.8 2.0 4.3 3.9 3.7 20.8 2.5 0.9 3.8 7.4 13.0 5.3 1.4 2.3 5.7 8.6 1.7 2.6 24.1 36.6 3.4 6.0 28.8 1.4 16.0 17.5 13.3 5.2 14.5 0.8 0.0 1.0 9.4 3.9 9.9 0.0 0.5 0.0 2.2 0.0 1.5 0.3 1.2 1.3 0.1 0.6 1.9 1.5 1.1 0.7 0.0 0.6 0.2 0.8 10.2 10.0 31.7 9.9 9.0 4.1 9.5 7.7 9.1 8.6 14.9 11.5 2.4 8.8 34.5 18.4 2.0 15.3 4.0 11.4 7.0 3.9 9.8 0.0 11.8 0.1 10.1 8.0 0.0 12.7 7.0 11.6 18.2 2.3 10.0 3.8 12.7 5.2 11.1 5.2 0.0 13.6 2.6 6.8 19.8 5.0 6.9 20.3 7.0 13.4 2.2 2.8 25.8 14.7 0.5 1.0 39.5 29.6 11.8 6.3 9.1 BCORL1 "CXorf10, FLJ11362" ENSG00000085185 "BCL6 corepressor like 1" Q5H9F3 X 129981107-130058083 "Cancer-related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Chromatin regulator, Repressor" "Autism spectrum disorder, Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enriched" "Detected in many" 7 "Syncytiotrophoblasts: 78.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "AN3-CA: 20.4;HAP1: 30.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA031775, HPA031777, HPA068568" Uncertain Approved "Nucleoplasm,Plasma membrane" NA NA Nucleoplasm "Plasma membrane" "HPA031775: AB_10602332, HPA031777: AB_10671578, HPA068568: AB_2686007" "unprognostic (8.07e-2)" "unprognostic (2.78e-2)" "unprognostic (7.09e-2)" "prognostic unfavorable (2.20e-5)" "unprognostic (4.58e-1)" "unprognostic (1.68e-3)" "unprognostic (1.96e-3)" "unprognostic (5.56e-3)" "unprognostic (2.39e-1)" "unprognostic (8.02e-2)" "unprognostic (4.46e-2)" "unprognostic (2.04e-1)" "prognostic unfavorable (5.00e-4)" "unprognostic (9.18e-2)" "unprognostic (2.60e-2)" "unprognostic (3.09e-1)" "unprognostic (1.41e-2)" 7.5 7.9 7.7 5.2 9.1 9.8 9.1 19.8 10.5 8.7 8.3 10.7 8.1 5.4 9.2 5.4 5.8 9.3 4.2 6.9 8.4 4.5 7.5 4.7 6.7 5.3 7.6 5.9 11.4 8.9 13.4 15.0 28.9 7.5 8.1 4.5 6.0 6.5 8.4 6.0 6.5 6.0 8.8 5.3 7.7 6.6 26.1 8.1 6.8 10.3 2.2 5.1 6.7 8.5 1.2 1.6 3.5 1.3 0.8 1.3 0.7 2.2 5.5 12.9 20.4 7.6 5.5 3.6 3.0 3.5 3.9 4.5 6.6 1.4 1.0 6.7 6.0 3.7 1.3 30.8 1.2 3.7 2.2 4.5 10.6 2.7 2.2 3.8 2.6 3.1 3.4 2.5 7.7 0.4 5.8 4.7 3.5 5.1 10.8 2.5 1.3 3.9 8.0 3.5 1.8 3.9 8.3 5.2 1.4 2.2 0.3 2.1 7.3 1.6 0.4 2.0 7.2 4.5 4.0 3.9 3.2 4.1 3.8 2.9 3.5 6.3 1.6 2.1 5.4 1.5 0.1 1.3 2.8 1.3 0.2 1.0 1.2 0.9 0.8 1.6 1.0 0.6 0.7 3.5 0.8 0.5 0.7 0.2 0.7 7.7 9.1 19.8 10.5 8.4 4.5 7.6 5.9 7.5 8.1 0.0 3.2 0.0 2.3 10.5 1.8 6.4 5.1 2.7 1.2 7.0 0.0 10.7 0.0 3.2 0.4 7.1 2.7 0.0 0.9 4.2 5.8 2.9 6.9 3.0 2.8 7.9 11.5 3.1 2.6 1.0 4.4 1.8 6.8 1.0 1.7 3.1 2.3 0.0 3.5 2.2 1.0 6.5 4.5 3.5 5.3 10.0 78.1 1.5 2.8 2.5 BIRC3 "API2, c-IAP2, cIAP2, hiap-1, MALT2, MIHC, RNF49" ENSG00000023445 "Baculoviral IAP repeat containing 3" Q13489 11 102317450-102339403 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Apoptosis, Ubl conjugation pathway" Transferase "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 46.0;lymphoid tissue: 46.3" "Cell type enhanced" "Detected in many" 16 "granulocytes: 530.1;monocytes: 1925.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "memory B-cell: 32.9;naive B-cell: 32.9" "Group enriched" "Detected in many" 10 "B-cells: 32.9;T-cells: 17.1" "Cell line enhanced" "Detected in many" "CAPAN-2: 38.4;Daudi: 33.7;HDLM-2: 31.9;hTERT-HME1: 33.6;U-266/70: 22.5;U-266/84: 19.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA002317 Enhanced Approved Supported Nucleoplasm,Cytosol NA NA "Nucleoplasm, Cytosol" "HPA002317: AB_1846748" "prognostic favorable (3.60e-4)" "unprognostic (2.89e-1)" "prognostic favorable (9.35e-4)" "unprognostic (3.28e-2)" "prognostic unfavorable (7.28e-4)" "unprognostic (5.83e-3)" "unprognostic (2.23e-1)" "unprognostic (3.88e-3)" "unprognostic (9.62e-2)" "unprognostic (1.29e-1)" "prognostic unfavorable (3.03e-4)" "unprognostic (3.21e-1)" "prognostic unfavorable (6.66e-6)" "unprognostic (6.42e-2)" "unprognostic (6.23e-3)" "unprognostic (1.00e-1)" "unprognostic (3.85e-2)" 6.9 3.3 1.4 43.9 2.3 5.1 5.4 0.5 2.0 5.3 13.1 0.5 2.8 6.8 2.9 3.7 8.4 3.9 13.9 6.0 2.2 1.3 10.8 12.5 21.8 46.3 2.8 1.2 3.4 7.0 1.1 14.5 0.9 2.2 8.7 6.2 1.1 9.2 4.7 2.2 5.5 46.0 7.3 3.0 34.9 15.9 3.2 2.7 34.2 3.0 4.1 34.0 12.6 6.2 32.9 0.8 2.0 2.6 2.5 17.1 2.8 6.5 5.3 0.0 0.1 0.1 0.7 0.6 0.5 4.4 0.6 0.7 0.9 38.4 33.7 17.4 0.3 5.5 3.6 0.0 0.9 2.1 31.9 0.1 0.1 1.6 0.2 6.6 0.5 0.7 0.7 4.7 2.1 33.6 1.2 0.1 2.7 0.1 0.0 0.8 0.0 2.3 0.3 0.1 3.1 0.2 0.0 0.3 1.7 8.7 3.4 0.0 0.1 0.5 0.6 0.3 0.2 1.7 0.3 1.7 7.3 0.8 0.4 6.7 22.5 19.2 11.9 1.3 1.9 0.9 2.0 0.9 0.4 1.4 2.2 2.5 32.9 10.7 3.5 0.8 32.9 7.5 2.2 0.5 2.5 2.6 0.3 17.1 2.8 1.4 2.3 0.5 2.0 2.2 1.3 2.8 1.2 2.2 2.7 134.0 68.1 285.1 318.0 89.9 0.3 12.0 76.5 30.8 73.9 38.4 0.0 1.7 6.6 193.4 1.3 50.1 284.0 46.7 153.8 0.5 71.9 371.3 530.1 3.4 11.1 0.0 14.5 7.4 18.1 1.3 4.6 71.9 182.2 1925.2 27.1 0.1 190.8 361.2 2.1 8.8 0.0 0.0 133.5 0.5 0.4 73.9 0.5 89.3 29.9 164.7 BLM "BS, RECQ2, RECQL3" ENSG00000197299 "Bloom syndrome RecQ like helicase" P54132 15 90717327-90816165 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "DNA damage, DNA repair, DNA replication" "DNA-binding, Helicase, Hydrolase" "Cancer-related genes, Disease mutation, Dwarfism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "lymphoid tissue: 36.7" "Cell type enhanced" "Detected in many" 6 "B-cells: 18.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA005689 Approved Supported Nucleoplasm,Cytosol NA NA Nucleoplasm Cytosol "HPA005689: AB_1845372" "unprognostic (2.77e-1)" "unprognostic (3.82e-3)" "unprognostic (4.03e-2)" "unprognostic (2.98e-2)" "unprognostic (4.75e-2)" "unprognostic (9.89e-2)" "unprognostic (6.12e-5)" "unprognostic (2.82e-2)" "unprognostic (4.55e-3)" "unprognostic (5.24e-3)" "unprognostic (1.80e-3)" "unprognostic (9.12e-2)" "unprognostic (1.55e-15)" "unprognostic (6.53e-3)" "unprognostic (6.55e-2)" "unprognostic (2.43e-1)" "unprognostic (1.83e-2)" 1.8 0.4 3.1 11.4 1.5 5.5 0.6 4.7 2.6 0.7 1.9 0.9 0.5 1.4 1.2 1.1 2.9 0.4 1.3 1.0 2.3 2.4 0.9 0.5 2.0 7.7 2.8 0.2 0.9 0.4 0.0 1.2 3.6 0.5 0.7 2.5 0.7 7.8 0.0 1.7 0.6 2.8 0.5 1.9 6.7 1.4 4.9 0.5 36.7 0.6 3.1 9.3 1.4 0.7 7.4 1.2 4.3 1.6 4.6 5.0 1.6 5.5 7.8 8.8 5.1 0.0 0.4 5.5 4.1 1.2 4.7 5.1 6.9 3.9 14.2 2.6 1.1 5.9 9.2 13.5 3.7 6.1 8.6 10.0 14.9 8.5 2.2 0.0 14.3 7.4 0.0 0.0 4.7 2.4 0.6 3.3 7.7 12.8 4.4 4.9 3.4 10.7 7.8 9.3 12.1 1.7 10.9 16.5 5.5 1.1 9.9 6.5 6.1 3.3 4.5 2.6 8.6 3.1 11.7 1.8 3.4 6.3 3.5 8.8 3.3 13.2 14.8 1.9 10.1 5.9 2.5 1.0 4.3 3.1 1.2 4.8 7.4 2.8 3.8 1.2 4.3 2.0 2.2 0.8 4.6 1.6 1.2 5.0 1.6 3.1 1.5 4.7 1.7 2.3 2.4 2.8 0.2 0.5 0.5 3.0 12.8 18.6 0.5 0.2 2.9 8.4 0.0 9.4 6.8 0.0 2.0 1.8 1.7 0.9 2.0 0.7 0.0 0.0 0.6 6.5 1.5 0.6 12.7 0.5 4.8 0.0 0.0 2.5 9.7 1.6 0.0 3.8 0.0 1.0 1.2 1.2 0.8 0.0 0.4 0.0 6.5 0.0 0.4 12.0 11.8 0.5 0.8 8.7 2.3 0.3 BMPR1A "ACVRLK3, ALK3, CD292" ENSG00000107779 "Bone morphogenetic protein receptor type 1A" P36894 10 86756601-86932838 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Kinase, Receptor, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB019398 Approved Approved Cytosol NA NA Cytosol "CAB019398: " "unprognostic (1.36e-1)" "unprognostic (2.46e-1)" "unprognostic (3.34e-1)" "unprognostic (9.61e-2)" "unprognostic (1.05e-3)" "unprognostic (9.34e-2)" "prognostic unfavorable (8.93e-4)" "unprognostic (3.64e-1)" "unprognostic (2.38e-2)" "unprognostic (1.53e-1)" "unprognostic (9.24e-2)" "unprognostic (9.42e-2)" "unprognostic (4.32e-2)" "unprognostic (1.80e-1)" "unprognostic (1.47e-1)" "unprognostic (1.01e-2)" "unprognostic (1.07e-1)" 8.9 7.0 9.4 7.9 12.4 0.9 10.7 14.1 9.2 19.4 20.6 10.9 7.7 6.2 16.3 12.3 8.4 10.9 10.8 11.0 7.7 6.1 8.2 4.6 7.4 2.9 7.3 7.6 16.1 10.6 10.0 14.0 7.4 8.5 12.8 9.3 10.9 12.6 14.2 8.4 11.3 9.8 16.5 12.2 3.4 12.1 7.8 9.2 0.3 19.4 7.8 5.7 16.0 11.4 1.8 1.1 3.6 0.8 0.9 1.4 0.3 7.3 3.7 14.3 12.1 7.5 4.8 2.5 7.4 7.7 4.3 5.1 6.2 6.4 2.2 3.4 9.4 3.1 7.8 6.3 8.0 6.4 2.4 3.6 2.8 3.5 10.3 4.0 3.8 19.7 4.2 3.4 5.8 4.3 6.4 0.0 4.1 4.4 1.5 5.0 3.1 2.6 3.1 7.7 2.6 1.7 0.0 5.6 0.0 8.9 6.9 1.4 4.6 8.2 4.2 4.9 18.2 7.1 1.9 3.7 3.1 5.0 6.4 6.8 0.4 6.8 2.8 2.7 2.6 2.5 2.0 0.8 0.6 1.4 0.5 0.9 1.8 1.4 1.2 0.3 1.5 1.0 1.1 3.6 0.9 0.6 1.1 0.7 0.3 9.4 12.4 14.1 9.2 7.7 6.1 7.3 7.6 8.5 9.2 32.8 24.8 0.0 6.7 10.8 6.0 19.0 10.2 13.4 9.1 10.4 19.6 10.0 1.7 9.8 0.6 2.1 9.0 0.0 8.1 0.7 13.3 12.9 15.0 7.2 2.7 11.1 17.3 8.0 4.0 1.7 31.1 3.5 8.5 1.0 13.6 12.9 7.7 3.5 29.4 4.7 19.0 6.5 14.1 2.3 3.6 8.5 4.2 0.0 10.0 4.2 BRAF BRAF1 ENSG00000157764 "B-Raf proto-oncogene, serine/threonine kinase" P15056 7 140719327-140924928 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Allosteric enzyme, Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Cardiomyopathy, Deafness, Disease mutation, Ectodermal dysplasia, FDA approved drug targets, Mental retardation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001328, CAB004552, HPA071048" Approved Approved Vesicles,Cytosol No No Vesicles Cytosol "CAB004552: AB_626760, HPA001328: AB_1078296, HPA071048: AB_2686336" "unprognostic (2.98e-3)" "unprognostic (5.66e-2)" "unprognostic (2.20e-2)" "unprognostic (2.66e-3)" "unprognostic (2.44e-1)" "unprognostic (1.48e-2)" "unprognostic (2.07e-2)" "unprognostic (4.23e-2)" "unprognostic (4.07e-2)" "unprognostic (1.58e-2)" "unprognostic (6.53e-2)" "unprognostic (1.91e-2)" "unprognostic (3.79e-3)" "unprognostic (2.08e-1)" "unprognostic (1.76e-1)" "unprognostic (8.01e-2)" "unprognostic (5.46e-2)" 13.1 12.1 20.1 16.5 20.4 27.8 14.2 29.9 21.5 12.4 12.3 9.5 12.5 9.3 15.3 17.0 11.8 11.5 12.0 13.6 13.2 12.2 13.7 12.8 15.9 13.3 9.9 17.8 16.8 13.2 28.9 24.8 13.7 15.3 14.5 11.0 10.7 11.6 16.6 12.9 15.6 10.5 13.0 10.9 12.3 12.0 24.9 12.2 13.5 16.6 7.5 12.1 18.6 18.1 2.6 1.9 7.5 2.4 7.0 5.6 1.1 5.5 4.7 6.9 8.3 8.4 11.0 11.1 6.2 6.6 5.0 7.2 5.1 6.0 9.5 4.8 6.4 8.0 3.1 6.1 4.9 9.3 8.8 5.0 6.2 4.6 4.7 7.2 10.0 6.2 7.3 5.6 5.3 11.1 7.4 5.8 7.1 9.7 17.1 8.8 2.9 13.3 10.5 6.4 5.4 3.0 8.7 5.9 7.7 4.9 10.7 8.1 6.8 7.2 4.4 6.5 7.1 4.1 6.8 8.6 5.5 4.2 11.7 5.0 19.8 11.2 15.2 8.9 10.1 5.9 3.3 2.0 7.5 3.1 1.7 2.1 2.6 3.0 2.4 1.6 2.6 5.6 2.8 4.1 7.0 2.4 1.9 2.7 1.1 20.1 20.4 29.9 21.5 13.2 12.2 9.9 17.8 15.3 12.2 20.8 34.2 19.5 20.3 19.2 29.1 12.7 5.1 24.1 25.0 24.4 33.4 12.4 6.6 10.9 55.6 17.1 7.5 0.0 8.6 10.3 13.1 23.9 24.3 8.7 7.9 23.8 18.4 8.6 14.8 30.8 15.3 17.2 15.1 10.0 8.1 11.8 12.5 6.6 9.6 9.6 32.5 6.5 17.3 33.7 23.0 21.0 63.2 17.5 8.1 23.8 BRCA1 "BRCC1, FANCS, PPP1R53, RNF53" ENSG00000012048 "BRCA1, DNA repair associated" P38398 17 43044295-43170245 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Cell cycle, DNA damage, DNA recombination, DNA repair, Fatty acid biosynthesis, Fatty acid metabolism, Lipid biosynthesis, Lipid metabolism, Transcription, Transcription regulation, Ubl conjugation pathway" "Activator, DNA-binding, Transferase" "Cancer-related genes, Disease mutation, Fanconi anemia, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 9 "Spermatocytes: 64.7;Spermatogonia: 61.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Group enriched" "Detected in all" 5 "dendritic cells: 9.1;granulocytes: 9.7;monocytes: 12.7" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB001946, HPA004840, HPA034966, HPA057371" Approved Supported "Nucleoplasm,Nuclear bodies" NA Yes "Nucleoplasm, Nuclear bodies" "CAB001946: , HPA004840: , HPA034966: AB_10795287, HPA057371: AB_2732611" "unprognostic (7.87e-3)" "unprognostic (6.97e-2)" "unprognostic (3.53e-3)" "unprognostic (2.39e-1)" "unprognostic (5.42e-2)" "unprognostic (7.07e-3)" "unprognostic (1.56e-3)" "unprognostic (4.14e-3)" "unprognostic (9.62e-3)" "unprognostic (2.47e-1)" "unprognostic (5.53e-3)" "unprognostic (1.28e-1)" "unprognostic (1.08e-4)" "unprognostic (1.08e-3)" "unprognostic (1.48e-1)" "unprognostic (2.12e-1)" "unprognostic (8.31e-2)" 4.8 4.3 6.0 9.6 11.3 15.3 5.1 12.9 10.6 5.4 9.2 3.4 6.8 4.3 5.4 5.5 9.1 5.5 3.3 6.5 6.6 5.3 4.2 7.7 4.9 13.0 7.5 5.9 5.1 4.7 4.2 11.0 5.3 10.5 4.1 10.4 3.7 5.4 7.4 7.3 8.3 6.7 5.5 9.2 5.9 5.1 17.6 7.0 10.9 15.6 7.3 14.6 5.5 5.6 2.0 9.1 9.7 12.7 1.4 1.3 10.7 15.7 25.6 14.1 11.2 2.3 5.2 13.8 18.6 8.0 15.6 14.9 15.5 12.3 36.4 3.4 7.1 18.5 18.3 19.1 10.4 26.2 16.6 14.0 17.1 20.1 13.4 0.5 30.5 14.9 1.4 1.7 23.5 7.5 4.0 8.1 17.0 25.8 15.6 14.7 10.5 25.5 10.1 7.7 10.6 6.8 17.6 29.7 14.9 5.8 15.3 9.7 10.4 14.3 4.7 7.0 10.0 12.6 14.1 5.2 14.0 11.4 18.1 19.3 7.3 17.8 28.0 11.3 18.1 14.6 4.6 12.7 1.8 1.3 4.0 1.3 1.1 1.3 1.0 9.1 2.0 1.2 1.3 9.7 1.4 1.5 1.4 0.4 10.7 6.0 11.3 12.9 10.6 6.6 5.3 7.5 5.9 10.5 7.0 0.0 3.2 5.2 3.8 2.6 8.3 10.4 7.6 13.4 5.7 1.8 21.6 7.0 0.0 2.6 11.1 2.9 1.0 0.0 1.0 17.5 2.9 2.4 8.1 16.1 8.6 11.1 0.0 5.5 4.0 5.2 2.3 5.3 0.0 3.6 3.7 2.8 1.6 3.1 1.4 0.8 21.1 6.5 1.4 64.7 61.1 1.9 3.3 2.5 3.5 2.5 BRCA2 "BRCC2, FACD, FAD, FAD1, FANCD, FANCD1, XRCC11" ENSG00000139618 "BRCA2, DNA repair associated" P51587 13 32315474-32400266 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cell cycle, DNA damage, DNA recombination, DNA repair" DNA-binding "Cancer-related genes, Disease mutation, Fanconi anemia, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 23.2;testis: 16.9" "Group enriched" "Detected in many" 4 "Erythroid cells: 23.3;monocytes: 31.5;Spermatocytes: 75.1;Spermatogonia: 82.4" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA026815 Uncertain Supported Nucleoplasm,Cytosol Yes No Nucleoplasm Cytosol "HPA026815: AB_10602692" "unprognostic (9.36e-2)" "unprognostic (2.50e-1)" "unprognostic (4.50e-3)" "unprognostic (1.06e-2)" "unprognostic (5.40e-2)" "unprognostic (2.26e-2)" "unprognostic (1.37e-2)" "unprognostic (1.15e-1)" "unprognostic (1.60e-2)" "unprognostic (2.01e-1)" "unprognostic (6.97e-3)" "unprognostic (4.06e-2)" "unprognostic (3.07e-9)" "unprognostic (2.36e-2)" "unprognostic (1.18e-1)" "unprognostic (1.88e-1)" "unprognostic (1.32e-1)" 2.4 1.0 0.6 13.8 0.6 11.6 3.2 0.6 0.6 1.8 4.0 0.2 0.2 1.4 1.5 2.7 3.0 1.0 0.7 2.1 0.6 0.7 1.0 1.4 3.5 5.3 0.7 0.5 1.4 3.3 0.4 0.7 7.0 0.8 0.9 2.0 0.1 1.8 0.3 3.3 1.8 3.2 0.8 2.1 6.6 1.5 16.9 0.1 23.2 0.9 4.8 4.2 1.3 1.7 1.3 1.9 0.4 0.2 1.5 0.8 0.0 4.0 3.5 6.1 4.6 0.6 1.6 6.2 4.3 2.7 5.0 4.6 8.3 5.3 14.2 2.9 2.1 6.9 5.4 5.0 2.5 9.7 9.2 2.7 9.0 2.2 3.2 0.2 12.8 4.5 0.4 0.3 9.2 6.4 0.5 4.1 7.2 5.9 4.9 5.7 4.6 10.3 7.6 7.2 4.6 1.9 10.1 15.7 2.7 1.3 4.3 2.3 4.4 5.2 2.3 2.1 2.2 2.7 6.4 3.2 5.8 6.2 6.4 6.0 1.9 2.9 7.3 3.0 5.1 5.5 0.1 0.2 0.2 0.3 0.2 0.1 0.9 0.4 0.2 0.2 1.3 0.6 0.8 0.4 1.5 0.2 1.9 0.4 0.0 0.6 0.6 0.6 0.6 0.6 0.7 0.7 0.5 0.8 0.1 8.9 1.6 1.9 2.8 2.3 0.0 1.6 0.0 4.0 2.3 0.0 0.0 9.1 0.0 1.8 4.3 3.6 1.0 23.3 1.4 9.1 3.5 0.6 3.5 0.8 8.2 0.0 1.2 2.5 6.7 2.5 2.0 13.2 3.3 31.5 3.0 0.2 1.1 1.5 1.1 0.6 0.0 12.9 2.0 75.1 82.4 1.1 4.6 3.8 5.3 1.4 BRIP1 "BACH1, FANCJ, OF" ENSG00000136492 "BRCA1 interacting protein C-terminal helicase 1" Q9BX63 17 61681266-61863521 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "DNA damage, DNA repair" "Helicase, Hydrolase" "Cancer-related genes, Disease mutation, Fanconi anemia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 30.1" "Group enriched" "Detected in many" 11 "Early spermatids: 136.2;Late spermatids: 148.4" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in some" "Low cell type specificity" "Detected in many" "Group enriched" "Detected in many" 4 "B-cells: 2.2;granulocytes: 2.1;T-cells: 3.7" "Cell line enhanced" "Detected in many" "MCF7: 42.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA005474 Approved Supported "Nucleoplasm,Nuclear membrane" NA Yes "Nucleoplasm, Nuclear membrane" "HPA005474: AB_2667333" "unprognostic (1.88e-1)" "unprognostic (1.55e-2)" "prognostic favorable (3.45e-5)" "unprognostic (6.85e-4)" "unprognostic (3.09e-1)" "prognostic favorable (3.62e-4)" "unprognostic (2.60e-3)" "unprognostic (5.60e-2)" "unprognostic (5.66e-3)" "unprognostic (6.71e-2)" "unprognostic (1.50e-3)" "unprognostic (2.75e-2)" "unprognostic (3.41e-12)" "unprognostic (1.19e-2)" "unprognostic (2.25e-1)" "unprognostic (3.96e-2)" "unprognostic (3.62e-3)" 1.0 0.9 0.7 6.3 3.5 9.1 1.1 0.6 1.4 1.4 2.6 0.2 0.6 2.8 1.5 1.2 3.7 0.8 1.8 0.4 0.5 0.5 0.6 2.3 1.3 4.0 0.5 0.9 2.1 1.3 0.1 0.4 1.7 0.7 1.0 2.8 0.4 1.4 0.0 0.4 2.7 5.5 1.0 0.5 2.3 1.3 10.8 0.4 30.1 0.4 2.0 6.6 1.3 1.7 2.2 0.5 2.1 0.3 0.6 3.7 0.5 12.5 4.3 12.4 7.1 0.4 1.1 2.7 11.6 6.8 12.4 16.1 4.4 4.0 7.5 2.7 2.4 3.6 4.5 6.4 2.4 16.8 1.9 7.8 7.6 6.8 5.4 0.1 9.8 4.5 0.2 0.1 9.9 2.6 1.7 2.7 7.4 5.3 5.1 7.8 42.2 15.5 3.4 2.7 3.0 3.7 9.7 23.9 3.6 1.7 5.7 5.0 12.9 4.5 1.6 1.8 4.9 4.2 3.8 2.3 18.3 13.4 6.7 13.3 3.2 6.1 8.0 3.7 4.7 4.5 2.1 0.3 1.5 0.5 0.2 0.6 2.2 1.2 0.6 0.4 1.8 1.8 0.9 1.0 0.6 0.2 0.5 3.7 0.5 0.7 3.5 0.6 1.4 0.5 0.5 0.5 0.9 0.7 0.4 0.0 0.3 1.5 1.3 2.1 0.1 0.5 0.0 1.4 6.8 0.0 0.0 0.7 0.0 0.3 136.2 0.3 0.9 0.0 0.2 2.5 0.6 0.1 0.0 3.0 1.4 0.0 0.0 0.6 0.3 148.4 1.1 0.4 3.3 1.0 1.5 0.3 0.5 0.0 1.1 0.0 0.2 0.0 0.9 13.3 4.5 0.4 0.2 0.8 2.5 0.3 BTK "AGMX1, ATK, IMD1, PSCTK1, XLA" ENSG00000010671 "Bruton tyrosine kinase" Q06187 X 101349447-101390796 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Adaptive immunity, Apoptosis, Immunity, Innate immunity, Transcription, Transcription regulation" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, Dwarfism, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "blood: 77.5;lymphoid tissue: 37.0" "Cell type enhanced" "Detected in some" 19 "B-cells: 86.8;granulocytes: 203.6;Hofbauer cells: 50.3;Kupffer cells: 53.4;Macrophages: 53.0;monocytes: 52.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "basophil: 77.5" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in some" "Daudi: 29.5;HEL: 40.9;HMC-1: 147.5;U-937: 21.4" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "HPA001198, HPA002028, CAB016689" Enhanced Supported "Plasma membrane,Cytosol" NA NA 610000 "Plasma membrane, Cytosol" "CAB016689: AB_1611894, HPA001198: AB_1078305, HPA002028: AB_1078306" "unprognostic (3.19e-2)" "unprognostic (2.51e-3)" "unprognostic (1.06e-2)" "unprognostic (3.66e-2)" "unprognostic (5.69e-2)" "unprognostic (3.76e-3)" "unprognostic (6.55e-2)" "unprognostic (3.58e-3)" "unprognostic (6.02e-2)" "unprognostic (3.12e-1)" "unprognostic (1.02e-1)" "unprognostic (1.41e-1)" "unprognostic (2.08e-3)" "unprognostic (7.80e-2)" "unprognostic (1.29e-2)" "unprognostic (1.56e-2)" "unprognostic (8.14e-2)" 7.3 2.4 3.3 23.5 5.6 14.0 2.6 0.8 3.6 2.3 3.0 4.7 0.3 2.2 1.9 2.6 2.4 2.0 3.7 3.3 3.3 2.5 2.2 2.5 10.7 25.1 5.4 1.2 1.2 1.5 0.2 1.4 3.2 4.1 2.5 4.5 1.5 3.2 1.0 1.0 2.5 12.9 3.3 10.8 37.0 3.1 1.3 6.3 4.0 1.7 1.8 36.7 5.8 2.0 13.7 13.2 77.5 20.7 0.0 0.0 6.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 29.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 40.9 0.0 0.0 0.0 16.4 147.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.6 0.3 0.0 0.0 0.0 11.5 0.2 0.0 0.0 12.3 0.0 1.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 9.8 0.0 0.0 0.0 0.0 0.0 0.3 0.2 14.0 0.0 21.4 0.0 77.5 11.3 19.3 0.0 18.1 0.0 13.7 0.0 0.0 13.2 13.7 0.0 0.0 4.5 0.0 20.7 6.0 0.0 6.1 3.3 5.6 0.8 3.6 3.3 2.5 5.4 1.2 4.1 6.3 3.0 12.8 86.8 0.1 0.9 0.0 0.4 0.0 0.0 1.2 0.0 0.0 1.1 0.0 0.0 0.2 0.6 0.0 23.3 0.0 0.4 0.5 0.0 203.6 0.0 50.3 0.0 0.0 1.3 53.4 0.0 0.3 53.0 3.3 52.3 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.3 0.4 1.6 0.3 1.6 0.8 0.0 0.1 BUB1B "Bub1A, BUBR1, MAD3L, SSK1" ENSG00000156970 "BUB1 mitotic checkpoint serine/threonine kinase B" O60566 15 40161023-40221136 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Apoptosis, Cell cycle, Cell division, Mitosis" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease mutation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 49.5;testis: 25.6" "Group enriched" "Detected in many" 7 "Spermatocytes: 66.9;Spermatogonia: 28.8" "Low cancer specificity" "Detected in all" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "naive B-cell: 2.8;plasmacytoid DC: 2.8" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" HPA008419 Supported Cytosol Yes Yes Cytosol "HPA008419: AB_1078308" "unprognostic (4.40e-2)" "unprognostic (2.23e-1)" "unprognostic (4.65e-2)" "unprognostic (2.44e-3)" "unprognostic (9.66e-2)" "unprognostic (3.52e-2)" "prognostic unfavorable (7.43e-6)" "prognostic unfavorable (3.56e-4)" "unprognostic (3.69e-3)" "unprognostic (2.32e-1)" "prognostic unfavorable (1.79e-4)" "unprognostic (1.76e-2)" "unprognostic (0.00e+0)" "unprognostic (3.75e-2)" "unprognostic (4.66e-2)" "unprognostic (2.20e-1)" "unprognostic (3.94e-2)" 1.0 0.9 0.3 18.4 0.6 11.4 1.5 0.4 0.5 1.3 4.0 0.4 0.1 3.3 1.1 0.8 6.5 0.5 1.1 0.6 0.4 0.4 0.8 0.7 1.8 8.7 0.4 0.3 0.6 0.5 0.0 0.4 3.4 0.5 0.6 4.4 0.3 1.6 0.1 0.7 2.3 2.9 1.2 0.6 5.4 1.7 25.6 0.1 49.5 0.5 3.1 10.6 1.1 2.0 2.8 2.8 0.0 0.2 0.7 0.7 0.5 21.8 11.1 35.5 14.1 0.9 2.5 11.5 20.8 11.7 22.3 19.4 16.2 8.4 19.8 11.7 7.5 20.5 24.7 33.5 11.3 24.3 17.0 18.0 28.9 28.7 15.0 0.0 26.1 15.9 0.5 0.6 13.6 12.8 4.4 16.1 22.9 24.9 21.1 22.2 7.4 20.4 15.9 24.0 18.4 12.7 21.9 29.2 15.0 6.8 11.1 23.2 14.3 12.8 12.3 4.5 16.2 14.3 13.5 9.3 17.1 18.1 17.0 18.4 11.1 18.8 32.4 9.1 29.3 22.2 0.0 0.0 0.0 0.2 0.2 0.3 2.4 0.7 0.6 0.7 2.8 0.1 0.4 0.0 0.7 0.1 2.8 0.0 0.5 0.3 0.6 0.4 0.5 0.4 0.4 0.4 0.3 0.5 0.1 3.0 1.4 0.8 0.3 0.7 0.4 0.4 0.0 0.0 3.4 0.0 0.0 1.3 0.0 0.3 2.5 0.0 0.3 0.0 0.0 5.1 0.4 0.2 0.0 0.2 4.3 0.0 0.0 1.3 0.6 2.4 1.4 1.5 0.0 0.0 1.4 0.0 0.8 0.8 0.4 0.0 0.1 6.5 0.0 66.9 28.8 0.3 0.7 0.8 1.7 0.4 CACNA1D "CACH3, CACN4, CACNL1A2, Cav1.3, CCHL1A2" ENSG00000157388 "Calcium voltage-gated channel subunit alpha1 D" Q01668 3 53328963-53813733 "Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel, Voltage-gated channel" "Cancer-related genes, Deafness, Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" 9 "Alveolar cells type 2: 45.9;Cone photoreceptor cells: 33.4;Intestinal endocrine cells: 57.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 9 "basophil: 7.2" "Lineage enriched" "Detected in single" 20 "granulocytes: 7.2" "Cell line enhanced" "Detected in some" "HMC-1: 14.4;RPMI-8226: 33.6;SK-BR-3: 6.3" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA020215 Uncertain Approved "Nuclear membrane" NA NA "Nuclear membrane" "HPA020215: AB_1845860" "unprognostic (5.85e-2)" "unprognostic (4.90e-3)" "unprognostic (5.09e-2)" "unprognostic (2.24e-2)" "unprognostic (7.55e-2)" "unprognostic (1.77e-2)" "unprognostic (1.92e-1)" "unprognostic (2.32e-2)" "unprognostic (2.95e-1)" "unprognostic (4.42e-2)" "unprognostic (3.90e-3)" "unprognostic (1.53e-1)" "prognostic favorable (8.34e-8)" "unprognostic (1.14e-1)" "unprognostic (3.05e-2)" "unprognostic (8.09e-3)" "unprognostic (6.70e-3)" 0.6 13.4 10.0 0.8 12.6 1.4 3.6 12.2 16.5 11.2 2.8 3.7 0.1 3.3 6.8 13.2 1.2 14.9 6.2 1.8 5.3 3.5 4.2 3.0 9.0 0.5 2.5 9.6 1.2 5.3 3.0 13.6 1.4 8.7 5.7 3.1 10.1 1.1 3.5 0.6 1.5 4.2 1.7 2.2 4.4 1.8 3.0 1.6 0.0 5.2 0.0 0.6 2.3 0.6 0.1 0.3 7.2 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.8 0.0 0.1 0.0 0.0 1.6 1.4 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.2 0.2 0.0 0.0 0.0 0.0 14.4 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 1.3 0.0 0.0 0.2 0.5 0.0 0.0 0.1 33.6 0.3 2.2 3.1 1.3 0.2 6.3 0.7 0.0 1.8 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 7.2 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 10.0 12.6 12.2 16.5 5.3 3.5 2.5 9.6 8.7 1.6 3.0 45.9 0.0 0.6 0.8 23.0 1.2 12.7 14.7 14.8 1.8 33.4 0.6 0.0 5.5 3.6 0.5 3.3 0.0 2.0 0.1 1.0 2.6 11.6 2.4 0.2 7.9 57.1 0.0 1.0 4.9 4.0 0.3 5.0 0.0 2.7 2.5 2.6 3.5 25.5 1.6 13.0 0.0 2.8 1.1 2.5 0.9 0.2 1.3 4.5 0.6 CALR "cC1qR, CRT, FLJ26680, RO, SSA" ENSG00000179218 Calreticulin P27797 19 12938578-12944489 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" Chaperone "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" 5 "Extravillous trophoblasts: 1318.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB001513, HPA002242, CAB019952, CAB079775" Enhanced Supported "Endoplasmic reticulum" "Intracellular and membrane" NA NA 450000000 "Endoplasmic reticulum" "CAB001513: , CAB019952: AB_2069792, CAB079775: AB_303403, HPA002242: AB_1078384" "unprognostic (1.49e-1)" "unprognostic (1.57e-1)" "unprognostic (8.46e-2)" "unprognostic (4.25e-2)" "unprognostic (9.44e-3)" "unprognostic (6.93e-2)" "unprognostic (2.47e-2)" "unprognostic (4.60e-2)" "unprognostic (2.61e-1)" "prognostic favorable (1.10e-4)" "unprognostic (2.07e-1)" "unprognostic (3.76e-1)" "prognostic unfavorable (1.11e-16)" "unprognostic (2.37e-1)" "unprognostic (1.96e-1)" "unprognostic (1.37e-1)" "unprognostic (5.27e-2)" 67.5 55.5 31.9 58.9 36.1 86.4 64.6 20.9 38.9 50.2 52.3 42.5 65.7 44.1 61.6 108.4 65.2 49.1 67.5 62.5 31.6 35.2 81.9 302.6 61.8 83.6 33.5 33.4 59.6 124.3 56.4 60.3 98.0 35.7 53.1 60.0 43.2 121.0 68.6 25.1 34.2 53.8 56.9 42.1 66.6 49.7 65.0 32.7 61.6 250.6 55.0 65.2 39.4 68.0 25.1 57.2 16.1 38.6 26.3 48.4 16.2 118.3 46.8 64.3 140.1 81.3 73.4 58.9 158.3 130.0 95.4 139.0 71.5 95.3 76.0 146.2 183.6 85.6 47.2 70.3 100.9 96.7 56.5 40.1 63.3 57.0 108.7 192.1 254.0 85.9 68.0 46.8 88.4 74.9 126.5 114.8 52.2 54.1 38.6 77.4 81.7 70.4 166.1 57.2 66.7 66.4 54.6 54.5 92.0 83.8 67.8 24.5 52.3 98.1 54.0 32.3 79.5 72.2 105.4 99.3 79.7 50.2 113.4 70.7 48.2 42.9 76.4 112.3 110.8 87.6 16.1 19.5 10.1 48.4 38.6 34.3 25.1 29.2 36.7 20.4 22.4 21.6 39.2 6.6 26.3 30.8 57.2 21.5 16.2 31.9 36.1 20.9 38.9 31.6 35.2 33.5 33.4 35.7 32.7 137.0 125.9 216.1 284.2 232.4 67.7 39.5 168.2 151.3 164.9 211.1 119.8 557.7 54.7 494.3 20.8 202.2 487.4 140.2 249.9 1318.6 319.8 346.7 204.2 513.5 724.5 33.4 339.2 328.4 165.0 18.8 295.1 261.1 202.4 256.1 263.3 298.5 397.7 287.1 292.4 139.9 115.0 200.5 213.6 255.0 394.6 186.7 806.5 193.7 294.0 285.1 CARD11 "BIMP3, CARMA1" ENSG00000198286 "Caspase recruitment domain family member 11" Q9BXL7 7 2906141-3043945 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 21.4;lymphoid tissue: 44.7" "Cell type enhanced" "Detected in some" 13 "B-cells: 19.1;Pancreatic endocrine cells: 15.2;T-cells: 24.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "plasmacytoid DC: 21.4" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "Daudi: 40.6;K-562: 16.2;RT4: 30.6;U-698: 36.2" "Not detected" "Not detected" "Low region specificity" "Detected in some" HPA052984 Approved NA NA "HPA052984: AB_2682005" "unprognostic (3.12e-2)" "unprognostic (1.75e-1)" "unprognostic (2.17e-1)" "unprognostic (8.46e-3)" "unprognostic (4.81e-1)" "unprognostic (3.44e-2)" "unprognostic (1.71e-1)" "unprognostic (2.31e-1)" "unprognostic (5.65e-2)" "unprognostic (5.11e-2)" "unprognostic (2.09e-2)" "unprognostic (3.09e-1)" "prognostic unfavorable (6.68e-8)" "unprognostic (3.74e-2)" "unprognostic (4.75e-2)" "unprognostic (1.31e-1)" "prognostic favorable (1.10e-4)" 1.2 1.7 1.4 44.7 1.0 9.0 0.9 0.7 1.4 1.7 1.4 1.2 0.6 1.9 0.8 0.5 2.7 1.2 11.4 0.8 1.4 2.3 1.9 1.4 3.8 25.0 2.1 0.5 0.9 1.4 0.1 1.0 0.5 1.1 2.8 1.2 1.2 6.7 1.0 0.3 0.5 14.2 1.4 2.9 27.4 3.9 1.4 1.5 22.8 1.3 1.7 28.6 9.4 5.2 4.6 21.4 0.3 0.0 3.3 5.5 1.8 5.4 0.8 0.0 0.0 0.0 0.0 4.2 0.0 0.0 0.2 0.0 10.7 12.0 40.6 10.1 0.0 0.0 9.1 0.0 0.1 0.1 13.8 0.4 0.0 1.0 0.1 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.3 7.8 4.5 16.2 0.0 0.0 0.1 1.5 0.0 15.3 6.8 0.0 1.9 0.0 10.1 3.9 30.6 0.1 0.5 0.0 0.0 0.0 6.4 0.0 0.8 5.1 0.0 4.1 0.0 0.0 4.2 0.0 36.2 0.0 0.0 0.0 0.3 0.0 0.0 5.5 0.0 5.2 3.8 3.2 3.6 0.6 4.6 2.1 3.8 0.1 3.3 0.0 21.4 2.2 1.8 1.4 1.0 0.7 1.4 1.4 2.3 2.1 0.5 1.1 1.5 0.0 0.0 19.1 0.3 0.0 0.4 1.7 0.0 0.0 0.0 1.8 0.0 0.0 0.0 4.6 0.1 0.0 0.0 0.0 4.7 0.0 0.5 0.3 5.7 0.0 1.5 0.0 0.0 0.0 1.5 0.0 0.3 2.2 3.3 0.0 0.0 0.0 15.2 0.0 0.0 0.0 0.0 0.0 0.4 1.4 0.0 0.3 0.0 24.5 0.0 3.1 CBL "c-Cbl, CBL2, RNF55" ENSG00000110395 "Cbl proto-oncogene" P22681 11 119206276-119313926 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Ubl conjugation pathway" Transferase "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 40.9" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 11.8" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004350, HPA027956" Enhanced Supported Cytosol NA NA Cytosol "CAB004350: AB_2244054, HPA027956: AB_10601094" "unprognostic (2.52e-1)" "unprognostic (1.32e-3)" "unprognostic (1.60e-1)" "unprognostic (1.15e-1)" "unprognostic (1.50e-2)" "unprognostic (2.92e-1)" "unprognostic (4.10e-3)" "unprognostic (9.75e-2)" "unprognostic (1.72e-1)" "unprognostic (1.52e-1)" "unprognostic (1.03e-2)" "unprognostic (5.23e-2)" "unprognostic (5.21e-2)" "unprognostic (5.27e-2)" "unprognostic (1.52e-1)" "unprognostic (1.12e-1)" "unprognostic (5.85e-2)" 9.9 5.5 9.1 17.0 11.1 11.1 8.8 10.7 12.0 6.2 7.5 8.7 3.0 5.7 9.9 5.3 7.5 7.4 6.3 5.9 8.0 9.6 5.5 4.0 10.3 16.3 8.1 6.9 6.3 5.6 16.6 4.1 9.1 9.3 5.3 7.5 6.4 5.4 7.1 3.9 7.4 8.6 10.6 8.9 13.3 7.3 32.3 5.1 40.9 6.0 5.5 15.6 7.6 7.7 1.8 3.3 11.8 3.7 0.6 1.9 1.0 6.3 4.8 16.9 10.6 5.1 6.0 10.0 6.9 7.2 6.7 6.6 10.3 7.9 15.1 6.2 8.7 13.8 9.3 11.6 5.9 14.7 8.6 2.7 15.5 3.7 3.1 6.2 18.0 17.7 5.3 6.5 17.0 18.4 7.1 16.5 14.8 12.5 6.3 12.0 6.9 9.6 10.1 8.8 5.7 5.4 10.4 8.5 2.8 5.9 5.1 2.3 7.1 12.8 5.6 4.6 12.1 5.8 15.2 13.7 10.4 7.4 7.2 9.0 2.1 3.1 12.3 4.2 15.6 7.4 0.8 3.2 2.4 1.3 3.7 1.1 1.8 1.6 1.3 3.3 1.8 1.8 1.9 11.8 0.6 3.1 1.8 1.4 1.0 9.1 11.1 10.7 12.0 8.0 9.6 8.1 6.9 9.3 5.1 8.9 8.8 18.8 4.9 16.0 12.4 5.9 7.6 1.4 4.5 10.4 43.2 5.2 1.7 5.8 22.7 17.8 6.3 0.0 5.8 8.0 8.0 6.2 3.5 2.6 15.0 12.7 8.1 19.0 52.9 32.8 7.2 29.9 15.1 5.4 4.3 17.5 8.7 8.6 12.0 3.1 33.8 25.8 17.6 38.1 26.2 19.2 5.8 20.0 4.5 9.5 CBLB "Cbl-b, RNF56" ENSG00000114423 "Cbl proto-oncogene B" Q13191 3 105655461-105869552 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Ubl conjugation pathway" Transferase "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "U-138 MG: 23.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA018327, HPA019880" Approved Supported Nucleoplasm,Cytosol NA NA Cytosol Nucleoplasm "HPA018327: AB_1846097, HPA019880: AB_1846099" "unprognostic (2.65e-1)" "unprognostic (9.42e-2)" "unprognostic (1.72e-2)" "unprognostic (2.38e-1)" "unprognostic (5.89e-3)" "unprognostic (2.80e-2)" "unprognostic (8.18e-2)" "unprognostic (1.10e-1)" "unprognostic (7.05e-2)" "unprognostic (1.66e-1)" "unprognostic (9.29e-2)" "unprognostic (1.50e-2)" "unprognostic (1.43e-2)" "unprognostic (8.21e-2)" "unprognostic (2.83e-1)" "unprognostic (1.20e-2)" "unprognostic (3.09e-2)" 38.4 9.0 3.7 19.5 4.9 15.5 16.3 24.4 3.8 13.7 18.7 5.9 7.7 9.3 13.8 12.2 8.3 12.5 13.4 27.5 3.8 4.8 7.4 6.7 16.3 19.1 4.4 1.9 17.7 6.8 3.4 13.5 25.4 7.9 12.9 8.0 11.6 9.1 6.3 10.3 8.5 13.8 25.6 5.7 16.4 12.4 9.2 5.2 11.6 13.5 7.0 18.0 24.9 24.1 5.1 3.1 2.8 2.1 10.3 9.9 1.6 1.6 2.3 7.7 3.8 8.9 9.0 5.0 5.8 2.9 1.7 2.7 2.9 2.0 3.6 4.0 3.0 2.7 2.9 1.0 1.0 2.1 2.8 2.9 2.0 12.0 1.9 13.1 1.4 1.5 8.6 3.1 4.5 12.3 6.4 5.6 3.7 2.1 11.7 3.6 2.1 2.0 0.9 2.7 2.0 3.3 4.2 2.3 0.6 4.1 7.4 6.0 6.5 6.8 0.8 8.9 5.6 1.7 2.9 3.1 23.9 2.0 3.2 1.4 6.6 0.6 5.7 6.4 1.2 1.5 0.7 1.5 2.8 9.9 0.9 8.8 2.2 5.1 5.6 1.3 5.1 4.4 8.0 1.0 10.3 2.1 3.1 5.6 1.6 3.7 4.9 24.4 3.8 3.8 4.8 4.4 1.9 7.9 5.2 14.9 6.7 21.6 6.8 9.6 44.8 39.9 0.0 10.7 6.8 12.2 25.5 8.9 5.0 6.0 27.4 22.6 8.7 0.0 6.9 53.5 21.6 9.6 8.1 6.7 12.2 3.2 12.1 39.3 11.3 9.0 6.9 10.4 15.1 5.4 16.2 7.4 11.7 7.0 10.3 3.1 27.4 6.5 19.9 9.8 15.8 6.0 38.0 52.3 10.7 3.0 CD79B "B29, IGB" ENSG00000007312 "CD79b molecule" P40259 17 63928740-63932354 "Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins" "Adaptive immunity, Immunity" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "blood: 138.8;lymphoid tissue: 56.6" "Cell type enriched" "Detected in many" 8 "B-cells: 486.9" "Low cancer specificity" "Detected in all" "Not detected" "Not detected" "Group enriched" "Detected in many" 5 "memory B-cell: 100.6;naive B-cell: 138.8" "Lineage enriched" "Detected in many" 6 "B-cells: 138.8" "Cell line enhanced" "Detected in some" "Daudi: 117.7;REH: 38.7;U-698: 161.1" "Not detected" "Not detected" "Not detected" "Not detected" "HPA009178, CAB009751, HPA044107" Enhanced Supported "Nucleoplasm,Plasma membrane,Cytosol" NA NA "Plasma membrane" "Nucleoplasm, Cytosol" "CAB009751: AB_2275844, HPA009178: AB_1078483, HPA044107: " "unprognostic (3.90e-3)" "unprognostic (1.61e-3)" "unprognostic (5.21e-2)" "unprognostic (3.45e-3)" "unprognostic (4.22e-3)" "prognostic favorable (2.35e-4)" "unprognostic (1.82e-1)" "unprognostic (9.25e-3)" "unprognostic (3.89e-2)" "unprognostic (1.48e-1)" "unprognostic (1.04e-1)" "unprognostic (2.87e-2)" "unprognostic (2.50e-3)" "unprognostic (1.89e-1)" "unprognostic (1.44e-1)" "unprognostic (4.28e-2)" "unprognostic (2.75e-1)" 1.7 0.7 0.4 50.6 0.4 11.1 1.2 0.3 0.4 0.6 1.7 0.3 0.3 0.7 0.6 0.5 2.6 0.6 1.4 3.4 0.4 0.2 2.3 1.7 1.3 56.6 0.4 0.3 0.6 1.6 0.0 9.0 0.5 0.3 1.0 1.3 0.8 8.9 0.9 1.2 0.9 22.4 0.5 0.4 56.0 1.8 0.6 0.3 3.7 1.4 1.7 46.6 4.5 0.9 138.8 4.2 0.5 25.0 3.4 9.2 9.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 117.7 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 6.5 0.0 0.0 0.0 2.5 0.0 0.0 0.0 38.7 0.1 0.5 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.7 0.0 1.8 0.1 0.0 0.4 0.0 0.0 5.9 5.7 161.1 0.0 0.2 0.0 0.5 1.1 0.0 4.2 16.5 4.8 100.6 5.4 2.8 4.2 138.8 3.7 2.2 0.5 3.4 25.0 0.6 9.2 9.0 0.4 0.4 0.3 0.4 0.4 0.2 0.4 0.3 0.3 0.3 0.0 2.2 486.9 0.3 3.9 0.0 0.8 2.5 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.5 7.1 0.0 23.3 0.0 0.4 4.3 0.3 15.0 0.5 4.7 0.0 1.2 62.0 14.1 1.1 1.1 3.5 20.3 1.0 0.0 0.0 0.0 0.0 1.8 0.8 0.0 0.0 3.3 0.7 0.1 2.8 0.3 34.6 0.0 0.1 CDC73 "C1orf28, FIHP, HRPT1, HRPT2, parafibromin" ENSG00000134371 "Cell division cycle 73" Q6P1J9 1 193121997-193253901 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cell cycle, Transcription, Transcription regulation, Wnt signaling pathway" "Cancer-related genes, Disease mutation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA002326, CAB016359, HPA069324" Supported Supported Nucleoplasm,Cytosol NA NA Nucleoplasm Cytosol "CAB016359: AB_628102, HPA002326: , HPA069324: " "unprognostic (4.41e-2)" "unprognostic (6.22e-2)" "unprognostic (1.90e-2)" "unprognostic (5.30e-2)" "unprognostic (2.88e-3)" "unprognostic (3.53e-2)" "unprognostic (2.48e-3)" "unprognostic (5.74e-2)" "unprognostic (1.25e-1)" "unprognostic (1.40e-1)" "unprognostic (7.23e-3)" "unprognostic (2.17e-1)" "unprognostic (5.44e-3)" "unprognostic (3.47e-1)" "unprognostic (2.49e-1)" "unprognostic (6.73e-3)" "unprognostic (2.98e-3)" 23.4 20.0 18.1 16.8 22.9 21.0 20.1 25.6 22.6 20.4 20.1 14.5 16.3 12.0 26.8 15.2 20.6 14.9 16.4 21.4 18.4 15.0 18.8 17.1 17.2 16.6 19.7 15.9 23.3 14.5 27.1 24.8 17.3 19.4 26.9 16.2 13.6 17.3 19.0 44.5 15.0 14.5 25.6 23.9 16.0 15.7 16.3 22.1 20.6 27.1 14.1 15.8 26.8 35.0 6.6 6.7 10.2 7.0 9.0 12.5 5.2 13.4 12.1 16.0 10.3 15.0 14.6 12.3 14.5 14.1 17.6 15.4 8.3 16.0 17.5 10.3 17.8 9.7 13.2 14.5 13.7 21.5 11.1 6.9 12.7 10.9 8.0 14.1 17.2 12.7 11.9 13.3 16.5 15.8 15.6 14.9 10.0 19.2 14.2 23.5 12.4 14.1 8.5 15.4 19.8 4.5 12.6 9.7 16.7 20.6 9.4 4.8 13.2 18.1 22.4 20.7 18.6 19.2 12.5 16.6 17.1 4.0 14.5 14.8 13.3 9.9 14.4 10.3 10.6 29.9 6.6 7.0 10.2 9.3 6.8 12.5 6.6 9.2 9.2 6.7 5.4 8.4 8.7 7.4 9.0 5.7 4.9 9.3 5.2 18.1 22.9 25.6 22.6 18.4 15.0 19.7 15.9 19.4 22.1 32.8 20.1 34.3 31.1 33.1 31.2 36.4 20.4 20.1 19.4 31.4 33.4 21.8 28.2 29.4 11.9 30.1 16.2 23.3 28.5 34.0 29.2 33.5 39.4 14.3 28.0 20.6 10.9 22.1 25.9 6.1 31.1 38.8 27.0 47.7 15.3 33.5 28.2 13.1 33.9 26.4 36.3 25.8 57.1 56.5 32.0 30.6 31.8 29.8 16.1 23.2 CDH1 "CD324, UVO, uvomorulin" ENSG00000039068 "Cadherin 1" P12830 16 68737225-68835548 "Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" "Cancer-related genes, Disease mutation, Ectodermal dysplasia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 125.5" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Group enriched" "Detected in some" 12 "myeloid DC: 2.8;plasmacytoid DC: 8.5" "Lineage enriched" "Detected in single" 18 "dendritic cells: 8.5" "Cell line enhanced" "Detected in some" "BEWO: 107.1;CACO-2: 36.0;CAPAN-2: 50.3;HaCaT: 48.6;hTCEpi: 34.3;MCF7: 29.7;OE19: 31.7;RT4: 37.0;T-47d: 32.0" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "CAB000087, HPA004812, CAB028364, CAB072855, CAB072856, CAB072857" Enhanced Supported "Golgi apparatus,Plasma membrane,Cell Junctions" NA NA 22000000 "Plasma membrane, Cell Junctions" "Golgi apparatus" "CAB000087: AB_2533003, CAB028364: AB_2076812, CAB072855: AB_2665698, CAB072856: AB_2665699, CAB072857: AB_2665700, HPA004812: AB_1078369" "unprognostic (3.95e-2)" "unprognostic (1.91e-1)" "unprognostic (1.12e-3)" "unprognostic (1.13e-1)" "unprognostic (1.42e-1)" "unprognostic (2.78e-1)" "unprognostic (5.04e-3)" "unprognostic (1.63e-1)" "unprognostic (5.47e-2)" "unprognostic (2.85e-1)" "unprognostic (1.19e-2)" "unprognostic (3.61e-1)" "prognostic favorable (2.06e-4)" "unprognostic (1.21e-1)" "unprognostic (2.62e-1)" "unprognostic (2.51e-1)" "unprognostic (5.92e-2)" 1.1 0.7 1.3 14.8 1.5 0.5 15.3 0.8 1.1 14.4 63.8 1.8 42.4 25.5 4.7 18.6 48.5 9.7 48.9 0.8 1.5 1.0 24.2 64.9 24.4 0.5 1.8 0.9 5.6 71.5 62.2 13.2 55.2 2.8 28.9 25.9 11.8 66.6 43.7 0.8 30.5 125.5 1.5 1.1 3.5 21.6 2.1 1.8 11.7 83.0 26.2 32.6 16.8 21.7 0.0 8.5 0.0 0.0 0.3 0.4 0.1 21.6 2.2 0.0 0.0 0.0 0.0 107.1 0.0 0.0 0.0 0.0 36.0 50.3 0.0 0.4 0.0 0.0 48.6 0.0 24.1 0.0 4.2 0.6 0.0 0.1 7.7 0.0 0.0 0.2 0.0 34.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 29.7 0.0 0.1 0.8 31.7 0.1 0.0 0.0 0.3 8.8 37.0 1.3 0.1 0.2 0.0 9.1 15.2 32.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.4 2.8 0.0 0.0 0.0 0.0 0.3 0.0 8.5 0.1 0.1 1.3 1.5 0.8 1.1 1.5 1.0 1.8 0.9 2.8 1.8 122.1 58.7 0.9 101.9 83.6 0.0 0.8 152.8 73.6 64.8 155.3 0.0 97.3 1.7 107.7 0.0 1.2 202.1 0.0 98.3 22.3 4.1 170.0 1.1 44.7 10.1 0.0 83.2 0.6 1.5 0.0 0.3 6.3 50.6 5.4 180.9 0.0 193.9 160.9 0.4 3.3 0.0 0.0 4.7 0.0 0.1 114.9 42.2 0.0 125.1 204.2 CDK12 "CRK7, CRKR, CRKRS, KIAA0904" ENSG00000167258 "Cyclin dependent kinase 12" Q9NYV4 17 39461511-39564907 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "mRNA processing, mRNA splicing" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "SK-BR-3: 87.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA008038, HPA073305" Supported Enhanced "Nucleoplasm,Nuclear speckles" NA NA "Nucleoplasm, Nuclear speckles" "HPA008038: AB_1078570, HPA073305: " "unprognostic (2.02e-1)" "unprognostic (1.80e-1)" "unprognostic (2.61e-2)" "unprognostic (7.56e-2)" "unprognostic (1.05e-1)" "unprognostic (3.19e-1)" "unprognostic (2.56e-3)" "unprognostic (2.37e-2)" "unprognostic (3.86e-2)" "unprognostic (3.00e-3)" "unprognostic (6.87e-3)" "unprognostic (1.86e-1)" "unprognostic (3.06e-2)" "unprognostic (9.10e-2)" "unprognostic (1.24e-1)" "unprognostic (2.22e-2)" "unprognostic (5.32e-1)" 16.0 13.1 12.4 17.4 9.2 32.4 14.0 23.4 17.8 18.2 17.6 9.6 15.7 11.1 15.7 12.0 16.9 12.2 12.5 11.0 10.1 6.7 10.2 18.5 13.5 15.2 10.9 14.3 17.4 11.3 19.0 12.2 18.4 9.5 12.7 11.7 10.4 15.6 11.1 11.1 17.0 16.5 11.0 10.6 16.3 11.8 18.9 8.3 29.0 15.0 5.4 17.3 16.3 20.5 5.1 4.0 10.4 2.9 6.6 4.0 0.9 8.9 11.1 6.7 6.2 4.9 5.5 6.2 8.1 6.9 11.1 8.3 13.6 5.5 12.7 7.1 8.5 11.3 14.6 13.3 10.2 10.8 8.3 11.4 13.7 7.5 10.5 4.8 18.7 9.6 5.9 7.1 13.5 10.7 4.6 6.7 7.7 23.2 8.4 6.3 4.2 15.3 4.8 7.0 4.4 5.0 10.1 14.4 7.2 4.2 10.7 7.2 4.6 10.3 87.5 7.0 10.1 11.2 8.1 7.2 10.1 8.1 7.0 10.4 6.9 4.9 17.9 7.2 7.9 6.6 10.4 2.9 4.1 4.0 2.2 3.0 2.9 2.5 2.7 1.8 5.1 2.9 2.7 9.7 6.6 1.8 4.0 2.0 0.9 12.4 9.2 23.4 17.8 10.1 6.7 10.9 14.3 9.5 8.3 23.8 26.1 37.7 45.0 57.5 45.4 12.1 35.7 29.4 40.9 36.6 60.9 27.7 11.6 24.4 15.9 29.6 32.0 23.3 23.8 24.7 35.7 62.9 27.8 38.9 23.9 33.4 29.9 27.6 37.0 14.0 34.5 34.5 25.3 27.9 26.9 31.5 36.1 31.6 31.8 12.9 67.7 32.3 33.0 113.1 90.5 60.3 48.7 42.9 28.8 77.9 CDK4 PSK-J3 ENSG00000135446 "Cyclin dependent kinase 4" P11802 12 57747727-57756013 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Cell cycle, Cell division" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Group enriched" "Detected in all" 10 "HBEC3-KT: 128.1;LHCN-M2: 141.4;RH-30: 445.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA006024, CAB013116, CAB069405" Supported Supported "Nucleoplasm,Nuclear membrane,Nucleoli,Cytosol" NA NA Cytosol "Nucleoplasm, Nuclear membrane, Nucleoli" "CAB013116: AB_2536376, CAB069405: AB_1613464, HPA006024: AB_2667497" "unprognostic (8.88e-2)" "unprognostic (2.53e-1)" "unprognostic (5.27e-2)" "unprognostic (9.01e-2)" "unprognostic (2.21e-1)" "unprognostic (1.10e-1)" "prognostic unfavorable (2.09e-7)" "unprognostic (7.39e-2)" "unprognostic (3.23e-3)" "unprognostic (2.93e-2)" "unprognostic (3.19e-2)" "unprognostic (9.10e-2)" "prognostic unfavorable (3.15e-5)" "unprognostic (3.32e-1)" "unprognostic (1.67e-1)" "unprognostic (3.64e-1)" "unprognostic (1.57e-2)" 32.2 43.1 13.8 22.2 15.7 24.0 45.0 13.1 17.9 36.3 28.2 20.1 22.8 15.2 51.4 28.1 29.9 31.0 32.3 27.4 14.5 12.1 24.0 36.9 26.8 26.4 18.3 13.7 61.4 54.4 18.9 34.2 25.0 16.0 37.2 26.9 26.2 29.3 24.1 27.8 25.6 20.7 34.1 13.5 27.2 23.9 24.6 17.5 29.2 54.3 32.1 27.5 33.6 30.9 29.6 25.5 2.6 19.9 15.8 32.1 22.2 9.5 11.1 14.6 13.0 13.4 11.8 9.8 5.5 18.0 24.4 20.2 15.8 9.1 13.9 10.0 8.6 14.4 7.4 20.2 128.1 18.5 6.8 9.3 13.0 7.5 11.1 15.7 14.7 9.0 11.6 9.4 14.9 17.2 16.6 15.6 13.3 13.8 12.0 141.4 13.9 14.1 12.0 17.2 10.0 11.2 12.6 445.0 12.9 7.6 15.1 13.3 12.4 9.8 7.4 14.7 10.5 9.8 17.9 7.1 11.4 10.8 12.9 11.1 6.0 9.7 21.4 10.5 13.7 13.7 1.7 14.3 2.6 26.2 19.9 27.0 29.6 23.1 23.7 21.0 28.1 32.1 28.5 1.2 15.8 12.0 25.5 16.6 22.2 13.8 15.7 13.1 17.9 14.5 12.1 18.3 13.7 16.0 17.5 20.8 25.0 32.0 62.9 79.7 15.3 0.5 48.4 4.0 23.9 45.4 9.8 64.6 59.7 71.7 10.1 44.2 11.3 23.3 53.6 108.9 77.4 41.8 68.1 32.1 111.7 17.5 43.8 34.4 23.2 6.8 59.2 34.0 50.6 54.1 33.5 51.3 55.4 7.0 59.4 66.3 15.3 32.3 54.2 25.9 40.3 75.3 39.1 34.1 78.3 32.5 CDKN2A "ARF, CDK4I, CDKN2, CMM2, INK4, INK4a, MLM, MTS1, p14, p14ARF, p16, p16INK4a, p19, p19Arf" ENSG00000147889 "Cyclin dependent kinase inhibitor 2A" "P42771, Q8N726" 9 21967753-21995301 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Apoptosis, Cell cycle, rRNA processing, Transcription, Transcription regulation, Ubl conjugation pathway" DNA-binding "Cancer-related genes, Disease mutation, Li-Fraumeni syndrome, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 22.6;pituitary gland: 39.3" "Cell type enhanced" "Detected in many" 13 "Early spermatids: 178.1;Late spermatids: 275.2;Pancreatic endocrine cells: 259.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "T-reg: 22.6" "Group enriched" "Detected in many" 8 "B-cells: 7.2;T-cells: 22.6" "Cell line enhanced" "Detected in many" "CAPAN-2: 50.2;HEK 293: 56.9;HeLa: 53.2;SK-MEL-30: 53.1" "Low region specificity" "Detected in some" "CAB000093, CAB000445, CAB018232, HPA047838" Enhanced Supported Nucleoli NA NA Nucleoli "CAB000093: AB_442119, CAB000445: , CAB018232: AB_785018, HPA047838: AB_2680174" "unprognostic (3.41e-2)" "unprognostic (4.51e-2)" "unprognostic (3.00e-3)" "prognostic unfavorable (1.82e-7)" "unprognostic (5.22e-2)" "prognostic favorable (5.19e-4)" "prognostic unfavorable (2.17e-4)" "unprognostic (1.25e-2)" "unprognostic (1.05e-1)" "unprognostic (1.04e-1)" "unprognostic (1.71e-1)" "unprognostic (1.56e-2)" "prognostic unfavorable (5.76e-7)" "unprognostic (9.41e-2)" "unprognostic (1.22e-2)" "unprognostic (3.05e-2)" "unprognostic (3.55e-1)" 5.4 8.6 2.9 4.5 3.9 1.8 5.3 1.7 3.1 1.2 2.5 4.4 0.1 1.2 1.2 1.9 6.3 3.0 2.6 0.7 1.7 1.0 0.9 1.2 3.0 3.0 3.6 1.6 1.5 1.5 8.5 39.3 6.7 5.0 1.9 1.1 1.2 2.4 2.9 0.9 1.3 3.7 1.0 3.0 8.9 6.0 13.0 1.9 3.9 1.4 3.0 14.0 2.7 1.5 7.2 0.2 0.8 1.8 0.4 22.6 2.2 2.1 0.0 0.3 14.1 0.1 0.1 6.1 2.3 0.0 19.7 35.1 3.5 50.2 7.2 32.3 1.6 0.0 6.0 5.9 36.5 15.9 31.0 56.9 0.0 53.2 2.3 1.5 3.6 3.0 3.8 0.0 19.8 11.0 42.3 2.0 0.0 0.0 33.0 18.0 0.1 0.3 0.0 0.4 4.0 29.3 0.0 13.4 26.5 4.0 0.0 33.1 2.3 38.2 6.3 53.1 1.7 7.5 0.1 6.6 0.1 0.4 0.0 0.1 14.7 8.3 29.5 0.0 9.5 0.1 0.8 1.3 0.2 6.2 0.6 9.7 7.2 8.0 11.0 0.2 7.0 0.5 4.7 0.4 0.4 1.8 0.0 22.6 2.2 2.9 3.9 1.7 3.1 1.7 1.0 3.6 1.6 5.0 1.9 0.0 0.0 1.5 0.7 1.5 0.2 4.0 0.0 14.7 1.2 10.4 0.0 20.9 0.0 32.4 178.1 2.2 6.9 0.0 22.9 52.3 3.6 10.0 4.6 0.0 6.6 0.0 68.2 0.6 8.2 275.2 2.8 1.8 8.5 26.2 6.2 0.8 259.8 10.5 1.8 0.0 0.0 0.0 1.0 5.7 4.1 0.4 7.7 12.5 2.3 34.0 CEBPA "C/EBP-alpha, CEBP" ENSG00000245848 "CCAAT/enhancer binding protein alpha" P49715 19 33299934-33302564 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Host-virus interaction, Transcription, Transcription regulation" "Activator, Developmental protein, DNA-binding" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "breast: 52.3;liver: 44.3" "Cell type enhanced" "Detected in many" 10 "Hepatocytes: 84.7;Hofbauer cells: 76.1;Suprabasal keratinocytes: 150.2;Syncytiotrophoblasts: 177.5" "Cancer enhanced" "Detected in all" "liver cancer: 70.6" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "basophil: 11.0;non-classical monocyte: 11.8" "Group enriched" "Detected in many" 13 "dendritic cells: 4.1;granulocytes: 11.0;monocytes: 11.8" "Cell line enhanced" "Detected in some" "BEWO: 43.5;Hep G2: 23.3;NB-4: 24.0;THP-1: 86.8;U-937: 27.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "HPA052734, HPA065037, HPA067937" Approved Approved Nucleoplasm,Vesicles NA NA Nucleoplasm Vesicles "HPA052734: AB_2681931, HPA065037: AB_2685410, HPA067937: AB_2685927" "unprognostic (1.80e-1)" "unprognostic (7.62e-3)" "unprognostic (2.09e-3)" "unprognostic (2.21e-2)" "unprognostic (3.38e-1)" "unprognostic (3.99e-2)" "unprognostic (1.94e-1)" "unprognostic (2.43e-3)" "unprognostic (5.95e-2)" "unprognostic (3.96e-2)" "unprognostic (3.09e-1)" "unprognostic (9.45e-2)" "unprognostic (8.02e-3)" "unprognostic (2.19e-1)" "unprognostic (1.98e-1)" "unprognostic (2.49e-2)" "unprognostic (2.72e-2)" 40.7 1.5 2.3 7.6 4.6 8.4 52.3 2.1 4.0 3.5 9.0 5.2 1.1 9.0 2.2 2.1 6.1 2.4 6.4 6.6 3.9 2.4 2.0 44.3 39.9 10.3 4.1 3.1 1.3 9.0 4.5 1.7 17.4 2.7 3.8 5.1 1.9 5.6 1.6 15.4 23.7 12.7 2.9 6.6 3.0 3.5 1.2 2.6 2.2 2.5 10.7 3.5 5.4 7.9 0.1 4.1 11.0 11.8 0.0 0.6 1.5 0.5 1.1 0.0 1.5 12.5 0.0 43.5 0.0 0.3 0.0 0.0 5.3 0.0 0.0 0.6 0.0 0.2 2.0 1.2 0.1 0.0 7.5 1.5 0.0 0.0 23.3 0.2 7.6 9.3 0.5 5.6 0.0 0.0 0.0 0.0 0.6 0.5 0.0 0.0 2.6 0.0 24.0 1.1 13.1 0.6 0.0 0.0 0.2 0.0 3.8 0.0 0.3 0.1 0.1 0.1 1.4 3.0 86.8 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.0 27.8 0.0 11.0 6.0 0.0 0.6 9.4 0.6 0.0 0.1 0.4 4.1 0.1 0.2 0.4 2.1 0.0 11.8 0.2 0.0 1.5 2.3 4.6 2.1 4.0 3.9 2.4 4.1 3.1 2.7 2.6 14.9 27.8 1.4 20.5 33.2 0.7 0.4 25.5 6.7 5.7 0.0 0.0 27.5 3.3 0.6 0.0 0.6 62.2 0.0 5.0 35.2 6.1 11.7 1.1 84.7 76.1 0.0 4.1 1.3 21.4 0.0 2.8 23.2 5.0 1.0 22.1 8.0 2.1 31.3 1.4 3.7 0.3 0.0 4.1 0.2 0.7 150.2 177.5 1.0 26.9 9.5 CHD4 "Mi-2b, Mi2-BETA" ENSG00000111642 "Chromodomain helicase DNA binding protein 4" Q14839 12 6570082-6614524 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Transcription, Transcription regulation" "Chromatin regulator, DNA-binding, Helicase, Hydrolase" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA012008 Supported Enhanced Nucleoplasm NA NA Nucleoplasm "HPA012008: AB_1846633" "unprognostic (6.11e-2)" "unprognostic (2.26e-2)" "unprognostic (1.71e-2)" "unprognostic (6.40e-3)" "unprognostic (8.99e-2)" "unprognostic (3.36e-3)" "prognostic unfavorable (6.03e-6)" "unprognostic (2.66e-2)" "unprognostic (1.05e-1)" "unprognostic (6.85e-2)" "unprognostic (3.15e-1)" "unprognostic (3.94e-1)" "unprognostic (2.06e-1)" "unprognostic (3.33e-1)" "unprognostic (1.82e-1)" "unprognostic (9.84e-2)" "unprognostic (1.66e-1)" 23.5 34.9 21.9 50.0 33.5 27.2 25.9 29.4 25.1 28.1 29.5 29.3 38.5 18.6 37.2 35.4 29.1 28.0 40.3 52.8 23.5 19.2 29.5 25.0 25.5 30.9 33.6 19.4 34.6 27.4 58.4 25.3 29.5 27.2 21.5 26.0 26.5 24.8 46.2 33.7 31.1 24.4 36.6 30.3 29.4 27.2 29.7 28.9 75.7 38.4 33.7 38.4 34.7 24.3 12.6 16.8 12.8 9.1 13.5 16.7 5.8 20.4 18.7 46.4 17.4 19.0 21.4 27.3 22.7 22.2 25.1 23.2 31.2 15.9 44.1 9.0 25.7 16.4 18.3 43.5 25.0 33.9 33.0 22.4 61.6 29.1 19.4 16.5 48.3 29.6 20.7 12.4 24.3 17.0 31.7 29.3 24.7 48.4 22.0 23.8 25.6 45.8 15.8 44.4 19.0 17.7 39.3 28.5 24.1 15.9 24.2 22.0 28.3 29.2 32.6 22.6 53.2 14.9 27.5 27.2 25.7 54.7 18.8 26.5 35.7 21.2 56.3 17.0 29.5 18.7 9.0 7.7 9.2 12.2 9.1 12.0 10.5 10.3 11.1 7.9 12.6 13.0 12.3 12.8 13.5 8.1 16.8 16.7 5.8 21.9 33.5 29.4 25.1 23.5 19.2 33.6 19.4 27.2 28.9 56.6 102.0 59.1 45.6 60.9 103.2 110.8 66.2 96.4 79.6 83.7 66.8 38.6 11.6 71.4 71.8 70.5 43.4 23.3 62.1 41.7 66.9 40.2 81.1 60.6 61.2 131.9 93.2 49.7 44.2 45.3 60.9 57.6 45.5 56.9 59.2 71.6 76.6 24.6 70.0 30.3 60.2 51.8 73.5 97.0 107.1 59.1 56.9 61.8 61.8 37.3 CIC KIAA0306 ENSG00000079432 "Capicua transcriptional repressor" Q96RK0 19 42268537-42295797 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Repressor" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB026388, HPA044341, HPA064725" Approved Supported Nucleoplasm,Vesicles NA NA Nucleoplasm Vesicles "CAB026388: , HPA044341: AB_2678901, HPA064725: AB_2685335" "unprognostic (2.02e-2)" "unprognostic (4.08e-1)" "unprognostic (1.41e-2)" "unprognostic (3.54e-3)" "unprognostic (3.67e-1)" "unprognostic (4.17e-3)" "unprognostic (1.49e-1)" "unprognostic (2.06e-1)" "unprognostic (4.87e-1)" "unprognostic (1.85e-2)" "unprognostic (1.72e-3)" "unprognostic (3.10e-1)" "unprognostic (4.23e-2)" "unprognostic (1.00e-1)" "unprognostic (2.38e-1)" "unprognostic (1.88e-2)" "unprognostic (1.56e-1)" 18.6 15.7 30.5 22.8 29.9 28.1 20.3 46.8 31.6 17.5 14.7 24.7 13.0 16.5 28.6 12.3 12.3 22.1 17.4 12.1 25.5 15.2 14.9 15.1 15.8 21.5 25.2 20.1 31.5 22.6 16.6 22.6 13.2 20.4 14.4 6.2 19.0 23.8 20.8 21.0 34.1 16.1 16.3 16.5 24.7 14.5 31.5 25.6 13.6 16.8 10.6 13.4 13.6 17.4 2.3 2.0 5.0 2.6 0.6 2.5 1.6 17.7 32.1 12.4 17.0 8.0 15.2 6.1 13.6 11.3 11.5 10.6 9.1 11.0 12.3 12.9 10.7 9.5 8.7 6.9 20.5 3.7 29.9 9.3 10.4 20.3 10.8 10.1 5.8 29.5 18.0 12.1 13.0 7.6 12.1 10.5 7.8 10.1 26.0 6.4 16.9 11.5 11.2 7.7 5.7 18.3 9.9 10.5 7.4 9.6 16.7 16.0 13.1 12.8 8.1 10.1 4.1 9.5 12.5 20.0 27.5 22.3 9.4 16.5 21.6 14.8 8.4 21.3 9.2 16.2 3.4 1.8 1.0 2.5 2.6 1.9 1.7 1.3 1.6 1.7 2.3 0.9 1.5 5.0 0.6 1.9 2.0 0.5 1.6 30.5 29.9 46.8 31.6 25.5 15.2 25.2 20.1 20.4 25.6 0.0 4.0 8.0 14.4 23.0 32.4 5.6 22.9 2.7 1.2 8.7 19.6 5.9 3.3 11.2 3.5 17.5 10.7 0.0 13.1 4.3 11.3 8.6 11.5 17.4 10.3 39.7 14.3 12.3 18.4 2.5 20.1 10.7 23.6 10.8 9.4 17.4 13.4 10.5 17.0 5.0 18.3 25.8 13.7 10.2 22.9 16.9 10.9 11.7 8.4 9.8 CNOT3 "KIAA0691, LENG2, NOT3, NOT3H" ENSG00000088038 "CCR4-NOT transcription complex subunit 3" O75175 19 54137717-54155708 "Cancer-related genes, Predicted intracellular proteins" "RNA-mediated gene silencing, Transcription, Transcription regulation, Translation regulation" "Developmental protein, Repressor" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "HEK 293: 72.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA006408 Approved Approved Cytosol NA NA Cytosol "HPA006408: AB_1078543" "unprognostic (1.23e-1)" "unprognostic (2.54e-1)" "unprognostic (1.75e-2)" "unprognostic (1.40e-1)" "unprognostic (4.86e-2)" "unprognostic (1.90e-1)" "prognostic unfavorable (2.22e-4)" "unprognostic (9.06e-2)" "unprognostic (1.43e-2)" "unprognostic (2.65e-2)" "unprognostic (9.30e-3)" "unprognostic (4.08e-3)" "prognostic unfavorable (2.77e-4)" "unprognostic (2.18e-1)" "unprognostic (1.73e-1)" "unprognostic (2.11e-1)" "unprognostic (2.66e-2)" 18.1 25.2 25.5 23.6 26.4 21.4 20.2 46.8 27.9 22.1 20.7 24.5 27.7 21.3 25.0 26.5 22.1 23.6 19.7 16.2 21.9 15.6 21.3 20.2 17.9 23.9 25.5 20.8 28.0 22.7 27.6 30.2 24.2 20.3 23.3 17.5 20.7 22.4 31.4 20.2 25.2 21.4 22.0 16.7 26.3 21.9 34.4 26.9 33.6 26.3 14.3 23.3 23.8 29.9 3.2 6.7 8.4 3.1 1.6 3.6 2.9 13.8 22.3 23.2 13.3 8.6 8.8 16.2 13.0 22.5 17.4 15.6 14.3 12.0 17.1 8.3 15.0 14.3 14.6 25.7 12.6 18.1 17.6 72.5 26.5 14.5 12.7 15.0 15.1 18.6 11.0 12.2 15.5 26.3 12.6 13.8 13.0 19.5 16.0 12.8 17.1 18.7 8.9 14.1 28.5 17.9 18.7 17.8 11.1 11.7 28.1 15.0 12.6 25.1 18.1 8.2 18.0 10.3 16.2 12.3 14.8 17.1 7.9 17.6 15.1 16.4 23.6 12.9 11.6 15.6 1.4 3.1 5.2 3.6 2.2 2.5 2.9 2.4 3.2 2.8 3.2 2.7 2.6 8.4 1.6 2.6 6.7 2.5 2.9 25.5 26.4 46.8 27.9 21.9 15.6 25.5 20.8 20.3 26.9 11.9 9.0 17.1 14.7 8.9 17.3 1.7 12.7 12.0 11.4 7.0 15.7 23.7 8.3 12.8 7.4 10.5 14.4 0.0 12.6 22.9 13.5 16.1 3.5 7.6 14.1 15.9 13.8 12.9 7.9 5.4 15.8 7.2 5.0 16.2 15.2 11.3 13.1 20.1 8.9 8.1 17.8 6.5 11.2 44.2 39.9 8.7 41.9 12.5 11.9 14.8 COL2A1 "AOM, SEDC, STL1" ENSG00000139219 "Collagen type II alpha 1 chain" P02458 12 47972965-48004554 "Cancer-related genes, Disease related genes, Predicted secreted proteins" "Cancer-related genes, Cataract, Deafness, Disease mutation, Dwarfism, Stickler syndrome" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 5 "epididymis: 22.7;pituitary gland: 11.0;retina: 8.1;stomach 1: 11.3" "Cell type enhanced" "Detected in some" 24 "Early spermatids: 12.7;Intestinal endocrine cells: 42.2;Muller glia cells: 19.5" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in some" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "AF22: 55.2;HAP1: 34.6;HEK 293: 12.8" "Not detected" "Not detected" "Not detected" "Not detected" "CAB002214, HPA055753" Approved Approved Nucleoplasm "Secreted to extracellular matrix" No NA Nucleoplasm "CAB002214: AB_563666, HPA055753: AB_2682908" "unprognostic (7.25e-2)" "unprognostic (1.20e-1)" "unprognostic (2.58e-1)" "unprognostic (3.44e-1)" "unprognostic (2.88e-2)" "unprognostic (3.08e-2)" "unprognostic (8.63e-2)" "unprognostic (2.77e-1)" "unprognostic (1.22e-1)" "unprognostic (3.12e-2)" "unprognostic (1.31e-4)" "unprognostic (2.64e-1)" "unprognostic (3.44e-3)" "unprognostic (1.89e-1)" "unprognostic (2.93e-1)" "unprognostic (2.07e-1)" "unprognostic (1.02e-1)" 0.0 0.0 0.1 2.2 0.3 0.0 0.7 0.9 0.9 0.0 0.2 0.3 0.0 0.0 0.3 22.7 0.0 0.0 0.0 0.0 0.5 1.3 0.0 0.0 1.4 0.0 0.0 0.7 1.3 0.0 0.0 11.0 0.4 1.9 2.6 0.4 8.1 0.0 0.0 0.0 0.0 0.2 0.0 0.6 0.0 11.3 2.8 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 55.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.2 0.0 0.0 0.0 34.6 0.0 0.0 0.0 12.8 0.0 0.0 1.9 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.7 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 4.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.9 0.9 0.5 1.3 0.0 0.7 1.9 0.0 0.0 0.0 0.0 0.2 0.1 0.6 0.8 0.0 0.0 0.0 0.0 0.0 1.5 0.0 0.0 12.7 0.0 0.0 0.0 0.0 0.2 0.4 0.1 0.0 0.0 0.2 0.0 42.2 0.0 0.0 7.1 0.9 0.0 0.0 0.0 0.3 19.5 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.5 0.7 0.0 0.7 0.0 0.9 0.1 CREBBP "CBP, KAT3A, RSTS, RTS" ENSG00000005339 "CREB binding protein" Q92793 16 3725054-3880726 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Biological rhythms, Host-virus interaction, Transcription, Transcription regulation" "Activator, Acyltransferase, Transferase" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004212, HPA055861" Supported Enhanced "Nucleoplasm,Nuclear bodies" No No Nucleoplasm "Nuclear bodies" "CAB004212: AB_626817, HPA055861: AB_2682948" "unprognostic (1.17e-1)" "unprognostic (8.51e-2)" "unprognostic (1.60e-1)" "unprognostic (1.63e-1)" "unprognostic (1.49e-1)" "unprognostic (5.09e-2)" "unprognostic (9.59e-3)" "unprognostic (6.98e-2)" "unprognostic (8.96e-2)" "unprognostic (1.08e-1)" "unprognostic (1.76e-1)" "unprognostic (2.84e-1)" "prognostic favorable (6.24e-5)" "unprognostic (1.47e-1)" "unprognostic (1.74e-1)" "unprognostic (3.97e-2)" "unprognostic (8.23e-2)" 18.5 10.9 17.2 22.8 17.5 37.0 17.4 42.6 18.8 20.1 17.2 16.8 17.1 9.9 25.1 15.2 14.1 18.9 21.3 14.5 17.1 8.7 11.1 12.3 16.9 14.4 20.5 12.0 31.6 23.4 24.3 13.0 13.3 15.8 18.4 11.6 14.6 14.9 16.7 28.2 20.4 16.4 17.0 13.6 17.4 14.7 29.1 20.2 29.6 19.5 13.8 16.1 19.0 29.9 4.7 2.3 10.6 3.8 2.0 2.7 1.1 5.6 14.5 18.8 8.3 11.5 11.4 9.8 8.1 13.7 14.0 13.7 13.1 10.6 15.6 9.7 15.5 9.0 10.9 21.6 6.7 16.0 26.3 8.7 12.2 13.4 8.3 12.8 12.2 17.6 10.1 6.8 15.6 18.9 8.7 10.5 8.0 13.9 21.4 7.6 19.3 8.1 5.9 15.4 5.4 6.0 38.3 14.9 11.9 5.4 7.6 15.7 10.3 13.9 13.7 8.2 12.7 12.2 12.0 16.3 17.2 17.2 8.8 7.4 10.0 10.8 30.3 3.5 7.3 12.1 2.9 1.7 1.3 2.7 2.2 1.4 4.7 1.3 2.0 1.0 3.3 1.4 1.7 10.6 2.0 3.8 2.3 1.3 1.1 17.2 17.5 42.6 18.8 17.1 8.7 20.5 12.0 15.8 20.2 41.7 45.9 13.8 25.5 49.9 31.9 37.0 43.3 32.1 33.0 10.4 23.6 14.6 5.0 17.4 38.0 35.3 24.0 0.0 17.7 9.4 24.3 32.2 30.0 25.1 17.8 27.0 14.5 32.5 38.7 57.1 52.3 33.5 16.9 27.9 22.4 31.4 22.7 17.3 48.1 10.7 15.8 45.3 36.0 33.1 46.0 51.4 25.7 35.9 23.8 31.6 CRLF2 "CRL2, TSLPR" ENSG00000205755 "Cytokine receptor like factor 2" Q9HC73 X 1187549-1212750 "Cancer-related genes, Predicted membrane proteins" Receptor "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "endometrium 1: 7.8" "Cell type enriched" "Detected in some" 9 "monocytes: 174.9" "Cancer enhanced" "Detected in single" "thyroid cancer: 1.0" "Not detected" "Not detected" "Cell type enriched" "Detected in single" 43 "plasmacytoid DC: 4.3" "Lineage enriched" "Detected in single" 43 "dendritic cells: 4.3" "Cell line enhanced" "Detected in some" "GAMG: 2.4;HMC-1: 18.5;RPMI-8226: 4.7;U-698: 4.0" "Intracellular and membrane" NA NA "unprognostic (7.84e-2)" "unprognostic (7.99e-4)" "unprognostic (6.02e-3)" "unprognostic (2.01e-2)" "unprognostic (1.15e-3)" "unprognostic (2.31e-6)" "unprognostic (1.72e-1)" "unprognostic (5.10e-2)" "unprognostic (4.59e-3)" "unprognostic (1.09e-1)" "unprognostic (1.46e-2)" "unprognostic (9.72e-3)" "unprognostic (6.88e-5)" "unprognostic (7.09e-3)" "unprognostic (4.81e-2)" "unprognostic (2.89e-2)" "unprognostic (1.62e-1)" 0.8 0.0 0.2 4.1 0.2 4.1 0.6 0.2 0.2 3.0 0.7 0.2 0.2 0.2 7.8 0.2 0.9 0.2 3.7 0.2 0.2 0.1 0.9 0.2 1.9 0.2 0.2 0.2 0.2 0.2 0.0 0.2 1.0 0.2 0.6 0.9 0.2 0.8 0.2 0.2 0.7 1.5 0.3 0.2 0.6 1.0 0.2 0.2 0.2 0.2 0.2 1.4 1.3 0.6 0.0 4.3 0.0 0.0 0.0 0.0 0.0 0.2 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.3 0.5 0.0 0.6 1.0 0.2 0.3 2.4 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.1 0.0 0.0 0.0 18.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.2 0.0 0.0 0.5 4.7 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.4 0.0 0.0 0.2 0.0 0.0 0.7 1.0 4.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.3 0.0 0.0 0.2 0.2 0.2 0.2 0.2 0.1 0.2 0.2 0.2 0.2 3.0 3.4 0.0 0.0 0.0 0.0 0.3 0.0 0.0 2.3 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 19.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 174.9 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 CSF3R "CD114, GCSFR" ENSG00000119535 "Colony stimulating factor 3 receptor" Q99062 1 36466043-36483278 "Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" Receptor "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "blood: 167.3;bone marrow: 88.9;lymphoid tissue: 71.4;placenta: 152.7" "Cell type enhanced" "Detected in many" 27 "Alveolar cells type 2: 228.0;Cytotrophoblasts: 271.6;Syncytiotrophoblasts: 999.2" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in some" 8 "neutrophil: 167.3" "Lineage enriched" "Detected in many" 8 "granulocytes: 167.3" "Group enriched" "Detected in some" 18 "BEWO: 34.9;NB-4: 9.4;THP-1: 22.9;U-937: 22.1" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "CAB017116, HPA048086" Enhanced "Intracellular and membrane" NA NA "CAB017116: , HPA048086: AB_2680257" "unprognostic (5.57e-3)" "unprognostic (8.05e-2)" "unprognostic (7.23e-2)" "unprognostic (3.87e-2)" "unprognostic (2.88e-1)" "unprognostic (2.92e-2)" "unprognostic (2.86e-2)" "unprognostic (1.35e-1)" "unprognostic (1.83e-1)" "unprognostic (5.65e-2)" "unprognostic (2.47e-1)" "unprognostic (3.44e-1)" "prognostic unfavorable (5.72e-4)" "unprognostic (6.33e-2)" "prognostic unfavorable (3.79e-4)" "unprognostic (2.03e-1)" "unprognostic (2.31e-2)" 8.5 1.5 2.9 39.5 3.2 88.9 2.4 0.7 2.9 1.1 1.1 4.2 0.4 0.6 0.7 1.1 1.2 6.9 4.3 5.6 2.6 2.0 1.7 4.5 26.9 27.5 7.2 1.1 1.1 1.3 0.3 1.1 152.7 3.8 1.3 0.5 2.1 1.6 0.5 0.6 0.3 1.6 3.1 7.1 71.4 2.2 1.4 3.3 1.1 1.0 0.4 0.9 4.6 3.9 0.0 8.2 167.3 22.1 0.2 0.0 10.3 0.0 0.0 0.0 0.0 0.0 0.0 34.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.9 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 9.4 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.7 0.0 22.9 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 22.1 0.0 0.0 22.1 0.6 0.0 4.8 0.0 0.0 0.0 0.0 8.2 0.0 0.0 0.0 167.3 0.2 1.8 0.2 0.0 10.3 2.9 3.2 0.7 2.9 2.6 2.0 7.2 1.1 3.8 3.3 23.8 228.0 2.4 0.6 0.9 0.0 1.4 0.0 12.0 18.2 0.0 0.0 271.6 0.0 0.0 0.4 1.9 0.0 0.0 0.0 49.1 3.0 0.2 17.4 0.8 60.8 0.0 0.0 3.7 146.3 0.4 0.3 62.6 0.0 3.6 0.0 0.2 0.1 0.0 0.0 0.4 0.2 0.0 0.3 0.0 0.2 0.1 999.2 0.5 0.0 2.2 CTCF ENSG00000102974 "CCCTC-binding factor" P49711 16 67562407-67639185 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Chromosome partition, Transcription, Transcription regulation" "Activator, Chromatin regulator, DNA-binding, Repressor" "Cancer-related genes, Disease mutation, Mental retardation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA004122, CAB062550, CAB068181, CAB068182" Supported Supported Nucleoplasm NA NA Nucleoplasm "CAB062550: AB_2665624, CAB068181: AB_2665625, CAB068182: AB_2665626, HPA004122: AB_2667139" "unprognostic (2.70e-1)" "unprognostic (4.21e-2)" "unprognostic (3.41e-2)" "unprognostic (4.70e-2)" "unprognostic (4.41e-2)" "unprognostic (2.70e-1)" "prognostic unfavorable (4.21e-4)" "unprognostic (1.71e-2)" "unprognostic (1.29e-1)" "unprognostic (1.14e-1)" "unprognostic (1.36e-2)" "unprognostic (1.99e-2)" "prognostic favorable (4.06e-4)" "unprognostic (3.47e-1)" "unprognostic (5.99e-2)" "unprognostic (4.58e-2)" "unprognostic (1.11e-2)" 19.1 17.5 22.3 35.0 24.3 32.2 20.2 31.6 26.6 23.0 19.4 20.5 21.0 16.5 24.2 15.4 23.1 21.7 20.3 17.6 21.8 16.7 19.5 19.5 17.2 27.9 22.3 21.0 24.6 21.2 42.4 21.8 23.5 17.9 19.4 23.2 14.3 19.9 24.9 29.4 25.2 21.4 22.0 20.2 26.1 18.5 14.8 22.9 68.8 20.7 16.2 35.5 22.6 26.7 10.1 7.9 9.6 6.2 4.9 7.2 1.9 11.0 17.1 22.8 9.0 10.4 8.9 18.5 10.6 11.3 15.7 15.0 14.0 11.5 34.7 8.6 9.2 8.9 14.4 21.9 11.9 17.7 12.3 14.4 21.1 9.7 16.0 7.1 23.8 20.2 7.2 14.5 11.7 13.1 9.4 11.9 27.9 18.4 14.5 13.0 21.7 50.0 9.1 19.8 12.7 11.5 36.6 18.7 19.1 9.6 16.1 19.5 13.5 19.2 11.2 9.3 12.5 13.8 14.8 11.3 13.6 14.1 10.3 11.6 12.7 15.9 50.6 7.8 14.3 14.5 9.4 3.4 4.9 6.7 3.4 6.3 7.9 7.2 5.4 3.1 10.1 5.9 6.7 9.6 4.9 6.2 7.9 5.4 1.9 22.3 24.3 31.6 26.6 21.8 16.7 22.3 21.0 17.9 22.9 20.8 28.0 26.8 21.6 19.8 33.6 32.3 38.2 17.4 38.7 22.7 7.9 20.9 16.6 25.5 0.9 30.1 18.7 46.7 29.1 27.5 18.8 26.1 18.5 21.3 20.8 42.9 30.0 20.3 23.2 2.0 23.0 23.7 11.8 24.4 25.6 30.4 26.6 14.0 26.9 19.5 27.1 19.4 21.7 15.8 25.6 21.7 24.7 32.3 21.2 29.4 CTNNB1 "armadillo, beta-catenin, CTNNB" ENSG00000168036 "Catenin beta 1" P35222 3 41194741-41260096 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cell adhesion, Host-virus interaction, Neurogenesis, Transcription, Transcription regulation, Wnt signaling pathway" Activator "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" 4 "Syncytiotrophoblasts: 451.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000108, CAB001950, HPA029159, HPA029160" Supported Enhanced "Plasma membrane" NA NA 1000000 "Plasma membrane" "CAB000108: , CAB001950: , HPA029159: AB_10599619, HPA029160: AB_10600996" "unprognostic (2.47e-1)" "unprognostic (3.48e-2)" "prognostic favorable (7.54e-4)" "unprognostic (1.61e-1)" "unprognostic (9.55e-2)" "unprognostic (1.05e-2)" "unprognostic (3.20e-3)" "unprognostic (2.79e-1)" "unprognostic (1.57e-1)" "unprognostic (1.80e-2)" "unprognostic (1.88e-2)" "unprognostic (9.05e-2)" "unprognostic (1.97e-3)" "unprognostic (1.82e-2)" "unprognostic (1.17e-1)" "unprognostic (2.61e-1)" "unprognostic (9.79e-2)" 52.9 54.5 38.8 33.5 45.9 46.3 70.5 78.8 59.3 71.7 49.6 57.3 34.2 48.7 79.2 42.5 46.3 49.8 45.0 42.1 38.6 41.5 46.9 53.2 53.6 31.6 37.0 47.0 84.2 38.6 59.2 44.0 82.6 41.5 50.8 50.1 75.9 53.9 49.7 31.2 44.7 70.4 66.5 39.4 41.0 37.3 29.0 39.3 40.1 62.3 44.5 36.6 46.9 54.2 10.1 13.5 7.5 14.5 11.1 13.5 4.8 22.5 30.0 63.3 35.4 34.1 28.0 48.6 25.4 36.1 42.5 42.3 20.7 32.2 18.5 23.2 44.9 19.1 16.9 45.8 73.4 45.6 17.1 31.2 29.8 39.9 73.8 25.5 16.9 14.4 40.8 33.3 50.8 30.9 34.8 37.3 8.9 21.1 11.5 47.1 22.8 11.8 9.1 57.6 30.1 23.3 8.9 41.2 12.3 26.3 70.4 15.1 25.6 42.1 21.5 113.0 78.5 35.2 35.2 48.1 32.0 24.5 20.5 37.2 7.2 11.1 19.7 32.8 21.3 53.4 4.3 8.1 6.9 11.2 14.5 13.5 9.6 10.5 12.1 13.5 10.1 10.7 10.8 7.5 11.1 13.7 11.7 12.6 4.8 38.8 45.9 78.8 59.3 38.6 41.5 37.0 47.0 41.5 39.3 128.1 177.9 34.4 112.8 189.7 38.8 66.6 99.3 119.1 161.5 59.3 31.4 274.7 29.9 114.0 5.5 164.1 147.7 46.7 68.4 90.6 121.0 101.1 113.2 146.9 108.7 12.7 90.0 114.2 130.0 5.0 55.3 139.8 192.3 115.4 132.0 103.7 102.3 182.4 81.7 57.4 56.6 45.3 106.2 71.5 40.7 152.9 451.2 62.8 118.4 109.3 CUX1 "CASP, CDP, CDP/Cut, CDP/Cux, CDP1, Clox, CUT, CUTL1, CUX, Cux/CDP, GOLIM6" ENSG00000257923 "Cut like homeobox 1" "P39880, Q13948" 7 101815904-102283958 "Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors" "Transcription, Transcription regulation, Transport" "Developmental protein, DNA-binding, Repressor" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "non-classical monocyte: 21.0" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003277, HPA003317" Approved Supported "Nucleoplasm,Golgi apparatus" NA NA "Nucleoplasm, Golgi apparatus" "HPA003277: AB_10601804, HPA003317: AB_2666891" "unprognostic (5.86e-2)" "unprognostic (5.39e-3)" "unprognostic (9.62e-3)" "unprognostic (1.73e-1)" "prognostic unfavorable (7.51e-4)" "unprognostic (5.85e-2)" "unprognostic (1.54e-1)" "unprognostic (1.04e-1)" "unprognostic (1.50e-1)" "unprognostic (2.89e-3)" "unprognostic (2.20e-1)" "unprognostic (2.50e-1)" "prognostic favorable (5.72e-7)" "unprognostic (1.12e-1)" "unprognostic (8.85e-2)" "unprognostic (1.97e-2)" "unprognostic (2.97e-1)" 19.3 12.7 22.9 19.2 24.4 19.5 12.3 48.6 29.9 31.6 26.4 23.1 17.3 22.2 52.1 17.4 23.9 24.5 23.2 53.8 18.8 18.3 27.4 16.0 22.0 11.8 20.4 11.7 33.0 41.4 34.4 30.2 24.4 16.9 22.8 17.2 26.8 26.3 16.9 31.0 15.9 25.3 27.5 31.6 15.0 23.4 8.3 17.1 44.0 33.5 23.2 24.1 31.8 21.9 2.0 12.1 4.7 21.0 3.0 2.2 4.5 14.5 15.6 11.0 13.7 9.0 18.6 6.9 14.7 15.6 6.2 4.1 9.3 9.4 18.9 23.6 14.5 11.5 12.0 7.0 11.8 3.7 9.0 7.8 6.6 11.6 7.7 23.9 8.5 3.6 12.9 24.1 4.8 10.9 17.9 8.0 12.2 15.3 16.0 5.8 30.0 27.8 10.5 4.5 22.5 16.4 18.4 9.2 22.3 10.2 16.7 10.2 30.3 12.8 32.2 12.5 9.6 6.3 10.3 11.9 26.3 17.8 19.8 8.3 10.5 4.9 40.8 24.3 7.9 18.3 2.1 8.6 1.5 2.1 8.8 2.2 2.0 1.6 2.2 7.0 1.7 1.6 2.2 4.7 3.0 21.0 12.1 1.5 4.5 22.9 24.4 48.6 29.9 18.8 18.3 20.4 11.7 16.9 17.1 92.3 45.5 28.3 27.6 23.4 53.5 101.2 28.1 46.8 45.5 38.4 64.8 44.1 8.3 29.7 7.2 31.1 49.5 0.0 20.8 48.4 40.9 44.0 11.5 30.9 29.9 50.9 40.8 32.5 70.3 7.4 38.3 36.4 16.9 25.2 44.2 49.6 28.5 54.3 57.3 53.1 57.1 25.8 24.5 12.0 13.8 37.9 73.6 20.8 37.2 42.8 CXCR4 "CD184, D2S201E, fusin, HM89, HSY3RR, LESTR, NPY3R, NPYR, NPYY3R" ENSG00000121966 "C-X-C motif chemokine receptor 4" P61073 2 136114349-136118165 "Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" "Host-virus interaction" "G-protein coupled receptor, Host cell receptor for virus entry, Receptor, Transducer" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 149.9;lymphoid tissue: 186.3" "Cell type enhanced" "Detected in many" 14 "B-cells: 772.9;Macrophages: 299.5;monocytes: 255.1;T-cells: 588.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "Daudi: 76.4;JURKAT: 43.5;Karpas-707: 41.0;MOLT-4: 69.2;REH: 36.7;U-266/70: 88.9;U-698: 89.4" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" NA NA "unprognostic (1.19e-1)" "unprognostic (1.46e-2)" "unprognostic (2.69e-1)" "unprognostic (5.97e-2)" "unprognostic (1.29e-2)" "unprognostic (1.12e-2)" "unprognostic (4.99e-2)" "unprognostic (9.25e-2)" "unprognostic (6.06e-2)" "prognostic favorable (2.05e-4)" "unprognostic (1.23e-1)" "unprognostic (2.66e-1)" "prognostic unfavorable (1.41e-7)" "prognostic unfavorable (5.67e-4)" "unprognostic (1.57e-1)" "unprognostic (3.47e-2)" "unprognostic (9.33e-2)" 15.4 26.5 3.0 39.1 3.4 149.9 9.7 0.8 2.1 7.7 8.7 6.8 1.5 1.6 8.3 3.8 16.4 9.1 12.0 5.4 4.1 4.7 8.2 7.1 29.3 94.5 6.5 1.3 6.3 3.1 0.7 8.1 7.8 6.1 6.8 7.0 10.0 10.6 2.2 3.2 2.3 57.8 3.8 22.9 82.4 8.0 7.2 3.4 186.3 9.2 4.6 97.5 50.0 6.6 47.3 16.8 37.8 7.2 4.0 32.0 11.9 0.1 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 76.4 0.2 0.0 0.0 0.0 0.2 0.0 0.0 3.8 0.9 4.6 12.1 0.0 0.0 10.5 8.3 0.0 0.0 0.0 0.0 0.0 7.3 43.5 0.1 41.0 0.0 0.2 69.2 9.4 1.2 5.9 0.4 36.7 8.5 13.3 0.6 0.0 4.2 3.5 0.0 0.2 0.0 0.4 0.0 20.7 1.0 0.0 0.2 0.0 0.0 88.9 15.0 89.4 0.0 17.4 0.0 17.9 7.2 29.6 22.9 3.8 18.7 30.1 21.1 21.7 6.6 47.3 32.0 30.1 37.8 4.0 2.1 16.8 18.9 11.9 3.0 3.4 0.8 2.1 4.1 4.7 6.5 1.3 6.1 3.4 14.9 64.2 772.9 4.0 36.5 4.4 3.6 2.5 4.0 6.8 3.5 0.0 1.4 11.6 3.6 0.9 19.0 0.0 46.7 0.8 2.2 30.2 4.8 11.6 5.5 168.4 0.0 1.7 22.7 175.5 1.7 1.4 299.5 108.0 255.1 0.1 1.0 1.6 0.0 2.5 2.1 0.6 45.3 16.3 0.5 5.5 31.1 5.3 588.4 0.4 3.2 CYLD "CYLD1, KIAA0849, USPL2" ENSG00000083799 "CYLD lysine 63 deubiquitinase" Q9NQC7 16 50742050-50801935 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Cell cycle, Immunity, Innate immunity, Ubl conjugation pathway, Wnt signaling pathway" "Hydrolase, Protease, Thiol protease" "Cancer-related genes, Disease mutation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "HDLM-2: 47.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB011713, HPA050095" Approved Supported "Nucleoplasm,Centriolar satellite" Yes No "Centriolar satellite" Nucleoplasm "CAB011713: AB_731794, HPA050095: AB_2681013" "unprognostic (9.83e-2)" "unprognostic (1.17e-2)" "unprognostic (5.01e-2)" "unprognostic (2.83e-2)" "unprognostic (3.84e-1)" "unprognostic (5.06e-2)" "unprognostic (3.87e-2)" "unprognostic (3.24e-2)" "unprognostic (9.46e-2)" "unprognostic (1.11e-1)" "unprognostic (1.18e-2)" "unprognostic (2.32e-1)" "unprognostic (1.03e-1)" "unprognostic (1.07e-1)" "unprognostic (3.43e-2)" "unprognostic (6.83e-2)" "unprognostic (8.42e-2)" 9.3 16.2 13.9 22.9 26.4 51.1 9.1 14.2 20.9 9.2 10.3 18.8 12.8 10.2 16.1 8.1 15.3 8.5 13.3 12.7 15.7 17.0 9.4 13.2 15.6 30.7 16.3 14.3 11.5 12.2 20.3 27.8 9.8 20.0 11.0 12.7 13.3 12.6 10.9 31.7 12.4 14.2 12.5 16.3 23.4 12.4 22.6 13.7 16.9 16.2 8.0 29.3 14.1 12.6 9.2 10.2 31.4 9.8 13.6 19.1 10.2 9.3 2.9 3.4 3.8 5.4 7.8 3.1 13.8 20.2 14.4 8.5 2.4 4.4 10.7 5.0 13.5 15.7 3.6 4.0 8.4 21.5 47.2 6.1 5.3 5.2 2.0 10.7 5.3 25.3 8.5 6.8 17.4 18.2 13.7 5.8 7.6 2.2 9.4 20.1 1.4 5.2 7.7 3.6 2.9 4.9 4.7 6.9 10.3 4.7 3.2 4.4 3.3 11.7 4.0 3.4 5.4 4.0 6.7 6.5 24.7 5.6 8.6 5.6 24.8 23.5 12.0 18.1 6.0 5.2 31.4 8.6 20.8 10.7 9.8 12.9 9.2 15.8 14.4 10.2 6.2 14.7 11.4 19.4 13.6 9.5 6.2 19.1 10.2 13.9 26.4 14.2 20.9 15.7 17.0 16.3 14.3 20.0 13.7 41.7 25.6 39.6 48.8 106.7 75.4 32.7 25.5 12.0 19.4 17.4 88.4 5.4 5.0 18.3 32.8 37.9 13.4 46.7 16.5 3.8 37.2 52.3 78.5 22.1 19.0 63.5 29.9 21.5 32.3 24.7 23.6 47.1 70.9 34.3 10.3 22.6 15.2 18.7 19.8 10.3 49.3 6.5 34.4 52.6 13.8 135.9 3.4 73.4 12.0 56.3 DAXX DAP6 ENSG00000204209 "Death domain associated protein" Q9UER7 6 33318558-33323016 "Cancer-related genes, Predicted intracellular proteins" "Apoptosis, Host-virus interaction, Transcription, Transcription regulation" "Chaperone, Chromatin regulator, Repressor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002224, HPA008736, HPA008797, CAB025546, HPA065779" Enhanced Enhanced "Nucleoplasm,Nuclear bodies" NA NA "Nucleoplasm, Nuclear bodies" "CAB002224: AB_563688, CAB025546: , HPA008736: AB_1078625, HPA008797: AB_2797218, HPA065779: AB_2685558" "prognostic favorable (6.05e-4)" "unprognostic (2.90e-1)" "unprognostic (9.66e-2)" "unprognostic (4.04e-2)" "unprognostic (8.55e-2)" "unprognostic (1.36e-1)" "unprognostic (1.46e-3)" "unprognostic (3.48e-1)" "unprognostic (1.92e-1)" "unprognostic (8.58e-3)" "unprognostic (1.34e-1)" "unprognostic (2.01e-2)" "prognostic unfavorable (6.32e-7)" "unprognostic (2.43e-1)" "unprognostic (5.37e-1)" "unprognostic (1.26e-1)" "unprognostic (1.04e-1)" 10.4 14.3 10.7 13.5 11.9 8.8 10.8 11.3 14.8 11.8 12.2 9.4 7.3 11.2 13.2 43.7 13.5 12.6 12.1 9.1 9.7 7.3 9.2 12.0 10.3 18.3 10.2 8.5 13.8 18.6 24.4 10.4 11.6 11.6 13.0 14.1 7.3 10.7 15.2 14.8 11.6 12.7 15.5 8.1 20.4 10.5 20.2 11.5 25.0 16.1 6.8 30.9 11.5 10.9 17.0 5.9 12.6 11.2 15.3 18.2 21.8 2.1 0.0 7.1 2.8 1.2 2.3 4.7 7.0 22.9 17.9 13.2 0.8 2.4 6.9 2.5 5.4 20.5 1.3 0.1 5.7 16.6 8.2 15.6 9.0 12.4 11.1 3.9 9.6 2.6 6.0 8.5 2.0 5.3 5.3 0.5 4.5 5.0 4.5 5.5 5.2 3.8 21.3 0.4 0.1 3.3 5.9 0.1 7.7 1.4 0.7 8.5 2.2 0.0 0.4 3.7 3.5 2.2 0.2 5.9 4.4 5.6 0.2 0.1 7.8 16.2 14.9 3.3 4.4 4.7 7.8 7.5 12.6 16.3 8.0 18.2 16.6 15.4 15.8 5.9 17.0 13.9 14.1 7.4 15.3 11.2 5.9 17.1 21.8 10.7 11.9 11.3 14.8 9.7 7.3 10.2 8.5 11.6 11.5 6.0 21.4 27.0 17.6 52.0 17.3 7.5 15.3 14.7 25.0 12.2 17.7 21.7 19.9 29.4 9.8 20.6 18.0 0.0 33.3 29.5 26.3 21.9 35.9 13.5 21.9 14.3 20.2 11.6 13.7 4.7 16.4 20.8 23.6 60.5 19.5 17.7 46.9 21.0 21.9 11.9 73.3 12.9 23.7 48.8 34.9 53.2 20.7 51.7 20.9 30.2 DDB2 "DDBB, FLJ34321, UV-DDB2, XPE" ENSG00000134574 "Damage specific DNA binding protein 2" Q92466 11 47214465-47239240 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "DNA damage, DNA repair, Ubl conjugation pathway" DNA-binding "Cancer-related genes, Disease mutation, Xeroderma pigmentosum" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enriched" "Detected in many" 6 "monocytes: 221.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB025912, HPA058406" Enhanced Supported "Nucleoplasm,Cell Junctions" NA NA "Nucleoplasm, Cell Junctions" "CAB025912: , HPA058406: AB_2683708" "prognostic favorable (7.29e-4)" "prognostic favorable (1.58e-4)" "unprognostic (1.49e-1)" "prognostic favorable (1.20e-4)" "unprognostic (4.29e-2)" "unprognostic (2.04e-2)" "unprognostic (2.96e-2)" "unprognostic (6.18e-2)" "unprognostic (2.25e-1)" "unprognostic (3.58e-3)" "unprognostic (3.53e-1)" "unprognostic (1.94e-1)" "unprognostic (4.57e-3)" "unprognostic (1.21e-2)" "unprognostic (4.25e-2)" "unprognostic (9.82e-3)" "unprognostic (1.07e-1)" 12.2 22.2 5.3 13.3 8.6 8.1 11.3 11.0 8.2 16.8 13.5 7.3 13.4 6.0 18.2 14.1 25.4 14.3 13.0 6.1 4.7 2.9 6.6 20.8 11.3 16.1 15.0 5.0 9.8 15.6 6.1 8.6 5.5 6.3 20.9 12.3 8.1 17.6 14.8 6.3 36.9 11.0 19.0 17.6 15.1 9.1 7.6 7.6 23.3 6.6 16.7 26.0 17.3 15.2 11.4 6.1 11.5 11.0 7.4 27.0 9.0 8.4 22.7 9.5 7.1 6.1 12.4 11.2 9.2 21.7 11.9 14.0 3.7 4.9 20.3 1.9 8.4 8.9 14.8 5.4 18.8 5.9 5.0 10.2 4.7 21.7 16.8 6.0 5.5 12.7 16.6 21.4 5.9 13.2 3.8 34.6 5.3 1.2 9.9 19.4 15.9 21.1 2.6 3.0 11.1 8.2 10.6 2.4 10.9 5.0 8.3 5.0 6.2 11.3 3.3 3.0 11.9 20.8 1.8 14.9 36.4 16.6 7.9 4.3 10.4 7.9 4.5 13.7 7.0 13.0 5.9 8.1 11.5 12.1 11.0 11.7 11.4 12.7 11.7 6.1 7.4 9.4 10.1 2.2 7.4 9.2 0.1 27.0 9.0 5.3 8.6 11.0 8.2 4.7 2.9 15.0 5.0 6.3 7.6 14.9 20.3 19.2 35.4 34.6 4.6 7.2 12.7 10.7 13.6 5.2 9.8 2.1 8.3 9.6 1.1 17.8 7.9 0.0 12.0 7.7 14.1 9.5 22.0 12.4 15.9 1.6 7.5 14.1 16.5 1.6 17.5 16.5 18.6 221.8 13.6 14.2 15.3 7.0 9.9 6.2 11.6 0.0 15.5 0.7 9.9 26.5 1.3 38.8 14.0 21.3 DDR2 "NTRKR3, TKT, TYRO10" ENSG00000162733 "Discoidin domain receptor tyrosine kinase 2" Q16832 1 162631373-162787400 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" Osteogenesis "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, Dwarfism, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" 8 "Fibroblasts: 84.7;Leydig cells: 58.4;Peritubular cells: 83.1;Smooth muscle cells: 68.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "gdT-cell: 1.1;MAIT T-cell: 1.3" "Lineage enriched" "Detected in single" 5 "T-cells: 1.3" "Cell line enhanced" "Detected in many" "ASC diff: 61.7;ASC TERT1: 61.0;BJ hTERT+: 45.1;fHDF/TERT166: 32.3;HSkMC: 43.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA070112 Supported "Plasma membrane,Actin filaments" Yes No 850000 "Plasma membrane, Actin filaments" "HPA070112: AB_2686229" "unprognostic (4.12e-2)" "unprognostic (2.73e-1)" "unprognostic (6.97e-3)" "unprognostic (4.52e-2)" "unprognostic (1.17e-1)" "unprognostic (8.16e-2)" "unprognostic (1.81e-1)" "unprognostic (1.19e-1)" "unprognostic (6.62e-2)" "unprognostic (2.24e-2)" "unprognostic (1.00e-1)" "unprognostic (1.15e-1)" "prognostic unfavorable (1.73e-7)" "unprognostic (1.56e-3)" "unprognostic (8.26e-3)" "unprognostic (7.57e-2)" "unprognostic (4.10e-3)" 42.1 43.5 4.7 10.9 6.9 0.2 15.6 7.9 7.1 30.3 30.4 9.0 18.6 3.3 24.2 17.7 25.0 13.4 16.6 15.4 7.9 4.7 4.0 3.3 8.9 5.1 12.9 3.4 26.4 2.2 2.1 4.0 6.6 12.7 21.8 9.1 30.7 6.4 19.3 5.2 6.1 10.1 34.3 19.7 3.4 14.1 8.3 7.5 0.0 8.6 12.8 4.1 29.0 18.3 0.1 0.2 0.0 0.0 0.2 1.3 0.0 0.1 0.0 0.0 16.3 61.7 61.0 0.2 24.0 45.1 10.5 15.1 0.0 0.0 0.0 0.0 32.3 2.1 0.0 0.0 0.1 14.4 12.9 0.1 0.0 0.1 0.0 26.8 0.0 0.0 43.3 0.1 18.5 0.5 17.0 12.1 0.1 0.1 5.1 9.6 0.0 0.0 0.0 0.1 0.0 0.1 0.0 6.9 0.1 0.0 0.0 0.0 9.9 0.0 0.0 0.8 0.9 0.0 0.0 0.6 16.8 3.7 8.5 3.3 0.7 1.3 0.0 15.2 0.0 17.0 0.0 0.0 0.0 1.1 0.0 1.3 0.0 0.8 0.1 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.2 0.0 0.0 4.7 6.9 7.9 7.1 7.9 4.7 12.9 3.4 12.7 7.5 3.0 2.9 0.0 2.4 11.2 3.1 23.3 2.5 4.0 1.2 0.0 0.0 0.5 0.0 0.5 6.9 21.3 2.0 0.0 1.5 0.4 84.7 4.1 1.1 3.0 1.1 0.0 1.2 24.5 2.1 4.0 58.4 1.5 21.9 0.0 0.7 19.0 1.5 1.7 83.1 0.9 2.9 38.8 68.4 0.9 0.9 7.5 0.8 1.3 0.6 3.3 DDX3X "DBX, DDX14, DDX3, HLP2" ENSG00000215301 "DEAD-box helicase 3, X-linked" O00571 X 41333284-41364472 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Apoptosis, Chromosome partition, Host-virus interaction, Immunity, Innate immunity, Ribosome biogenesis, Transcription, Transcription regulation, Translation regulation" "DNA-binding, Helicase, Hydrolase, RNA-binding" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" 5 "Late spermatids: 631.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001648, HPA005631, HPA059585" Supported Supported Approved Nucleoplasm,Cytosol NA NA 110000 Cytosol Nucleoplasm "HPA001648: AB_1078635, HPA005631: AB_1078633, HPA059585: AB_2684073" "unprognostic (2.42e-2)" "unprognostic (1.11e-1)" "unprognostic (8.01e-3)" "unprognostic (1.66e-1)" "unprognostic (8.12e-2)" "unprognostic (6.43e-2)" "unprognostic (1.17e-3)" "unprognostic (1.88e-1)" "unprognostic (9.80e-2)" "unprognostic (1.40e-1)" "unprognostic (3.25e-2)" "unprognostic (2.05e-1)" "unprognostic (1.51e-1)" "unprognostic (2.95e-1)" "unprognostic (4.77e-1)" "unprognostic (9.44e-2)" "unprognostic (2.93e-2)" 80.9 49.3 26.1 40.0 34.5 49.3 46.5 31.1 36.2 52.4 43.3 35.1 21.3 29.5 56.4 25.9 53.5 56.3 42.6 47.6 30.8 24.5 55.6 77.9 45.3 40.4 41.4 29.0 60.1 30.9 68.7 60.2 79.9 37.9 30.0 29.2 30.8 37.4 26.5 63.4 42.2 54.0 57.2 53.9 46.1 43.0 27.0 39.0 49.2 45.6 44.0 42.6 55.8 50.2 13.1 20.5 32.0 21.6 17.3 21.5 17.9 45.8 51.1 47.7 26.2 56.2 47.7 29.1 33.5 47.1 34.4 27.6 52.5 30.9 0.5 23.9 37.4 41.4 31.0 58.3 47.1 57.3 27.2 45.4 29.2 50.8 31.5 29.2 54.7 52.5 34.5 33.4 57.9 56.0 38.5 53.9 25.7 53.6 28.9 31.9 34.7 34.4 17.1 45.9 24.4 20.6 40.4 50.8 37.4 32.4 61.9 32.6 49.4 75.8 38.9 40.1 50.2 35.0 37.2 48.6 35.5 37.9 37.9 39.7 33.7 40.0 45.3 35.7 33.2 33.6 22.5 20.2 17.5 14.8 21.1 21.5 13.1 14.5 16.3 20.5 9.0 16.3 15.1 32.0 17.3 21.6 6.9 14.3 17.9 26.1 34.5 31.1 36.2 30.8 24.5 41.4 29.0 37.9 39.0 80.4 161.8 98.4 138.2 234.8 74.1 130.3 81.5 65.6 85.3 55.8 123.7 79.4 36.5 59.8 317.8 170.8 178.1 116.8 73.8 80.3 155.2 122.4 162.7 142.1 107.7 57.2 176.3 120.3 200.6 631.6 61.5 160.4 121.4 72.1 136.1 88.8 86.2 143.8 59.1 71.7 117.4 71.1 155.5 15.7 55.7 291.5 144.6 132.3 100.9 182.7 DICER1 "Dicer, HERNA, K12H4.8-LIKE, KIAA0928, MNG1" ENSG00000100697 "Dicer 1, ribonuclease III" Q9UPY3 14 95086228-95158010 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "RNA-mediated gene silencing" "Endonuclease, Helicase, Hydrolase, Nuclease, RNA-binding" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA000694, CAB068185" Approved Supported Cytosol NA NA Cytosol "CAB068185: AB_2665650, HPA000694: AB_1078661" "unprognostic (2.97e-1)" "unprognostic (2.70e-2)" "unprognostic (1.21e-1)" "unprognostic (1.72e-1)" "unprognostic (6.75e-2)" "unprognostic (9.62e-2)" "unprognostic (1.96e-2)" "unprognostic (7.73e-2)" "unprognostic (1.21e-1)" "unprognostic (8.52e-3)" "unprognostic (5.73e-2)" "unprognostic (9.22e-2)" "unprognostic (4.22e-2)" "unprognostic (9.07e-2)" "unprognostic (2.58e-1)" "unprognostic (6.04e-3)" "unprognostic (3.74e-2)" 23.2 12.5 18.4 22.4 33.3 20.5 23.2 28.5 29.9 19.0 18.1 31.4 22.4 13.0 20.8 20.6 23.4 18.5 16.2 15.3 22.0 14.1 19.5 23.6 22.4 20.3 29.7 19.6 23.8 19.8 26.9 30.9 29.9 23.2 20.3 19.7 14.5 19.5 18.9 28.0 20.7 17.3 19.0 26.8 20.7 17.1 20.6 32.0 17.0 23.8 14.7 20.3 20.7 24.1 2.5 1.8 10.7 7.2 1.2 3.3 1.0 12.9 13.6 25.4 9.4 6.6 9.9 20.1 10.7 6.5 6.8 8.3 17.2 10.0 14.7 11.6 10.0 7.1 15.3 20.1 10.1 14.4 22.7 9.0 22.2 7.4 12.4 6.6 13.6 13.6 9.2 8.3 9.2 14.1 5.9 10.2 11.6 9.3 13.1 11.5 18.2 15.2 9.0 7.2 9.1 6.7 12.1 20.8 8.1 9.1 20.7 21.1 11.9 10.8 11.1 12.2 14.1 12.6 10.0 10.1 5.3 10.5 10.2 12.0 14.9 21.3 20.8 5.5 11.0 9.4 3.1 3.0 1.2 1.6 3.1 3.3 1.9 1.5 1.2 1.8 2.5 1.5 1.3 10.7 1.2 7.2 1.6 1.6 1.0 18.4 33.3 28.5 29.9 22.0 14.1 29.7 19.6 23.2 32.0 50.6 47.2 32.6 39.2 24.4 99.7 34.3 38.2 32.1 51.2 43.6 53.0 39.4 5.0 30.3 19.8 39.1 29.6 23.3 19.9 20.7 34.6 55.9 11.5 50.5 41.7 101.7 44.3 41.1 94.2 12.0 50.3 46.8 21.9 19.0 30.6 35.0 28.4 23.0 49.5 22.6 68.5 32.3 35.0 34.9 52.5 24.1 21.5 23.0 31.6 49.7 DNM2 "CMT2M, CMTDI1, CMTDIB, DI-CMTB, DYN2, DYNII" ENSG00000079805 "Dynamin 2" P50570 19 10718079-10833488 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters" "Endocytosis, Phagocytosis" "Hydrolase, Motor protein" "Cancer-related genes, Charcot-Marie-Tooth disease, Disease mutation, Neurodegeneration, Neuropathy" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA054246 Supported Approved "Golgi apparatus,Cytosol" NA NA 500000 "Golgi apparatus, Cytosol" "HPA054246: AB_2682427" "unprognostic (2.30e-1)" "unprognostic (5.23e-2)" "unprognostic (4.72e-2)" "unprognostic (1.23e-1)" "unprognostic (1.76e-1)" "prognostic favorable (8.91e-4)" "prognostic unfavorable (3.63e-4)" "unprognostic (1.03e-1)" "unprognostic (3.79e-1)" "unprognostic (1.89e-1)" "unprognostic (4.75e-2)" "unprognostic (5.35e-2)" "unprognostic (5.47e-2)" "unprognostic (5.40e-3)" "unprognostic (2.68e-1)" "unprognostic (1.61e-1)" "unprognostic (1.99e-3)" 23.8 32.6 18.5 29.3 31.2 53.4 20.4 25.7 29.7 20.1 51.4 57.5 46.0 32.1 20.4 16.8 29.9 19.7 27.0 35.0 20.8 18.0 38.5 25.1 39.2 28.2 48.3 18.0 17.9 32.2 19.5 20.0 32.3 32.2 24.0 42.5 24.5 24.7 37.7 46.6 40.6 50.8 18.6 43.1 37.6 48.2 23.3 36.4 39.1 23.5 21.1 41.5 35.7 31.5 3.4 11.1 8.6 9.8 10.1 5.8 4.6 35.0 29.0 21.3 16.9 22.0 21.5 27.3 23.5 22.3 34.8 29.6 28.9 23.2 25.5 42.3 25.3 16.6 30.8 29.0 25.5 29.2 31.2 23.0 48.9 25.9 32.3 27.1 26.8 46.4 22.1 19.7 26.6 25.1 21.2 33.8 26.3 39.3 43.9 21.4 42.5 37.3 25.6 24.2 41.6 35.2 37.9 23.1 28.7 22.9 52.9 30.7 20.1 26.8 23.0 16.8 24.8 18.4 32.0 30.6 38.3 13.0 53.7 31.0 36.4 37.1 23.5 28.6 41.1 18.9 3.0 4.5 8.6 5.6 8.2 5.1 3.4 4.2 5.8 5.3 3.1 2.4 4.1 8.5 10.1 9.8 11.1 4.8 4.6 18.5 31.2 25.7 29.7 20.8 18.0 48.3 18.0 32.2 36.4 29.8 21.1 33.5 15.2 20.6 26.5 23.8 15.3 5.3 18.2 48.8 21.6 21.9 43.1 30.7 37.5 27.5 130.4 0.0 27.6 96.1 18.2 17.4 18.5 18.7 42.3 41.3 20.7 20.3 22.9 75.8 15.5 40.5 18.6 50.5 92.3 16.0 35.8 87.7 26.2 31.5 27.7 25.8 19.8 8.0 13.3 27.6 26.5 39.9 56.9 19.7 DNMT3A ENSG00000119772 "DNA methyltransferase 3 alpha" Q9Y6K1 2 25227855-25342590 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transcription factors" "Chromatin regulator, DNA-binding, Methyltransferase, Repressor, Transferase" "Cancer-related genes, Disease mutation, Dwarfism, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 8 "Cone photoreceptor cells: 119.8;Horizontal cells: 90.6;Rod photoreceptor cells: 144.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "NTERA-2: 25.7;REH: 25.4;SH-SY5Y: 31.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009469, HPA026588" Approved Supported Nucleoplasm NA NA Nucleoplasm "CAB009469: AB_2093990, HPA026588: AB_1847812" "unprognostic (2.38e-1)" "unprognostic (2.94e-1)" "unprognostic (5.65e-2)" "prognostic unfavorable (1.55e-4)" "unprognostic (8.38e-2)" "unprognostic (7.27e-2)" "prognostic unfavorable (1.58e-4)" "unprognostic (2.24e-1)" "unprognostic (7.25e-2)" "unprognostic (2.72e-1)" "prognostic favorable (1.18e-4)" "unprognostic (2.35e-2)" "prognostic unfavorable (2.49e-4)" "unprognostic (1.43e-1)" "unprognostic (1.87e-1)" "unprognostic (1.14e-1)" "unprognostic (2.70e-2)" 7.8 12.4 13.7 12.7 15.5 10.8 8.6 21.6 20.1 9.0 12.7 14.5 7.6 9.1 13.0 12.2 8.0 9.6 8.9 8.2 12.3 6.7 9.4 6.9 9.5 13.6 15.3 10.1 18.3 12.1 6.3 12.6 20.8 10.7 9.3 9.2 12.0 8.5 9.2 29.1 6.6 11.4 11.3 7.9 17.5 11.6 6.6 15.2 20.8 9.1 10.5 11.8 9.8 8.4 3.0 4.1 4.9 4.1 8.7 8.3 2.3 1.1 3.5 14.9 3.6 1.6 1.2 19.5 1.0 0.9 2.0 1.6 8.8 5.7 0.0 2.2 1.9 1.6 1.0 1.6 2.2 1.2 3.7 2.6 6.4 5.3 10.5 3.9 1.3 4.1 3.6 1.1 2.6 0.9 3.9 8.3 14.5 7.3 1.4 1.5 8.5 13.9 15.1 25.7 5.9 1.9 25.4 16.4 2.1 1.2 1.5 8.8 31.3 1.2 8.4 2.6 13.4 1.0 6.7 2.8 2.5 3.3 0.6 1.3 3.2 2.2 8.6 0.9 3.8 2.6 4.7 1.8 3.1 5.2 3.0 7.0 2.3 3.4 4.9 2.0 3.0 8.3 6.6 4.9 8.7 4.1 4.1 2.8 2.3 13.7 15.5 21.6 20.1 12.3 6.7 15.3 10.1 10.7 15.2 6.0 13.3 10.0 8.3 4.6 74.9 13.7 5.1 9.4 12.5 19.2 119.8 30.2 5.0 13.8 1.5 14.6 5.3 0.0 8.5 9.4 14.7 11.7 36.9 5.5 19.8 90.6 12.6 6.2 10.5 1.1 17.8 11.9 6.8 4.6 11.5 22.7 9.2 10.5 14.5 5.6 144.9 19.4 8.2 2.3 13.4 2.3 26.9 18.7 11.0 6.7 DROSHA "Etohi2, HSA242976, RN3, RNASE3L, RNASEN" ENSG00000113360 "Drosha ribonuclease III" Q9NRR4 5 31400497-31532196 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Ribosome biogenesis, RNA-mediated gene silencing" "Endonuclease, Hydrolase, Nuclease, RNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA031150 Supported Nucleoplasm,Cytosol NA NA Nucleoplasm Cytosol "HPA031150: AB_2673761" "unprognostic (8.37e-3)" "unprognostic (1.81e-1)" "unprognostic (9.56e-2)" "prognostic unfavorable (6.79e-4)" "unprognostic (5.40e-2)" "unprognostic (6.03e-2)" "prognostic unfavorable (1.39e-4)" "unprognostic (3.11e-1)" "unprognostic (4.08e-2)" "unprognostic (9.08e-2)" "unprognostic (1.86e-1)" "unprognostic (5.43e-2)" "unprognostic (1.12e-1)" "unprognostic (1.74e-1)" "unprognostic (2.39e-1)" "unprognostic (6.94e-2)" "unprognostic (2.32e-2)" 15.7 16.8 18.4 17.7 32.1 12.2 16.1 33.7 33.7 17.4 16.3 19.1 12.2 15.9 22.3 25.8 16.0 18.2 14.1 15.2 16.6 15.1 15.3 11.7 13.9 17.8 13.6 16.4 26.7 17.8 23.9 38.9 17.0 18.9 17.2 19.2 23.7 17.5 19.2 23.6 16.0 17.5 16.9 19.4 16.8 16.0 12.8 16.4 25.6 21.9 13.4 19.8 18.2 16.2 4.7 6.4 3.3 4.8 4.8 6.4 3.1 12.4 15.7 17.4 23.6 9.3 11.4 25.1 16.5 8.1 15.4 11.5 16.5 16.2 14.0 19.0 12.1 17.9 10.9 21.4 12.5 17.2 13.1 15.1 17.2 51.6 11.9 8.4 19.2 51.4 8.9 8.8 17.2 8.3 11.8 13.1 15.0 21.8 6.6 13.4 12.4 18.5 14.4 16.4 10.1 12.6 16.8 33.3 10.1 8.7 14.2 9.1 12.0 41.9 17.2 10.1 16.2 15.8 11.1 11.4 14.9 17.3 13.3 15.6 12.1 19.8 15.4 10.3 21.7 14.2 1.8 2.4 3.3 5.2 2.6 5.5 4.2 5.4 6.0 5.2 4.7 6.4 4.4 0.8 4.8 4.8 6.4 5.1 3.1 18.4 32.1 33.7 33.7 16.6 15.1 13.6 16.4 18.9 16.4 11.9 14.7 3.0 4.6 3.2 18.2 21.0 7.6 20.1 15.9 5.2 0.0 6.6 3.3 7.2 2.5 6.2 7.3 0.0 7.0 6.4 7.4 5.0 9.2 5.1 6.7 6.4 10.9 9.2 7.8 4.3 10.0 3.2 1.7 9.0 10.1 10.5 7.8 8.6 12.4 4.2 16.8 6.5 4.7 5.8 8.4 3.0 4.1 5.7 10.0 5.1 EGFR "ERBB, ERBB1" ENSG00000146648 "Epidermal growth factor receptor" P00533 7 55019021-55211628 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins" "Host-virus interaction" "Developmental protein, Host cell receptor for virus entry, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "placenta: 102.3" "Cell type enhanced" "Detected in many" 8 "Cytotrophoblasts: 207.2;Syncytiotrophoblasts: 315.1" "Cancer enhanced" "Detected in all" "glioma: 136.0" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in many" 12 "A-431: 345.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "CAB000035, HPA001200, HPA018530, CAB068186, CAB073534" Enhanced Enhanced "Plasma membrane,Cell Junctions" "Secreted to blood" NA NA 4740000 93000000 "Plasma membrane, Cell Junctions" "CAB000035: , CAB068186: AB_2665679, CAB073534: , HPA001200: AB_1078723, HPA018530: AB_1848044" "unprognostic (2.62e-2)" "unprognostic (9.56e-3)" "unprognostic (1.59e-1)" "unprognostic (7.51e-2)" "unprognostic (1.08e-1)" "unprognostic (1.27e-2)" "unprognostic (6.11e-2)" "unprognostic (4.88e-2)" "unprognostic (2.85e-2)" "unprognostic (3.30e-3)" "unprognostic (1.78e-3)" "unprognostic (1.04e-1)" "unprognostic (1.93e-3)" "unprognostic (6.98e-3)" "unprognostic (1.72e-1)" "unprognostic (6.62e-2)" "prognostic unfavorable (2.04e-5)" 16.2 8.4 4.9 7.5 6.8 0.1 39.8 5.1 8.5 13.8 7.8 3.3 10.7 3.6 8.2 11.7 15.6 8.8 8.5 4.8 6.8 2.7 7.6 23.5 14.2 2.3 4.1 3.9 10.4 10.1 1.8 2.1 102.3 5.6 10.9 6.7 9.2 15.4 12.9 10.7 32.5 6.3 15.5 3.5 3.3 7.8 5.5 5.9 3.2 12.8 15.5 8.0 10.2 28.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 345.9 4.4 1.1 1.5 7.1 4.4 1.2 3.4 4.6 2.1 1.6 0.8 3.7 0.2 0.8 2.9 9.0 13.9 0.0 15.3 2.5 0.1 0.2 0.0 1.9 0.2 1.8 0.0 0.0 2.1 14.0 5.3 28.6 3.1 0.2 0.0 0.0 0.0 4.5 0.2 0.0 0.0 0.3 1.3 2.2 0.0 0.6 0.0 2.6 3.7 0.0 1.3 2.9 3.5 0.7 1.2 0.3 0.8 1.0 1.9 0.5 14.9 3.2 0.0 0.3 0.2 2.6 0.1 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.9 6.8 5.1 6.6 6.8 2.7 4.1 3.9 5.6 5.9 89.3 37.5 4.2 67.7 76.2 1.5 7.3 53.5 16.0 59.1 21.0 5.9 207.2 0.0 30.6 4.6 10.9 15.9 23.3 21.0 36.6 45.3 37.8 0.0 77.4 24.2 0.0 4.1 6.7 7.0 2.2 118.8 1.3 16.9 2.8 25.3 106.1 41.7 17.3 125.5 14.0 2.3 77.6 23.1 1.6 2.7 78.5 315.1 0.0 20.0 46.4 EP300 "KAT3B, p300" ENSG00000100393 "E1A binding protein p300" Q09472 22 41091786-41180079 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Biological rhythms, Cell cycle, Host-virus interaction, Transcription, Transcription regulation" "Acyltransferase, Transferase" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000146, HPA003128, HPA004112" Supported Enhanced Nucleoplasm NA NA Nucleoplasm "CAB000146: AB_2533138, HPA003128: AB_1078745, HPA004112: AB_1078746" "unprognostic (7.67e-2)" "unprognostic (5.56e-2)" "unprognostic (2.29e-1)" "unprognostic (2.52e-1)" "unprognostic (6.10e-3)" "unprognostic (1.66e-1)" "unprognostic (2.21e-2)" "unprognostic (2.13e-1)" "unprognostic (1.54e-1)" "unprognostic (8.97e-2)" "unprognostic (1.74e-2)" "unprognostic (8.54e-2)" "prognostic favorable (7.45e-5)" "unprognostic (7.97e-2)" "unprognostic (1.41e-1)" "unprognostic (1.01e-1)" "unprognostic (8.66e-2)" 16.8 14.8 19.1 13.9 15.5 45.3 14.5 33.0 20.6 14.8 16.8 15.6 18.9 11.1 18.1 11.6 16.8 15.7 16.5 10.7 16.6 8.3 11.5 12.2 14.1 12.9 16.9 12.7 20.2 15.7 26.4 14.5 27.7 13.8 13.2 12.2 12.3 15.3 17.9 19.5 18.2 17.4 13.8 12.7 15.9 14.7 20.6 18.6 29.3 16.9 10.9 14.1 18.7 22.5 4.3 4.4 9.8 3.9 5.7 3.9 2.3 15.7 11.3 19.2 11.9 12.2 13.2 17.2 7.6 11.0 11.4 11.0 14.4 5.8 16.4 6.7 15.0 10.5 12.7 27.7 10.4 12.7 15.9 18.4 12.3 13.0 11.2 13.9 29.2 13.9 12.9 10.9 16.5 13.8 10.0 12.6 9.5 13.0 22.6 9.0 5.8 8.4 9.1 13.8 19.8 7.9 17.3 9.0 10.2 10.8 20.9 6.1 6.5 26.9 13.7 13.1 16.7 9.7 17.0 16.3 11.4 13.8 8.1 10.8 15.5 7.3 25.6 8.4 9.0 10.8 5.0 3.2 3.0 3.7 3.9 3.2 4.3 3.6 3.9 4.4 2.9 3.1 2.6 9.8 5.7 2.1 3.0 2.6 2.3 19.1 15.5 33.0 20.6 16.6 8.3 16.9 12.7 13.8 18.6 62.5 45.1 44.7 19.0 21.9 43.6 25.4 53.5 29.4 18.2 24.4 33.4 15.3 3.3 13.2 12.6 27.2 22.2 46.7 16.0 15.4 23.4 24.1 24.3 24.1 15.9 23.8 23.7 34.4 59.8 3.4 26.7 31.6 8.5 20.8 23.1 31.8 20.2 26.6 28.7 9.2 31.1 25.8 15.6 20.6 29.9 22.6 25.3 26.6 20.3 30.6 EPAS1 "bHLHe73, HIF2A, HLF, MOP2, PASD2" ENSG00000116016 "Endothelial PAS domain protein 1" Q99814 2 46293667-46386703 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Angiogenesis, Differentiation, Transcription, Transcription regulation" "Activator, Developmental protein, DNA-binding" "Cancer-related genes, Congenital erythrocytosis, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lung: 200.8" "Cell type enhanced" "Detected in many" 6 "Endothelial cells: 341.0;Ito cells: 438.9;Smooth muscle cells: 281.4;Syncytiotrophoblasts: 292.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 16 "basophil: 14.9;eosinophil: 7.1" "Lineage enriched" "Detected in single" 21 "granulocytes: 14.9" "Cell line enhanced" "Detected in many" "BEWO: 46.9;BJ hTERT+: 46.2;HHSteC: 58.7;RT4: 58.1;TIME: 58.0;U-138 MG: 50.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA031200, HPA069697" Supported Nucleoplasm,Cytosol NA NA Nucleoplasm Cytosol "HPA031200: AB_2673785, HPA069697: AB_2732139" "unprognostic (1.74e-1)" "unprognostic (9.47e-2)" "unprognostic (1.29e-2)" "unprognostic (2.74e-1)" "unprognostic (5.25e-2)" "unprognostic (1.75e-1)" "unprognostic (2.22e-2)" "unprognostic (8.67e-2)" "unprognostic (6.00e-2)" "unprognostic (9.72e-2)" "unprognostic (1.55e-2)" "unprognostic (9.29e-2)" "prognostic favorable (2.63e-4)" "unprognostic (6.66e-3)" "unprognostic (7.75e-2)" "unprognostic (7.56e-2)" "unprognostic (1.36e-1)" 71.2 14.2 12.5 17.1 15.7 0.8 101.7 5.3 13.9 24.9 20.9 8.9 11.3 12.0 28.8 13.0 21.6 24.8 35.2 40.0 12.8 11.0 35.2 31.2 200.8 27.2 14.3 11.1 20.2 15.5 18.1 9.4 119.6 18.4 20.7 11.5 41.2 13.3 18.7 25.2 13.0 15.6 19.2 12.5 20.5 12.8 13.8 8.0 1.1 43.8 15.2 10.3 32.2 39.3 0.0 0.0 14.9 0.1 0.7 0.1 0.1 5.3 5.7 0.3 0.4 27.6 17.8 46.9 16.9 46.2 9.7 10.6 1.0 0.9 0.0 4.2 32.2 9.7 2.6 0.1 13.5 7.3 0.1 0.2 0.0 1.8 12.0 58.7 0.0 3.4 26.0 18.7 19.0 13.4 7.2 33.4 0.1 0.5 0.0 5.9 4.6 0.1 0.1 0.2 3.7 3.2 0.1 0.6 1.7 6.0 58.1 0.2 12.0 13.3 30.6 3.6 12.5 2.0 2.3 58.0 50.4 1.4 6.7 1.4 0.0 0.0 0.0 36.7 0.9 1.2 14.9 0.1 7.1 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.7 0.0 0.0 0.1 0.1 12.5 15.7 5.3 12.6 12.8 11.0 14.3 11.1 18.4 8.0 71.5 137.9 8.1 61.5 42.7 3.5 58.5 50.9 30.8 96.7 3.5 9.8 93.6 1.7 15.5 12.6 341.0 66.4 0.0 45.9 256.0 104.5 46.7 40.4 77.4 47.9 0.0 4.1 438.9 58.4 41.8 11.5 23.9 27.0 0.0 13.6 89.1 25.9 40.4 6.0 24.0 57.7 278.1 281.4 1.2 1.7 29.1 292.5 9.6 11.6 58.0 ERBB2 "CD340, HER-2, HER2, NEU, NGL" ENSG00000141736 "Erb-b2 receptor tyrosine kinase 2" P04626 17 39687914-39730426 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Transcription, Transcription regulation" "Activator, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" 6 "Collecting duct cells: 129.1;Enterocytes: 93.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "gdT-cell: 8.8" "Lineage enriched" "Detected in many" 4 "T-cells: 8.8" "Group enriched" "Detected in many" 41 "OE19: 366.2;SK-BR-3: 179.8" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB000043, HPA001060, HPA001338, HPA001383, CAB020416, CAB062555" Enhanced Enhanced "Plasma membrane,Cytosol" NA NA 430000 "Plasma membrane" Cytosol "CAB000043: AB_2335701, CAB020416: AB_442047, CAB062555: AB_2665610, HPA001060: AB_2666185, HPA001338: AB_2666279, HPA001383: AB_1078500" "unprognostic (1.97e-1)" "unprognostic (6.60e-3)" "unprognostic (6.21e-2)" "prognostic unfavorable (8.99e-8)" "unprognostic (2.96e-2)" "unprognostic (1.40e-2)" "unprognostic (1.97e-2)" "unprognostic (9.04e-2)" "unprognostic (1.79e-2)" "unprognostic (1.20e-3)" "prognostic unfavorable (9.17e-4)" "unprognostic (3.92e-1)" "prognostic favorable (2.41e-14)" "unprognostic (9.29e-2)" "unprognostic (1.40e-1)" "unprognostic (3.75e-2)" "unprognostic (1.96e-1)" 5.8 2.4 5.2 10.4 7.0 0.1 20.1 4.2 7.0 19.1 46.5 9.1 55.2 21.6 14.9 18.7 40.9 22.7 26.6 24.8 6.3 3.1 37.5 21.5 17.6 3.7 5.1 5.6 19.3 16.2 27.7 8.1 60.8 7.5 23.6 16.6 15.9 28.7 58.1 8.9 35.3 47.2 10.9 4.5 4.0 17.1 6.5 3.7 2.8 35.7 20.8 22.9 19.7 20.3 1.3 0.3 2.1 0.4 0.9 8.8 2.2 2.1 2.5 2.9 1.8 3.5 2.4 3.9 1.5 2.5 3.3 2.8 1.9 5.8 0.1 3.1 3.5 1.8 6.7 0.1 3.4 1.5 0.2 2.2 0.1 2.0 3.1 2.0 0.0 0.0 2.4 3.2 2.0 1.2 3.2 1.3 0.1 0.3 0.1 2.4 3.3 0.3 0.1 5.2 366.2 0.6 0.2 1.1 0.3 3.4 6.7 0.5 0.1 2.9 179.8 0.9 3.7 5.0 0.1 0.1 1.7 2.2 2.1 0.9 0.3 0.1 0.1 0.1 0.0 5.6 1.6 0.4 0.8 8.8 0.3 0.7 0.9 0.5 2.5 0.3 1.3 1.0 2.5 2.1 0.9 0.2 0.2 0.4 2.2 5.2 7.0 4.2 7.0 6.3 3.1 5.1 5.6 7.5 3.7 38.7 34.4 1.3 21.0 12.5 4.3 13.5 30.6 10.7 15.9 129.1 11.8 9.7 6.6 27.1 0.3 4.6 93.2 0.0 22.3 75.4 11.0 33.4 0.0 10.4 3.5 6.4 15.0 12.3 2.4 0.7 17.0 1.8 10.1 1.0 56.6 30.9 26.2 42.1 21.5 20.7 5.9 0.0 10.3 7.1 5.3 16.6 19.0 2.2 63.0 28.1 ERBB3 "HER3, LCCS2" ENSG00000065361 "Erb-b2 receptor tyrosine kinase 3" P21860 12 56076799-56103505 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" 5 "Cholangiocytes: 180.9;Enterocytes: 163.1;Paneth cells: 165.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "basophil: 5.3" "Lineage enriched" "Detected in many" 4 "granulocytes: 5.3" "Cell line enhanced" "Detected in many" "Hep G2: 30.9;MCF7: 20.2;OE19: 31.8;RT4: 24.2;SK-BR-3: 28.4;SK-MEL-30: 37.9;T-47d: 31.5;WM-115: 40.2" "Low region specificity" "Detected in many" "CAB025331, HPA045396" Uncertain Supported "Plasma membrane,Actin filaments" "Secreted - unknown location" NA NA 420000 "Plasma membrane" "Actin filaments" "CAB025331: , HPA045396: AB_2679312" "unprognostic (2.97e-1)" "unprognostic (2.71e-2)" "unprognostic (1.91e-1)" "unprognostic (8.97e-2)" "unprognostic (1.63e-1)" "unprognostic (1.07e-3)" "unprognostic (2.31e-3)" "unprognostic (2.66e-2)" "unprognostic (9.89e-2)" "unprognostic (4.30e-2)" "unprognostic (4.76e-3)" "unprognostic (5.77e-2)" "unprognostic (1.06e-2)" "unprognostic (4.56e-2)" "unprognostic (1.57e-1)" "unprognostic (6.72e-3)" "unprognostic (2.07e-2)" 1.1 1.4 11.6 12.6 16.5 0.6 26.8 2.0 16.7 6.8 40.5 40.3 12.0 37.7 2.8 7.5 29.4 5.7 22.9 3.4 18.6 9.0 16.5 33.9 13.4 0.5 23.5 9.3 0.9 21.5 11.4 1.0 15.4 14.9 16.8 29.7 5.5 36.8 22.3 1.1 30.7 41.3 3.2 27.4 0.5 32.9 1.2 23.8 0.0 4.5 7.4 8.5 11.8 14.4 0.9 0.7 5.3 0.6 1.2 1.2 0.2 10.0 0.6 0.8 0.3 0.0 0.0 16.4 0.8 1.9 1.1 1.1 5.5 18.2 0.0 0.2 0.2 0.1 8.6 1.2 1.9 0.6 0.2 0.8 0.0 0.3 30.9 0.0 0.0 0.1 0.4 2.5 0.2 0.0 0.2 0.0 0.1 0.7 0.3 0.1 20.2 0.1 0.3 2.8 31.8 0.4 0.1 1.9 0.5 2.1 24.2 0.9 0.3 0.7 28.4 37.9 2.7 31.5 0.1 0.0 0.1 1.1 0.6 0.1 0.2 0.1 0.1 0.1 0.0 40.2 5.3 0.4 0.8 0.9 0.4 0.4 0.4 0.7 0.3 0.3 0.9 0.6 1.2 3.3 1.2 0.6 0.7 0.8 0.2 11.6 16.5 2.0 16.7 18.6 9.0 23.5 9.3 14.9 23.8 110.2 61.2 1.3 13.0 16.3 1.5 1.4 180.9 21.4 61.4 33.2 2.0 44.4 1.7 41.9 0.9 2.2 163.1 0.0 77.1 73.6 2.7 83.4 1.1 83.9 5.5 0.0 89.5 6.7 1.9 0.0 1.4 1.7 52.3 2.8 134.3 11.3 75.9 165.5 0.0 31.8 1.1 6.5 1.7 2.4 2.3 32.2 84.1 1.5 124.3 62.5 ERBB4 "ALS19, HER4" ENSG00000178568 "Erb-b2 receptor tyrosine kinase 4" Q15303 2 211375717-212538841 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Apoptosis, Lactation, Transcription, Transcription regulation" "Activator, Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Amyotrophic lateral sclerosis, Cancer-related genes, Disease mutation, FDA approved drug targets, Neurodegeneration" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "fallopian tube: 24.5" "Cell type enhanced" "Detected in many" 10 "Bipolar cells: 11.2;Cardiomyocytes: 15.3;Ciliated cells: 26.8;Club cells: 17.0;Collecting duct cells: 12.2;Muller glia cells: 12.4" "Cancer enhanced" "Detected in many" "breast cancer: 4.1" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "AF22: 9.6;EFO-21: 7.2;HEK 293: 5.3;RPTEC TERT1: 7.8;SCLC-21H: 4.4;T-47d: 7.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000276, HPA012016, CAB025522" Enhanced NA NA 140000 "CAB000276: , CAB025522: , HPA012016: AB_1846541" "unprognostic (1.48e-1)" "unprognostic (3.28e-1)" "unprognostic (4.31e-3)" "unprognostic (1.76e-3)" "unprognostic (3.59e-1)" "unprognostic (2.75e-1)" "unprognostic (2.88e-1)" "unprognostic (9.56e-2)" "unprognostic (2.07e-1)" "unprognostic (4.67e-3)" "unprognostic (1.07e-1)" "unprognostic (3.61e-1)" "unprognostic (7.14e-3)" "unprognostic (1.49e-3)" "unprognostic (1.41e-1)" "unprognostic (1.14e-1)" "unprognostic (4.11e-2)" 1.6 1.9 15.1 1.2 15.0 1.0 13.4 18.6 14.1 7.8 1.1 7.6 8.8 1.1 1.5 1.2 1.3 24.5 1.2 7.0 14.3 6.5 11.9 1.1 2.9 1.2 7.8 10.7 1.3 2.4 10.8 5.1 1.3 8.8 1.7 1.1 2.0 9.7 18.1 3.8 1.8 1.2 1.1 7.3 1.2 1.5 7.6 12.0 0.0 4.5 1.1 1.2 1.4 0.7 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 9.6 0.2 0.0 0.0 0.0 0.0 0.3 0.5 0.1 0.0 0.0 0.0 7.2 1.0 0.0 0.4 0.2 0.0 0.0 0.1 5.3 0.0 1.7 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 2.8 0.0 0.0 0.5 0.0 7.8 0.4 4.4 0.2 0.0 0.1 0.1 0.1 7.1 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 15.1 15.0 18.6 14.1 14.3 6.5 7.8 10.7 8.8 12.0 0.0 9.3 0.0 0.8 0.6 11.2 15.3 0.0 26.8 17.0 12.2 0.0 0.0 5.0 0.4 4.1 0.1 0.0 0.0 0.4 0.1 0.2 2.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 1.3 1.7 0.0 3.3 0.0 0.0 12.4 0.0 0.0 0.4 0.0 1.4 6.5 3.1 1.9 1.5 1.1 0.0 0.0 0.0 1.0 ERCC2 "EM9, MAG, MGC102762, MGC126218, MGC126219, TFIIH, XPD" ENSG00000104884 "ERCC excision repair 2, TFIIH core complex helicase subunit" P18074 19 45349837-45370918 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Chromosome partition, DNA damage, DNA repair, Host-virus interaction, Transcription, Transcription regulation" "DNA-binding, Helicase, Hydrolase" "Cancer-related genes, Cataract, Cockayne syndrome, Deafness, Disease mutation, Dwarfism, Ichthyosis, Xeroderma pigmentosum" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 6 "Spermatocytes: 33.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB005375, HPA038057, HPA069266" Approved Supported Nucleoplasm,Cytosol NA NA Nucleoplasm Cytosol "CAB005375: AB_2100152, HPA038057: AB_2675810, HPA069266: AB_2686104" "unprognostic (1.10e-1)" "unprognostic (5.48e-1)" "unprognostic (5.08e-2)" "unprognostic (9.92e-3)" "unprognostic (1.35e-1)" "unprognostic (1.23e-2)" "unprognostic (1.67e-3)" "unprognostic (1.46e-1)" "unprognostic (3.41e-1)" "unprognostic (1.06e-1)" "prognostic favorable (3.26e-4)" "unprognostic (3.36e-2)" "unprognostic (2.44e-3)" "unprognostic (1.94e-1)" "unprognostic (5.47e-1)" "unprognostic (8.99e-2)" "unprognostic (3.45e-2)" 7.4 15.6 11.4 10.6 17.7 6.7 7.1 9.5 23.8 9.4 8.1 11.7 7.8 7.9 11.7 6.0 6.7 10.0 10.1 7.9 9.4 9.1 8.7 13.2 6.5 9.9 8.2 10.5 9.5 13.1 12.9 10.9 7.2 14.0 8.2 6.4 12.5 9.5 11.8 15.9 10.7 7.1 11.2 5.3 9.7 8.3 17.2 7.8 10.8 10.2 5.1 8.3 9.3 6.6 7.8 17.2 5.0 13.9 11.3 9.8 8.7 12.6 6.2 12.9 18.1 7.7 9.1 6.8 18.0 12.4 23.3 17.9 14.3 8.7 4.5 10.3 17.5 8.5 6.5 9.0 15.1 8.9 10.9 14.8 7.7 11.7 15.1 16.3 12.2 13.6 10.5 2.4 26.6 15.1 13.0 13.5 13.0 18.6 5.1 16.0 6.1 7.1 8.1 5.9 11.6 10.9 13.8 9.2 3.8 6.7 11.2 7.5 8.2 16.0 11.3 6.4 10.2 10.7 16.2 17.5 22.3 12.2 9.4 40.0 11.9 6.8 6.5 6.6 7.4 9.8 0.0 13.3 5.0 7.7 13.9 9.8 7.8 7.4 7.4 17.2 5.8 7.1 7.4 0.4 11.3 10.9 8.3 7.4 8.7 11.4 17.7 9.5 23.8 9.4 9.1 8.2 10.5 14.0 7.8 6.0 4.3 3.6 3.9 5.6 0.0 6.0 10.2 6.7 5.7 5.2 0.0 9.4 11.6 7.6 4.1 3.8 2.9 0.0 7.0 10.0 6.8 3.5 0.0 11.5 9.8 0.0 6.9 9.2 7.3 2.2 6.1 4.6 3.3 1.8 7.8 0.0 6.2 3.5 7.4 11.3 0.0 0.0 5.2 33.8 11.0 5.0 4.0 2.9 7.7 3.3 ERCC3 "BTF2, GTF2H, RAD25, TFIIH, XPB" ENSG00000163161 "ERCC excision repair 3, TFIIH core complex helicase subunit" P19447 2 127257290-127294176 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "DNA damage, DNA repair, Host-virus interaction, Transcription, Transcription regulation" "DNA-binding, Helicase, Hydrolase" "Cancer-related genes, Cockayne syndrome, Deafness, Disease mutation, Dwarfism, Ichthyosis, Xeroderma pigmentosum" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB037153, HPA046077" Approved Enhanced Nucleoplasm NA NA Nucleoplasm "CAB037153: AB_796181, HPA046077: AB_2679527" "unprognostic (2.31e-1)" "unprognostic (1.15e-1)" "unprognostic (3.03e-2)" "unprognostic (1.07e-3)" "unprognostic (1.05e-1)" "unprognostic (8.85e-2)" "prognostic unfavorable (1.62e-7)" "unprognostic (2.74e-1)" "unprognostic (9.13e-3)" "unprognostic (9.25e-2)" "unprognostic (1.25e-1)" "unprognostic (2.46e-2)" "prognostic unfavorable (4.30e-6)" "unprognostic (3.71e-1)" "unprognostic (8.50e-2)" "unprognostic (5.73e-2)" "unprognostic (3.92e-2)" 17.4 20.0 26.1 23.8 28.9 20.5 21.0 35.9 32.0 22.1 19.4 19.7 17.1 11.5 21.6 15.7 19.1 23.6 20.4 20.4 23.2 18.8 17.5 17.4 19.4 23.1 19.7 25.8 23.3 22.4 32.0 26.4 16.3 21.5 20.1 17.1 18.3 18.0 21.8 30.1 19.7 17.3 26.1 16.0 24.5 17.4 39.5 20.1 24.1 19.3 15.8 25.9 22.4 20.8 11.8 13.9 7.2 9.7 18.8 16.2 11.7 22.2 15.3 19.0 20.1 21.1 14.5 23.5 20.5 26.6 33.2 32.2 23.4 16.3 16.9 17.0 18.7 21.5 20.0 28.9 21.6 28.9 26.4 25.9 21.2 18.7 24.6 15.7 18.4 23.1 15.0 20.3 38.3 16.4 21.2 21.3 22.2 20.6 11.1 20.9 22.0 26.2 19.8 27.6 14.5 23.9 21.6 21.8 14.0 18.5 20.8 23.0 24.8 17.5 26.7 26.8 22.7 14.4 21.1 16.9 20.0 22.9 18.1 24.3 19.9 38.8 26.5 17.7 8.9 21.3 6.6 9.5 7.2 16.0 9.7 16.2 11.5 11.8 13.5 13.9 11.8 15.8 10.9 3.1 18.8 7.9 11.3 16.1 11.7 26.1 28.9 35.9 32.0 23.2 18.8 19.7 25.8 21.5 20.1 20.8 13.4 8.2 8.1 6.8 0.0 10.5 5.1 32.1 22.7 7.0 0.0 15.9 1.7 12.0 3.5 14.3 4.9 0.0 13.1 10.3 12.0 6.2 9.3 7.8 12.5 0.0 5.8 12.3 12.6 3.1 15.3 9.2 8.5 12.6 8.2 0.0 12.9 5.8 12.0 7.0 0.0 12.9 8.5 34.7 27.5 8.3 12.2 13.8 9.9 5.6 ERCC4 "FANCQ, RAD1, XPF" ENSG00000175595 "ERCC excision repair 4, endonuclease catalytic subunit" Q92889 16 13920157-13952345 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "DNA damage, DNA repair" "DNA-binding, Endonuclease, Hydrolase, Nuclease" "Cancer-related genes, Cockayne syndrome, Disease mutation, Dwarfism, Fanconi anemia, Xeroderma pigmentosum" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 9 "Early spermatids: 121.2;Late spermatids: 71.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000156, HPA045828" Approved Supported "Nucleoplasm,Nuclear bodies,Plasma membrane" NA NA "Nucleoplasm, Nuclear bodies" "Plasma membrane" "CAB000156: , HPA045828: AB_2679463" "unprognostic (2.05e-1)" "unprognostic (1.52e-1)" "unprognostic (2.12e-3)" "unprognostic (9.41e-2)" "unprognostic (3.35e-1)" "unprognostic (1.40e-2)" "unprognostic (1.64e-2)" "unprognostic (2.26e-1)" "unprognostic (3.59e-1)" "unprognostic (1.56e-1)" "unprognostic (1.18e-1)" "unprognostic (8.49e-2)" "unprognostic (5.26e-2)" "unprognostic (1.67e-1)" "unprognostic (1.15e-1)" "unprognostic (6.30e-2)" "unprognostic (5.88e-4)" 8.4 12.7 8.6 7.0 11.3 5.3 6.4 8.9 9.7 8.1 6.7 9.9 6.0 4.1 8.5 6.8 6.7 8.5 6.8 7.8 7.2 7.1 6.9 7.2 6.9 6.8 10.5 8.8 9.9 7.6 13.3 13.0 5.9 9.6 8.3 5.4 7.1 6.4 7.0 31.3 6.9 5.7 8.5 10.3 7.7 6.6 14.2 8.9 13.7 9.7 5.6 6.4 9.1 7.8 8.4 7.9 8.3 6.8 8.9 7.4 2.6 5.4 7.0 6.4 9.2 10.7 10.1 5.0 7.2 7.7 6.5 8.3 2.4 5.4 9.1 10.4 6.3 5.7 6.9 9.5 4.9 10.1 12.3 5.6 4.5 7.8 6.0 9.8 6.1 5.1 7.6 6.9 8.6 7.3 6.3 8.6 5.5 7.0 10.7 9.1 4.5 8.0 4.1 4.7 2.8 3.7 9.2 13.0 11.2 4.0 3.7 5.3 6.3 8.8 7.2 6.7 5.4 9.1 4.6 9.7 9.6 7.1 8.6 6.3 9.5 11.2 6.3 9.2 7.3 9.8 8.3 6.2 5.4 6.8 6.8 7.4 6.2 6.4 5.1 5.5 8.4 6.4 6.9 7.2 8.9 5.7 7.9 5.8 2.6 8.6 11.3 8.9 9.7 7.2 7.1 10.5 8.8 9.6 8.9 17.9 15.7 9.7 6.8 4.2 0.0 7.9 12.7 18.7 5.7 5.2 0.0 13.6 8.3 10.4 121.2 9.5 2.8 0.0 7.3 5.9 9.9 7.6 1.1 15.7 10.5 0.0 9.2 16.0 11.3 71.5 13.8 10.6 10.1 11.8 5.3 0.0 8.2 0.0 19.8 9.3 0.0 25.8 5.9 46.6 16.7 4.8 10.3 16.0 6.1 4.0 ERCC5 "ERCM2, XPGC" ENSG00000134899 "ERCC excision repair 5, endonuclease" P28715 13 102807146-102876001 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "DNA damage, DNA repair" "DNA-binding, Endonuclease, Hydrolase, Nuclease" "Cancer-related genes, Cockayne syndrome, Deafness, Disease mutation, Dwarfism, Xeroderma pigmentosum" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 5 "Early spermatids: 44.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA045845, HPA050126, HPA050374" Supported Enhanced Nucleoplasm NA NA Nucleoplasm "HPA045845: AB_2679471, HPA050126: AB_2681027, HPA050374: AB_2681106" "unprognostic (1.28e-3)" "unprognostic (1.32e-3)" "unprognostic (1.86e-2)" "unprognostic (9.28e-3)" "unprognostic (6.19e-2)" "unprognostic (8.73e-2)" "unprognostic (1.23e-1)" "unprognostic (8.72e-2)" "unprognostic (2.52e-1)" "unprognostic (2.55e-1)" "unprognostic (7.77e-3)" "unprognostic (5.76e-3)" "prognostic unfavorable (2.96e-6)" "unprognostic (3.56e-2)" "unprognostic (1.56e-1)" "unprognostic (1.67e-1)" "prognostic favorable (6.82e-4)" 22.3 19.1 15.9 16.1 17.8 23.7 20.1 26.4 20.8 19.7 27.0 17.9 27.0 25.0 22.1 25.7 21.0 15.1 21.1 15.4 14.6 13.1 18.7 28.1 19.9 26.4 17.1 16.2 22.9 22.3 15.7 25.6 17.9 19.0 20.1 23.1 15.9 20.5 24.7 14.6 25.8 31.1 17.0 19.4 30.6 21.9 14.0 17.8 40.8 21.8 16.6 26.0 22.4 19.6 10.1 10.8 23.4 17.4 17.7 17.5 12.0 14.8 5.4 10.8 6.8 21.7 20.4 6.6 15.1 20.0 8.7 11.4 8.3 20.8 9.3 7.6 15.2 6.1 15.5 9.6 13.8 9.1 14.1 5.4 13.9 15.7 7.2 10.6 28.3 18.2 19.4 13.3 10.1 15.7 13.8 15.2 19.7 6.5 8.5 15.3 4.0 15.2 19.6 4.7 17.9 7.6 8.3 8.1 9.4 18.0 8.3 7.3 10.8 7.9 13.3 8.0 8.7 11.9 26.4 15.3 6.8 3.4 5.7 9.4 12.5 3.8 4.7 26.4 11.5 8.4 23.4 9.8 18.3 16.7 12.3 15.5 9.6 15.5 17.5 10.8 10.1 16.6 16.1 7.2 17.7 17.4 7.7 16.6 12.0 15.9 17.8 26.4 20.8 14.6 13.1 17.1 16.2 19.0 17.8 3.0 7.4 14.6 5.7 6.4 0.0 25.5 7.6 6.7 13.6 0.0 0.0 7.7 0.0 1.0 44.4 9.0 18.4 0.0 1.1 6.6 8.2 3.7 18.5 17.1 9.3 0.0 4.7 10.4 14.3 23.3 20.4 9.9 6.8 1.0 19.0 0.0 1.4 16.4 14.9 1.2 0.0 19.4 6.1 10.6 6.4 6.0 4.8 25.4 16.6 4.3 ESR1 "ER-alpha, Era, ESR, NR3A1" ENSG00000091831 "Estrogen receptor 1" P03372 6 151656691-152129619 "Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding, Receptor" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "cervix, uterine: 64.5;endometrium 1: 68.9" "Group enriched" "Detected in many" 6 "Early spermatids: 36.0;Hepatocytes: 48.4;Horizontal cells: 58.8" "Group enriched" "Detected in many" 9 "breast cancer: 40.2;endometrial cancer: 24.3;ovarian cancer: 8.7" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "naive CD4 T-cell: 2.5" "Low lineage specificity" "Detected in many" "Group enriched" "Detected in some" 9 "MCF7: 24.9;T-47d: 32.2" "Low region specificity" "Detected in single" "Low region specificity" "Detected in many" "CAB000037, HPA000449, HPA000450, CAB055099, CAB072858" Enhanced Approved Nucleoplasm,Vesicles NA NA Vesicles Nucleoplasm "CAB000037: AB_563706, CAB055099: AB_2101946, CAB072858: AB_2665701, HPA000449: AB_1078753, HPA000450: AB_1078754" "unprognostic (8.28e-2)" "unprognostic (3.02e-2)" "unprognostic (1.43e-2)" "prognostic favorable (5.47e-7)" "unprognostic (4.79e-1)" "unprognostic (2.43e-3)" "unprognostic (4.10e-5)" "unprognostic (9.92e-2)" "unprognostic (2.20e-1)" "unprognostic (7.17e-2)" "unprognostic (7.35e-2)" "unprognostic (3.45e-1)" "unprognostic (1.20e-2)" "unprognostic (7.91e-3)" "unprognostic (6.45e-2)" "unprognostic (1.25e-1)" "unprognostic (1.52e-1)" 3.0 0.9 0.5 1.6 0.5 0.2 16.2 0.8 0.4 64.5 1.5 0.2 2.2 0.1 68.9 27.7 1.1 26.7 1.9 1.1 0.5 0.8 1.5 6.6 3.6 1.6 0.4 0.1 14.2 0.4 0.0 9.3 0.9 0.6 3.6 0.1 2.6 1.6 4.1 2.0 0.6 0.5 20.8 0.4 1.6 0.3 1.9 0.4 1.9 1.3 2.2 2.5 3.8 23.7 0.6 1.0 0.0 0.8 0.3 2.5 1.0 0.3 0.0 0.1 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.6 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.1 0.4 0.0 0.0 0.0 0.6 0.0 24.9 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.4 0.0 1.8 0.0 0.0 0.0 0.3 0.0 0.1 32.2 0.0 0.0 0.1 0.1 0.3 0.0 3.0 0.5 0.0 0.1 0.3 0.0 0.0 0.8 0.0 0.3 0.2 1.0 0.6 1.3 0.4 1.0 0.4 2.5 0.9 0.0 0.3 0.0 0.0 0.3 1.0 0.5 0.5 0.8 0.4 0.5 0.8 0.4 0.1 0.6 0.4 0.0 0.6 0.0 1.4 0.9 3.8 4.5 0.0 1.4 1.2 0.0 7.9 0.1 1.7 0.0 36.0 0.6 0.0 0.0 0.2 0.1 4.7 0.6 2.3 48.4 0.9 58.8 1.7 6.7 4.7 6.9 3.7 2.4 1.7 0.0 0.0 2.7 0.2 0.0 2.1 3.3 4.0 0.0 1.4 1.6 1.2 1.5 0.1 0.0 0.0 8.4 ETNK1 "EKI, EKI1" ENSG00000139163 "Ethanolamine kinase 1" Q9HBU6 12 22625075-22690665 "Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins" "Lipid biosynthesis, Lipid metabolism, Phospholipid biosynthesis, Phospholipid metabolism" "Kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 4 "Early spermatids: 201.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA010712, HPA029407" Approved Approved "Nucleoplasm,Plasma membrane,Cytosol" NA NA "Nucleoplasm, Plasma membrane, Cytosol" "HPA010712: AB_2668349, HPA029407: AB_2673026" "unprognostic (2.06e-1)" "unprognostic (7.48e-2)" "unprognostic (1.23e-3)" "unprognostic (2.19e-1)" "unprognostic (8.79e-3)" "unprognostic (1.31e-2)" "prognostic unfavorable (5.85e-4)" "unprognostic (3.98e-3)" "unprognostic (8.30e-2)" "unprognostic (7.97e-3)" "unprognostic (2.01e-1)" "unprognostic (1.64e-2)" "unprognostic (4.53e-3)" "unprognostic (2.77e-1)" "unprognostic (2.91e-1)" "unprognostic (3.01e-1)" "prognostic favorable (1.75e-4)" 15.7 17.7 15.2 41.1 19.4 13.7 16.9 19.7 22.2 12.9 33.2 16.4 14.6 27.2 16.6 24.1 14.7 13.1 27.3 10.4 15.6 23.9 22.0 30.2 19.6 18.5 17.2 15.8 17.2 14.9 15.8 30.6 13.4 18.9 13.8 19.5 15.9 16.7 14.7 8.2 17.8 24.5 10.0 17.1 18.3 53.7 22.3 17.5 33.4 17.6 8.2 16.5 14.2 18.6 16.2 10.7 28.1 17.6 14.0 15.7 13.4 6.7 14.0 15.6 14.4 11.3 11.4 11.6 8.0 6.0 8.3 8.6 10.8 17.1 20.1 7.2 5.2 8.7 5.1 13.7 3.8 15.0 16.7 11.1 16.6 6.2 9.3 10.8 15.9 15.3 7.4 3.7 11.2 9.5 13.3 10.3 7.9 19.9 8.5 11.0 4.6 17.3 32.4 30.2 8.7 9.2 15.6 13.8 16.1 13.8 9.2 5.0 8.8 8.7 7.6 12.5 22.4 11.8 15.4 8.8 6.6 10.6 8.9 12.0 6.2 7.7 21.6 8.4 10.4 11.0 28.1 11.7 12.1 12.9 17.5 12.7 16.2 14.1 11.9 10.7 13.0 15.7 15.5 11.5 14.0 17.6 9.7 15.3 13.4 15.2 19.4 19.7 22.2 15.6 23.9 17.2 15.8 18.9 17.5 44.7 25.1 40.9 63.3 128.1 40.4 11.0 53.5 72.3 35.2 41.8 47.1 27.9 23.2 26.3 201.9 28.7 55.0 0.0 39.6 20.3 28.6 70.5 33.5 38.4 37.5 25.4 103.9 27.6 78.9 26.1 22.5 44.7 64.1 22.6 52.6 21.4 29.0 46.1 20.1 26.4 35.5 38.8 44.3 47.7 15.1 148.8 63.0 39.2 36.0 60.2 EXT1 "LGCR, LGS, ttv" ENSG00000182197 "Exostosin glycosyltransferase 1" Q16394 8 117794490-118111853 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Glycosyltransferase, Transferase" "Cancer-related genes, Disease mutation, Hereditary multiple exostoses, Tumor suppressor" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 66.4" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "BJ hTERT+: 55.5;fHDF/TERT166: 56.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA044394 Uncertain NA Yes 9600000 "HPA044394: AB_10963838" "unprognostic (1.29e-2)" "prognostic unfavorable (7.04e-4)" "unprognostic (2.73e-2)" "unprognostic (2.02e-3)" "unprognostic (2.19e-1)" "unprognostic (7.55e-2)" "unprognostic (1.99e-1)" "prognostic unfavorable (1.20e-5)" "unprognostic (1.70e-1)" "unprognostic (3.01e-2)" "unprognostic (1.31e-2)" "unprognostic (6.58e-2)" "unprognostic (1.27e-2)" "unprognostic (9.84e-2)" "unprognostic (9.49e-2)" "prognostic unfavorable (4.64e-4)" "unprognostic (1.85e-1)" 13.8 11.9 5.8 20.5 4.6 2.1 16.5 7.3 7.4 13.3 17.1 4.1 8.7 23.2 11.5 12.5 11.2 8.8 19.3 14.4 4.6 3.1 8.8 66.4 19.9 8.3 3.0 6.8 10.4 17.9 7.1 6.4 15.6 4.8 9.8 16.0 13.2 9.8 13.3 4.2 12.3 32.0 16.8 4.3 20.1 11.5 5.0 2.7 8.7 12.0 10.3 7.2 11.0 18.5 0.8 1.7 1.2 4.5 0.7 2.4 1.0 17.3 5.0 7.6 3.0 13.7 11.1 3.5 32.5 55.5 24.0 22.1 5.2 1.7 0.3 14.6 56.1 17.9 11.0 3.3 19.1 33.8 6.5 5.6 0.7 4.7 4.1 6.4 0.0 1.2 6.9 5.1 29.1 26.8 30.1 14.7 1.6 0.4 4.8 11.1 1.4 0.8 0.0 2.4 9.2 6.5 0.0 2.8 0.5 9.4 6.3 2.4 2.2 5.0 2.3 4.8 20.2 3.2 0.2 19.5 20.2 18.6 18.6 9.5 2.8 2.7 1.6 18.8 0.0 5.4 0.3 4.4 0.2 0.2 4.5 1.3 0.8 0.5 0.6 1.0 0.1 0.5 0.9 1.2 0.7 2.2 1.7 2.4 1.0 5.8 4.6 7.3 7.4 4.6 3.1 3.0 6.8 4.8 2.7 17.9 5.9 1.4 18.7 48.7 21.1 6.2 28.1 5.3 6.8 7.0 13.7 5.2 0.0 34.9 1.3 16.6 42.3 0.0 17.2 3.2 32.1 10.0 6.9 22.6 2.2 9.5 4.6 17.8 28.9 1.6 16.1 5.4 18.6 5.4 20.7 6.0 21.6 14.0 33.9 5.0 24.5 0.0 28.1 0.5 4.3 41.4 10.2 2.2 21.2 17.9 EXT2 SOTV ENSG00000151348 "Exostosin glycosyltransferase 2" Q93063 11 44095549-44245429 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins" "Glycosyltransferase, Transferase" "Cancer-related genes, Disease mutation, Epilepsy, Hereditary multiple exostoses, Mental retardation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA078409 Supported "Golgi apparatus" NA NA 20000000 "Golgi apparatus" "HPA078409: AB_2686884" "unprognostic (5.87e-2)" "unprognostic (3.05e-3)" "unprognostic (3.48e-2)" "unprognostic (3.94e-1)" "unprognostic (1.42e-1)" "prognostic unfavorable (2.50e-4)" "unprognostic (1.77e-3)" "unprognostic (2.22e-2)" "unprognostic (1.97e-1)" "unprognostic (2.05e-1)" "unprognostic (1.74e-3)" "unprognostic (3.70e-2)" "prognostic unfavorable (5.36e-6)" "unprognostic (7.07e-3)" "unprognostic (2.97e-1)" "unprognostic (3.85e-1)" "unprognostic (1.36e-2)" 24.5 19.5 11.6 17.2 18.5 6.6 25.8 14.5 23.0 26.8 25.0 15.5 17.5 17.6 37.1 25.5 16.7 26.0 23.4 22.7 11.7 13.0 19.2 36.3 22.3 16.8 11.8 12.3 29.3 21.8 25.7 17.3 58.0 16.2 23.7 20.6 22.9 24.7 22.8 16.9 20.2 34.0 35.0 12.2 18.7 19.3 20.0 11.4 16.2 24.7 16.7 13.0 20.2 23.2 6.7 14.9 13.0 12.0 17.8 17.6 9.8 13.1 18.2 9.9 30.7 45.6 33.6 13.6 40.8 51.1 24.2 33.0 12.9 9.1 9.1 18.6 47.8 25.6 21.0 10.5 29.0 29.3 18.2 14.5 8.4 9.6 9.9 18.0 8.4 18.1 26.0 19.2 14.6 22.9 28.5 34.3 8.7 11.2 16.4 17.6 10.1 5.8 5.1 10.6 16.8 13.0 7.3 28.2 4.6 14.0 12.5 7.1 7.9 25.8 10.6 6.8 18.3 17.6 9.0 31.0 32.7 21.4 32.0 26.2 7.4 9.7 6.7 21.5 6.5 34.9 9.3 11.9 13.0 15.6 12.0 17.6 6.4 12.5 14.4 14.9 6.7 11.9 11.7 2.6 17.8 8.5 5.1 9.6 9.8 11.6 18.5 14.5 23.0 11.7 13.0 11.8 12.3 16.2 11.4 14.9 8.8 10.5 13.2 13.5 11.5 9.2 5.1 5.3 10.3 12.2 13.7 27.3 5.0 28.2 30.2 16.7 20.5 0.0 20.6 30.2 24.4 17.7 5.8 15.5 16.2 12.7 1.7 21.5 11.9 17.4 25.3 7.7 5.0 10.0 14.0 16.6 21.7 14.0 26.9 7.0 14.3 19.4 16.9 36.9 21.7 11.0 29.5 7.5 13.3 14.6 EZH2 "ENX-1, EZH1, KMT6, KMT6A" ENSG00000106462 "Enhancer of zeste 2 polycomb repressive complex 2 subunit" Q15910 7 148807383-148884321 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Biological rhythms, Transcription, Transcription regulation" "Chromatin regulator, Methyltransferase, Repressor, Transferase" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 25.5;lymphoid tissue: 44.1" "Cell type enhanced" "Detected in many" 8 "Early spermatids: 72.2;Spermatocytes: 126.7;Spermatogonia: 62.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB009589 Enhanced Supported Nucleoplasm NA NA Nucleoplasm "CAB009589: " "unprognostic (2.42e-1)" "unprognostic (3.95e-3)" "unprognostic (1.57e-1)" "unprognostic (3.30e-3)" "unprognostic (1.33e-1)" "unprognostic (3.85e-3)" "prognostic unfavorable (2.11e-6)" "unprognostic (2.21e-2)" "prognostic unfavorable (1.96e-4)" "unprognostic (2.32e-3)" "unprognostic (1.58e-3)" "unprognostic (1.69e-3)" "prognostic unfavorable (8.18e-12)" "prognostic favorable (6.97e-4)" "unprognostic (1.83e-1)" "unprognostic (2.12e-1)" "unprognostic (6.67e-2)" 2.0 1.7 1.8 10.6 1.6 25.5 1.4 4.9 2.7 2.6 4.8 1.1 0.1 3.8 1.7 2.8 11.0 0.9 3.0 0.9 0.8 0.6 1.7 3.3 2.3 12.6 1.3 0.3 2.2 3.8 0.6 1.7 3.4 1.4 1.4 5.1 1.8 3.2 1.6 3.7 6.4 4.8 1.5 1.2 5.8 2.7 19.6 1.3 44.1 0.9 5.5 12.4 2.6 3.5 1.5 4.7 1.3 3.9 8.5 10.3 1.7 17.0 8.0 27.3 18.2 0.8 1.4 14.9 13.3 5.4 11.0 11.1 12.0 19.7 30.2 6.5 5.0 10.0 10.5 14.0 4.6 14.0 43.2 14.0 12.9 9.9 9.3 2.2 28.6 10.6 1.2 2.6 8.2 4.4 3.3 6.4 29.3 27.3 20.1 9.8 19.3 55.6 23.9 21.7 15.0 10.8 34.4 15.3 18.7 5.1 8.2 26.1 16.6 16.7 12.7 4.4 7.3 9.3 12.3 3.9 11.7 5.4 23.3 23.8 18.0 19.6 30.4 10.7 19.6 22.9 0.5 2.2 1.3 1.7 1.5 1.3 1.5 3.4 2.9 4.7 0.8 1.9 1.2 0.2 8.5 3.9 1.0 10.3 1.7 1.8 1.6 4.9 2.7 0.8 0.6 1.3 0.3 1.4 1.3 0.0 7.9 6.7 5.7 23.6 4.8 6.5 2.5 14.7 7.9 7.0 33.4 13.6 3.3 9.1 72.2 7.1 6.7 23.3 7.4 29.5 10.8 4.4 21.8 1.3 10.4 14.3 8.6 4.3 8.9 19.2 2.8 10.9 13.5 19.0 10.2 2.0 10.1 9.3 0.7 1.0 21.1 6.5 9.9 126.7 62.4 25.3 25.5 18.7 18.6 4.0 FAM46C FLJ20202 ENSG00000183508 "Family with sequence similarity 46 member C" Q5VWP2 1 117605934-117628372 "Cancer-related genes, Predicted intracellular proteins" "Host-virus interaction" "Nucleotidyltransferase, RNA-binding, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "pancreas: 114.0" "Group enriched" "Detected in many" 9 "Early spermatids: 418.3;Late spermatids: 1175.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "basophil: 16.3" "Group enriched" "Detected in many" 17 "B-cells: 9.7;granulocytes: 16.3;T-cells: 9.2" "Cell line enhanced" "Detected in some" "Karpas-707: 74.8;RPMI-8226: 44.6;U-266/70: 20.8;U-266/84: 17.2" "Not detected" "Not detected" "Low region specificity" "Detected in many" HPA054049 Uncertain Supported Nucleoplasm NA NA Nucleoplasm "HPA054049: AB_2682356" "unprognostic (3.76e-2)" "unprognostic (3.85e-3)" "unprognostic (3.24e-3)" "prognostic favorable (3.75e-5)" "unprognostic (1.17e-1)" "unprognostic (1.55e-3)" "unprognostic (3.29e-1)" "unprognostic (2.88e-2)" "unprognostic (5.75e-2)" "unprognostic (1.36e-3)" "unprognostic (9.41e-3)" "unprognostic (3.91e-2)" "prognostic favorable (2.77e-5)" "unprognostic (6.26e-2)" "unprognostic (3.16e-2)" "unprognostic (3.08e-2)" "unprognostic (1.10e-2)" 3.2 1.8 1.2 24.5 1.1 28.9 4.4 1.1 1.1 8.1 16.1 1.8 8.4 5.6 4.8 16.6 6.9 3.3 9.7 6.4 1.2 1.1 5.0 5.5 11.2 16.3 1.2 0.1 8.3 114.0 7.2 5.3 10.6 3.9 6.4 9.5 4.4 37.8 11.9 10.0 1.8 10.6 4.7 1.4 19.1 12.2 34.0 0.2 1.5 10.3 10.9 37.0 9.5 8.6 9.7 0.2 16.3 0.0 0.6 9.2 2.1 0.0 0.0 0.0 0.3 0.0 0.0 0.3 0.1 6.7 0.1 0.0 0.4 0.0 1.2 0.0 0.2 0.0 0.0 0.0 0.1 0.0 4.2 0.4 9.2 0.0 0.0 0.0 5.4 11.9 0.0 0.0 0.1 0.0 0.0 0.0 2.5 1.2 74.8 0.0 0.9 0.0 5.5 0.9 1.1 0.6 0.0 0.0 44.6 0.0 0.9 0.5 0.0 0.4 0.6 0.4 0.1 0.4 0.0 0.1 0.0 0.5 0.0 0.1 20.8 17.2 0.4 0.4 1.9 0.6 16.3 0.0 10.5 2.5 0.0 2.2 9.7 2.5 3.1 0.0 8.0 0.3 1.4 1.1 0.6 0.0 0.2 9.2 2.1 1.2 1.1 1.1 1.1 1.2 1.1 1.2 0.1 3.9 0.2 6.0 42.9 52.6 7.5 7.6 0.0 0.0 5.1 21.4 36.4 0.0 0.0 1.9 0.0 0.0 418.3 2.8 12.0 93.5 0.0 2.0 7.3 6.6 7.0 4.3 1.1 0.0 19.0 0.0 1.5 1175.9 13.3 2.0 45.5 0.0 35.3 1.1 0.0 8.6 8.5 0.0 0.0 6.5 9.2 12.5 8.5 5.6 1.8 32.0 26.4 7.9 FANCA "FA-H, FAA, FACA, FAH, FANCH" ENSG00000187741 "Fanconi anemia complementation group A" O15360 16 89737549-89816657 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "DNA damage, DNA repair" "Cancer-related genes, Disease mutation, Fanconi anemia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 20.6;testis: 28.8" "Cell type enhanced" "Detected in many" 6 "Erythroid cells: 23.3;Spermatocytes: 22.3;Spermatogonia: 33.2" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA063236 Supported Nucleoplasm NA Yes Nucleoplasm "HPA063236: AB_2684966" "unprognostic (5.99e-2)" "unprognostic (5.68e-2)" "unprognostic (2.36e-1)" "unprognostic (5.12e-2)" "unprognostic (1.87e-1)" "unprognostic (7.11e-2)" "unprognostic (1.45e-4)" "unprognostic (9.21e-2)" "unprognostic (1.58e-2)" "unprognostic (2.05e-1)" "unprognostic (4.82e-3)" "unprognostic (8.48e-4)" "unprognostic (7.82e-10)" "unprognostic (3.67e-2)" "unprognostic (2.05e-1)" "unprognostic (2.94e-1)" "unprognostic (1.62e-1)" 2.1 2.0 2.2 16.5 3.7 17.1 1.7 5.7 6.6 1.7 5.1 1.1 0.6 5.0 1.7 3.1 6.6 1.9 1.6 1.7 1.8 1.4 2.1 5.8 3.3 11.1 1.3 2.7 1.6 1.8 2.3 1.9 11.2 2.4 1.7 6.3 1.5 2.2 0.5 0.7 5.0 5.4 2.0 1.6 6.9 3.5 28.8 0.8 20.6 1.7 4.6 17.6 2.9 2.5 7.4 6.5 9.9 9.2 7.5 9.5 4.2 9.3 14.4 17.3 15.1 1.1 2.2 13.2 11.7 6.4 19.8 8.3 12.6 15.6 23.1 5.5 4.0 6.6 14.5 11.6 8.7 20.9 5.4 19.5 6.8 18.5 25.8 0.7 6.9 7.5 0.7 0.9 16.0 5.1 2.8 6.2 11.7 16.3 7.1 10.3 21.7 13.8 30.0 11.2 12.9 9.0 25.2 13.9 4.2 4.9 8.9 15.5 8.4 17.5 5.2 2.2 10.4 9.4 12.5 4.6 15.9 16.8 8.8 12.2 6.4 7.5 22.9 7.5 15.5 15.1 2.6 7.9 9.9 4.7 8.8 3.3 7.4 2.8 4.1 6.5 5.5 0.7 3.0 9.8 7.5 9.2 0.4 9.5 4.2 2.2 3.7 5.7 6.6 1.8 1.4 1.3 2.7 2.4 0.8 0.0 0.6 13.1 1.4 3.1 8.8 1.6 0.0 1.4 3.4 15.7 9.8 10.9 1.7 1.6 5.3 0.8 2.0 23.3 1.4 7.5 1.3 0.5 2.3 4.0 7.7 3.2 1.7 7.4 4.3 3.5 1.4 6.3 0.0 0.0 6.1 1.4 1.5 0.0 0.0 6.8 7.2 0.0 1.0 22.3 33.2 1.6 21.2 3.2 6.3 2.1 FANCC "FA3, FAC, FACC" ENSG00000158169 "Fanconi anemia complementation group C" Q00597 9 95099054-95426796 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "DNA damage, DNA repair" "Cancer-related genes, Disease mutation, Fanconi anemia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 29.7" "Group enriched" "Detected in many" 5 "Early spermatids: 190.4;Late spermatids: 63.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in many" 6 "basophil: 10.4" "Lineage enriched" "Detected in many" 6 "granulocytes: 10.4" "Cell line enhanced" "Detected in all" "RH-30: 31.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB017793, HPA030771" Approved Supported Nucleoplasm NA NA Nucleoplasm "CAB017793: , HPA030771: AB_2673604" "unprognostic (1.48e-2)" "unprognostic (4.33e-2)" "unprognostic (1.10e-1)" "unprognostic (2.63e-1)" "unprognostic (2.14e-1)" "unprognostic (1.32e-2)" "unprognostic (3.41e-3)" "unprognostic (1.26e-2)" "unprognostic (7.45e-3)" "unprognostic (1.37e-1)" "unprognostic (8.00e-3)" "unprognostic (3.19e-2)" "prognostic favorable (6.03e-6)" "unprognostic (2.35e-2)" "unprognostic (1.82e-1)" "unprognostic (1.49e-1)" "unprognostic (5.71e-2)" 4.9 2.7 4.3 8.6 7.0 3.6 4.6 29.7 7.7 4.6 6.4 4.9 5.1 7.1 6.3 4.1 4.5 3.6 5.2 3.2 4.0 2.7 10.0 25.7 6.7 3.7 7.3 1.6 3.3 5.4 2.9 12.1 4.3 6.7 4.4 6.1 4.0 4.0 4.2 4.5 7.7 8.1 2.9 6.4 3.4 4.4 19.6 7.3 7.9 4.3 3.2 6.0 3.5 4.0 1.0 1.3 10.4 1.7 0.3 1.5 0.7 13.6 9.2 12.2 10.6 1.2 3.2 7.7 5.9 3.9 9.5 8.8 10.5 5.8 7.8 4.2 4.3 7.3 16.7 12.3 5.2 5.2 7.4 5.8 6.1 10.4 5.4 2.0 6.1 6.8 2.7 2.2 7.6 3.4 2.6 5.2 7.6 9.1 3.4 6.8 9.6 5.7 3.5 5.8 14.5 5.2 12.2 31.5 3.6 3.9 3.5 17.7 9.4 11.3 4.0 3.4 6.4 4.2 5.1 2.5 8.3 12.2 9.1 8.4 3.6 6.6 4.1 4.5 5.6 9.8 10.4 0.4 0.0 1.3 0.8 1.3 1.0 0.7 1.5 0.4 1.0 1.2 1.0 0.1 0.3 1.7 1.3 1.3 0.7 4.3 7.0 29.7 7.7 4.0 2.7 7.3 1.6 6.7 7.3 3.0 2.1 0.0 2.3 2.3 5.4 1.6 5.1 1.4 3.4 0.0 3.9 2.3 1.7 4.1 190.4 4.3 3.3 0.0 3.6 4.0 2.0 2.5 5.7 25.1 1.8 9.5 0.0 4.3 2.7 63.3 6.1 1.3 1.7 3.6 4.5 2.6 3.4 0.0 2.1 7.7 4.2 0.0 1.6 13.0 10.6 2.4 1.9 1.0 3.8 2.5 FANCD2 "FA-D2, FACD, FAD, FANCD" ENSG00000144554 "Fanconi anemia complementation group D2" Q9BXW9 3 10026414-10101930 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cell cycle, DNA damage, DNA repair" "Cancer-related genes, Disease mutation, Fanconi anemia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 24.4;testis: 23.3" "Cell type enhanced" "Detected in many" 9 "Erythroid cells: 46.7;Spermatocytes: 55.1;Spermatogonia: 32.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "BEWO: 46.0" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB016117, HPA063742" Approved Supported "Nucleoplasm,Nucleoli,Nuclear bodies,Cytosol" No No Nucleoplasm "Nucleoli, Nuclear bodies, Cytosol" "CAB016117: AB_2278211, HPA063742: AB_2685110" "unprognostic (3.25e-2)" "unprognostic (1.09e-1)" "unprognostic (6.21e-2)" "unprognostic (1.12e-2)" "unprognostic (2.92e-1)" "unprognostic (3.36e-2)" "unprognostic (1.08e-5)" "unprognostic (2.96e-2)" "unprognostic (1.59e-3)" "prognostic unfavorable (5.00e-5)" "unprognostic (1.23e-2)" "unprognostic (9.14e-2)" "unprognostic (4.41e-10)" "unprognostic (9.11e-3)" "unprognostic (3.99e-1)" "unprognostic (7.76e-2)" "unprognostic (2.89e-2)" 2.0 1.3 0.8 10.3 2.6 12.2 2.4 1.6 2.7 1.7 2.9 1.1 1.0 2.2 2.2 1.8 4.7 2.4 2.5 1.1 0.8 0.9 2.3 1.0 2.4 9.5 1.3 1.2 3.5 3.5 0.6 1.1 5.3 1.4 2.2 4.9 1.6 3.3 0.4 3.0 3.3 6.2 1.2 2.0 7.3 2.4 23.3 1.6 24.4 1.6 5.6 14.6 2.2 2.4 6.8 3.7 5.3 2.6 2.1 2.9 1.0 8.7 9.3 17.8 5.0 0.9 1.4 46.0 8.0 3.6 11.5 9.4 6.9 8.7 17.1 3.8 2.6 9.5 7.6 18.3 6.2 11.5 8.1 12.4 23.3 14.3 6.6 0.1 17.3 14.6 0.4 1.0 13.0 7.2 1.6 6.9 14.7 14.2 19.6 8.7 10.0 14.4 6.7 21.4 6.7 6.5 15.8 14.5 12.1 4.0 9.8 4.9 9.8 9.8 7.7 3.1 13.5 11.8 11.0 4.0 9.6 11.0 5.8 11.6 8.3 16.3 28.9 5.5 17.8 16.3 5.3 1.4 3.7 1.5 1.0 1.3 4.9 2.0 1.2 0.9 6.8 2.5 1.9 3.3 2.1 2.6 3.7 2.9 1.0 0.8 2.6 1.6 2.7 0.8 0.9 1.3 1.2 1.4 1.6 0.0 0.3 9.7 2.8 4.0 2.8 1.6 0.0 1.4 1.2 1.8 9.8 6.6 0.0 1.6 4.4 1.5 0.7 46.7 2.9 12.7 1.3 2.2 1.1 1.0 5.0 0.0 1.2 3.7 3.4 5.6 2.0 5.2 3.3 7.2 2.0 0.8 1.4 2.8 1.4 0.5 5.8 19.4 0.8 55.1 32.4 2.4 5.8 3.8 5.0 2.3 FANCG "FAG, XRCC9" ENSG00000221829 "Fanconi anemia complementation group G" O15287 9 35073835-35080016 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "DNA damage, DNA repair" "Cancer-related genes, Disease mutation, Fanconi anemia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 6 "Extravillous trophoblasts: 17.3;Spermatogonia: 23.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB008105, HPA045335" Approved Approved "Nucleoli,Plasma membrane,Cytosol" NA Yes "Plasma membrane, Cytosol" Nucleoli "CAB008105: AB_2231542, HPA045335: AB_2679292" "unprognostic (9.41e-2)" "unprognostic (2.62e-2)" "unprognostic (1.82e-1)" "unprognostic (1.05e-1)" "unprognostic (2.09e-1)" "unprognostic (5.83e-3)" "prognostic unfavorable (2.02e-4)" "unprognostic (8.92e-2)" "unprognostic (1.42e-2)" "unprognostic (2.27e-3)" "unprognostic (9.01e-2)" "unprognostic (5.62e-2)" "prognostic unfavorable (2.38e-7)" "unprognostic (1.14e-2)" "unprognostic (1.59e-1)" "unprognostic (1.24e-1)" "unprognostic (2.10e-1)" 5.8 5.0 4.4 7.1 6.5 14.9 7.5 13.9 8.5 6.2 5.9 5.3 8.4 6.7 6.8 3.2 9.2 8.6 4.7 5.9 7.6 4.0 5.2 4.5 5.1 9.9 8.7 4.4 9.2 17.0 6.7 4.8 7.6 6.6 7.0 5.5 3.5 8.7 9.7 2.9 8.9 6.5 6.4 4.2 8.6 5.8 8.9 7.6 25.6 9.3 4.8 9.2 6.8 6.9 6.8 4.8 8.9 2.5 8.8 9.2 3.4 15.7 19.6 14.4 13.3 3.2 5.1 12.1 11.1 8.0 21.8 21.0 9.3 9.9 15.6 7.7 3.5 15.6 9.7 11.9 10.2 8.4 18.3 7.2 11.2 21.0 5.7 0.9 11.3 12.9 4.2 2.0 19.0 8.6 3.8 11.1 19.2 7.3 21.0 11.0 14.0 19.1 15.6 14.9 11.8 15.1 19.9 16.9 11.0 5.1 6.7 7.0 12.7 7.3 10.4 4.1 6.5 13.5 8.2 6.7 10.4 20.7 13.3 14.9 5.7 10.8 9.4 9.2 8.4 14.2 8.9 0.8 7.7 7.4 2.5 6.5 6.8 6.1 5.7 2.2 6.5 4.8 5.0 1.3 8.8 2.3 4.8 9.2 3.4 4.4 6.5 13.9 8.5 7.6 4.0 8.7 4.4 6.6 7.6 3.0 5.8 5.2 3.6 3.9 4.3 1.0 0.0 0.0 2.3 3.5 3.9 8.2 3.3 3.7 0.3 2.8 1.6 0.0 2.0 17.3 3.8 3.5 13.9 1.0 6.5 4.8 1.7 3.7 0.3 0.4 3.1 2.0 3.3 3.6 3.9 3.5 2.3 3.2 3.9 1.7 3.0 0.0 2.7 10.9 23.7 2.3 5.5 5.3 5.0 3.3 FAS "APO-1, APT1, CD95, FAS1, TNFRSF6" ENSG00000026103 "Fas cell surface death receptor" P25445 10 88990582-89015785 "Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins" Apoptosis "Calmodulin-binding, Receptor" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 7 "Basal glandular cells: 100.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 40.1" "Group enriched" "Detected in all" 5 "granulocytes: 40.1;T-cells: 30.9" "Cell line enhanced" "Detected in many" "HDLM-2: 28.0;Karpas-707: 44.7" "Low region specificity" "Detected in all" HPA027444 Uncertain Supported "Nuclear bodies,Plasma membrane,Cytosol" "Secreted to blood" NA NA 11900000 450000 "Plasma membrane" "Nuclear bodies, Cytosol" "HPA027444: AB_10601378" "unprognostic (6.84e-2)" "unprognostic (2.88e-3)" "unprognostic (8.38e-3)" "unprognostic (1.94e-1)" "unprognostic (2.35e-2)" "unprognostic (9.56e-2)" "unprognostic (7.00e-2)" "unprognostic (2.05e-1)" "unprognostic (3.01e-1)" "unprognostic (7.70e-2)" "unprognostic (1.26e-2)" "unprognostic (1.98e-1)" "unprognostic (1.52e-3)" "unprognostic (2.10e-1)" "unprognostic (2.32e-2)" "unprognostic (4.95e-3)" "unprognostic (1.65e-1)" 13.5 26.3 6.1 17.3 7.7 12.4 10.6 2.1 7.2 15.6 14.2 6.1 7.0 5.9 15.7 16.6 14.1 14.2 14.5 8.9 8.2 2.7 11.7 21.9 28.6 15.6 6.0 3.9 24.7 4.1 4.5 4.6 9.0 7.5 22.3 21.3 4.4 7.1 8.5 4.3 9.6 16.3 12.5 10.2 15.3 5.0 7.3 5.1 12.5 10.0 15.8 14.4 14.8 21.4 3.0 4.0 40.1 6.8 1.2 30.9 3.9 8.7 3.4 1.8 5.6 14.5 21.4 0.0 19.2 19.5 0.7 3.8 0.0 9.5 1.7 7.4 18.0 3.2 1.4 0.3 16.2 1.3 28.0 2.8 0.1 1.8 5.7 13.9 0.9 0.4 26.5 14.5 12.0 26.0 9.4 1.7 6.4 0.0 44.7 19.6 0.8 2.8 1.4 0.2 0.0 0.9 0.2 0.1 1.8 27.1 2.8 0.1 0.1 2.8 0.0 0.3 2.8 6.1 0.3 4.2 6.2 3.4 5.7 4.4 17.5 1.8 0.1 5.1 3.5 1.8 11.3 3.2 9.4 3.3 3.9 4.8 3.0 10.4 7.2 4.0 0.7 1.2 3.4 40.1 1.2 6.8 0.0 30.9 3.9 6.1 7.7 2.1 7.2 8.2 2.7 6.0 3.9 7.5 5.1 53.6 14.4 3.7 100.3 40.8 0.0 1.2 15.3 21.4 21.6 8.7 0.0 0.4 0.0 6.7 5.4 8.4 12.0 0.0 3.8 0.2 34.9 22.7 3.5 15.3 5.0 1.6 8.1 2.5 6.9 3.5 17.5 12.7 11.8 20.8 15.0 17.1 4.3 0.0 13.1 11.5 0.7 6.5 33.4 4.8 1.3 38.3 0.3 37.9 23.2 22.7 FAT1 "CDHF7, CDHR8, FAT" ENSG00000083857 "FAT atypical cadherin 1" Q14517 4 186587783-186726722 "Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 76.4" "Cell type enhanced" "Detected in many" 4 "Basal keratinocytes: 75.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "fHDF/TERT166: 64.9;LHCN-M2: 47.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001869, HPA023882" Enhanced "Intracellular and membrane" NA NA 120000 "HPA001869: AB_1078818, HPA023882: AB_1848429" "unprognostic (1.98e-1)" "unprognostic (4.91e-2)" "unprognostic (2.50e-2)" "unprognostic (1.86e-1)" "unprognostic (1.53e-2)" "unprognostic (5.82e-3)" "unprognostic (2.31e-1)" "prognostic unfavorable (4.22e-4)" "unprognostic (6.10e-2)" "unprognostic (3.05e-2)" "unprognostic (1.15e-3)" "unprognostic (6.80e-2)" "unprognostic (3.57e-2)" "unprognostic (8.03e-3)" "unprognostic (9.41e-2)" "unprognostic (6.25e-3)" "unprognostic (4.27e-2)" 15.5 1.3 7.9 12.3 9.8 0.4 15.4 11.9 8.4 15.9 40.4 11.8 8.1 17.9 20.6 14.0 9.7 9.6 28.2 21.1 10.0 6.0 29.1 13.3 10.9 1.4 11.4 6.2 9.7 13.8 7.5 10.5 14.6 24.7 15.9 22.9 5.0 13.9 18.2 3.0 13.1 76.4 18.3 12.8 1.7 11.5 7.0 11.2 1.3 10.5 10.2 6.7 17.5 9.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.9 19.0 18.9 0.0 18.9 22.8 4.6 25.4 41.9 12.4 7.9 11.3 11.2 0.0 6.1 64.9 8.0 9.2 7.4 31.3 16.9 0.0 3.0 0.0 6.7 11.4 9.4 8.2 6.8 8.2 11.3 23.0 15.0 17.0 0.2 10.3 0.1 0.0 47.7 6.0 14.6 0.0 4.2 9.5 3.2 0.0 5.2 0.4 18.6 17.9 2.0 7.6 4.4 7.5 3.0 13.5 0.0 3.0 5.4 35.4 13.7 0.4 15.7 0.1 0.0 0.1 8.1 0.0 12.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.9 9.8 11.9 8.4 10.0 6.0 11.4 6.2 24.7 11.2 14.9 4.1 0.0 25.5 75.6 5.2 20.3 35.7 16.0 25.0 50.6 0.0 1.1 5.0 21.9 0.6 5.1 58.5 0.0 23.2 3.5 24.9 37.8 16.1 22.9 0.3 0.0 13.9 1.8 1.0 0.4 13.6 3.1 11.8 0.0 54.8 4.2 24.0 23.0 35.0 21.4 0.3 38.8 54.6 1.8 7.7 40.9 1.4 0.0 38.7 20.0 FAT4 "CDHF14, CDHR11, FAT-J" ENSG00000196159 "FAT atypical cadherin 4" Q6V0I7 4 125316399-125492932 "Cancer-related genes, Disease related genes, Predicted membrane proteins" "Cell adhesion" "Cancer-related genes, Deafness, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in some" 15 "Endothelial cells: 11.1;Fibroblasts: 9.3;Ito cells: 30.7" "Low cancer specificity" "Detected in many" "Cell type enriched" "Detected in single" 12 "NK-cell: 1.1" "Lineage enriched" "Detected in single" 12 "NK-cells: 1.1" "Cell line enhanced" "Detected in many" "ASC diff: 12.3;ASC TERT1: 9.1;fHDF/TERT166: 8.9;HSkMC: 10.5;HUVEC TERT2: 11.1;TIME: 17.3" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA052819 Approved Approved Cytosol NA NA 7900000 Cytosol "HPA052819: AB_2681963" "unprognostic (1.18e-1)" "unprognostic (1.77e-1)" "unprognostic (7.99e-2)" "unprognostic (1.09e-1)" "unprognostic (2.31e-1)" "unprognostic (2.81e-4)" "unprognostic (6.17e-3)" "unprognostic (1.28e-1)" "unprognostic (1.77e-2)" "unprognostic (2.78e-2)" "unprognostic (1.63e-1)" "unprognostic (1.39e-1)" "prognostic favorable (1.89e-4)" "unprognostic (2.38e-2)" "unprognostic (1.71e-1)" "unprognostic (1.30e-2)" "unprognostic (2.49e-3)" 3.8 0.5 0.9 0.8 0.7 0.0 3.2 0.0 0.5 4.4 7.1 0.3 2.7 0.6 1.9 2.1 4.1 5.0 1.0 0.4 2.6 2.0 5.3 0.1 0.9 5.3 0.5 6.7 0.4 2.5 3.6 1.9 1.0 2.3 1.1 1.4 2.4 3.3 0.6 2.1 2.4 0.1 3.9 0.2 3.0 2.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.7 6.0 0.6 12.3 9.1 0.0 2.0 2.4 1.0 1.0 0.0 0.3 0.0 2.5 8.9 1.2 0.0 2.2 2.5 0.6 0.0 1.0 1.3 2.5 0.0 4.0 0.8 0.0 10.5 1.4 0.5 5.5 7.2 11.1 0.0 0.0 1.6 5.0 0.1 0.4 0.0 0.4 0.0 0.2 0.7 1.2 0.0 0.1 0.0 0.1 1.2 0.3 0.0 0.0 0.3 0.0 0.0 17.3 6.1 1.7 2.1 0.9 0.2 0.0 0.0 1.6 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 6.0 0.0 0.0 0.1 1.4 1.3 5.3 0.0 0.0 0.0 5.2 0.0 0.1 0.0 0.7 0.8 11.1 0.0 0.0 0.2 0.0 9.3 0.1 0.0 6.8 0.2 0.0 0.0 30.7 2.4 0.0 5.5 0.0 3.3 0.0 0.0 1.2 0.2 0.0 4.6 0.6 0.1 0.0 3.9 0.0 0.6 0.5 0.0 0.0 0.0 0.0 FBXO11 "FBX11, UBR6" ENSG00000138081 "F-box protein 11" Q86XK2 2 47789316-47905793 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Ubl conjugation pathway" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA002690 Supported Nucleoplasm,Nucleoli NA NA "Nucleoplasm, Nucleoli" "HPA002690: AB_1848448" "unprognostic (1.18e-1)" "unprognostic (8.65e-3)" "unprognostic (3.93e-2)" "unprognostic (2.05e-2)" "unprognostic (7.92e-2)" "unprognostic (1.42e-1)" "unprognostic (3.85e-2)" "unprognostic (1.02e-1)" "unprognostic (2.55e-2)" "unprognostic (9.82e-2)" "unprognostic (5.77e-2)" "unprognostic (2.33e-2)" "unprognostic (3.21e-2)" "unprognostic (1.55e-1)" "unprognostic (3.71e-1)" "unprognostic (2.19e-1)" "unprognostic (3.20e-2)" 18.0 13.8 18.6 15.7 18.8 17.5 26.1 42.2 31.7 21.3 15.3 12.7 15.1 10.4 28.9 16.8 14.5 16.3 15.0 14.1 16.9 13.6 14.3 17.0 22.3 15.0 17.4 21.7 28.9 12.4 25.2 14.4 14.5 19.7 15.3 13.3 12.0 15.6 16.5 22.9 14.5 13.5 19.9 16.4 14.5 13.3 25.1 16.0 14.6 17.3 9.8 17.2 19.3 21.9 4.7 4.3 8.2 2.7 4.8 6.6 2.0 25.5 13.3 31.9 27.2 22.4 21.1 19.0 17.9 24.6 16.7 16.5 11.2 13.0 16.5 23.4 25.1 20.8 12.7 21.8 18.9 24.7 11.0 10.8 15.4 10.9 17.8 21.5 16.0 16.4 20.6 21.3 14.9 25.2 26.6 21.4 8.3 15.0 17.1 20.5 12.3 15.3 15.6 19.4 16.9 13.1 20.0 29.6 12.3 23.9 20.9 22.5 26.6 16.9 15.9 26.1 24.7 7.4 13.7 23.1 20.8 19.2 13.9 19.6 14.8 7.7 30.1 14.1 15.1 21.1 8.2 2.3 4.3 3.8 2.7 3.8 4.7 3.4 4.1 3.1 3.6 6.6 4.1 4.1 4.8 2.4 4.3 3.6 2.0 18.6 18.8 42.2 31.7 16.9 13.6 17.4 21.7 19.7 16.0 14.9 36.6 13.7 38.4 59.5 42.4 7.8 12.7 37.5 23.9 17.4 31.4 16.6 10.0 15.5 22.2 26.9 15.8 0.0 13.2 13.7 43.3 34.1 27.8 17.0 21.7 52.4 23.0 29.4 42.9 29.9 27.9 40.9 33.7 17.2 16.7 30.9 20.6 14.4 37.4 11.3 39.1 19.4 35.3 51.9 40.4 51.6 30.1 26.6 16.9 57.8 FBXW7 "AGO, CDC4, FBW7, FBX30, FBXW6, FLJ11071, SEL-10, SEL10" ENSG00000109670 "F-box and WD repeat domain containing 7" Q969H0 4 152320544-152536063 "Cancer-related genes, Predicted intracellular proteins" "Biological rhythms, Host-virus interaction, Ubl conjugation pathway" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 60.1;skin 1: 45.0" "Cell type enhanced" "Detected in many" 7 "Basal keratinocytes: 179.3;Suprabasal keratinocytes: 152.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "U-266/70: 38.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB013793, CAB029987" Supported Supported Nucleoplasm,Vesicles NA NA "Nucleoplasm, Vesicles" "CAB013793: AB_2533451, CAB029987: AB_2246842" "unprognostic (3.32e-1)" "unprognostic (9.02e-2)" "unprognostic (1.84e-2)" "unprognostic (3.08e-2)" "unprognostic (3.87e-1)" "unprognostic (1.36e-3)" "unprognostic (4.37e-1)" "unprognostic (1.94e-1)" "unprognostic (8.28e-2)" "unprognostic (3.29e-1)" "unprognostic (5.32e-3)" "unprognostic (3.19e-2)" "prognostic unfavorable (1.52e-4)" "unprognostic (3.38e-2)" "unprognostic (1.41e-1)" "unprognostic (5.49e-3)" "unprognostic (2.17e-3)" 9.2 6.8 27.0 8.9 27.9 11.1 9.8 27.2 60.1 5.5 6.1 3.6 3.8 4.9 6.0 18.3 9.8 10.6 6.3 10.9 21.4 10.1 4.1 7.3 6.9 9.8 9.1 40.5 6.4 8.0 6.4 7.3 6.2 37.2 5.1 6.9 2.8 7.6 5.3 15.8 45.0 6.5 6.1 6.4 10.1 8.0 13.7 5.7 6.5 6.8 10.6 12.3 7.9 6.5 2.9 2.2 16.6 3.4 7.8 5.0 1.3 4.9 4.0 10.3 7.5 7.2 5.2 8.6 7.2 6.6 4.5 4.2 8.0 6.4 12.9 2.0 6.9 3.4 3.0 8.9 16.2 6.3 7.3 4.2 6.0 4.9 5.7 7.3 14.6 5.5 8.2 25.8 7.7 13.1 4.7 7.8 10.5 9.4 13.8 5.6 7.0 16.8 5.8 5.0 4.2 3.2 16.9 4.4 2.5 5.5 8.6 6.6 5.7 4.6 6.3 3.9 12.2 3.4 6.9 8.2 6.1 6.9 3.1 4.0 38.0 21.7 12.6 4.9 4.8 4.3 16.6 3.1 1.7 5.0 3.4 3.3 2.9 3.7 3.2 1.8 2.4 3.9 3.2 5.5 7.8 2.5 2.2 3.3 1.3 27.0 27.9 27.2 60.1 21.4 10.1 9.1 40.5 37.2 5.7 8.9 18.5 27.6 32.1 179.3 67.8 54.1 7.6 8.1 13.6 8.7 29.5 9.7 3.3 11.6 13.1 26.4 13.5 0.0 11.7 33.1 24.6 28.4 15.1 15.6 9.4 11.1 13.9 17.8 16.2 7.4 14.1 20.2 27.0 16.2 11.7 30.1 15.8 15.8 10.6 6.0 40.5 12.9 25.6 57.9 80.3 152.9 26.1 34.6 11.3 48.9 FES FPS ENSG00000182511 "FES proto-oncogene, tyrosine kinase" P07332 15 90883695-90895776 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Proto-oncogene, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 60.8;lymphoid tissue: 49.7" "Cell type enhanced" "Detected in many" 11 "Hofbauer cells: 40.6;Kupffer cells: 93.1;Macrophages: 37.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "eosinophil: 60.8" "Group enriched" "Detected in many" 4 "dendritic cells: 32.6;granulocytes: 60.8;monocytes: 30.5" "Cell line enhanced" "Detected in many" "HEL: 21.3;HL-60: 19.0;HMC-1: 40.7;NB-4: 24.9;THP-1: 37.4;U-937: 16.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" HPA001376 Approved Approved Nucleoplasm,Vesicles,Cytosol NA NA "Nucleoplasm, Cytosol" Vesicles "HPA001376: AB_1078847" "unprognostic (1.07e-2)" "unprognostic (2.54e-2)" "prognostic unfavorable (5.78e-4)" "unprognostic (2.31e-2)" "unprognostic (4.05e-3)" "unprognostic (7.33e-2)" "unprognostic (1.74e-1)" "unprognostic (2.22e-1)" "unprognostic (1.58e-3)" "unprognostic (1.35e-1)" "unprognostic (4.66e-2)" "unprognostic (5.15e-3)" "unprognostic (1.78e-3)" "unprognostic (2.53e-3)" "unprognostic (6.08e-2)" "unprognostic (1.18e-1)" "unprognostic (1.40e-1)" 14.9 3.4 4.8 9.7 4.1 38.3 12.7 2.4 5.7 6.8 5.4 3.2 4.7 3.0 7.4 5.6 4.9 7.6 7.3 7.9 4.2 2.2 5.2 11.8 12.7 23.3 3.7 0.9 6.4 3.7 1.8 2.7 8.1 7.2 7.7 2.4 5.3 33.8 6.3 3.4 3.5 5.2 5.4 6.9 49.7 4.3 3.2 4.7 3.1 7.2 4.1 4.5 7.2 9.4 1.1 32.6 60.8 30.5 9.3 0.1 13.8 0.1 0.2 0.3 3.6 1.0 3.1 6.1 0.9 0.0 1.8 1.0 0.9 0.0 2.3 0.1 2.0 0.0 0.5 0.6 0.1 0.5 1.2 0.3 21.3 0.0 3.8 2.1 19.0 40.7 3.1 0.0 2.6 0.0 0.0 10.8 3.2 0.6 0.0 0.0 6.9 0.6 24.9 1.0 0.8 0.0 2.8 0.0 0.0 0.0 0.1 0.1 0.0 0.0 1.0 0.9 1.1 0.0 37.4 8.4 0.0 3.7 0.1 0.0 0.0 2.7 0.8 0.1 16.1 0.8 10.4 30.5 60.8 0.1 17.6 0.0 1.1 0.0 0.0 32.6 0.9 0.0 0.0 20.0 9.3 7.3 12.9 0.0 13.8 4.8 4.1 2.4 5.7 4.2 2.2 3.7 0.9 7.2 4.7 3.0 8.0 6.4 4.7 3.4 0.0 2.5 5.1 0.0 0.0 1.8 0.0 4.5 3.3 4.8 1.1 24.5 0.4 0.0 3.9 3.8 6.2 4.0 28.8 8.2 40.6 0.0 2.9 22.7 93.1 4.7 8.3 37.3 6.8 27.1 2.1 2.3 2.0 0.0 9.6 1.3 1.9 12.9 7.2 3.5 9.1 2.5 3.8 10.2 2.6 5.2 FGFR2 "BEK, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25" ENSG00000066468 "Fibroblast growth factor receptor 2" P21802 10 121478334-121598458 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins" Apoptosis "Heparin-binding, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Craniosynostosis, Disease mutation, Ectodermal dysplasia, FDA approved drug targets, Lacrimo-auriculo-dento-digital syndrome, Mental retardation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 74.8" "Cell type enhanced" "Detected in many" 16 "Cholangiocytes: 191.1;Club cells: 52.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 15 "basophil: 10.8;eosinophil: 4.6" "Lineage enriched" "Detected in single" 35 "granulocytes: 10.8" "Cell line enhanced" "Detected in some" "AN3-CA: 58.9;BEWO: 19.8;CACO-2: 15.4;HaCaT: 17.8;HAP1: 19.1;NTERA-2: 18.9;T-47d: 15.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010886, HPA035305" Uncertain Supported "Nucleoplasm,Vesicles,Cell Junctions" "Secreted - unknown location" NA NA 500000 "Cell Junctions" "Nucleoplasm, Vesicles" "CAB010886: AB_259379, HPA035305: AB_10672862" "unprognostic (5.53e-2)" "prognostic favorable (8.79e-4)" "unprognostic (1.08e-1)" "unprognostic (5.23e-2)" "unprognostic (1.73e-1)" "prognostic favorable (9.32e-4)" "unprognostic (1.53e-1)" "unprognostic (4.96e-3)" "unprognostic (1.74e-1)" "unprognostic (1.56e-1)" "unprognostic (1.07e-1)" "unprognostic (3.74e-2)" "unprognostic (1.01e-1)" "unprognostic (6.11e-2)" "unprognostic (2.54e-1)" "unprognostic (6.93e-2)" "unprognostic (2.25e-1)" 2.1 8.8 16.4 3.0 30.3 0.0 9.9 15.8 21.3 6.8 14.1 55.7 5.6 4.2 22.0 6.6 10.2 12.5 12.5 1.4 20.6 11.1 11.4 16.1 13.1 1.0 41.2 13.3 7.4 12.8 25.5 2.5 6.2 30.2 11.7 8.7 16.4 23.8 24.3 0.4 45.4 4.7 18.3 74.8 0.5 9.3 2.9 32.1 0.8 23.4 1.6 3.4 6.9 8.5 0.1 0.1 10.8 0.1 0.1 0.3 0.0 2.2 0.1 9.2 58.9 0.0 0.0 19.8 0.1 0.0 0.0 0.0 15.4 0.3 0.0 4.2 0.9 0.0 17.8 19.1 4.0 0.0 0.0 4.1 0.0 0.0 0.3 0.4 0.0 3.8 0.0 8.5 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 3.5 0.0 0.0 18.9 2.7 0.0 0.0 0.0 2.3 5.7 5.0 0.1 0.1 0.1 10.8 0.0 11.5 15.8 0.0 0.0 0.1 2.9 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.1 10.8 0.1 4.6 0.1 0.0 0.0 0.0 0.3 0.0 0.0 0.1 0.0 0.1 0.5 0.1 0.0 0.1 0.0 0.0 16.4 30.3 15.8 21.3 20.6 11.1 41.2 13.3 30.2 32.1 17.9 31.8 0.0 29.5 35.6 0.0 2.7 191.1 18.7 52.4 34.9 0.0 12.6 0.0 4.0 2.9 0.5 2.6 0.0 0.2 2.7 17.5 9.8 0.0 4.3 2.0 0.0 2.4 3.1 0.3 6.5 1.1 1.3 5.0 1.0 32.0 1.6 0.6 1.4 5.6 11.5 0.1 0.0 2.1 0.9 7.7 24.2 3.3 1.5 3.0 27.7 FGFR3 "ACH, CD333, CEK2, JTK4" ENSG00000068078 "Fibroblast growth factor receptor 3" P22607 4 1793293-1808872 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins" Apoptosis "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Craniosynostosis, Deafness, Disease mutation, Dwarfism, Ectodermal dysplasia, FDA approved drug targets, Lacrimo-auriculo-dento-digital syndrome" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "skin 1: 131.7" "Cell type enhanced" "Detected in many" 9 "Basal keratinocytes: 92.2;Cholangiocytes: 94.3;Suprabasal keratinocytes: 77.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "CACO-2: 19.3;HaCaT: 15.1;Hep G2: 32.5;NTERA-2: 15.8;RT4: 19.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004231, HPA067204" Enhanced Supported "Endoplasmic reticulum" "Intracellular and membrane" NA NA 670000 "Endoplasmic reticulum" "CAB004231: AB_627596, HPA067204: AB_2685804" "unprognostic (1.34e-1)" "unprognostic (5.29e-3)" "unprognostic (1.49e-1)" "prognostic unfavorable (3.77e-4)" "unprognostic (5.90e-2)" "unprognostic (1.24e-3)" "unprognostic (7.22e-2)" "unprognostic (2.54e-1)" "unprognostic (1.99e-1)" "unprognostic (2.17e-1)" "unprognostic (1.38e-1)" "unprognostic (2.88e-2)" "unprognostic (1.30e-1)" "unprognostic (9.11e-3)" "unprognostic (1.98e-1)" "unprognostic (4.74e-2)" "unprognostic (1.97e-1)" 1.5 1.5 24.7 1.7 30.3 1.6 4.2 10.2 22.0 4.1 4.9 15.8 3.4 9.9 1.8 2.7 26.9 2.0 5.0 2.0 21.6 11.7 9.6 7.4 4.5 1.3 17.6 21.5 1.1 23.0 1.2 3.0 5.6 15.1 3.7 3.8 1.7 3.8 9.0 1.7 131.7 7.4 1.3 9.0 2.1 4.9 8.1 10.6 0.1 1.3 8.5 7.3 8.5 10.1 0.1 0.6 0.1 0.1 0.2 0.3 0.0 0.0 1.5 9.2 2.6 0.0 0.1 9.4 1.1 0.1 0.4 0.2 19.3 0.4 0.0 7.7 0.3 0.4 15.1 2.6 0.1 0.1 0.1 9.7 6.0 1.5 32.5 0.0 0.0 0.2 0.0 5.1 0.1 0.0 0.0 0.0 0.9 6.5 0.0 0.0 9.6 0.4 0.2 15.8 8.8 0.0 0.5 0.5 0.1 1.3 19.3 2.7 0.7 0.8 1.6 0.0 11.1 9.0 1.1 0.4 0.0 0.9 0.2 0.6 0.0 0.0 0.0 0.1 0.7 0.5 0.0 0.1 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.2 0.0 0.6 0.1 0.0 24.7 30.3 10.2 22.0 21.6 11.7 17.6 21.5 15.1 10.6 0.0 23.8 2.4 3.6 92.2 0.0 2.0 94.3 0.0 21.6 14.0 0.0 0.4 0.0 4.8 5.4 0.9 20.6 0.0 0.6 9.2 7.0 3.3 0.0 27.0 0.5 0.0 4.1 14.7 1.2 0.4 0.6 1.2 11.8 1.0 20.7 0.2 0.4 17.3 0.4 7.5 0.6 0.0 2.8 0.4 17.9 77.5 0.7 0.0 13.0 11.8 FGFR4 "CD334, JTK2" ENSG00000160867 "Fibroblast growth factor receptor 4" P22455 5 177086886-177098144 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters" "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "gallbladder: 33.6;kidney: 37.7;liver: 45.3" "Cell type enhanced" "Detected in many" 11 "Cholangiocytes: 50.9;Hepatocytes: 23.7;Proximal tubular cells: 19.5;Sertoli cells: 19.4;Undifferentiated cells: 33.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in some" "Cell type enhanced" "Detected in some" "neutrophil: 3.0" "Low lineage specificity" "Detected in many" "Group enriched" "Detected in many" 4 "CACO-2: 43.0;Hep G2: 43.0;RH-30: 69.1" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB005196, HPA027273, HPA027369, HPA028251" Approved "Intracellular and membrane" NA NA 4300000 "CAB005196: AB_631512, HPA027273: AB_10600212, HPA027369: AB_10599427, HPA028251: AB_10601221" "unprognostic (1.96e-1)" "unprognostic (2.10e-2)" "unprognostic (1.12e-1)" "unprognostic (9.06e-3)" "unprognostic (2.87e-1)" "unprognostic (1.95e-2)" "unprognostic (7.85e-3)" "unprognostic (9.19e-2)" "unprognostic (4.25e-1)" "unprognostic (4.46e-2)" "unprognostic (1.16e-1)" "unprognostic (3.48e-2)" "unprognostic (1.78e-1)" "unprognostic (1.71e-3)" "unprognostic (2.41e-1)" "unprognostic (5.75e-2)" "unprognostic (4.68e-2)" 0.5 5.7 0.7 14.3 0.6 0.1 1.6 2.6 0.5 2.8 10.4 0.9 0.7 13.5 0.9 4.8 1.6 1.7 33.6 0.7 0.8 0.3 37.7 45.3 25.3 2.5 0.7 1.0 13.6 26.0 0.0 0.7 1.3 0.8 4.0 3.7 2.0 1.6 0.3 4.3 0.5 17.3 1.6 0.8 11.2 5.4 2.9 0.4 0.3 0.8 2.3 0.7 1.9 3.6 1.1 0.9 3.0 1.1 0.4 0.4 0.0 0.7 12.1 0.2 2.9 0.0 0.0 5.9 0.0 0.0 0.0 0.0 43.0 1.6 1.3 5.6 0.0 0.6 0.6 2.4 0.4 0.0 0.7 2.8 0.1 0.6 43.0 1.3 0.1 1.0 0.2 0.0 2.1 0.0 0.0 0.0 0.8 4.0 0.1 0.9 9.8 0.0 0.8 7.3 7.6 1.0 1.9 69.1 7.2 5.8 0.1 0.4 0.7 0.4 3.1 1.4 1.6 2.9 0.6 0.2 0.0 5.8 0.0 0.1 0.4 0.4 0.7 0.0 0.2 0.5 1.5 1.1 0.4 0.4 0.3 0.3 1.1 0.4 0.0 0.1 0.6 0.4 0.4 3.0 0.4 0.3 0.9 0.2 0.0 0.7 0.6 2.6 0.5 0.8 0.3 0.7 1.0 0.8 0.4 0.0 0.0 0.8 0.6 0.6 0.4 0.8 50.9 0.0 0.0 3.5 0.0 1.1 3.3 8.4 0.1 0.1 10.6 0.0 4.4 3.2 1.7 0.3 0.0 23.7 0.3 0.0 4.1 2.5 0.8 0.0 0.6 0.0 0.0 1.0 5.2 0.9 3.6 2.9 1.4 19.5 0.1 19.4 0.5 1.6 12.8 0.4 7.3 0.0 33.6 0.6 FH fumarase ENSG00000091483 "Fumarate hydratase" P07954 1 241497603-241519761 "Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "DNA damage, DNA repair, Tricarboxylic acid cycle" Lyase "Cancer-related genes, Disease mutation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 93.4" "Cell type enhanced" "Detected in all" 4 "Early spermatids: 161.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB017785, HPA025770, HPA025948, HPA027341" Enhanced Supported Enhanced Mitochondria NA NA 2800000 Mitochondria "CAB017785: , HPA025770: AB_10599603, HPA025948: AB_10602177, HPA027341: AB_10601222" "unprognostic (1.03e-2)" "unprognostic (3.82e-2)" "unprognostic (9.46e-3)" "unprognostic (2.18e-1)" "unprognostic (2.10e-1)" "unprognostic (2.07e-1)" "unprognostic (2.28e-2)" "unprognostic (1.55e-1)" "unprognostic (5.14e-2)" "unprognostic (1.85e-2)" "unprognostic (1.27e-2)" "unprognostic (1.09e-1)" "prognostic favorable (2.76e-7)" "unprognostic (1.05e-1)" "unprognostic (1.05e-1)" "unprognostic (4.41e-2)" "unprognostic (1.24e-2)" 14.3 28.1 15.7 10.4 20.2 9.3 13.3 15.7 24.4 10.5 22.7 9.9 16.7 23.2 13.7 10.7 17.7 10.3 9.5 59.0 22.9 13.9 35.0 93.4 9.9 13.3 15.2 19.4 9.4 13.9 25.2 11.4 14.3 18.4 12.3 24.4 10.2 18.4 20.6 65.1 13.4 21.4 14.7 14.4 11.1 17.5 14.0 11.7 13.8 12.3 45.2 13.4 13.4 11.2 16.0 26.4 4.5 18.8 10.4 13.9 8.9 29.3 24.6 23.3 21.0 22.9 27.1 37.0 36.4 28.5 41.1 25.8 35.1 18.3 18.6 24.1 27.8 18.0 41.8 35.6 27.0 35.8 21.3 11.5 17.5 26.0 30.0 20.6 40.8 15.9 19.6 16.9 23.0 26.0 14.4 25.2 41.2 53.1 24.1 29.9 14.6 35.1 27.3 24.8 42.8 52.8 29.1 25.5 83.6 39.6 24.9 30.0 26.0 30.6 36.3 23.2 16.8 27.7 27.7 24.8 18.5 23.8 32.6 60.5 21.6 23.1 22.6 20.6 46.9 26.5 4.5 12.8 2.7 9.7 18.8 12.6 16.0 11.4 9.0 26.4 14.1 13.9 12.7 0.7 10.4 15.7 13.2 13.2 8.9 15.7 20.2 15.7 24.4 22.9 13.9 15.2 19.4 18.4 11.7 35.7 27.5 27.0 18.6 17.7 23.0 151.3 33.1 30.8 22.7 22.7 13.7 91.1 66.3 49.6 161.2 17.9 46.4 23.3 39.2 43.6 21.6 16.1 18.5 73.1 45.3 33.4 17.2 11.6 12.6 20.1 22.2 26.8 23.6 29.7 35.6 28.0 29.4 35.1 25.1 58.8 32.6 38.8 21.7 82.8 44.5 16.3 138.9 12.9 60.7 16.3 FLCN "BHD, MGC17998, MGC23445" ENSG00000154803 Folliculin Q8NFG4 17 17212212-17237188 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "GTPase activation" "Cancer-related genes, Disease mutation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" 5 "Cone photoreceptor cells: 74.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "SuSa: 34.9" "CAB015158, HPA028760" Supported Supported "Plasma membrane,Cytosol" NA NA Cytosol "Plasma membrane" "CAB015158: AB_2231645, HPA028760: AB_10601323" "unprognostic (1.99e-1)" "unprognostic (1.77e-1)" "unprognostic (1.53e-2)" "unprognostic (1.74e-1)" "unprognostic (3.85e-2)" "unprognostic (3.69e-1)" "unprognostic (3.73e-2)" "unprognostic (1.32e-1)" "unprognostic (3.58e-2)" "unprognostic (3.90e-1)" "prognostic favorable (4.49e-4)" "unprognostic (6.45e-3)" "unprognostic (2.55e-3)" "unprognostic (1.92e-1)" "unprognostic (9.71e-2)" "unprognostic (2.62e-2)" "unprognostic (1.65e-1)" 11.9 15.3 23.6 10.8 41.6 15.6 13.9 49.4 26.9 18.0 21.3 18.5 10.4 25.0 22.1 15.8 11.0 14.5 17.6 17.2 17.2 8.6 9.6 15.5 15.6 11.6 24.2 13.5 25.2 13.7 6.1 20.3 13.3 18.1 15.4 10.7 14.8 10.5 14.8 22.7 12.6 20.2 15.4 14.8 16.5 15.3 12.5 29.1 6.6 15.8 3.9 8.0 15.0 14.8 6.0 2.4 10.5 6.8 4.5 5.0 3.1 5.9 14.5 5.3 6.9 17.4 9.9 7.9 5.3 8.9 8.5 11.8 11.0 4.9 2.9 7.4 6.4 19.6 6.9 6.5 3.3 4.4 5.6 5.5 6.0 4.3 6.3 16.1 2.2 16.8 14.6 11.4 13.3 9.9 7.7 6.9 4.3 8.2 7.7 8.1 7.7 3.9 3.7 5.4 8.2 3.6 8.0 24.7 3.4 5.1 6.6 6.5 4.1 5.6 3.4 9.3 34.9 5.1 4.2 8.1 20.0 8.7 27.6 7.0 3.8 3.6 2.8 12.7 5.1 7.9 3.6 4.7 2.8 2.9 6.8 4.1 5.3 3.5 2.5 2.4 6.0 3.9 3.4 10.5 4.5 2.2 2.4 5.0 3.1 23.6 41.6 49.4 26.9 17.2 8.6 24.2 13.5 18.1 29.1 23.8 13.0 15.9 10.7 16.4 17.0 17.3 7.6 4.0 4.5 7.0 74.6 8.1 1.7 10.3 10.9 10.1 26.4 46.7 7.2 5.4 15.2 11.3 1.1 20.2 14.4 44.5 24.6 23.4 23.7 13.4 25.9 13.7 10.1 5.4 9.4 18.9 9.6 12.2 19.1 4.3 16.8 19.4 11.4 5.2 10.2 15.8 28.3 11.3 10.6 11.6 FLT3 "CD135, FLK2, STK1" ENSG00000122025 "Fms related tyrosine kinase 3" P36888 13 28003274-28100592 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, RAS pathway related proteins" "Host-virus interaction" "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 29.9;brain: 19.3;lymphoid tissue: 15.0" "Cell type enhanced" "Detected in some" 25 "Kupffer cells: 29.6;Macrophages: 12.4;monocytes: 55.9" "Cancer enhanced" "Detected in some" "breast cancer: 1.8" "Region enhanced" "Detected in many" "cerebellum: 19.3" "Group enriched" "Detected in some" 11 "myeloid DC: 29.9;plasmacytoid DC: 12.1" "Lineage enriched" "Detected in many" 16 "dendritic cells: 29.9" "Group enriched" "Detected in some" 11 "REH: 28.5;THP-1: 17.5" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA047539 Approved "Endoplasmic reticulum" NA NA 180000 "Endoplasmic reticulum" "HPA047539: AB_2680080" "unprognostic (2.19e-3)" "unprognostic (3.16e-3)" "unprognostic (6.54e-3)" "unprognostic (9.96e-2)" "unprognostic (3.88e-1)" "unprognostic (3.96e-7)" "unprognostic (7.99e-3)" "unprognostic (1.65e-2)" "unprognostic (5.37e-2)" "unprognostic (1.01e-2)" "unprognostic (1.96e-1)" "unprognostic (1.03e-1)" "unprognostic (4.56e-2)" "unprognostic (3.65e-1)" "unprognostic (3.91e-2)" "unprognostic (2.51e-1)" "unprognostic (2.22e-1)" 0.9 0.6 0.6 7.2 1.1 7.5 2.6 19.3 3.5 0.9 1.2 0.1 0.1 0.4 0.8 0.8 1.0 1.2 4.6 0.5 0.9 1.7 2.8 0.7 2.7 15.0 1.8 1.1 0.5 5.7 0.0 0.4 0.0 7.4 0.6 1.4 0.1 2.3 0.6 0.4 1.2 3.0 1.3 4.4 8.8 0.9 1.2 0.0 8.2 0.6 0.0 5.8 2.4 0.7 0.1 29.9 1.4 1.8 0.8 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 2.1 0.5 0.0 0.0 28.5 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 17.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 1.8 1.4 0.0 0.3 0.0 0.1 0.0 0.0 29.9 0.0 0.0 0.0 0.0 0.8 0.0 12.1 0.0 1.2 0.6 1.1 19.3 3.5 0.9 1.7 1.8 1.1 7.4 0.0 0.0 0.0 0.8 0.0 0.2 0.0 0.3 2.5 0.0 0.0 0.0 0.0 0.0 0.0 2.2 3.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.5 0.0 0.0 1.3 29.6 1.6 0.0 12.4 1.7 55.9 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.5 0.5 0.0 0.0 0.0 0.0 FOXA1 HNF3A ENSG00000129514 "Forkhead box A1" P55317 14 37589984-37596059 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, Chromatin regulator, Developmental protein, DNA-binding, Repressor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "liver: 47.0;prostate: 44.4" "Cell type enhanced" "Detected in many" 9 "Basal glandular cells: 103.5;Glandular cells: 100.2;Intestinal endocrine cells: 81.2;Urothelial cells: 133.4" "Cancer enhanced" "Detected in many" "prostate cancer: 127.0" "Region enriched" "Detected in single" 6 "midbrain: 2.0" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "Hep G2: 16.6;MCF7: 36.1;PC-3: 25.2;RT4: 33.8;SK-BR-3: 34.2;T-47d: 48.4" "Group enriched" "Detected in some" 15 "hypothalamus: 1.0;midbrain: 1.3;thalamus: 1.1" "Region enriched" "Detected in single" 6 "midbrain: 6.1" "CAB011595, HPA050505" Enhanced Supported "Nucleoplasm,Nucleoli fibrillar center" NA NA Nucleoplasm "Nucleoli fibrillar center" "CAB011595: AB_2104842, HPA050505: AB_2681148" "unprognostic (1.61e-1)" "unprognostic (8.80e-2)" "unprognostic (1.12e-1)" "unprognostic (4.65e-1)" "unprognostic (2.58e-1)" "unprognostic (1.51e-1)" "unprognostic (1.74e-1)" "unprognostic (1.78e-1)" "unprognostic (1.71e-1)" "unprognostic (3.01e-1)" "unprognostic (1.54e-2)" "unprognostic (6.30e-2)" "unprognostic (0.00e+0)" "unprognostic (3.67e-1)" "unprognostic (2.58e-1)" "unprognostic (1.69e-2)" "prognostic favorable (1.00e-4)" 0.1 0.0 0.1 6.1 0.1 0.0 23.5 0.1 0.3 1.5 9.4 0.1 0.1 4.6 0.1 0.5 7.2 1.3 6.5 0.1 0.1 0.3 0.4 47.0 13.2 0.1 2.0 0.1 0.6 0.2 0.0 1.1 0.1 0.2 44.4 6.0 0.2 9.4 0.7 0.1 0.7 5.1 2.4 0.1 0.1 13.0 0.6 0.1 0.2 0.1 4.4 9.9 12.5 11.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 1.5 0.0 0.9 0.0 0.0 0.2 0.0 0.1 0.0 0.0 7.4 0.9 0.0 0.5 0.0 0.0 8.4 4.7 1.1 0.0 0.0 8.3 0.0 1.4 16.6 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.6 0.0 0.1 0.3 0.0 0.0 36.1 0.0 0.1 0.0 11.0 25.2 0.0 0.4 0.1 3.5 33.8 4.3 0.0 1.6 34.2 0.0 0.0 48.4 0.1 0.0 0.3 0.0 0.1 1.1 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.3 0.1 0.3 2.0 0.1 0.2 0.1 26.8 38.7 0.0 103.5 0.9 0.0 1.1 25.5 52.2 37.5 3.5 0.0 0.0 0.0 1.8 0.3 0.3 14.7 0.0 2.1 0.0 0.0 100.2 2.3 27.6 0.0 0.0 81.2 1.3 1.2 0.5 0.0 0.1 3.3 1.8 34.4 0.0 3.1 21.0 0.0 0.0 0.0 0.0 0.1 0.5 1.3 0.1 0.0 0.0 25.3 133.4 FOXL2 "BPES, BPES1" ENSG00000183770 "Forkhead box L2" P58012 3 138944224-138947140 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Differentiation, Transcription, Transcription regulation" DNA-binding "Cancer-related genes, Disease mutation, Premature ovarian failure" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "cervix, uterine: 13.9;ovary: 55.5;parathyroid gland: 15.3" "Not detected" "Not detected" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in some" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "A-431: 5.6;fHDF/TERT166: 6.5;HEL: 9.2;hTCEpi: 8.5;K-562: 9.4;SiHa: 6.5;THP-1: 6.7" "Not detected" "Not detected" HPA069613 Enhanced Supported "Nucleoplasm,Midbody ring" NA NA Nucleoplasm "Midbody ring" "HPA069613: AB_2686160" "unprognostic (1.46e-1)" "unprognostic (3.28e-2)" "unprognostic (4.76e-3)" "unprognostic (2.05e-1)" "unprognostic (5.16e-4)" "unprognostic (3.55e-2)" "unprognostic (2.35e-3)" "unprognostic (5.08e-2)" "unprognostic (3.79e-2)" "unprognostic (2.19e-1)" "unprognostic (9.63e-8)" "unprognostic (2.16e-2)" "unprognostic (4.65e-1)" "unprognostic (2.90e-2)" "unprognostic (1.61e-2)" 0.0 1.5 0.3 0.0 1.2 0.0 0.0 0.3 1.0 13.9 0.0 0.6 0.0 0.0 10.0 0.4 0.1 6.4 0.0 0.1 0.4 0.2 0.0 0.0 0.0 0.0 0.3 0.4 55.5 0.6 15.3 13.1 1.4 0.8 0.2 0.0 1.7 0.0 0.4 0.0 0.2 0.0 0.9 0.3 0.0 0.0 0.8 0.2 0.0 0.2 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.6 2.2 0.3 4.0 0.1 0.0 1.7 0.2 0.0 0.4 0.1 0.0 0.4 0.0 2.7 6.5 0.2 1.3 0.0 0.0 0.1 0.0 0.0 9.2 1.1 0.0 0.0 0.1 0.0 0.0 8.5 0.0 0.0 1.4 0.0 0.0 9.4 0.0 3.2 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.5 1.8 0.0 0.0 6.5 0.0 0.0 0.3 0.0 6.7 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 1.2 0.3 1.0 0.4 0.2 0.3 0.4 0.8 0.2 0.0 0.0 0.0 0.1 0.5 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.2 0.9 0.0 0.0 0.0 0.0 GATA1 "ERYF1, GATA-1, GF1, NF-E1, NFE1" ENSG00000102145 "GATA binding protein 1" P15976 X 48786554-48794311 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding, Repressor" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 10 "blood: 78.3;bone marrow: 37.0" "Group enriched" "Detected in some" 10 "Early spermatids: 11.8;Erythroid cells: 23.3;granulocytes: 35.9;Late spermatids: 20.9" "Not detected" "Not detected" "Not detected" "Not detected" "Cell type enriched" "Detected in some" 6 "eosinophil: 78.3" "Lineage enriched" "Detected in single" 784 "granulocytes: 78.3" "Group enriched" "Detected in some" 9 "HEL: 50.8;HMC-1: 52.4;K-562: 54.0" "Not detected" "Not detected" "Low region specificity" "Detected in all" "HPA000232, HPA000233, CAB009195" Enhanced Supported Nucleoplasm NA NA Nucleoplasm "CAB009195: AB_2232148, HPA000232: AB_1078949, HPA000233: AB_1078951" "unprognostic (1.93e-1)" "unprognostic (7.54e-2)" "unprognostic (8.95e-3)" "unprognostic (3.84e-3)" "unprognostic (2.25e-1)" "unprognostic (3.00e-4)" "unprognostic (4.87e-2)" "unprognostic (3.48e-2)" "unprognostic (4.44e-2)" "unprognostic (1.95e-2)" "unprognostic (6.04e-2)" "unprognostic (7.71e-3)" "unprognostic (4.13e-2)" "unprognostic (2.24e-1)" "unprognostic (2.78e-1)" "unprognostic (9.10e-2)" "unprognostic (2.71e-2)" 0.7 0.2 0.1 2.4 0.7 37.0 0.3 0.0 0.3 0.7 0.3 0.0 0.0 0.6 4.9 2.4 0.4 0.3 0.6 2.3 0.1 0.3 0.4 0.8 5.6 0.2 0.6 0.0 0.1 0.1 0.1 0.5 2.8 0.3 1.4 0.4 1.6 0.3 0.2 0.1 0.6 0.8 2.4 0.3 4.9 0.5 3.1 0.0 1.5 0.6 1.1 0.6 0.9 0.6 0.0 0.0 78.3 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 50.8 0.0 0.0 0.0 0.0 52.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 54.0 0.1 0.0 0.0 0.0 6.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 12.2 0.0 78.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.7 0.1 0.7 0.0 0.3 0.1 0.3 0.6 0.0 0.3 0.0 0.0 2.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 11.8 0.0 0.0 23.3 0.0 0.7 0.0 0.0 35.9 0.0 0.5 0.0 0.0 0.0 0.0 20.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.0 GATA2 NFE1B ENSG00000179348 "GATA binding protein 2" P23769 3 128479427-128493185 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Phagocytosis, Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 81.2;ductus deferens: 85.8;seminal vesicle: 209.1" "Group enriched" "Detected in many" 5 "Extravillous trophoblasts: 226.1;granulocytes: 616.3;Syncytiotrophoblasts: 268.8" "Cancer enhanced" "Detected in all" "prostate cancer: 36.7" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 339 "basophil: 81.2" "Lineage enriched" "Detected in single" 813 "granulocytes: 81.2" "Cell line enhanced" "Detected in many" "BEWO: 57.0;HEL: 70.3;HMC-1: 38.1;SH-SY5Y: 66.4" "Low region specificity" "Detected in many" "Low region specificity" "Detected in some" "HPA005633, CAB024847" Enhanced Supported Nucleoplasm NA NA Nucleoplasm "CAB024847: , HPA005633: AB_1078954" "unprognostic (1.71e-1)" "unprognostic (8.90e-2)" "unprognostic (1.12e-1)" "unprognostic (8.61e-2)" "unprognostic (8.67e-2)" "unprognostic (4.17e-2)" "unprognostic (5.96e-3)" "unprognostic (7.30e-2)" "unprognostic (3.98e-2)" "unprognostic (4.12e-2)" "unprognostic (3.58e-2)" "unprognostic (3.04e-1)" "prognostic favorable (2.04e-4)" "unprognostic (2.50e-1)" "unprognostic (8.07e-2)" "unprognostic (2.08e-1)" "prognostic favorable (5.22e-5)" 7.0 6.2 2.1 1.5 2.4 2.5 7.9 1.2 1.9 22.4 2.8 1.4 85.8 2.5 20.6 5.4 3.2 23.0 9.7 4.8 1.5 1.0 7.6 0.6 16.1 2.2 1.8 1.1 4.6 5.8 3.4 4.5 51.8 2.4 27.8 1.8 6.1 1.9 209.1 3.5 4.1 3.4 8.4 1.4 5.1 2.9 2.7 1.5 0.4 3.3 2.7 1.5 22.4 12.4 0.0 0.0 81.2 0.0 0.0 0.0 0.4 4.7 1.1 0.2 3.1 0.4 0.1 57.0 10.6 9.1 3.6 1.3 1.9 2.1 0.1 3.0 6.3 0.3 5.0 2.9 0.0 1.5 0.0 1.6 70.3 7.8 3.1 0.8 7.1 38.1 0.0 0.0 0.1 0.0 0.5 5.7 0.0 18.4 0.1 0.0 1.7 0.0 14.4 0.2 0.0 0.3 0.0 1.4 0.0 0.1 4.2 4.4 66.4 2.7 14.1 0.4 3.0 2.7 2.9 10.2 0.2 0.1 2.5 1.4 0.0 0.0 0.0 0.1 0.4 0.7 81.2 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 2.1 2.4 1.2 1.9 1.5 1.0 1.8 1.1 2.4 1.5 6.0 48.7 0.5 16.6 4.2 0.2 6.1 0.0 1.4 3.4 71.5 0.0 50.4 1.7 0.3 5.8 56.9 0.0 0.0 12.6 226.1 5.8 36.8 616.3 0.0 9.5 0.0 2.9 34.4 0.8 4.0 0.6 2.9 8.5 0.0 0.0 0.0 1.3 0.0 0.4 0.1 0.2 0.0 7.6 0.5 2.8 2.0 268.8 0.0 0.1 10.0 GNA11 "FBH, FBH2, FHH2, HHC2" ENSG00000088256 "G protein subunit alpha 11" P29992 19 3094410-3124004 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" Transducer "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "intestine: 103.3" "Cell type enhanced" "Detected in many" 9 "Enterocytes: 264.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 9.1" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA048886 Approved NA NA "HPA048886: AB_2680544" "unprognostic (4.64e-3)" "unprognostic (2.21e-1)" "unprognostic (3.12e-1)" "unprognostic (2.23e-2)" "unprognostic (1.30e-1)" "unprognostic (1.53e-2)" "prognostic unfavorable (4.86e-4)" "unprognostic (2.56e-2)" "unprognostic (1.40e-1)" "unprognostic (6.26e-2)" "unprognostic (7.85e-3)" "unprognostic (2.43e-1)" "prognostic favorable (1.48e-11)" "unprognostic (1.05e-2)" "unprognostic (1.01e-1)" "unprognostic (2.47e-1)" "unprognostic (3.02e-1)" 19.3 14.2 17.3 13.7 17.1 5.9 14.2 38.5 28.0 16.1 40.8 18.6 18.3 65.9 19.8 14.5 17.2 19.8 19.5 21.9 16.0 12.8 17.8 16.6 15.1 5.0 11.7 12.6 19.4 19.6 14.2 13.8 20.0 14.1 18.2 23.0 27.1 17.5 30.5 27.3 20.0 103.3 17.6 12.2 10.5 17.2 20.1 12.5 3.9 18.0 13.5 7.6 19.2 22.1 2.4 3.9 9.1 2.4 0.7 2.2 0.4 20.5 12.6 11.4 19.8 16.9 11.2 12.6 20.5 20.4 27.7 22.7 15.7 10.6 5.1 11.3 28.5 17.1 15.0 14.4 16.3 17.7 11.1 8.5 1.4 13.6 9.0 16.7 1.3 4.6 15.4 14.2 18.7 11.3 14.3 22.0 1.7 10.3 1.0 18.5 9.6 1.4 6.1 7.9 14.3 11.3 9.0 10.1 4.7 13.4 16.1 25.8 16.3 14.7 17.6 10.2 7.8 12.7 2.9 18.9 18.3 13.0 33.0 27.3 0.5 1.5 3.3 13.1 1.1 19.8 2.8 2.4 0.5 1.1 1.3 1.4 1.3 0.9 1.1 0.4 2.4 2.2 1.6 9.1 0.7 2.4 3.9 0.3 0.4 17.3 17.1 38.5 28.0 16.0 12.8 11.7 12.6 14.1 12.5 29.8 23.7 9.0 7.9 29.0 17.2 15.5 38.2 22.7 6.8 26.2 35.3 11.2 6.6 18.6 27.8 23.8 264.0 0.0 21.8 10.5 18.3 14.0 4.6 26.3 7.4 42.9 52.5 62.6 6.2 13.4 46.3 3.2 21.9 0.0 73.7 28.4 28.3 80.7 75.7 16.1 14.9 19.4 17.3 17.6 9.1 36.0 17.0 2.2 62.2 12.7 GNAQ "G-ALPHA-q, GAQ" ENSG00000156052 "G protein subunit alpha q" P50148 9 77716087-78031458 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" Transducer "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "basophil: 18.4" "Lineage enriched" "Detected in many" 5 "granulocytes: 18.4" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010036, HPA048886" Uncertain Approved "Nuclear speckles,Plasma membrane,Cytosol" NA NA 28000000 "Nuclear speckles" "Plasma membrane, Cytosol" "CAB010036: AB_631536, HPA048886: AB_2680544" "unprognostic (2.10e-1)" "unprognostic (8.53e-2)" "unprognostic (1.45e-1)" "unprognostic (4.37e-2)" "unprognostic (1.87e-1)" "unprognostic (6.83e-3)" "unprognostic (1.05e-1)" "unprognostic (3.84e-2)" "unprognostic (2.46e-1)" "unprognostic (2.16e-1)" "unprognostic (1.85e-1)" "unprognostic (1.44e-1)" "prognostic favorable (1.11e-7)" "unprognostic (1.90e-1)" "unprognostic (3.13e-1)" "unprognostic (1.05e-1)" "unprognostic (2.01e-1)" 12.7 12.6 24.3 9.9 20.8 21.8 11.6 12.5 29.6 13.1 16.6 17.1 9.1 7.9 13.7 11.2 13.1 10.0 11.6 5.6 24.2 18.3 12.1 12.3 23.1 11.8 19.1 14.6 13.5 8.5 12.7 7.6 12.1 14.3 13.0 16.0 10.4 9.8 15.9 5.9 5.1 9.0 18.2 23.9 5.8 15.5 6.0 14.8 18.6 13.3 4.0 4.8 14.5 13.1 0.8 2.8 18.4 3.5 3.3 2.0 1.2 12.0 13.7 12.2 13.4 15.5 15.9 17.6 16.4 12.4 7.2 8.7 4.2 9.9 0.0 13.3 15.0 10.1 19.8 9.1 9.9 9.0 0.4 5.3 33.0 12.0 8.4 14.0 20.1 12.4 10.8 12.2 13.9 14.2 15.0 17.7 29.8 5.8 0.1 12.6 15.3 23.2 12.8 9.9 19.4 1.9 8.6 15.0 0.1 16.4 25.8 13.7 20.9 11.8 10.0 12.3 12.0 9.1 7.5 22.1 12.7 0.8 17.2 9.5 0.1 0.0 0.1 8.8 11.9 13.1 18.4 2.2 4.6 0.8 1.9 1.6 0.8 1.8 1.0 2.4 0.8 2.0 1.6 7.7 3.3 3.5 2.8 1.9 1.2 24.3 20.8 12.5 24.0 24.2 18.3 19.1 14.6 14.3 14.8 163.8 71.4 6.4 33.6 42.0 29.9 5.9 43.3 42.8 35.2 73.3 15.7 39.3 6.6 28.1 13.1 85.4 69.5 46.7 34.7 42.2 42.9 51.3 49.7 51.3 47.8 77.9 88.6 107.4 139.4 6.8 36.5 92.7 45.5 72.1 90.6 37.0 44.3 48.9 49.1 35.4 4.2 25.8 40.1 4.7 6.6 18.9 24.3 21.8 67.3 50.3 GNAS "GNAS1, GNASXL, GPSA, NESP, NESP55, SCG6, SgVI" ENSG00000087460 "GNAS complex locus" "O95467, P63092, P84996, Q5JWF2" 20 58839718-58911192 "Cancer-related genes, Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters" Transducer "Cancer-related genes, Cushing syndrome, Disease mutation, Dwarfism, Obesity, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "pituitary gland: 303.3;thyroid gland: 304.5" "Cell type enhanced" "Detected in all" 5 "Horizontal cells: 1781.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010337, HPA018122, HPA027478, HPA028386" Uncertain Approved "Nucleoplasm,Plasma membrane,Cytosol" "Intracellular and membrane" NA NA Nucleoplasm "Plasma membrane, Cytosol" "CAB010337: AB_631538, HPA018122: AB_1849236, HPA027478: AB_10599284, HPA028386: AB_10601983" "unprognostic (7.48e-2)" "unprognostic (1.41e-1)" "unprognostic (3.90e-2)" "unprognostic (4.77e-2)" "unprognostic (8.37e-3)" "unprognostic (2.82e-2)" "unprognostic (4.53e-3)" "unprognostic (8.01e-2)" "unprognostic (4.29e-2)" "prognostic favorable (8.76e-4)" "unprognostic (2.07e-2)" "unprognostic (1.58e-1)" "prognostic unfavorable (3.49e-4)" "unprognostic (5.24e-3)" "unprognostic (1.61e-1)" "unprognostic (8.25e-2)" "unprognostic (1.36e-1)" 56.2 79.0 84.2 34.4 44.5 42.1 87.4 86.0 107.4 43.2 42.3 25.4 27.0 33.2 37.2 44.7 41.0 43.6 34.4 106.0 71.0 144.0 39.6 35.3 46.6 44.6 75.8 64.7 43.6 118.1 120.9 303.3 49.8 85.6 36.3 31.5 42.7 171.6 31.1 172.9 26.3 34.9 40.5 61.4 36.9 42.4 18.2 27.4 56.0 304.5 80.6 41.0 37.3 44.6 27.3 41.5 29.9 36.2 25.3 24.2 24.6 9.7 32.8 55.4 25.8 94.2 43.0 49.8 56.4 51.6 64.5 46.3 95.8 50.6 32.0 87.9 73.2 46.2 42.3 50.8 75.1 43.7 21.1 30.6 35.6 49.9 62.7 43.5 20.7 22.4 51.3 38.2 31.3 42.2 51.2 48.9 39.5 31.2 43.7 42.5 133.6 105.4 50.6 17.6 6.4 34.7 64.9 48.5 56.5 51.7 38.7 68.7 157.4 78.4 77.9 62.9 50.7 59.5 56.7 53.7 85.7 77.0 30.8 53.1 76.8 49.5 67.6 37.6 10.1 43.7 29.9 24.8 29.5 20.7 35.7 22.1 26.7 22.0 22.2 37.8 27.3 21.3 24.2 29.1 25.3 36.2 41.5 23.3 24.6 84.2 44.5 86.0 107.4 71.0 144.0 75.8 64.7 85.6 27.4 205.4 224.1 189.5 151.9 115.9 363.0 884.0 242.0 250.3 255.9 247.7 53.0 672.6 376.4 220.5 577.5 343.9 323.7 303.7 196.1 292.5 221.9 260.9 133.0 165.2 333.8 1781.3 444.7 335.7 327.9 1338.6 245.7 276.8 210.9 147.9 250.3 861.2 313.5 239.3 185.3 130.9 175.1 207.0 226.4 48.2 25.4 103.0 1013.3 142.4 268.2 212.5 GPC3 "DGSX, OCI-5, SDYS, SGB, SGBS, SGBS1" ENSG00000147257 "Glypican 3" P51654 X 133535745-133985895 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "Protease inhibitor" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "placenta: 262.7" "Cell type enhanced" "Detected in many" 10 "Fibroblasts: 127.3;Muller glia cells: 96.7;Syncytiotrophoblasts: 124.3" "Cancer enhanced" "Detected in all" "liver cancer: 269.0" "Low region specificity" "Detected in some" "Group enriched" "Detected in some" 4 "naive CD4 T-cell: 5.0;naive CD8 T-cell: 3.5;NK-cell: 1.7" "Group enriched" "Detected in many" 12 "NK-cells: 1.7;T-cells: 5.0" "Group enriched" "Detected in some" 5 "HAP1: 54.2;Hep G2: 214.3" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA006316 Supported "Plasma membrane" "Intracellular and membrane" NA NA "Plasma membrane" "HPA006316: AB_1078994" "unprognostic (2.06e-1)" "unprognostic (2.36e-1)" "unprognostic (9.51e-2)" "unprognostic (4.17e-2)" "unprognostic (1.78e-1)" "unprognostic (1.46e-1)" "unprognostic (6.10e-2)" "unprognostic (1.17e-2)" "unprognostic (2.07e-2)" "unprognostic (3.92e-3)" "unprognostic (6.06e-2)" "unprognostic (1.71e-1)" "unprognostic (3.81e-3)" "prognostic unfavorable (4.83e-4)" "unprognostic (1.43e-1)" "unprognostic (2.21e-1)" "unprognostic (1.60e-1)" 30.1 5.9 0.4 3.6 0.7 0.0 50.2 0.6 0.4 3.3 4.5 0.5 2.2 0.5 2.5 11.7 2.0 3.4 9.2 8.0 0.4 1.1 21.2 1.1 37.0 1.9 1.6 0.4 6.0 4.6 0.3 16.9 262.7 1.6 3.6 1.0 6.3 3.8 2.3 4.1 5.5 1.8 3.3 2.1 0.9 4.0 2.1 0.3 2.3 7.2 11.2 3.0 7.6 8.0 0.0 0.2 0.0 0.0 1.7 5.0 0.6 0.0 0.0 2.4 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 16.8 0.0 0.0 0.0 0.0 0.0 0.0 54.2 0.0 0.0 0.0 2.5 0.0 0.1 214.3 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 16.5 0.0 0.0 0.0 0.0 0.0 14.8 0.7 1.8 4.4 0.0 0.0 0.0 26.0 0.0 2.7 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.8 0.5 0.2 0.0 5.0 3.5 0.0 1.7 0.0 0.0 0.0 0.6 0.4 0.7 0.6 0.4 0.4 1.1 1.6 0.4 1.6 0.3 0.0 1.7 0.0 5.4 9.3 0.2 0.3 0.0 44.2 35.2 5.2 0.0 43.0 16.6 0.3 0.9 0.5 0.3 0.0 1.3 32.7 127.3 0.9 0.0 0.0 24.0 0.0 1.7 2.5 0.0 1.3 9.8 1.4 3.3 0.0 1.5 96.7 2.2 0.2 2.8 26.9 1.9 0.0 5.0 1.6 6.1 3.4 124.3 0.0 2.1 0.5 GRIN2A "GluN2A, NMDAR2A" ENSG00000183454 "Glutamate ionotropic receptor NMDA type subunit 2A" Q12879 16 9753404-10182754 "Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "Cancer-related genes, Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 5 "brain: 25.2" "Cell type enhanced" "Detected in some" 9 "Cardiomyocytes: 14.9;Early spermatids: 13.4;Late spermatids: 13.0;Muller glia cells: 17.7;Rod photoreceptor cells: 12.1" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "fHDF/TERT166: 7.8;hTERT-RPE1: 3.4;RPMI-8226: 2.9;U-138 MG: 8.5" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" CAB022725 Enhanced NA NA "CAB022725: " "unprognostic (6.43e-2)" "unprognostic (2.47e-1)" "unprognostic (5.97e-2)" "unprognostic (3.21e-2)" "unprognostic (3.13e-2)" "unprognostic (1.59e-2)" "unprognostic (1.62e-1)" "unprognostic (2.10e-1)" "unprognostic (2.08e-1)" "unprognostic (5.39e-2)" "unprognostic (1.47e-1)" "unprognostic (1.69e-1)" "unprognostic (3.75e-3)" "unprognostic (4.79e-3)" "unprognostic (2.05e-1)" "unprognostic (3.92e-3)" "unprognostic (3.33e-2)" 0.9 1.0 5.4 0.5 5.9 0.4 0.6 8.5 25.2 0.6 0.7 1.5 0.0 0.9 0.8 4.5 2.1 4.1 0.5 4.0 8.0 1.9 0.9 0.4 1.0 0.5 1.7 10.3 0.5 0.6 0.4 0.3 0.4 1.4 0.5 0.7 1.4 0.7 1.0 0.5 1.2 0.7 0.9 1.2 0.4 1.1 5.2 0.8 0.0 0.8 0.0 0.7 0.6 0.5 0.6 0.0 0.3 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.1 1.9 0.6 1.4 0.0 0.1 0.0 0.0 7.8 0.0 0.1 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 3.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.3 0.0 0.0 0.0 2.9 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.7 0.0 0.0 0.0 8.5 0.8 0.0 0.1 0.0 0.0 0.0 1.2 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.6 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 5.4 5.9 8.5 17.9 8.0 1.9 1.7 10.3 1.4 0.8 0.0 0.0 0.0 1.9 1.6 3.6 14.9 0.0 0.0 0.0 0.0 3.9 0.0 0.0 0.6 13.4 0.1 0.0 0.0 0.2 0.0 0.2 0.4 0.0 0.0 0.1 1.6 0.0 0.0 0.0 13.0 0.9 0.0 0.0 0.0 0.0 17.7 1.2 0.0 0.0 0.0 12.1 0.0 4.2 3.2 3.8 0.4 0.0 0.0 0.0 0.3 H3F3A "H3.3A, H3F3" ENSG00000163041 "H3 histone family member 3A" P84243 1 226061851-226072001 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" DNA-binding "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 258.7" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "neutrophil: 258.7" "Lineage enriched" "Detected in all" 5 "granulocytes: 258.7" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB011481, CAB037178, HPA042570" Supported Supported Nucleoplasm NA NA Nucleoplasm "CAB011481: AB_880446, CAB037178: AB_532248, HPA042570: AB_2678056" "unprognostic (1.82e-1)" "unprognostic (1.95e-2)" "unprognostic (1.00e-1)" "unprognostic (2.19e-3)" "unprognostic (2.83e-2)" "unprognostic (3.74e-1)" "unprognostic (9.83e-3)" "unprognostic (4.71e-2)" "unprognostic (1.77e-3)" "unprognostic (3.69e-2)" "unprognostic (1.29e-1)" "unprognostic (1.29e-1)" "prognostic unfavorable (1.21e-6)" "unprognostic (3.66e-2)" "unprognostic (8.03e-3)" "unprognostic (2.21e-3)" "unprognostic (6.03e-2)" 39.0 43.4 37.2 83.4 33.4 126.8 67.9 45.0 42.8 44.6 54.0 31.6 62.9 47.9 43.4 60.6 66.3 42.4 49.6 59.4 36.1 31.2 45.9 59.2 73.2 217.9 37.8 23.2 44.4 79.7 30.8 34.8 59.1 29.2 38.4 59.4 42.7 49.0 49.7 37.0 47.1 50.0 42.0 48.6 71.9 41.4 87.6 31.7 148.9 38.5 71.0 84.1 43.5 47.6 39.2 44.6 258.7 56.9 23.6 34.9 60.5 53.9 30.8 120.2 67.8 33.4 38.9 90.3 25.6 31.1 41.6 32.9 32.1 90.0 51.9 56.9 31.4 20.7 51.8 59.4 46.6 40.9 32.1 102.6 64.2 45.6 42.9 33.1 65.9 78.0 35.6 54.0 29.1 38.3 56.4 61.5 67.9 90.4 88.9 47.3 31.2 136.8 122.6 163.0 137.1 61.1 92.6 87.8 133.8 86.0 57.7 117.4 174.5 73.0 92.4 63.2 71.8 104.7 154.7 34.6 30.3 42.3 40.9 74.1 39.6 50.7 90.7 28.9 63.0 64.7 40.0 56.9 80.8 23.1 44.9 23.6 39.2 25.0 24.9 44.6 36.0 23.7 25.7 258.7 23.6 50.8 36.6 34.9 60.5 37.2 33.4 45.0 42.8 36.1 31.2 37.8 23.2 29.2 31.7 485.3 628.9 1112.7 1421.3 1190.0 539.7 34.4 1036.9 1187.2 831.4 919.5 155.1 1193.7 1374.4 1195.9 1414.0 1038.4 1355.7 2359.5 1184.4 1689.1 947.0 1270.6 649.3 699.9 1338.0 554.6 1437.2 842.8 2198.6 1327.8 1016.5 1622.8 1010.6 1191.2 1707.9 908.2 1197.9 2104.2 985.0 1310.8 429.3 976.6 889.6 588.0 858.5 1210.5 1352.2 961.6 1983.9 1893.1 H3F3B H3.3B ENSG00000132475 "H3 histone family member 3B" P84243 17 75776434-75785893 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" DNA-binding "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 570.8;bone marrow: 441.9" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "neutrophil: 570.8" "Lineage enriched" "Detected in all" 6 "granulocytes: 570.8" "Low cell line specificity" "Detected in all" "CAB037166, CAB037187, CAB037221, HPA042570" Supported Enhanced Nucleoplasm NA NA Nucleoplasm "CAB037166: AB_2115285, CAB037187: AB_477069, CAB037221: AB_477076, HPA042570: AB_2678056" "unprognostic (1.66e-1)" "unprognostic (8.42e-3)" "unprognostic (3.42e-2)" "unprognostic (1.06e-1)" "unprognostic (1.81e-1)" "unprognostic (1.95e-1)" "unprognostic (2.41e-1)" "unprognostic (2.43e-3)" "unprognostic (3.37e-2)" "unprognostic (1.64e-1)" "unprognostic (5.88e-2)" "unprognostic (1.07e-1)" "unprognostic (1.26e-3)" "unprognostic (9.20e-2)" "unprognostic (4.81e-2)" "unprognostic (2.33e-1)" "unprognostic (1.99e-1)" 57.2 41.2 38.1 58.9 48.6 441.9 71.4 60.2 47.0 86.6 44.6 65.9 42.7 37.9 60.5 77.7 93.2 70.2 75.8 35.1 38.5 33.9 42.8 48.1 64.2 62.3 50.4 41.2 141.0 90.9 33.0 41.5 58.5 42.7 60.5 26.6 65.8 58.4 55.4 71.1 114.0 58.0 63.7 51.8 65.9 45.1 66.9 46.2 78.6 58.9 69.1 55.7 78.5 71.9 78.9 88.1 570.8 98.4 80.0 77.2 203.5 117.9 104.8 43.8 43.2 25.0 39.2 60.6 55.9 49.5 68.7 55.2 112.2 84.0 59.1 53.4 32.5 48.6 46.5 34.6 77.3 39.1 32.2 78.0 52.7 55.9 94.9 56.5 87.5 67.9 42.8 47.9 70.4 90.8 30.6 51.6 38.6 74.6 106.3 35.3 173.6 125.6 73.5 35.1 38.2 117.1 93.6 80.2 64.4 54.2 70.1 88.9 98.7 56.7 83.2 120.0 24.4 65.2 94.6 48.1 123.3 109.1 53.2 148.0 128.6 76.0 71.0 65.2 83.5 67.2 182.8 98.4 259.3 74.4 86.9 70.2 78.9 71.8 70.5 86.7 65.3 77.2 64.5 570.8 80.0 78.9 88.1 76.0 203.5 38.1 48.6 60.2 47.0 38.5 33.9 50.4 41.2 42.7 46.2 851.6 868.5 887.7 3350.2 2457.1 1722.8 361.5 690.4 1184.5 958.9 922.9 382.9 1428.6 1080.9 1926.0 2467.5 1156.8 1059.1 327.1 1563.3 1285.8 1898.2 1719.4 1592.3 352.8 1655.2 575.2 1610.5 672.8 901.1 452.7 934.0 1810.8 1808.5 1233.6 1221.5 2460.8 1745.6 1627.3 545.9 699.9 1161.2 983.1 2751.1 2035.3 943.0 3026.0 2929.8 1269.9 852.2 2611.9 HIF1A "bHLHe78, HIF-1alpha, HIF1, MOP1, PASD8" ENSG00000100644 "Hypoxia inducible factor 1 alpha subunit" Q16665 14 61695513-61748259 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "eosinophil: 47.8" "Lineage enriched" "Detected in all" 6 "granulocytes: 47.8" "Cell line enhanced" "Detected in many" "LHCN-M2: 119.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA000907, HPA001275, CAB017442" Approved Enhanced "Nucleoplasm,Nuclear bodies,Plasma membrane" NA NA "Nucleoplasm, Nuclear bodies" "Plasma membrane" "CAB017442: AB_10621732, HPA000907: AB_2666139, HPA001275: AB_1079057" "unprognostic (1.07e-2)" "unprognostic (1.13e-3)" "unprognostic (9.41e-2)" "unprognostic (1.07e-1)" "unprognostic (2.51e-2)" "unprognostic (1.90e-1)" "unprognostic (2.94e-3)" "unprognostic (3.40e-1)" "unprognostic (4.05e-1)" "unprognostic (1.39e-1)" "unprognostic (1.77e-2)" "unprognostic (8.39e-2)" "unprognostic (1.24e-1)" "unprognostic (3.23e-2)" "unprognostic (3.58e-1)" "unprognostic (7.35e-2)" "unprognostic (3.88e-2)" 31.9 62.0 15.6 45.2 17.8 125.2 24.9 22.7 18.5 45.7 15.3 12.3 23.5 10.8 17.7 31.3 31.2 21.7 50.0 19.4 17.5 16.5 76.4 42.7 42.8 27.3 18.3 11.0 34.5 12.7 13.7 26.8 24.2 25.1 17.6 13.9 14.0 24.6 36.2 8.0 17.4 16.9 18.7 27.2 57.3 16.0 21.1 12.4 24.7 26.9 18.4 28.8 37.8 21.5 6.6 6.0 47.8 6.8 6.2 7.9 5.1 38.0 15.2 15.3 43.7 24.3 39.2 20.7 31.7 38.2 39.9 36.0 6.6 12.6 9.3 23.9 39.1 11.4 9.0 9.8 52.0 50.0 4.0 5.1 5.7 14.0 11.4 54.2 2.4 6.2 68.3 16.5 29.3 31.4 53.9 25.1 5.4 3.8 0.0 119.1 7.9 7.4 2.9 13.8 6.0 20.1 0.5 34.3 2.7 51.5 25.3 12.9 14.3 59.4 8.5 20.9 21.8 8.9 4.5 14.9 90.7 20.3 30.0 26.6 5.0 7.2 10.6 47.8 4.7 24.5 11.2 6.8 47.8 3.8 5.5 4.9 6.5 5.0 4.4 6.0 6.6 7.9 5.1 18.2 6.2 5.6 2.9 3.4 5.1 15.6 17.8 22.7 13.2 17.5 16.5 18.3 11.0 25.1 12.4 65.5 115.1 54.6 71.5 94.4 49.4 37.3 86.6 33.5 69.4 247.7 47.1 22.6 87.9 226.7 3.1 113.7 30.7 0.0 216.2 57.6 82.5 54.8 217.2 23.7 123.2 147.8 63.8 177.4 143.9 3.6 22.5 156.8 97.8 76.7 36.5 141.2 213.6 23.0 45.6 116.2 52.0 51.8 129.7 27.4 24.9 76.9 21.3 60.6 34.8 75.6 HIST1H3B "H3/l, H3FL" ENSG00000274267 "Histone cluster 1 H3 family member b" P68431 6 26031650-26032060 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" DNA-binding "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 13 "lymphoid tissue: 343.5" "Cell type enriched" "Detected in some" 5 "Spermatogonia: 5.1" "Low cancer specificity" "Detected in many" "Cell type enhanced" "Detected in some" "T-reg: 1.4" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "U-266/84: 12.0" HPA042570 Approved NA NA "HPA042570: AB_2678056" "unprognostic (2.82e-1)" "unprognostic (2.64e-2)" "unprognostic (1.09e-1)" "unprognostic (5.59e-2)" "unprognostic (1.37e-1)" "unprognostic (2.34e-2)" "unprognostic (2.31e-2)" "unprognostic (1.17e-1)" "unprognostic (1.13e-1)" "unprognostic (2.03e-2)" "unprognostic (1.08e-2)" "unprognostic (5.34e-2)" "unprognostic (2.31e-7)" "unprognostic (8.52e-2)" "unprognostic (2.78e-1)" "unprognostic (1.90e-3)" 1.7 0.7 0.0 36.1 0.0 18.1 3.6 0.0 0.3 0.8 6.9 0.0 0.0 0.3 0.8 2.5 11.8 0.5 1.9 2.4 0.0 0.6 0.3 3.4 10.4 0.0 0.0 0.3 0.3 0.3 0.0 7.8 0.0 0.3 0.8 0.0 1.0 0.3 0.3 0.3 6.3 0.8 0.0 14.7 0.5 26.9 0.0 343.5 0.8 18.2 27.7 0.3 0.0 0.8 0.1 1.2 0.0 0.0 1.4 3.1 1.8 4.6 1.3 4.0 0.0 0.4 0.0 0.2 0.8 0.8 0.7 1.1 1.0 3.0 2.0 0.3 1.2 0.7 1.6 1.2 1.7 2.0 4.4 3.2 6.0 1.3 0.0 2.4 2.1 2.9 0.0 0.6 0.0 0.1 1.0 0.9 6.5 5.9 1.1 1.0 7.4 7.4 3.1 0.7 3.2 4.3 2.9 8.5 0.5 0.0 2.1 1.7 5.1 1.6 0.5 0.1 2.8 1.5 1.4 1.4 4.1 0.7 1.7 9.6 12.0 3.9 3.4 4.6 2.7 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.8 0.8 0.1 0.5 0.0 0.2 1.2 0.0 0.0 0.0 1.4 3.1 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.1 0.0 0.0 0.6 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 5.1 0.1 0.2 0.0 0.6 0.1 HNF1A "HNF1, LFB1, MODY3, TCF1" ENSG00000135100 "HNF1 homeobox A" 12 120978543-121002512 "Cancer-related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "intestine: 24.2;kidney: 17.2;liver: 15.6" "Cell type enhanced" "Detected in some" 8 "Enterocytes: 16.0;Hepatocytes: 13.9;Paneth cells: 14.4;Proximal tubular cells: 13.2;Undifferentiated cells: 8.9" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in single" "Group enriched" "Detected in some" 6 "A549: 6.2;CACO-2: 20.5;Hep G2: 22.4;OE19: 10.7" "Not detected" "Not detected" "Not detected" "Not detected" "CAB010430, HPA035231" Enhanced Supported Nucleoplasm NA NA Nucleoplasm "CAB010430: AB_2116746, HPA035231: AB_2674528" "unprognostic (5.92e-3)" "unprognostic (8.47e-2)" "unprognostic (4.12e-3)" "unprognostic (6.18e-3)" "unprognostic (3.72e-1)" "unprognostic (1.27e-2)" "unprognostic (9.18e-2)" "unprognostic (9.18e-2)" "unprognostic (2.99e-1)" "unprognostic (2.01e-1)" "unprognostic (9.77e-3)" "unprognostic (5.21e-2)" "unprognostic (6.25e-3)" "unprognostic (5.55e-2)" "unprognostic (2.48e-1)" "unprognostic (6.93e-3)" 0.1 0.0 0.1 0.8 0.1 0.0 0.1 0.1 0.1 0.1 17.3 0.1 0.1 13.7 0.1 1.5 0.1 0.8 5.1 0.1 0.1 0.0 17.2 15.6 0.1 0.1 0.1 0.1 0.2 6.3 0.0 0.1 0.1 0.1 0.1 2.1 0.1 0.1 0.1 0.1 0.0 24.2 0.5 0.1 0.1 3.6 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.5 0.5 1.8 0.3 0.3 0.4 0.2 0.0 6.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 20.5 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 22.4 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 10.7 0.0 0.0 0.0 0.0 2.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.8 0.3 0.2 0.2 0.3 0.2 0.3 0.4 0.4 0.1 0.5 0.4 0.4 1.6 0.3 0.3 0.5 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.5 0.1 0.6 0.8 2.5 0.0 0.0 1.8 0.0 0.0 0.0 2.3 0.0 0.0 16.0 0.0 4.6 0.1 0.0 0.4 0.0 13.9 0.1 0.0 4.6 0.0 0.0 0.0 0.0 0.0 0.0 1.0 6.7 0.5 3.2 14.4 0.0 13.2 0.2 0.0 0.1 0.1 0.0 0.3 0.0 0.0 8.9 0.2 HRAS HRAS1 ENSG00000174775 "HRas proto-oncogene, GTPase" P01112 11 532242-537287 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins" Hydrolase "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002015, HPA049830, HPA070222" Approved Approved Nucleoplasm,Cytosol NA NA "Nucleoplasm, Cytosol" "CAB002015: , HPA049830: AB_2680903, HPA070222: " "unprognostic (3.06e-2)" "unprognostic (2.98e-2)" "unprognostic (7.01e-2)" "unprognostic (3.08e-3)" "unprognostic (3.49e-3)" "unprognostic (3.87e-1)" "prognostic unfavorable (2.32e-4)" "unprognostic (1.07e-1)" "unprognostic (2.25e-1)" "unprognostic (1.50e-1)" "unprognostic (2.88e-3)" "unprognostic (9.85e-2)" "unprognostic (2.81e-1)" "unprognostic (1.85e-1)" "unprognostic (1.80e-1)" "unprognostic (1.58e-2)" "unprognostic (1.38e-1)" 12.3 11.4 25.2 9.1 34.5 5.0 16.2 16.1 25.3 7.9 9.5 8.1 10.8 8.9 6.2 9.2 22.3 8.3 10.9 28.7 22.2 22.4 8.2 6.5 8.9 8.0 23.2 12.9 7.7 9.7 11.7 10.3 10.1 15.0 10.0 6.2 8.2 10.1 12.7 51.8 32.0 8.2 8.4 17.0 6.5 7.2 6.1 11.0 5.9 8.1 24.5 9.3 9.9 19.8 2.1 1.1 0.7 4.6 0.1 2.0 0.3 22.1 19.7 9.4 8.4 5.8 4.1 12.2 11.0 5.9 17.4 14.8 9.9 8.8 8.6 3.4 15.0 12.3 17.6 10.0 26.8 4.9 7.0 22.4 4.4 7.9 8.6 8.9 3.5 3.4 6.3 30.0 9.4 10.2 3.6 8.6 7.2 8.9 12.5 9.7 18.2 12.9 12.2 9.6 7.7 19.5 10.3 11.9 7.6 9.7 5.5 36.7 14.6 10.3 18.3 7.9 5.9 15.0 6.8 13.7 15.5 12.2 5.7 14.2 4.6 6.2 6.5 14.6 6.4 14.5 0.0 0.6 0.7 1.4 1.2 1.6 0.8 1.4 1.3 0.7 2.1 2.0 0.6 0.0 0.1 4.6 1.1 2.0 0.3 25.2 34.5 16.1 21.1 22.2 22.4 23.2 12.9 15.0 11.0 11.9 12.5 12.6 82.5 116.5 44.6 21.9 15.3 17.4 4.5 33.2 17.7 72.6 63.0 32.7 1.1 22.2 44.1 0.0 32.3 45.3 34.0 46.2 2.3 13.4 33.9 46.1 28.2 19.0 7.6 5.2 15.8 17.6 60.8 16.2 22.1 28.3 35.8 21.0 21.5 42.9 29.1 32.3 38.7 4.7 23.4 127.5 65.3 12.2 21.3 96.6 IDH1 ENSG00000138413 "Isocitrate dehydrogenase (NADP(+)) 1, cytosolic" O75874 2 208236227-208266074 "Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Glyoxylate bypass, Tricarboxylic acid cycle" Oxidoreductase "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 6 "Cytotrophoblasts: 277.8;Hepatocytes: 306.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "Hep G2: 107.6;RT4: 75.1" "Low region specificity" "Detected in all" "CAB033218, HPA035248, HPA057936, CAB062556" Enhanced Approved "Nuclear bodies,Cytosol" NA NA 16000000 "Nuclear bodies, Cytosol" "CAB033218: AB_2123166, CAB062556: AB_2665593, HPA035248: AB_10600714, HPA057936: AB_2683559" "unprognostic (2.79e-1)" "unprognostic (1.00e-1)" "unprognostic (1.02e-1)" "unprognostic (2.47e-3)" "unprognostic (1.93e-1)" "unprognostic (2.39e-2)" "prognostic unfavorable (6.93e-5)" "unprognostic (3.32e-1)" "unprognostic (2.20e-3)" "unprognostic (8.03e-2)" "unprognostic (5.54e-2)" "unprognostic (4.18e-3)" "prognostic unfavorable (2.45e-5)" "unprognostic (2.09e-1)" "unprognostic (1.77e-1)" "unprognostic (1.13e-1)" "unprognostic (2.69e-2)" 41.3 82.3 6.2 8.8 7.0 1.3 20.9 6.5 8.3 12.6 35.2 8.7 38.0 30.6 8.0 29.9 30.3 8.8 18.7 10.8 6.3 6.2 20.5 91.0 19.8 14.3 8.1 4.7 19.4 21.5 4.8 6.2 24.1 8.7 38.5 23.1 15.4 18.7 39.0 4.7 7.4 54.1 10.1 9.3 21.3 20.4 15.6 8.4 3.5 7.9 11.0 11.9 43.4 12.1 4.9 22.8 6.4 31.6 7.4 6.6 12.0 9.5 16.1 23.0 9.3 41.8 29.9 13.1 4.0 18.3 6.7 16.4 25.4 23.4 1.9 25.4 12.4 28.6 14.8 16.5 19.3 6.5 1.3 6.2 8.2 13.2 107.6 55.7 5.3 8.2 25.7 41.0 15.4 11.2 10.7 18.5 5.6 8.2 6.6 10.3 6.1 3.8 9.2 42.0 68.5 6.6 3.6 8.4 5.4 30.4 75.1 3.9 6.9 15.2 14.7 49.7 25.4 5.6 15.7 12.2 6.9 6.9 9.7 4.3 3.2 5.0 2.5 22.2 32.5 5.5 5.7 31.6 4.8 4.5 14.5 5.1 4.9 4.0 5.3 22.8 4.9 3.3 3.9 6.4 7.4 6.5 8.4 6.6 12.0 6.2 7.0 6.5 8.3 6.3 6.2 8.1 4.7 8.7 8.4 11.9 38.0 25.9 15.5 11.0 19.3 16.8 58.6 14.7 27.3 27.9 23.6 277.8 18.3 23.8 6.9 15.5 112.0 0.0 76.5 152.3 23.7 78.5 13.9 306.5 146.5 11.1 56.1 41.1 109.5 7.7 22.7 46.5 25.3 53.3 85.9 26.7 42.8 52.6 27.6 74.2 45.5 12.9 12.2 7.7 30.8 13.0 80.0 16.0 106.9 38.2 IDH2 ENSG00000182054 "Isocitrate dehydrogenase (NADP(+)) 2, mitochondrial" P48735 15 90083045-90102504 "Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Glyoxylate bypass, Tricarboxylic acid cycle" Oxidoreductase "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "heart muscle: 126.2;skeletal muscle: 190.7" "Cell type enhanced" "Detected in many" 8 "Cytotrophoblasts: 682.3;Distal tubular cells: 989.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "MOLT-4: 69.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA007831 Enhanced Supported Mitochondria NA NA 53000000 Mitochondria "HPA007831: AB_1851397" "unprognostic (2.45e-2)" "prognostic favorable (5.15e-5)" "unprognostic (2.92e-1)" "unprognostic (1.53e-1)" "unprognostic (3.53e-1)" "unprognostic (8.46e-2)" "unprognostic (3.83e-2)" "unprognostic (2.55e-3)" "unprognostic (1.86e-2)" "unprognostic (1.89e-2)" "unprognostic (2.76e-1)" "unprognostic (4.90e-2)" "unprognostic (2.19e-3)" "unprognostic (3.92e-3)" "unprognostic (4.46e-1)" "unprognostic (1.30e-2)" "unprognostic (2.58e-2)" 5.4 2.0 14.9 10.1 16.6 22.6 8.8 4.9 19.1 6.4 16.2 13.8 12.4 16.1 5.9 15.3 23.7 6.0 9.4 126.2 10.2 9.3 25.0 93.2 6.9 15.8 14.4 12.0 3.0 25.1 8.4 3.3 15.1 11.9 13.3 14.5 6.0 28.0 21.9 190.7 11.0 13.9 15.8 11.0 7.5 27.9 1.2 7.6 28.2 3.4 69.0 13.6 11.0 8.6 16.8 32.8 17.2 56.3 22.2 29.5 31.2 10.3 5.9 30.6 30.3 4.3 5.2 26.0 13.0 19.8 12.3 13.2 2.8 9.0 12.3 3.7 10.7 11.7 3.6 4.4 3.9 5.8 24.2 2.9 21.0 2.2 20.6 5.2 14.4 21.3 11.0 2.2 2.9 2.3 14.9 25.1 43.6 3.1 10.6 9.4 30.2 69.1 22.4 9.1 14.2 2.4 58.6 21.9 36.7 18.9 12.5 44.1 22.4 16.1 64.4 5.2 17.8 51.9 44.5 6.0 21.9 3.2 2.8 6.0 17.5 3.2 1.4 7.0 30.3 12.6 9.0 26.4 17.2 26.1 48.0 12.4 16.8 18.7 29.5 32.8 9.8 10.2 18.2 5.1 22.2 56.3 17.8 15.9 31.2 14.9 16.6 4.9 19.1 10.2 9.3 14.4 12.0 11.9 7.6 6.0 21.8 67.0 66.5 35.4 5.3 402.1 104.4 56.2 21.6 71.5 9.8 682.3 989.8 188.2 4.7 25.3 53.5 23.3 255.6 386.0 36.6 189.5 30.1 240.4 229.9 9.5 59.3 41.1 60.4 2.5 13.0 70.5 55.6 96.4 122.1 17.5 127.7 132.1 33.2 128.5 5.1 12.9 38.3 0.5 4.5 58.6 479.2 123.2 268.2 90.1 IKBKB "IKK-beta, IKK2, IKKB, NFKBIKB" ENSG00000104365 "Inhibitor of nuclear factor kappa B kinase subunit beta" O14920 8 42271302-42332653 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins" "Host-virus interaction" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease mutation, FDA approved drug targets, SCID" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 8 "Cone photoreceptor cells: 127.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001249, CAB004447" Enhanced Supported Cytosol NA NA Cytosol "CAB004447: AB_627785, HPA001249: AB_1079126" "unprognostic (1.04e-1)" "unprognostic (2.30e-2)" "unprognostic (1.31e-1)" "unprognostic (1.73e-3)" "unprognostic (1.26e-1)" "unprognostic (1.27e-3)" "unprognostic (1.95e-1)" "unprognostic (1.25e-3)" "unprognostic (1.75e-1)" "unprognostic (1.55e-1)" "unprognostic (3.27e-1)" "unprognostic (1.73e-1)" "unprognostic (1.20e-2)" "unprognostic (1.89e-2)" "unprognostic (9.20e-2)" "unprognostic (3.02e-1)" "prognostic favorable (1.46e-6)" 9.1 10.8 10.9 17.0 16.7 9.3 10.0 26.1 16.9 10.3 10.3 12.4 11.4 4.7 15.3 13.2 17.9 16.4 14.9 7.9 13.1 6.9 12.4 9.9 14.9 12.2 20.3 7.9 9.6 13.3 18.0 13.6 11.2 11.9 14.0 10.9 10.5 11.4 9.7 17.6 22.2 9.8 16.4 10.5 18.7 10.8 8.3 18.6 12.9 14.3 8.4 17.1 18.1 12.8 12.6 14.8 14.1 9.6 11.9 11.2 5.8 3.6 12.9 3.7 6.3 14.3 12.4 4.7 3.2 11.3 9.5 8.4 2.9 6.7 7.1 5.5 8.8 9.0 4.1 5.0 12.7 12.3 6.9 5.7 9.9 6.0 2.3 10.9 1.9 10.4 8.2 9.7 9.1 14.2 18.7 14.0 4.7 8.4 3.5 20.8 4.1 6.9 3.1 3.6 11.8 4.1 7.1 6.3 4.1 10.7 3.3 1.1 2.1 2.0 3.6 5.2 6.9 4.8 8.3 7.2 6.7 3.5 5.2 2.3 2.1 2.1 5.0 7.9 4.7 7.6 14.1 9.6 10.4 10.1 7.6 10.3 9.4 10.5 11.2 8.9 12.6 10.2 10.4 11.4 11.9 9.0 14.8 9.9 5.8 10.9 16.7 26.1 16.9 13.1 6.9 20.3 7.9 11.9 18.6 11.9 24.0 17.7 29.3 21.6 11.3 4.5 15.3 14.7 13.6 15.7 127.6 8.6 1.7 11.4 2.0 27.7 11.8 0.0 11.8 4.6 9.8 23.2 36.9 10.2 15.8 17.5 10.9 15.4 26.9 3.0 15.3 17.7 18.6 13.6 15.1 11.6 13.3 14.4 12.0 4.8 52.3 6.5 6.4 2.6 6.4 25.5 12.7 20.3 13.6 25.7 IL7R CD127 ENSG00000168685 "Interleukin 7 receptor" P16871 5 35852695-35879603 "Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" Receptor "Cancer-related genes, Disease mutation, SCID" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "blood: 70.3;intestine: 34.0;lung: 52.6;lymphoid tissue: 133.1" "Group enriched" "Detected in many" 5 "monocytes: 441.0;T-cells: 326.6" "Low cancer specificity" "Detected in all" "Not detected" "Not detected" "Group enriched" "Detected in many" 5 "gdT-cell: 19.2;MAIT T-cell: 70.3;memory CD4 T-cell: 39.9;memory CD8 T-cell: 28.0;naive CD4 T-cell: 34.5;naive CD8 T-cell: 22.5;NK-cell: 19.1" "Group enriched" "Detected in many" 33 "NK-cells: 19.1;T-cells: 70.3" "Cell line enhanced" "Detected in many" "BJ: 22.2;BJ hTERT+ SV40 Large T+: 20.1;fHDF/TERT166: 41.6;HBF TERT88: 38.3;REH: 86.5" "Low region specificity" "Detected in single" "Not detected" "Not detected" "CAB010215, HPA067550" Supported "Plasma membrane" "Intracellular and membrane" NA NA 180000 "Plasma membrane" "CAB010215: AB_673727, HPA067550: " "unprognostic (2.93e-3)" "unprognostic (3.38e-2)" "unprognostic (3.82e-3)" "unprognostic (5.58e-3)" "unprognostic (3.06e-2)" "unprognostic (1.74e-1)" "unprognostic (2.51e-3)" "unprognostic (5.53e-2)" "unprognostic (1.12e-1)" "unprognostic (9.29e-3)" "unprognostic (1.43e-1)" "unprognostic (2.69e-1)" "unprognostic (1.76e-2)" "unprognostic (5.64e-2)" "unprognostic (3.27e-3)" "unprognostic (2.22e-1)" "unprognostic (1.78e-1)" 6.7 3.6 0.7 34.0 0.7 3.1 4.8 0.5 0.6 4.8 20.6 0.3 0.9 3.5 1.8 2.9 6.6 3.7 8.5 1.9 0.7 0.7 7.0 2.7 52.6 133.1 0.8 0.1 2.5 1.7 0.0 1.5 1.2 0.8 3.3 5.4 1.7 13.2 1.8 0.9 1.8 34.0 1.2 1.5 32.3 7.8 3.0 0.4 130.9 5.1 5.3 42.9 12.6 4.6 0.4 0.3 1.3 0.2 19.1 70.3 12.7 0.1 0.0 0.1 0.1 0.1 0.1 0.2 22.2 11.2 20.1 11.9 0.1 0.1 2.1 0.0 41.6 3.7 3.5 0.0 1.3 38.3 1.8 0.2 0.6 2.4 0.0 0.3 0.2 1.6 0.3 0.0 4.3 0.9 0.5 0.5 0.1 0.1 0.3 15.7 0.0 0.5 0.2 0.1 0.0 1.0 86.5 1.2 0.1 0.0 1.2 0.0 0.0 3.7 0.3 0.0 0.1 0.1 0.0 1.5 7.9 13.4 3.4 2.9 0.2 0.0 2.5 4.0 2.1 6.1 0.5 0.2 0.1 19.2 0.2 70.3 0.2 39.9 28.0 0.1 0.4 34.5 22.5 1.3 19.1 0.2 0.3 6.7 12.7 0.7 0.7 0.5 0.6 0.7 0.7 0.8 0.1 0.8 0.4 14.9 19.4 10.9 1.9 10.3 0.0 3.2 0.0 10.7 4.5 0.0 0.0 0.1 0.0 0.9 0.1 3.6 0.0 23.3 1.6 0.1 7.1 1.1 18.5 4.5 10.4 0.0 0.0 17.8 12.7 0.0 0.0 79.7 20.3 441.0 0.0 0.0 0.2 0.9 0.0 0.6 0.0 0.0 9.0 0.0 0.0 9.2 0.2 326.6 0.0 3.8 IRS4 "IRS-4, PY160" ENSG00000133124 "Insulin receptor substrate 4" O14654 X 108732482-108736409 "Cancer-related genes, Predicted intracellular proteins" Transducer "Cancer-related genes, Congenital hypothyroidism, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 6 "pituitary gland: 56.0" "Not detected" "Not detected" "Low cancer specificity" "Detected in some" "Region enriched" "Detected in single" 7 "hypothalamus: 4.6" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "HEK 293: 14.0;NTERA-2: 1.7;RT4: 4.1;WM-115: 3.1" "Group enriched" "Detected in some" 5 "basal ganglia: 12.8;hypothalamus: 52.4" "Group enriched" "Detected in many" 6 "basal ganglia: 21.5;hypothalamus: 55.3" HPA017372 Uncertain NA NA "HPA017372: AB_2669600" "unprognostic (3.74e-3)" "unprognostic (3.27e-2)" "unprognostic (1.32e-2)" "unprognostic (2.52e-1)" "unprognostic (1.89e-1)" "unprognostic (2.12e-1)" "unprognostic (1.65e-1)" "unprognostic (1.05e-2)" "unprognostic (1.77e-1)" "unprognostic (9.28e-4)" "unprognostic (8.71e-2)" 0.0 0.0 0.2 0.0 0.3 0.0 0.1 0.0 0.6 1.9 0.0 0.1 0.3 0.1 2.6 0.3 0.3 0.5 0.0 0.0 0.3 4.6 0.0 0.0 0.1 0.0 0.5 0.1 9.5 0.0 0.0 56.0 0.1 0.6 0.2 0.0 2.7 0.0 0.5 0.0 0.6 0.0 1.0 0.2 0.1 0.5 0.1 0.5 5.1 3.3 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 14.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.0 0.0 0.0 4.1 0.0 0.0 0.0 0.0 0.2 0.6 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.3 0.0 0.3 0.3 4.6 0.5 0.1 0.6 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 JAK1 "JAK1A, JAK1B, JTK3" ENSG00000162434 "Janus kinase 1" P23458 1 64833229-64966504 "Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "ASC diff: 70.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB013088 Approved NA NA "CAB013088: " "prognostic favorable (9.63e-4)" "unprognostic (1.24e-1)" "prognostic favorable (2.81e-4)" "unprognostic (5.10e-2)" "unprognostic (1.16e-1)" "unprognostic (4.21e-2)" "unprognostic (1.53e-1)" "unprognostic (7.00e-3)" "unprognostic (8.40e-2)" "unprognostic (7.88e-3)" "unprognostic (1.66e-2)" "unprognostic (8.84e-2)" "prognostic favorable (2.67e-4)" "unprognostic (2.35e-1)" "unprognostic (2.04e-1)" "unprognostic (7.30e-2)" "unprognostic (3.51e-1)" 46.7 20.4 15.5 31.1 16.5 21.2 56.6 24.3 20.4 27.3 27.1 16.3 16.5 13.8 28.2 22.0 27.0 20.7 27.7 27.3 15.3 16.5 31.4 38.3 36.5 61.4 15.6 14.1 33.3 29.1 28.3 39.8 22.9 25.1 26.0 22.2 18.1 19.8 21.3 45.1 29.7 29.3 30.7 16.3 52.7 20.9 17.3 15.0 62.7 29.0 17.9 42.5 37.2 29.3 20.2 15.4 34.9 17.1 68.1 27.5 25.8 11.2 14.6 6.1 0.6 70.7 40.1 7.9 17.5 25.9 14.6 17.2 4.8 6.2 17.1 13.6 31.1 27.2 6.3 4.1 13.5 20.8 22.5 6.6 23.1 7.7 10.4 26.1 8.8 16.1 35.1 18.8 22.0 23.0 17.4 45.4 8.5 8.4 18.3 16.1 6.4 4.8 5.9 4.2 12.9 8.8 6.9 17.6 6.3 37.6 19.8 4.3 12.9 24.0 11.3 10.3 12.7 24.0 5.5 41.2 17.5 7.8 39.6 9.3 11.5 5.2 13.5 16.3 11.7 7.9 31.2 10.9 31.5 22.8 15.2 27.5 20.2 22.0 25.7 15.4 16.1 24.3 20.7 34.9 68.1 17.1 10.5 26.5 25.8 15.5 16.5 24.3 20.4 15.3 16.5 15.6 14.1 25.1 15.0 47.6 79.3 120.3 114.0 103.6 35.7 98.8 79.0 41.5 63.7 106.4 21.6 5.5 36.5 152.3 100.2 130.9 49.5 23.3 184.7 94.8 76.6 173.3 55.4 77.3 52.1 20.6 63.8 178.0 138.0 72.8 88.9 109.3 47.2 252.5 54.9 54.4 180.7 49.2 79.5 61.6 35.1 161.7 144.2 30.5 50.9 145.2 10.2 159.2 38.1 188.3 JAK2 JTK10 ENSG00000096968 "Janus kinase 2" O60674 9 4984390-5128183 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Adaptive immunity, Immunity, Innate immunity" "Chromatin regulator, Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 4 "Kupffer cells: 36.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "basophil: 40.8" "Lineage enriched" "Detected in all" 4 "granulocytes: 40.8" "Group enriched" "Detected in many" 5 "ASC diff: 19.4;HDLM-2: 27.4;HEL: 56.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB013089, HPA040820, HPA043870" Approved Supported "Nucleoplasm,Plasma membrane,Focal adhesion sites" No No Nucleoplasm "Plasma membrane, Focal adhesion sites" "CAB013089: AB_2533647, HPA040820: AB_2677151, HPA043870: AB_2678708" "unprognostic (2.24e-3)" "unprognostic (2.76e-2)" "unprognostic (1.50e-2)" "unprognostic (7.67e-2)" "unprognostic (5.50e-2)" "unprognostic (3.09e-2)" "unprognostic (1.48e-1)" "unprognostic (7.36e-2)" "unprognostic (1.09e-1)" "unprognostic (5.49e-3)" "unprognostic (1.58e-1)" "unprognostic (1.72e-2)" "unprognostic (3.85e-1)" "unprognostic (4.53e-2)" "unprognostic (3.43e-2)" "unprognostic (1.96e-1)" "unprognostic (7.37e-3)" 19.8 8.8 11.5 19.0 10.5 19.0 17.7 14.7 14.4 17.8 10.6 7.0 10.3 7.2 14.8 13.6 12.4 13.4 14.6 27.6 10.3 6.7 7.7 5.6 16.1 19.4 7.0 10.5 15.9 6.7 10.1 7.5 12.0 10.0 12.0 7.4 9.4 7.2 7.4 14.4 19.0 12.3 10.4 11.7 21.5 14.1 10.1 9.0 13.6 8.6 6.5 13.5 13.9 15.6 2.1 9.6 40.8 7.5 3.4 2.1 2.5 2.5 1.5 1.5 2.5 19.4 5.0 0.4 3.5 3.0 2.7 1.8 0.1 0.8 0.1 0.8 2.1 2.2 0.9 1.6 2.1 2.0 27.4 0.5 56.1 3.0 0.7 4.0 3.8 2.9 4.1 0.9 1.1 1.8 3.3 2.5 2.0 4.0 6.5 4.8 0.9 0.9 5.4 1.3 1.3 1.7 1.9 2.8 0.8 2.0 1.3 1.7 0.9 1.0 1.5 1.1 1.6 0.8 6.7 5.1 4.1 1.4 4.2 2.4 1.2 2.3 0.5 5.3 1.9 2.0 40.8 7.5 13.4 2.1 7.3 1.7 2.1 1.6 1.2 9.6 1.9 0.9 1.1 7.1 3.4 5.8 3.6 1.6 2.5 11.5 10.5 14.7 14.4 10.3 6.7 7.0 10.5 10.0 9.0 14.9 6.4 6.9 2.8 8.7 7.4 22.0 0.0 5.3 7.9 7.0 7.9 1.8 1.7 3.0 7.4 8.7 3.9 23.3 3.4 0.8 7.0 1.7 13.9 1.6 11.9 7.9 2.9 4.9 36.0 5.3 21.9 27.7 5.0 16.2 4.2 12.2 5.4 14.4 31.5 2.5 11.1 0.0 5.0 14.9 5.7 7.3 2.9 5.0 3.3 4.1 JAK3 "JAK-3, JAK3_HUMAN, JAKL, L-JAK, LJAK" ENSG00000105639 "Janus kinase 3" P52333 19 17824780-17848071 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Adaptive immunity, Immunity, Innate immunity" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, SCID" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "lymphoid tissue: 68.3" "Cell type enhanced" "Detected in many" 7 "B-cells: 18.2;Ito cells: 14.1;Peritubular cells: 13.8;T-cells: 24.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in some" "HDLM-2: 20.6;HEL: 9.2;HMC-1: 9.4;Karpas-707: 24.0;U-266/70: 9.3;U-266/84: 13.8;U-937: 14.0" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA070314 Enhanced Approved "Plasma membrane,Cytosol" NA NA "Plasma membrane, Cytosol" "HPA070314: AB_2686251" "unprognostic (5.59e-3)" "prognostic favorable (6.42e-5)" "unprognostic (5.71e-2)" "unprognostic (2.34e-1)" "unprognostic (6.13e-3)" "unprognostic (1.11e-3)" "unprognostic (4.21e-2)" "unprognostic (2.60e-1)" "unprognostic (2.38e-2)" "unprognostic (2.36e-1)" "unprognostic (3.58e-2)" "unprognostic (1.94e-1)" "prognostic unfavorable (2.89e-14)" "unprognostic (2.28e-1)" "unprognostic (2.21e-2)" "unprognostic (4.43e-2)" "unprognostic (7.61e-2)" 6.8 1.7 4.0 24.5 8.5 12.0 2.7 2.4 3.1 1.9 2.3 1.0 0.0 2.2 1.7 2.0 2.5 3.5 3.6 4.3 2.7 2.8 3.8 2.0 8.4 68.3 7.5 0.0 11.0 2.0 0.4 2.3 4.1 5.3 3.0 2.4 1.6 6.1 1.5 0.7 1.3 9.5 2.5 8.4 36.1 3.2 1.8 5.8 20.9 3.4 1.7 28.8 5.3 2.4 7.4 4.5 16.9 9.6 8.4 15.0 6.8 0.1 0.3 0.3 1.1 0.4 1.5 0.2 0.5 0.0 0.0 0.1 0.0 0.9 0.4 2.0 0.4 0.3 0.1 0.0 0.2 0.0 20.6 0.0 9.2 0.0 0.8 0.7 0.0 9.4 5.1 0.2 0.0 0.0 0.0 0.2 2.1 0.0 24.0 0.0 0.4 3.6 0.0 0.2 0.5 0.7 4.7 0.0 0.4 0.5 0.0 0.0 0.3 0.1 0.2 0.0 0.1 2.0 1.4 0.4 0.0 0.4 0.0 0.0 9.3 13.8 2.5 0.1 14.0 0.2 1.2 4.9 0.2 12.6 9.6 14.5 6.5 15.0 13.1 4.5 7.4 14.9 13.0 16.9 8.4 8.8 3.7 11.8 6.8 4.0 8.5 2.4 3.1 2.7 2.8 7.5 0.0 5.3 5.8 0.0 5.8 18.2 0.5 0.7 0.3 1.4 0.0 0.0 1.2 1.8 0.0 0.9 0.0 0.6 1.0 5.8 0.0 0.0 0.3 0.7 2.3 0.2 4.7 0.0 11.5 0.0 0.0 14.1 10.8 0.9 11.5 3.5 3.3 12.6 0.0 0.8 0.4 0.0 13.8 0.1 0.5 6.5 2.1 0.3 0.7 0.9 1.1 24.5 0.0 0.5 KCNJ5 "CIR, GIRK4, KATP1, Kir3.4, LQT13" ENSG00000120457 "Potassium voltage-gated channel subfamily J member 5" P48544 11 128891356-128921035 "Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Voltage-gated channel" "Cancer-related genes, Disease mutation, Long QT syndrome" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adrenal gland: 40.7;ductus deferens: 54.6;pituitary gland: 23.4" "Group enriched" "Detected in many" 4 "Alveolar cells type 2: 10.6;Hofbauer cells: 37.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in some" "neutrophil: 2.9" "Low lineage specificity" "Detected in single" "Cell line enriched" "Detected in some" 13 "HBEC3-KT: 17.5" "Group enriched" "Detected in many" 6 "basal ganglia: 3.1;hypothalamus: 8.0;midbrain: 2.2;thalamus: 4.0" "Low region specificity" "Detected in all" "HPA014722, HPA017353, CAB022569" Approved NA NA "CAB022569: , HPA014722: AB_1852133, HPA017353: AB_1852135" "unprognostic (2.01e-1)" "unprognostic (2.43e-3)" "unprognostic (2.56e-3)" "unprognostic (5.81e-2)" "unprognostic (4.24e-2)" "unprognostic (3.60e-2)" "unprognostic (2.90e-1)" "unprognostic (3.54e-2)" "unprognostic (6.83e-2)" "unprognostic (1.96e-1)" "unprognostic (3.17e-1)" "unprognostic (9.29e-2)" "unprognostic (1.81e-2)" "unprognostic (6.82e-2)" "unprognostic (9.49e-2)" "unprognostic (1.88e-2)" "unprognostic (2.23e-2)" 1.8 40.7 0.8 0.3 1.9 0.2 0.9 0.3 1.2 0.8 0.8 1.9 54.6 0.4 0.3 1.1 0.6 0.6 1.3 8.7 1.6 2.5 2.0 0.3 3.4 0.8 3.7 0.8 0.8 16.6 0.7 23.4 4.3 3.4 0.8 0.4 3.3 0.9 21.7 0.3 0.4 0.5 0.7 4.5 7.7 1.5 0.7 0.9 2.3 0.7 0.4 0.3 1.1 0.5 0.9 0.4 2.9 0.7 0.6 0.4 0.4 0.0 0.0 0.2 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.2 0.3 0.1 0.1 0.0 0.3 0.1 0.4 17.5 0.0 0.2 0.1 0.1 0.6 0.1 0.0 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.1 0.3 0.4 0.3 0.0 0.2 0.0 0.4 0.3 0.0 0.0 0.0 0.9 0.0 0.1 0.0 0.1 0.1 0.2 0.1 0.0 0.2 0.0 0.1 0.0 0.2 0.2 0.1 0.0 0.5 0.2 0.1 0.1 1.3 0.0 2.2 0.7 0.6 0.4 0.3 0.3 0.3 0.2 0.3 0.3 0.9 0.3 0.4 2.9 0.6 0.4 0.4 0.2 0.4 0.8 1.9 0.3 1.2 1.6 2.5 3.7 0.8 3.4 0.9 0.0 10.6 0.0 2.3 1.3 1.7 5.8 0.0 0.0 0.0 1.8 0.0 0.7 0.0 0.0 2.1 0.6 0.0 0.0 3.2 0.6 2.1 0.4 0.0 0.0 37.1 1.6 0.0 0.6 1.8 4.5 0.9 1.9 3.3 1.8 0.0 0.3 1.3 0.0 0.7 0.0 1.4 0.0 0.1 0.2 0.7 1.5 1.0 0.0 0.0 0.5 KDM5C "DXS1272E, JARID1C, MRX13, SMCX, XE169" ENSG00000126012 "Lysine demethylase 5C" P41229 X 53191321-53225422 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Biological rhythms, Transcription, Transcription regulation" "Chromatin regulator, Dioxygenase, Oxidoreductase, Repressor" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA038244, HPA046147" Enhanced Nucleoplasm,Cytosol NA NA Nucleoplasm Cytosol "HPA038244: AB_2675911, HPA046147: AB_2679555" "unprognostic (1.19e-1)" "unprognostic (1.13e-1)" "unprognostic (1.56e-2)" "unprognostic (7.10e-2)" "unprognostic (9.75e-2)" "unprognostic (2.19e-1)" "prognostic unfavorable (2.11e-4)" "unprognostic (2.08e-2)" "unprognostic (2.11e-1)" "unprognostic (1.24e-1)" "unprognostic (5.45e-2)" "unprognostic (1.58e-2)" "unprognostic (5.05e-3)" "unprognostic (1.96e-2)" "unprognostic (6.91e-2)" "unprognostic (1.30e-1)" "unprognostic (1.00e-1)" 19.5 22.9 22.4 22.6 24.7 26.3 17.9 43.0 31.7 25.9 19.5 23.4 16.7 22.2 29.2 13.3 26.9 24.8 15.2 17.6 21.6 15.3 17.0 18.8 20.6 25.8 24.6 21.8 33.1 22.5 37.7 31.8 34.0 22.8 18.7 13.5 17.0 25.6 17.1 36.6 28.4 22.2 23.6 16.0 25.0 19.4 10.6 26.2 29.0 22.2 11.3 24.5 21.5 26.4 4.5 4.3 4.8 4.0 2.8 6.1 3.8 16.9 23.1 24.8 19.0 17.2 15.7 17.6 10.6 12.4 14.4 13.4 15.6 11.1 15.8 13.8 13.9 40.6 15.2 28.0 22.7 11.0 11.8 41.4 15.3 24.7 11.0 21.2 18.1 30.6 12.4 16.7 28.1 34.7 20.6 21.2 13.2 29.7 10.5 10.5 21.7 13.2 20.4 21.0 8.8 21.7 15.0 14.8 17.1 9.1 16.3 18.7 24.1 32.2 29.9 12.1 23.8 20.9 16.0 14.5 16.1 13.9 14.4 10.3 15.3 12.4 12.0 20.9 21.5 11.9 3.0 3.8 2.7 6.1 3.6 5.1 4.5 3.7 5.7 3.1 3.2 4.5 2.9 4.8 2.8 4.0 4.3 4.3 3.8 22.4 24.7 43.0 31.7 21.6 15.3 24.6 21.8 22.8 26.2 11.9 12.2 11.9 9.7 10.8 25.0 7.7 17.8 12.0 12.5 7.0 23.6 10.6 3.3 13.4 0.6 14.3 21.7 0.0 18.7 11.4 11.3 12.4 12.7 19.8 12.4 23.8 30.0 18.4 14.6 1.7 13.6 9.4 13.5 10.0 27.8 10.9 20.8 24.6 14.9 4.2 16.1 0.0 10.3 7.0 14.6 13.9 17.4 10.2 15.6 15.9 KDR "CD309, FLK1, VEGFR, VEGFR2" ENSG00000128052 "Kinase insert domain receptor" P35968 4 55078259-55125595 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins" "Angiogenesis, Differentiation, Host-virus interaction" "Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Group enriched" "Detected in many" 6 "Endothelial cells: 100.3;Ito cells: 200.7;Muller glia cells: 229.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 9 "HUVEC TERT2: 32.5;TIME: 36.7" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" CAB004028 Enhanced Supported "Plasma membrane" "Intracellular and membrane" NA NA 7400000 "Plasma membrane" "CAB004028: AB_2212507" "unprognostic (1.61e-1)" "unprognostic (2.03e-1)" "unprognostic (9.65e-2)" "unprognostic (1.97e-1)" "unprognostic (9.63e-2)" "unprognostic (1.22e-2)" "unprognostic (1.78e-3)" "unprognostic (2.59e-2)" "unprognostic (1.19e-2)" "unprognostic (1.10e-1)" "unprognostic (8.79e-3)" "unprognostic (1.34e-1)" "prognostic unfavorable (7.26e-4)" "unprognostic (4.00e-2)" "unprognostic (2.30e-1)" "unprognostic (3.22e-1)" "unprognostic (1.86e-1)" 19.7 6.2 1.8 4.4 3.1 0.4 20.5 1.1 2.2 11.4 6.0 1.8 11.5 2.3 28.8 10.2 5.2 9.5 6.2 12.1 2.3 1.7 7.8 10.4 13.2 14.1 3.1 2.9 6.0 8.1 8.0 6.8 34.5 3.9 9.5 1.4 27.6 7.1 10.3 5.3 3.0 3.8 7.7 2.6 4.4 4.2 5.3 1.2 0.5 20.0 5.3 3.0 4.4 12.0 0.1 0.1 0.7 0.0 0.2 0.2 0.1 0.0 0.0 1.7 0.0 0.2 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 3.0 0.0 0.0 3.8 0.0 0.0 0.3 0.0 0.0 0.2 0.2 32.5 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.8 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 36.7 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.4 0.0 0.1 0.1 0.0 0.7 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.1 0.0 0.2 0.0 0.1 0.0 0.1 1.8 3.1 1.1 2.2 2.3 1.7 3.1 2.9 3.9 1.2 0.0 8.2 7.5 0.4 2.3 7.4 4.8 0.0 6.7 30.7 0.0 0.0 0.1 0.0 0.5 0.8 100.3 0.0 0.0 0.0 0.1 1.9 0.4 2.3 1.3 0.4 0.0 0.0 200.7 14.5 0.6 0.0 1.0 6.8 0.0 0.0 229.2 0.3 0.0 0.4 0.0 6.0 0.0 1.4 0.2 0.2 2.4 0.1 0.0 0.0 0.4 KEAP1 "INrf2, KIAA0132, KLHL19, MGC10630, MGC1114, MGC20887, MGC4407, MGC9454" ENSG00000079999 "Kelch like ECH associated protein 1" Q14145 19 10486120-10503741 "Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins" "Host-virus interaction, Ubl conjugation pathway" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA005558, CAB025337" Approved Supported "Nucleoplasm,Centriolar satellite,Cytosol" NA NA "Nucleoplasm, Centriolar satellite" Cytosol "CAB025337: , HPA005558: AB_1079175" "unprognostic (1.98e-1)" "prognostic favorable (3.28e-4)" "unprognostic (1.61e-1)" "unprognostic (1.02e-1)" "unprognostic (1.42e-1)" "unprognostic (1.63e-2)" "unprognostic (2.64e-2)" "unprognostic (1.46e-1)" "unprognostic (1.48e-1)" "unprognostic (5.22e-3)" "unprognostic (2.04e-1)" "unprognostic (9.99e-2)" "unprognostic (1.29e-1)" "unprognostic (7.71e-3)" "unprognostic (5.06e-1)" "unprognostic (8.18e-2)" "unprognostic (1.60e-2)" 16.0 13.7 13.5 10.4 14.3 9.1 12.4 13.2 15.1 13.1 15.7 15.4 13.8 13.6 11.0 12.7 26.3 15.1 12.7 19.7 13.9 13.7 13.2 22.0 10.8 15.5 16.7 7.4 11.8 14.3 11.1 10.2 11.5 14.3 13.9 8.8 11.8 11.3 13.9 63.9 16.8 13.8 11.6 16.5 11.3 10.6 12.2 13.8 13.1 14.5 29.1 16.1 14.5 11.2 14.6 23.7 21.3 19.8 21.0 30.8 19.6 17.3 31.8 8.8 11.7 18.2 15.5 9.4 14.8 11.0 15.2 13.6 22.6 17.5 24.7 39.0 16.4 11.3 15.6 17.5 11.5 7.5 23.9 19.2 37.3 9.5 26.7 17.6 19.5 20.3 16.0 15.6 17.1 8.0 12.7 14.4 7.4 22.8 45.8 13.2 24.0 14.1 53.6 25.7 16.6 26.8 25.7 11.0 28.9 9.8 20.8 24.3 12.7 20.6 13.8 12.8 8.1 11.9 26.1 17.7 24.5 13.2 27.4 17.9 26.7 33.4 24.2 18.9 23.3 17.9 16.1 19.8 21.3 30.8 17.0 29.3 14.6 21.5 28.3 23.7 5.7 13.5 19.1 10.9 21.0 16.6 16.3 25.4 19.6 13.5 14.3 13.2 12.8 13.9 13.7 16.7 7.4 14.3 13.8 26.8 17.3 19.6 22.6 19.5 21.5 20.3 20.4 13.4 17.0 10.4 7.9 22.5 11.6 29.0 22.3 24.1 31.5 0.0 31.3 21.0 19.7 21.7 11.5 28.8 25.7 25.4 25.8 27.0 14.8 34.6 27.0 14.9 10.1 57.7 20.6 39.6 26.7 21.0 24.4 19.1 11.1 12.9 15.6 19.5 17.3 19.3 22.4 22.4 27.9 21.7 KIT "C-Kit, CD117, PBT, SCFR" ENSG00000157404 "KIT proto-oncogene receptor tyrosine kinase" P10721 4 54657918-54740715 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins" "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "breast: 65.5" "Group enriched" "Detected in many" 10 "granulocytes: 496.5;Melanocytes: 200.8" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 6 "basophil: 12.7;eosinophil: 10.0;NK-cell: 9.7" "Group enriched" "Detected in many" 6 "granulocytes: 12.7;NK-cells: 9.7" "Group enriched" "Detected in some" 13 "HEL: 48.8;HMC-1: 102.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB003288, HPA004471, CAB068253, CAB072867, HPA073252" Enhanced Supported Supported "Plasma membrane" NA NA 48000000 "Plasma membrane" "CAB003288: AB_2335702, CAB068253: AB_2665717, CAB072867: AB_2665718, HPA004471: AB_1078431, HPA073252: AB_2686589" "unprognostic (1.55e-2)" "unprognostic (1.91e-1)" "unprognostic (4.04e-2)" "unprognostic (8.19e-2)" "unprognostic (3.96e-2)" "unprognostic (2.18e-2)" "unprognostic (2.33e-2)" "unprognostic (1.97e-2)" "unprognostic (3.60e-2)" "unprognostic (1.64e-1)" "unprognostic (2.20e-1)" "unprognostic (1.92e-2)" "prognostic favorable (5.63e-4)" "unprognostic (1.34e-3)" "unprognostic (1.87e-1)" "unprognostic (1.29e-2)" "unprognostic (2.30e-1)" 8.1 1.6 9.5 6.6 11.8 3.7 65.5 18.3 12.0 12.1 10.3 6.5 10.2 5.8 8.9 4.2 9.9 2.5 15.5 2.4 36.0 4.4 9.4 1.1 13.8 3.8 3.6 6.0 28.5 2.1 1.3 2.3 6.2 5.7 9.6 10.4 20.7 12.9 6.9 1.3 14.6 8.9 10.2 3.9 3.2 12.8 4.0 4.5 0.4 28.9 4.3 4.9 9.8 12.5 0.0 1.8 12.7 0.9 9.7 1.9 0.1 0.0 0.0 0.8 0.0 0.1 0.0 0.0 0.6 0.9 2.6 3.2 0.0 0.0 0.0 0.0 1.4 0.1 0.0 0.5 0.0 2.2 0.0 1.2 48.8 0.0 0.0 0.0 0.0 102.6 0.0 0.0 0.0 0.0 0.0 5.7 0.8 0.6 0.1 0.0 0.0 0.2 0.4 1.4 0.0 0.0 0.1 0.0 0.0 0.0 4.8 1.2 0.4 0.0 0.0 0.0 3.0 0.0 0.5 0.0 0.1 0.0 1.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 12.7 0.0 10.0 0.1 0.0 1.9 0.0 0.3 0.7 1.8 0.0 0.0 0.0 0.8 9.7 0.9 0.0 0.0 0.1 9.5 11.8 18.3 12.0 36.0 4.4 3.6 6.0 5.7 4.5 6.0 34.8 1.4 1.1 12.7 0.0 0.4 5.1 0.0 5.7 3.5 0.0 0.0 3.3 0.8 0.0 2.4 0.0 0.0 0.0 0.1 1.3 0.5 496.5 0.0 0.3 0.0 5.2 1.8 0.3 0.0 1.1 3.1 200.8 0.0 0.3 2.4 0.0 0.0 0.0 0.6 0.3 0.0 0.5 0.0 8.2 3.3 0.2 2.2 0.3 0.3 KLF4 "EZF, GKLF" ENSG00000136826 "Kruppel like factor 4" O43474 9 107484852-107490482 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skin 1: 92.1" "Cell type enhanced" "Detected in many" 6 "Mucus-secreting cells: 685.3;Suprabasal keratinocytes: 589.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 10 "classical monocyte: 5.2;intermediate monocyte: 7.4;myeloid DC: 4.4;non-classical monocyte: 2.9" "Group enriched" "Detected in many" 12 "dendritic cells: 4.4;monocytes: 7.4" "Cell line enhanced" "Detected in many" "hTCEpi: 32.8;hTERT-HME1: 20.3;OE19: 17.5;U-2197: 49.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" HPA002926 Enhanced Supported Nucleoplasm NA NA Nucleoplasm "HPA002926: AB_1852541" "unprognostic (2.06e-1)" "unprognostic (1.42e-2)" "unprognostic (1.14e-2)" "unprognostic (2.45e-1)" "unprognostic (1.55e-1)" "unprognostic (6.58e-3)" "unprognostic (3.44e-2)" "unprognostic (6.49e-2)" "unprognostic (3.45e-1)" "unprognostic (1.29e-2)" "unprognostic (1.18e-2)" "unprognostic (1.08e-1)" "prognostic favorable (3.93e-5)" "unprognostic (2.55e-1)" "unprognostic (1.67e-1)" "unprognostic (8.13e-2)" "unprognostic (8.32e-2)" 29.2 8.5 2.7 23.8 3.9 14.4 23.7 1.8 3.5 39.1 28.9 5.6 5.5 10.2 17.8 18.6 34.9 22.0 32.4 18.6 2.4 2.2 4.8 5.1 35.6 4.4 2.7 2.2 18.6 2.3 2.7 2.8 41.0 6.2 11.3 29.6 11.7 11.9 6.5 13.6 92.1 39.4 16.0 3.3 21.8 22.2 11.2 2.0 1.9 7.8 81.1 30.7 16.8 24.1 0.0 4.4 0.4 7.4 0.1 0.0 1.3 5.7 2.3 0.2 0.0 6.0 15.5 2.2 2.0 10.6 2.7 3.2 0.8 7.3 0.0 0.3 2.6 9.4 4.2 2.6 1.5 1.0 0.0 1.1 0.0 4.0 0.1 9.0 0.0 0.0 2.0 32.8 5.5 20.3 0.6 0.2 0.1 0.2 0.0 1.5 3.7 0.0 0.7 1.8 17.5 11.5 0.1 0.6 0.1 0.8 1.6 0.1 0.1 1.6 4.8 6.0 4.8 0.7 2.5 1.2 1.6 0.0 49.8 0.8 0.0 0.0 0.0 1.6 1.0 2.8 0.0 5.2 0.0 0.0 7.4 0.0 0.0 0.0 0.0 4.4 0.0 0.0 0.0 0.4 0.1 2.9 0.4 0.0 1.3 2.7 3.9 1.8 3.5 2.4 2.2 2.7 2.2 6.2 2.0 11.9 47.4 12.3 228.3 387.3 0.4 56.5 17.8 18.7 29.6 1.8 7.9 33.0 1.7 21.1 201.9 242.7 430.0 0.0 34.8 55.7 240.7 170.1 55.2 3.9 80.6 0.0 118.8 142.4 148.1 123.4 133.2 214.3 195.7 12.6 685.3 1.7 32.1 447.5 57.0 1.2 1.8 38.8 108.2 4.1 15.1 589.1 90.3 5.3 253.4 169.8 KLF6 "BCD1, COPEB, CPBP, GBF, PAC1, ST12, Zf9" ENSG00000067082 "Kruppel like factor 6" Q99612 10 3775996-3785281 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" 4 "Basal glandular cells: 1442.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB013529, HPA069585" Supported Supported Nucleoplasm,Nucleoli,Vesicles,Cytosol No No Nucleoplasm "Nucleoli, Vesicles, Cytosol" "CAB013529: AB_2533431, HPA069585: AB_2686157" "unprognostic (1.23e-1)" "unprognostic (1.53e-2)" "unprognostic (1.47e-3)" "unprognostic (4.53e-2)" "unprognostic (1.47e-1)" "unprognostic (7.55e-2)" "unprognostic (2.00e-1)" "unprognostic (1.08e-3)" "unprognostic (1.61e-1)" "unprognostic (2.83e-2)" "unprognostic (1.36e-2)" "unprognostic (2.35e-2)" "prognostic favorable (2.28e-4)" "unprognostic (8.07e-3)" "unprognostic (4.85e-2)" "unprognostic (6.87e-2)" "unprognostic (1.37e-2)" 69.8 10.0 8.4 26.3 10.6 80.6 101.1 7.4 10.1 28.6 31.7 10.3 9.7 11.0 24.9 28.8 38.6 28.0 38.6 18.6 7.8 5.1 32.2 32.5 46.0 35.8 13.8 4.2 20.2 23.8 7.5 4.7 26.1 11.2 20.1 21.0 13.2 26.9 16.5 57.8 60.2 44.8 42.8 17.0 20.3 26.7 14.3 10.0 12.5 41.0 28.8 21.5 44.7 30.7 15.6 29.8 77.8 18.7 13.0 30.8 23.2 13.2 3.6 6.9 2.2 40.3 40.4 4.3 22.8 11.7 24.4 16.6 9.3 17.9 3.8 5.3 24.7 19.0 8.1 4.2 21.1 20.5 18.6 2.5 0.5 4.1 8.7 17.3 2.5 13.1 13.3 40.3 17.4 33.2 8.7 24.9 2.5 4.1 29.7 31.0 0.9 4.6 3.8 2.6 7.1 6.5 3.0 7.1 13.4 24.0 13.2 3.0 2.9 5.6 16.3 34.2 19.6 8.0 2.1 32.4 33.1 4.6 19.5 10.4 5.7 18.5 7.0 8.9 3.3 10.2 50.9 17.0 43.7 27.1 14.2 23.9 15.6 30.8 26.8 13.1 12.5 9.6 14.8 77.8 13.0 18.7 29.8 22.2 23.2 8.4 10.6 7.4 10.1 7.8 5.1 13.8 4.2 11.2 10.0 1158.3 540.6 237.0 1442.7 520.2 42.2 53.1 293.0 254.3 251.4 130.9 31.4 113.5 18.3 616.6 54.4 455.0 961.8 70.0 474.3 369.8 410.0 832.0 597.5 234.2 510.8 35.0 381.0 212.4 420.1 42.4 120.8 593.9 458.9 839.6 556.8 32.1 706.5 466.4 125.9 61.9 78.0 135.8 372.0 6.2 13.6 549.2 163.8 409.2 300.8 382.6 KMT2D "ALR, CAGL114, MLL2, MLL4, TNRC21" ENSG00000167548 "Lysine methyltransferase 2D" O14686 12 49018975-49059774 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Transcription, Transcription regulation" "Chromatin regulator, Methyltransferase, Transferase" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 5 "Cone photoreceptor cells: 49.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "neutrophil: 5.9" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" HPA035977 Approved Approved "Nucleoplasm,Plasma membrane,Cytosol" Yes No "Plasma membrane, Cytosol" Nucleoplasm "HPA035977: AB_10670673" "unprognostic (8.33e-2)" "unprognostic (1.49e-1)" "unprognostic (9.14e-2)" "unprognostic (2.52e-1)" "unprognostic (8.07e-2)" "unprognostic (6.91e-3)" "unprognostic (7.35e-2)" "unprognostic (2.29e-1)" "unprognostic (3.57e-1)" "unprognostic (5.14e-2)" "unprognostic (7.23e-2)" "unprognostic (3.07e-1)" "unprognostic (1.68e-2)" "unprognostic (7.10e-2)" "unprognostic (1.87e-1)" "unprognostic (3.20e-2)" "unprognostic (7.60e-2)" 12.1 7.6 4.9 6.7 10.8 26.1 6.8 11.7 10.5 9.5 6.5 5.8 13.0 5.5 15.7 7.4 8.8 8.9 5.8 9.1 6.1 3.5 6.2 6.5 22.9 9.6 6.7 3.3 9.7 11.6 13.3 9.2 12.9 13.7 6.7 6.6 9.8 7.6 8.0 16.1 13.6 9.4 7.1 9.1 13.6 8.3 7.3 5.7 6.2 11.0 6.1 7.6 7.0 6.3 2.0 2.2 5.9 0.5 1.5 0.8 0.6 17.1 16.3 16.5 13.3 17.1 11.5 17.7 9.1 9.5 11.8 6.3 28.6 7.3 17.8 11.8 12.7 8.5 11.6 21.7 10.0 9.8 10.4 17.4 22.6 17.1 15.3 11.7 26.8 22.7 9.7 14.4 16.5 17.1 14.1 17.5 18.5 28.3 9.9 13.3 18.9 13.3 25.0 15.6 23.7 14.1 20.0 10.2 6.4 9.9 19.0 13.8 11.7 14.0 13.8 9.5 15.0 13.7 23.5 23.3 9.3 16.6 8.1 15.2 14.1 9.1 17.3 10.7 13.9 6.9 0.6 0.5 3.0 0.8 0.2 0.4 0.3 0.3 0.5 0.3 2.0 0.3 0.8 5.9 1.5 0.1 2.2 0.0 0.6 4.9 10.8 11.7 10.5 6.1 3.5 6.7 3.3 13.7 5.7 8.9 18.4 11.1 6.5 12.5 25.2 4.7 12.7 5.3 9.1 17.4 49.1 6.6 1.7 5.8 2.5 12.6 11.1 0.0 5.2 4.6 8.5 8.3 8.1 12.3 8.3 20.6 12.6 17.2 19.7 1.1 8.9 9.6 10.1 4.6 10.5 5.2 7.2 8.6 10.3 4.3 38.9 6.5 3.3 3.7 3.2 15.4 9.5 10.4 10.1 8.4 KRAS "KRAS1, KRAS2" ENSG00000133703 "KRAS proto-oncogene, GTPase" P01116 12 25204789-25250936 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, RAS pathway related proteins" Hydrolase "Cancer-related genes, Cardiomyopathy, Deafness, Disease mutation, Ectodermal dysplasia, Mental retardation, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA049830 Approved NA NA 5800000 "HPA049830: AB_2680903" "unprognostic (2.24e-2)" "unprognostic (2.16e-2)" "unprognostic (4.86e-3)" "unprognostic (1.08e-2)" "unprognostic (7.39e-2)" "unprognostic (1.51e-1)" "unprognostic (1.47e-2)" "unprognostic (3.74e-2)" "unprognostic (1.79e-1)" "unprognostic (2.39e-1)" "prognostic unfavorable (3.59e-4)" "unprognostic (6.42e-2)" "prognostic favorable (2.75e-5)" "unprognostic (1.95e-2)" "unprognostic (2.37e-1)" "unprognostic (2.81e-2)" "unprognostic (9.97e-2)" 11.7 9.9 14.4 15.5 19.5 24.1 10.6 21.1 25.6 10.3 26.2 7.3 7.9 16.1 11.3 7.7 25.1 10.1 13.9 9.3 13.6 16.6 14.0 17.9 14.9 15.1 11.6 15.8 13.1 13.6 12.7 9.8 15.7 21.1 12.1 28.1 9.8 16.2 9.8 10.0 14.0 23.7 17.2 11.3 15.7 23.6 7.8 9.5 18.5 11.1 10.6 16.3 16.8 14.3 10.0 7.1 20.8 18.9 9.4 13.8 5.0 6.8 6.9 15.5 8.7 5.8 7.9 31.2 7.0 8.8 7.3 8.7 24.0 15.7 15.7 4.2 12.1 9.8 7.5 18.1 7.6 13.8 10.7 6.3 14.8 7.4 5.9 6.1 13.8 11.3 7.3 10.4 8.8 7.9 13.4 10.6 11.5 10.5 7.5 10.7 5.8 19.0 21.1 34.1 11.2 2.8 16.5 16.4 22.6 10.8 12.1 4.7 13.3 8.3 11.0 8.3 42.6 12.2 10.0 12.2 8.2 10.9 15.4 8.6 6.6 11.0 17.0 6.3 8.1 5.9 20.8 7.8 12.4 11.9 14.4 7.5 10.0 10.4 13.0 7.1 8.6 13.8 12.1 19.0 9.4 18.9 7.1 6.7 5.0 14.4 19.5 21.1 25.6 13.6 16.6 11.6 15.8 21.1 9.5 44.7 28.0 47.9 74.6 89.6 61.8 13.7 71.4 22.7 23.9 36.6 68.7 77.0 49.7 64.2 2.8 58.3 123.1 46.7 79.4 16.4 50.1 116.8 23.1 52.1 45.9 87.4 75.6 73.6 60.9 2.5 37.7 60.3 59.1 92.0 88.6 31.5 107.1 78.0 48.4 38.6 62.1 25.8 43.4 57.5 37.0 136.1 116.4 56.8 58.1 134.2 LEF1 "TCF10, TCF1ALPHA, TCF7L3" ENSG00000138795 "Lymphoid enhancer binding factor 1" Q9UJU2 4 108047545-108168956 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation, Wnt signaling pathway" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "lymphoid tissue: 231.5" "Cell type enhanced" "Detected in many" 12 "Distal tubular cells: 11.6;Melanocytes: 32.1;Spermatocytes: 21.3;T-cells: 13.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "naive CD4 T-cell: 42.2" "Lineage enriched" "Detected in many" 5 "T-cells: 42.2" "Group enriched" "Detected in many" 5 "JURKAT: 98.3;MOLT-4: 93.3;REH: 72.0" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA002087, CAB019405" Enhanced Approved Nucleoplasm NA NA Nucleoplasm "CAB019405: AB_823558, HPA002087: AB_1079245" "unprognostic (1.03e-3)" "unprognostic (7.36e-3)" "unprognostic (2.97e-2)" "prognostic favorable (1.37e-5)" "unprognostic (9.08e-2)" "unprognostic (5.24e-2)" "unprognostic (3.81e-2)" "unprognostic (1.10e-2)" "unprognostic (1.77e-1)" "unprognostic (5.21e-2)" "unprognostic (9.99e-2)" "unprognostic (1.37e-1)" "prognostic unfavorable (2.47e-6)" "unprognostic (1.12e-1)" "unprognostic (5.22e-2)" "unprognostic (7.88e-2)" "unprognostic (8.91e-2)" 0.9 13.5 3.5 9.3 5.4 7.6 2.0 1.6 3.4 3.6 1.0 2.9 0.8 0.4 6.0 3.5 3.4 5.0 2.8 0.5 4.7 5.2 2.7 0.3 2.4 25.3 4.9 1.9 1.8 0.8 0.0 1.1 7.8 3.1 2.8 1.0 1.6 3.1 0.7 0.5 2.4 3.9 2.9 4.4 7.0 0.9 8.2 2.3 231.5 2.7 1.3 20.6 4.8 3.2 0.3 0.1 0.5 0.0 8.9 42.2 9.5 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 1.2 0.3 0.7 4.1 0.0 0.0 0.0 0.0 0.4 0.0 1.2 0.0 0.5 0.0 2.9 1.0 0.0 0.0 0.0 3.6 0.5 0.0 0.1 0.0 0.1 0.6 0.0 98.3 2.1 0.0 0.4 0.1 93.3 0.0 0.2 1.0 0.2 72.0 1.4 0.0 0.3 0.2 0.4 0.8 0.0 0.0 13.8 1.1 0.3 0.0 0.0 1.9 1.6 0.0 2.4 6.0 2.5 16.5 1.2 0.0 7.9 0.0 0.0 0.0 2.6 0.0 0.5 0.1 19.7 8.8 0.0 0.3 42.2 29.2 0.5 8.9 0.0 0.1 25.7 9.5 3.5 5.4 1.6 3.4 4.7 5.2 4.9 1.9 3.1 2.3 3.0 3.4 0.0 1.1 3.0 0.0 1.2 0.0 4.0 1.2 0.0 0.0 0.1 11.6 0.0 3.1 3.6 0.0 0.0 0.0 0.1 1.8 1.4 0.0 0.0 0.2 0.0 0.0 0.0 0.0 6.9 0.6 0.8 32.1 0.0 0.0 0.4 0.2 0.0 0.0 0.3 0.0 0.0 5.9 21.3 9.6 1.1 0.3 13.1 0.1 0.3 LRP1B "LRP-DIT, LRPDIT" ENSG00000168702 "LDL receptor related protein 1B" Q9NZR2 2 140231423-142131701 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" Endocytosis Receptor "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 25.7;thyroid gland: 14.9" "Group enriched" "Detected in some" 5 "Bipolar cells: 15.8;Early spermatids: 4.6;Late spermatids: 4.3" "Cancer enhanced" "Detected in some" "glioma: 1.3" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 13 "myeloid DC: 1.4;plasmacytoid DC: 1.2" "Lineage enriched" "Detected in single" 14 "dendritic cells: 1.4" "Cell line enhanced" "Detected in some" "ASC diff: 4.2;HEK 293: 4.5;HeLa: 2.3;HSkMC: 2.2;U-138 MG: 4.9;U-87 MG: 2.6" "Low region specificity" "Detected in all" "HPA069094, HPA074788" Approved Approved Vesicles NA NA 63000 Vesicles "HPA069094: AB_2686082, HPA074788: AB_2797273" "unprognostic (5.31e-4)" "unprognostic (3.68e-2)" "unprognostic (2.61e-1)" "unprognostic (7.36e-4)" "unprognostic (5.19e-2)" "unprognostic (1.26e-1)" "unprognostic (2.00e-2)" "unprognostic (3.49e-1)" "unprognostic (3.75e-1)" "unprognostic (7.02e-3)" "unprognostic (1.64e-3)" "unprognostic (1.05e-1)" "unprognostic (2.94e-3)" "unprognostic (4.85e-3)" "unprognostic (1.52e-1)" "unprognostic (1.66e-2)" "unprognostic (1.36e-1)" 4.8 4.5 17.6 1.3 14.1 1.2 2.6 23.2 25.7 1.4 1.3 6.5 0.0 1.2 1.3 6.8 1.3 1.9 1.4 1.6 18.3 9.3 2.2 1.6 1.4 1.2 10.8 16.7 3.0 1.2 1.1 12.7 1.2 12.8 3.5 1.3 0.1 2.5 3.8 10.5 1.7 1.3 1.3 8.2 1.2 1.5 1.9 10.6 0.0 14.9 0.0 1.3 1.2 1.4 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 4.2 0.0 0.0 0.2 0.9 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.1 1.0 0.2 0.2 0.6 4.5 0.0 2.3 0.0 0.0 0.0 0.0 2.2 0.0 0.0 0.4 1.7 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 1.9 0.2 0.0 0.0 0.4 0.0 0.0 0.0 4.9 0.1 0.0 0.0 0.0 0.0 0.0 2.6 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 17.6 14.1 23.2 21.3 18.3 9.3 10.8 16.7 12.8 10.6 0.0 0.0 0.0 0.3 0.2 15.8 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 4.6 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.3 1.1 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.7 0.0 0.8 0.0 0.3 0.1 0.1 0.3 0.0 0.0 0.0 0.6 LZTR1 "BTBD29, LZTR-1" ENSG00000099949 "Leucine zipper like transcription regulator 1" Q8N653 22 20982013-20999038 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Ubl conjugation pathway" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA067852, HPA068772, HPA071248" Approved Approved Nucleoplasm,Centrosome,Cytosol No No Nucleoplasm "Centrosome, Cytosol" "HPA067852: , HPA068772: AB_2686031, HPA071248: AB_2686372" "unprognostic (1.88e-2)" "unprognostic (1.01e-1)" "unprognostic (1.90e-1)" "unprognostic (1.08e-1)" "unprognostic (1.06e-1)" "unprognostic (2.44e-2)" "prognostic unfavorable (5.15e-4)" "unprognostic (9.81e-2)" "unprognostic (3.55e-1)" "unprognostic (3.78e-2)" "unprognostic (1.01e-2)" "unprognostic (2.64e-1)" "unprognostic (1.16e-3)" "unprognostic (4.29e-2)" "unprognostic (1.65e-1)" "unprognostic (6.25e-2)" "unprognostic (1.25e-2)" 21.2 16.9 17.3 15.6 17.4 10.3 17.9 20.7 24.7 18.5 18.3 25.3 20.6 18.9 24.9 14.0 16.5 18.3 21.2 15.8 15.4 10.9 17.2 13.1 16.2 12.8 19.6 16.5 21.7 16.2 24.9 26.0 18.8 19.0 16.9 12.9 18.9 17.5 18.0 17.2 15.0 15.7 21.9 14.0 19.3 14.5 10.8 19.2 10.8 19.6 12.6 12.5 18.5 16.4 1.6 2.2 0.2 3.4 1.8 3.0 1.5 6.3 5.2 7.8 9.4 17.9 12.4 6.3 13.0 9.1 7.4 10.2 3.0 2.6 6.7 4.8 14.5 6.9 8.6 5.8 10.6 3.0 12.5 13.6 7.2 6.8 4.5 9.6 3.9 9.6 11.4 5.4 9.4 6.8 11.8 14.4 6.3 30.0 11.7 8.4 3.8 6.9 3.7 2.4 7.7 5.7 8.2 11.3 2.6 5.9 8.6 7.7 11.4 7.1 12.3 7.6 4.9 5.7 7.2 12.8 17.4 8.9 7.8 7.0 5.1 4.4 2.0 7.8 3.8 8.4 0.0 2.5 0.2 3.0 3.1 1.6 1.6 1.5 2.8 2.2 1.0 2.1 1.5 0.1 1.8 3.4 1.2 0.5 1.5 17.3 17.4 20.7 24.7 15.4 10.9 19.6 16.5 19.0 19.2 11.9 10.4 9.7 1.4 1.9 8.1 11.2 2.5 6.7 5.7 8.7 5.9 3.6 1.7 6.6 0.8 9.5 7.8 0.0 4.3 3.2 5.4 2.0 5.7 6.2 6.9 3.2 8.7 12.3 11.6 1.3 8.1 4.9 6.8 4.6 9.1 6.6 5.7 5.9 9.2 6.1 9.3 0.0 7.2 2.6 1.7 3.1 3.0 6.9 5.8 0.9 MAP2K1 "MAPKK1, MEK1, PRKMK1" ENSG00000169032 "Mitogen-activated protein kinase kinase 1" Q02750 15 66386817-66492312 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins" "Kinase, Serine/threonine-protein kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Cardiomyopathy, Disease mutation, Ectodermal dysplasia, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB003834, HPA026430" Approved Enhanced "Plasma membrane,Cytosol" NA NA 62000 "Plasma membrane, Cytosol" "CAB003834: AB_562310, HPA026430: AB_1853742" "unprognostic (4.05e-2)" "unprognostic (1.23e-2)" "unprognostic (2.07e-1)" "unprognostic (4.92e-2)" "prognostic unfavorable (1.95e-4)" "unprognostic (1.81e-3)" "unprognostic (5.78e-2)" "unprognostic (9.91e-3)" "unprognostic (1.11e-1)" "unprognostic (1.77e-1)" "unprognostic (1.45e-1)" "unprognostic (7.62e-3)" "unprognostic (1.20e-1)" "unprognostic (2.71e-1)" "unprognostic (1.96e-1)" "unprognostic (1.15e-1)" "unprognostic (9.40e-3)" 28.6 16.9 33.9 19.1 54.1 29.0 23.6 32.5 48.4 12.5 12.1 8.4 10.2 10.0 11.8 16.5 22.0 10.6 14.4 19.1 49.2 26.4 15.3 53.1 16.4 23.3 17.6 31.2 13.5 11.7 23.4 12.0 15.4 17.2 14.4 12.9 9.1 13.2 12.4 39.5 12.3 10.9 16.9 17.4 14.5 10.8 7.8 12.6 12.6 12.3 9.7 27.9 13.6 18.7 4.6 16.2 5.5 8.2 8.4 7.9 2.7 33.6 15.9 31.9 13.3 19.3 14.5 18.5 24.4 20.9 26.5 23.7 23.8 27.7 30.9 30.3 20.1 20.2 30.0 29.8 35.7 31.3 24.9 17.8 9.9 16.6 12.9 15.6 13.0 14.8 11.2 22.1 19.2 28.5 28.3 20.7 15.8 17.5 39.6 38.7 13.0 10.5 17.1 16.3 31.2 13.9 11.9 19.7 27.5 25.7 14.5 19.7 11.0 19.8 15.5 20.5 26.9 14.0 11.2 28.5 34.6 21.2 24.4 36.2 24.5 43.6 19.7 36.5 23.1 16.1 3.2 8.2 5.5 7.4 8.2 6.7 3.0 6.6 6.9 8.3 4.6 7.9 4.9 3.9 8.4 7.3 16.2 4.9 2.7 33.9 54.1 32.5 46.9 49.2 26.4 17.6 31.2 17.2 12.6 26.8 21.9 30.2 40.5 73.6 8.5 16.9 38.2 6.7 13.6 24.4 13.7 40.9 39.7 65.3 10.2 19.0 20.0 46.7 20.4 39.4 31.3 59.4 9.2 116.5 44.9 9.5 20.8 17.2 91.3 18.3 20.8 67.7 50.6 88.4 17.0 33.9 70.1 21.0 20.5 28.5 5.6 6.5 53.6 16.3 44.5 58.8 43.3 40.5 16.8 65.5 MAP2K2 "MEK2, PRKMK2" ENSG00000126934 "Mitogen-activated protein kinase kinase 2" P36507 19 4090321-4124129 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins" "Kinase, Serine/threonine-protein kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Cardiomyopathy, Disease mutation, Ectodermal dysplasia, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 9 "Late spermatids: 596.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "CAB003835, HPA051993" Supported Supported Cytosol NA NA Cytosol "CAB003835: AB_562312, HPA051993: AB_2681685" "unprognostic (4.39e-1)" "prognostic favorable (3.72e-4)" "unprognostic (4.24e-1)" "unprognostic (1.26e-3)" "unprognostic (2.58e-1)" "prognostic favorable (7.98e-4)" "unprognostic (2.08e-3)" "unprognostic (2.11e-1)" "unprognostic (2.65e-1)" "unprognostic (1.06e-1)" "unprognostic (7.45e-3)" "unprognostic (4.95e-2)" "unprognostic (1.32e-1)" "prognostic favorable (5.43e-5)" "unprognostic (2.91e-2)" "unprognostic (2.25e-1)" "unprognostic (4.90e-2)" 23.9 33.0 35.6 27.6 36.1 46.7 30.2 31.2 43.4 22.6 38.8 24.6 27.0 70.9 21.8 23.2 32.8 21.7 27.9 41.4 33.1 31.0 22.7 42.0 24.1 44.5 34.4 29.2 30.8 46.0 18.9 29.7 21.3 26.1 25.7 24.3 21.7 41.5 24.0 134.9 27.4 56.7 19.0 25.2 25.9 28.3 42.0 20.9 44.1 26.2 42.2 29.1 20.0 26.9 11.4 10.7 28.3 10.6 11.3 12.1 4.5 36.8 40.7 22.3 31.3 30.9 37.3 22.3 24.3 32.6 33.3 30.2 35.2 20.0 31.6 23.0 27.7 26.8 26.6 17.4 26.0 25.8 26.8 21.2 11.5 22.2 38.9 47.3 21.1 24.3 41.1 25.3 23.4 31.2 44.6 29.4 28.8 22.0 62.4 28.0 46.3 41.8 29.7 25.5 27.2 29.6 32.0 14.7 36.1 29.1 23.7 30.3 30.2 22.3 30.9 75.8 26.9 23.8 36.4 25.9 27.3 23.8 69.8 37.4 62.8 38.0 22.1 42.4 38.2 46.8 15.2 9.1 28.3 11.9 10.6 9.7 8.9 9.7 12.1 10.7 11.4 8.9 11.6 14.4 11.3 8.7 6.0 9.2 4.5 35.6 36.1 31.2 43.4 33.1 31.0 34.4 29.2 26.1 20.9 8.9 38.8 57.0 73.8 31.5 79.0 54.9 17.8 10.7 19.4 38.4 39.3 23.7 124.3 17.7 223.1 33.7 242.0 0.0 38.5 28.5 33.0 88.2 19.6 43.1 46.2 114.4 60.6 34.4 35.6 596.7 33.1 29.7 40.5 12.6 77.6 82.3 41.7 90.9 21.5 75.0 82.4 25.8 32.5 25.9 14.5 55.8 29.7 45.4 69.4 97.8 MAP2K4 "JNKK1, MEK4, MKK4, PRKMK4, SERK1" ENSG00000065559 "Mitogen-activated protein kinase kinase 4" P45985 17 12020824-12143830 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" "Apoptosis, Stress response" "Kinase, Serine/threonine-protein kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 13.2" "Low lineage specificity" "Detected in all" "Cell line enriched" "Detected in all" 5 "SuSa: 67.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB007751, HPA060074" Enhanced Approved "Nucleoplasm,Cell Junctions" NA NA Nucleoplasm "Cell Junctions" "CAB007751: , HPA060074: AB_2684197" "unprognostic (1.55e-1)" "unprognostic (1.85e-1)" "unprognostic (4.47e-2)" "unprognostic (1.02e-2)" "unprognostic (1.04e-1)" "unprognostic (2.70e-1)" "unprognostic (2.89e-1)" "unprognostic (2.16e-1)" "unprognostic (1.93e-3)" "unprognostic (2.53e-1)" "unprognostic (2.76e-3)" "unprognostic (4.82e-2)" "unprognostic (5.32e-3)" "unprognostic (3.13e-1)" "unprognostic (2.30e-1)" "unprognostic (7.00e-2)" "unprognostic (1.79e-1)" 10.7 13.2 23.7 9.4 21.0 3.1 14.4 25.0 42.7 12.5 11.5 7.9 8.5 9.6 12.1 17.8 18.5 11.5 10.7 14.9 31.7 29.3 15.8 20.6 11.4 14.6 24.5 27.1 13.0 11.1 19.6 16.7 15.1 23.4 14.5 13.1 6.5 9.8 13.2 20.6 14.4 9.9 13.5 16.3 10.7 10.7 10.3 9.8 10.3 16.5 11.6 13.4 11.1 11.2 2.8 1.8 13.2 4.3 3.5 3.3 2.3 10.6 9.2 12.1 6.2 6.7 8.7 7.7 7.3 9.6 8.3 8.0 5.4 3.7 4.4 5.9 11.3 5.4 7.1 10.5 10.1 12.5 7.8 12.3 4.9 5.4 10.2 7.9 4.7 7.4 7.2 10.0 9.7 10.2 8.6 7.5 6.3 5.2 2.6 10.4 3.9 5.6 4.4 7.0 11.5 4.5 7.0 13.6 3.0 11.4 6.9 2.4 7.2 8.4 4.5 7.0 67.1 5.7 3.4 6.8 4.1 6.3 5.6 8.6 5.1 5.7 3.5 7.7 3.7 5.9 0.6 2.7 2.0 3.0 1.5 2.7 2.8 2.4 2.4 1.8 2.7 2.0 3.3 13.2 3.5 4.3 1.8 2.6 2.3 23.7 21.0 25.0 42.7 31.7 29.3 24.5 27.1 23.4 9.8 8.9 14.2 10.8 26.3 36.9 14.2 21.2 10.2 2.7 21.6 14.0 7.9 10.7 21.6 11.2 6.3 8.7 11.8 0.0 12.4 8.6 12.9 32.3 1.1 16.3 10.2 17.5 11.5 10.4 17.7 5.8 10.9 11.7 11.8 19.0 13.8 10.3 14.7 11.5 12.0 17.7 9.7 12.9 12.0 7.9 8.1 34.4 21.2 9.5 10.6 40.3 MAP3K1 "MAPKKK1, MEKK, MEKK1" ENSG00000095015 "Mitogen-activated protein kinase kinase kinase 1" Q13233 5 56815574-56896152 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 5 "Kupffer cells: 81.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "SH-SY5Y: 27.5;THP-1: 25.7" "Region enriched" "Detected in many" 6 "olfactory region: 22.5" "Low region specificity" "Detected in all" "CAB004500, HPA046509" Approved Approved Cytosol NA NA Cytosol "CAB004500: AB_627926, HPA046509: AB_2679678" "unprognostic (1.77e-1)" "unprognostic (1.71e-2)" "unprognostic (4.09e-1)" "unprognostic (2.18e-1)" "unprognostic (3.48e-2)" "unprognostic (5.39e-3)" "unprognostic (5.20e-3)" "unprognostic (2.52e-2)" "unprognostic (1.35e-1)" "unprognostic (1.41e-1)" "unprognostic (1.05e-2)" "unprognostic (6.73e-2)" "unprognostic (1.97e-3)" "unprognostic (2.18e-2)" "unprognostic (1.58e-1)" "unprognostic (9.92e-3)" "unprognostic (1.11e-1)" 6.7 4.9 5.4 14.6 4.8 15.2 14.9 8.0 4.5 7.6 6.7 5.4 7.3 4.3 7.1 9.4 12.7 7.2 5.9 4.3 3.7 3.2 9.5 4.4 8.8 21.4 6.4 3.1 8.4 9.2 6.3 7.9 8.1 4.5 8.3 4.5 12.6 15.4 9.7 3.5 21.8 11.2 4.0 3.8 21.3 5.5 8.5 5.1 11.7 19.2 6.6 18.2 6.0 11.7 6.6 2.8 6.7 7.2 2.7 5.8 2.3 6.6 4.0 6.3 4.2 1.0 0.8 10.6 1.3 1.7 4.0 5.6 18.7 5.0 5.9 0.4 1.5 3.4 3.4 5.2 2.3 5.6 2.0 2.3 3.3 1.8 8.8 2.5 5.2 9.2 1.0 2.5 1.2 2.0 1.1 1.7 2.0 2.8 10.7 1.0 2.9 3.6 7.1 2.9 3.4 0.5 5.7 4.4 20.3 7.0 6.9 2.6 27.5 3.9 4.9 11.2 5.8 13.4 25.7 5.0 0.4 3.4 1.5 2.4 7.8 4.0 11.3 0.6 3.1 6.8 6.7 4.5 1.0 1.2 6.8 1.2 6.6 3.8 1.8 2.8 5.1 2.5 0.9 2.6 2.7 7.2 1.5 5.8 2.3 5.4 4.8 8.0 4.5 3.7 3.2 6.4 3.1 4.5 5.1 6.0 9.8 47.7 14.5 46.5 15.2 2.7 50.9 4.0 12.5 34.9 45.2 12.9 6.6 14.2 1.6 13.5 6.6 0.0 12.8 7.7 11.3 11.9 7.0 12.1 26.3 27.0 9.8 17.2 81.7 1.9 4.9 40.3 35.4 45.9 10.1 10.6 13.0 7.0 1.8 20.1 34.7 6.5 5.2 10.0 15.0 47.8 5.6 16.6 8.9 10.0 MAPK1 "ERK, ERK2, MAPK2, p41mapk, PRKM1, PRKM2" ENSG00000100030 "Mitogen-activated protein kinase 1" P28482 22 21754500-21867680 "Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins" "Apoptosis, Cell cycle, Host-virus interaction, Transcription, Transcription regulation" "DNA-binding, Kinase, Repressor, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 80.3" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "K-562: 81.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003995, CAB004229, HPA005700, HPA030069" Approved NA NA 250000 "CAB004229: AB_627547, HPA003995: AB_1078751, HPA005700: AB_1078750, HPA030069: AB_10602035" "unprognostic (9.41e-3)" "unprognostic (2.68e-1)" "unprognostic (2.50e-3)" "unprognostic (4.17e-1)" "unprognostic (4.44e-3)" "unprognostic (1.72e-1)" "prognostic unfavorable (4.95e-4)" "unprognostic (2.29e-1)" "unprognostic (1.67e-1)" "unprognostic (1.58e-1)" "unprognostic (8.43e-3)" "unprognostic (1.04e-1)" "unprognostic (1.35e-2)" "unprognostic (2.08e-1)" "unprognostic (1.94e-1)" "unprognostic (1.41e-1)" "unprognostic (6.49e-2)" 16.1 21.1 32.9 18.3 80.3 20.2 13.6 31.0 54.5 18.6 18.5 23.2 9.6 13.7 17.4 10.6 25.7 16.9 14.9 22.8 32.4 23.4 21.7 16.4 19.9 16.6 18.4 23.6 16.0 19.8 27.4 10.9 17.2 27.6 16.4 19.9 14.2 15.8 17.8 28.2 17.5 15.1 22.8 20.4 19.8 17.2 24.2 21.5 19.5 23.0 11.1 21.4 17.7 15.3 2.5 3.2 13.5 4.9 7.0 13.7 2.5 19.7 12.5 16.1 9.2 19.1 19.2 6.1 21.8 20.4 19.6 19.0 9.9 10.5 10.9 10.9 29.2 18.0 18.8 18.9 17.4 25.6 44.0 17.7 19.8 11.7 11.6 15.7 27.8 20.6 14.3 14.0 23.7 21.9 15.4 26.7 11.9 81.1 12.5 23.9 8.1 18.0 6.1 6.1 26.8 12.3 19.8 39.7 2.9 11.2 16.2 13.1 7.3 23.6 14.2 12.7 16.7 10.7 9.4 23.3 16.4 21.4 18.8 13.8 12.0 14.6 17.0 15.5 13.6 17.7 1.0 4.0 5.8 13.7 4.6 3.9 2.0 2.9 4.9 3.2 2.5 2.8 5.1 13.5 7.0 4.9 3.2 2.7 2.5 32.9 80.3 31.0 54.5 32.4 23.4 18.4 23.6 27.6 21.5 44.7 30.2 28.0 22.1 53.3 23.8 34.6 63.7 21.4 33.0 48.8 51.1 18.0 16.6 24.0 33.2 31.2 46.6 23.3 33.6 18.2 31.5 37.5 93.2 59.4 47.7 27.0 57.3 57.7 88.6 9.9 30.2 59.7 38.8 15.4 44.2 32.3 39.5 28.8 41.8 37.6 21.0 32.3 32.2 70.0 47.7 54.1 16.0 95.8 30.7 34.8 MAX "bHLHd4, bHLHd5, bHLHd6, bHLHd7, bHLHd8" ENSG00000125952 "MYC associated factor X" P61244 14 65006174-65102695 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding, Repressor" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "HMC-1: 94.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000328, HPA003474" Supported Supported "Nucleoplasm,Golgi apparatus,Vesicles" NA NA Nucleoplasm "Golgi apparatus, Vesicles" "CAB000328: AB_2281783, HPA003474: AB_1079317" "unprognostic (4.50e-3)" "unprognostic (1.51e-3)" "unprognostic (4.08e-2)" "unprognostic (2.87e-1)" "unprognostic (8.37e-2)" "unprognostic (2.42e-2)" "unprognostic (1.13e-3)" "unprognostic (1.30e-3)" "unprognostic (1.53e-2)" "unprognostic (7.36e-3)" "unprognostic (7.19e-2)" "unprognostic (1.66e-2)" "prognostic unfavorable (5.57e-4)" "unprognostic (2.99e-1)" "unprognostic (4.68e-2)" "prognostic favorable (2.12e-4)" "unprognostic (6.03e-2)" 33.4 25.5 31.3 31.5 38.6 68.7 25.8 59.0 38.2 34.6 29.4 37.2 26.3 31.5 34.3 24.0 47.6 38.2 27.9 30.1 29.9 28.4 26.3 21.8 31.4 43.4 37.1 21.6 39.7 20.0 17.4 23.7 30.2 32.7 31.9 25.0 26.8 33.6 37.7 27.8 32.1 40.2 30.7 34.8 42.9 24.8 15.7 40.9 41.3 30.2 22.5 40.7 35.1 40.7 18.7 19.1 87.5 23.6 19.2 30.0 44.8 28.9 11.3 7.0 11.3 18.4 14.4 9.1 10.2 15.6 12.7 15.7 7.2 20.4 24.1 8.6 12.2 11.3 14.5 17.5 14.2 9.6 24.3 10.6 37.5 7.5 7.9 21.6 14.1 94.4 17.2 10.1 11.7 13.0 16.6 14.1 16.3 17.6 9.8 12.9 16.0 32.6 48.6 9.3 17.1 18.6 18.5 11.0 10.8 11.8 9.7 15.1 9.8 13.4 14.3 13.1 6.5 14.0 18.0 17.6 11.7 14.2 10.8 8.1 12.1 10.2 15.3 14.6 13.6 11.7 87.5 23.6 80.6 21.7 20.1 23.7 18.7 25.4 22.1 19.1 17.6 26.6 22.3 49.5 19.2 17.4 18.3 30.0 44.8 31.3 38.6 59.0 38.2 29.9 28.4 37.1 21.6 32.7 40.9 26.8 27.2 50.6 55.5 151.2 22.4 25.5 22.9 21.4 27.3 17.4 19.6 34.8 44.7 33.9 34.8 46.7 63.2 0.0 27.8 36.5 43.0 52.7 62.2 19.1 53.4 44.5 42.5 68.2 78.5 71.7 72.2 46.3 54.0 34.3 40.5 43.3 45.6 87.7 56.6 49.1 15.0 135.8 55.6 40.5 26.6 157.8 45.2 59.0 24.2 65.0 MED12 "CAGH45, FGS1, HOPA, KIAA0192, OKS, OPA1, TNRC11, TRAP230" ENSG00000184634 "Mediator complex subunit 12" Q93074 X 71118556-71142454 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Activator, Repressor" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003184, HPA003185" Enhanced Approved Nucleoplasm NA NA Nucleoplasm "HPA003184: AB_1079349, HPA003185: AB_1079350" "unprognostic (1.39e-1)" "unprognostic (2.23e-1)" "unprognostic (5.42e-2)" "unprognostic (2.07e-1)" "unprognostic (6.89e-3)" "unprognostic (7.14e-2)" "unprognostic (1.68e-2)" "unprognostic (1.15e-2)" "unprognostic (2.10e-1)" "unprognostic (1.53e-1)" "unprognostic (2.45e-1)" "unprognostic (2.50e-1)" "unprognostic (1.22e-3)" "unprognostic (1.28e-1)" "unprognostic (1.02e-1)" "unprognostic (3.67e-1)" "unprognostic (5.16e-2)" 18.2 31.3 12.3 15.3 14.7 16.6 18.1 18.0 15.1 16.8 12.8 19.8 21.3 10.2 21.7 16.5 13.1 17.7 14.2 12.9 12.9 8.5 13.3 9.8 14.0 15.3 15.7 10.7 28.8 14.2 20.1 17.9 23.0 11.6 16.5 11.8 18.6 14.6 20.3 14.9 17.6 14.8 16.4 11.2 27.3 14.2 15.3 12.9 33.1 17.8 12.6 15.9 15.4 16.4 4.0 5.1 9.7 3.7 5.0 7.4 3.6 8.7 10.3 16.3 9.7 12.0 10.7 24.1 6.2 8.9 9.9 7.1 12.4 8.3 11.5 8.2 10.7 6.8 8.7 19.0 7.8 7.9 12.1 14.7 19.1 23.2 16.7 9.4 17.5 16.9 12.4 8.5 12.9 15.0 12.7 15.2 14.7 17.7 20.2 9.7 14.7 18.4 10.0 9.3 11.2 13.5 17.3 18.2 8.7 7.5 17.4 9.1 11.0 14.3 7.3 8.1 17.5 8.8 8.7 13.2 10.8 12.8 9.9 4.3 10.0 5.5 8.4 6.3 9.8 7.2 9.7 3.7 7.2 5.9 3.6 5.0 4.0 4.1 5.4 3.9 4.0 4.6 3.9 7.7 5.0 2.4 5.1 7.4 3.6 12.3 14.7 18.0 15.1 12.9 8.5 15.7 10.7 11.6 12.9 8.9 3.4 5.2 5.2 5.4 7.1 8.1 15.3 2.7 6.8 8.7 5.9 17.0 1.7 5.4 0.2 8.7 6.8 0.0 5.4 6.2 7.8 5.7 9.2 3.4 8.0 12.7 7.5 14.1 6.7 0.9 13.0 9.2 5.0 6.4 7.8 5.8 8.6 8.4 12.7 2.2 4.5 0.0 5.0 6.4 7.4 5.0 22.8 6.4 6.4 6.8 MEN1 ENSG00000133895 "Menin 1" O00255 11 64803510-64811294 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Chromatin regulator, DNA-binding, Repressor" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA030342 Uncertain Supported Nucleoplasm,Cytosol NA NA Nucleoplasm Cytosol "HPA030342: AB_10610138" "unprognostic (2.06e-1)" "unprognostic (1.76e-1)" "unprognostic (3.78e-2)" "unprognostic (2.31e-2)" "unprognostic (1.05e-1)" "unprognostic (8.41e-2)" "prognostic unfavorable (1.08e-4)" "unprognostic (2.66e-1)" "unprognostic (2.59e-1)" "unprognostic (1.42e-2)" "unprognostic (4.96e-2)" "unprognostic (1.36e-1)" "unprognostic (7.39e-2)" "prognostic favorable (6.31e-5)" "unprognostic (1.40e-1)" "unprognostic (3.03e-1)" "unprognostic (3.76e-1)" 12.1 20.6 13.2 15.6 17.7 11.8 12.5 25.8 26.9 15.5 14.9 16.4 22.2 16.9 14.8 18.4 18.9 17.6 14.7 9.0 12.4 11.5 15.9 23.0 12.8 22.1 12.5 15.6 19.7 25.9 16.8 18.0 16.1 16.0 15.9 11.6 16.6 23.3 19.9 8.4 21.6 15.8 11.0 9.8 20.6 15.3 21.2 12.3 33.2 23.9 6.2 20.3 13.7 15.5 5.2 2.9 3.4 1.5 1.8 4.8 1.0 16.3 22.0 14.1 22.1 15.8 10.2 16.6 11.8 11.7 18.4 12.4 12.7 16.2 23.3 19.3 9.1 15.4 23.4 19.1 16.3 11.1 19.9 28.2 19.3 17.7 16.9 14.0 12.4 13.1 11.7 12.3 15.5 12.8 11.1 17.0 30.0 28.0 8.9 10.2 30.6 31.3 25.1 18.4 13.8 33.1 24.3 16.0 22.3 11.9 15.2 19.9 17.5 13.9 19.7 14.3 10.5 29.3 13.8 10.7 17.4 16.7 20.8 9.9 14.0 16.2 11.8 13.8 9.7 11.0 0.9 1.3 3.4 3.7 1.5 4.8 3.7 2.6 4.6 1.3 5.2 4.5 2.6 0.2 1.8 0.5 2.9 1.9 1.0 13.2 17.7 25.8 26.9 12.4 11.5 12.5 15.6 16.0 12.3 3.0 4.8 19.3 3.8 5.0 8.3 3.7 2.5 1.4 1.2 3.5 5.9 15.7 3.3 7.3 0.9 4.4 8.4 0.0 6.2 18.5 4.6 4.9 1.1 9.4 7.9 3.2 4.1 8.0 0.3 0.6 11.2 2.6 8.5 6.4 8.7 8.4 7.1 10.1 3.5 6.2 5.7 12.9 2.7 16.6 15.5 6.0 13.6 6.7 9.5 3.0 MET "DFNB97, HGFR, RCCP2" ENSG00000105976 "MET proto-oncogene, receptor tyrosine kinase" P08581 7 116672390-116798386 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins" "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Deafness, Disease mutation, FDA approved drug targets, Non-syndromic deafness, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" 6 "Alveolar cells type 2: 78.1;Club cells: 116.0;Urothelial cells: 88.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in single" "Cell line enhanced" "Detected in many" "A-431: 45.3;CAPAN-2: 49.5" "Group enriched" "Detected in many" 5 "amygdala: 3.5;basal ganglia: 9.9;cerebral cortex: 7.6;hippocampal formation: 8.0;olfactory region: 9.1" "Low region specificity" "Detected in many" "CAB005282, CAB018577, HPA055607" Approved Approved "Plasma membrane,Cytosol" "Secreted to blood" NA NA 179000000 70000000 "Plasma membrane, Cytosol" "CAB005282: AB_631940, CAB018577: AB_649068, HPA055607: AB_2682860" "unprognostic (1.60e-2)" "unprognostic (7.71e-2)" "unprognostic (2.53e-2)" "unprognostic (1.58e-1)" "unprognostic (3.57e-3)" "prognostic unfavorable (6.75e-4)" "unprognostic (1.68e-1)" "unprognostic (3.22e-2)" "unprognostic (3.81e-2)" "unprognostic (2.52e-2)" "prognostic unfavorable (1.21e-7)" "unprognostic (1.86e-1)" "unprognostic (1.25e-1)" "unprognostic (5.53e-2)" "unprognostic (8.88e-2)" "unprognostic (2.01e-2)" "unprognostic (2.20e-1)" 16.2 1.1 1.8 4.5 2.3 4.3 11.2 0.9 15.2 9.9 6.5 2.4 2.4 4.4 7.5 5.2 5.1 4.6 12.3 5.4 5.7 1.8 20.1 30.2 15.6 1.4 3.6 2.1 2.0 9.3 0.7 8.1 24.4 2.6 8.0 6.6 34.1 12.2 8.4 12.8 7.2 8.6 4.0 2.3 5.7 10.6 2.7 2.4 0.5 21.4 7.0 2.1 10.1 15.0 0.2 0.3 1.2 0.2 0.3 0.4 0.0 45.3 26.1 0.0 0.1 2.0 2.0 1.8 25.9 10.5 14.0 11.8 5.4 49.5 2.0 43.2 16.2 37.7 12.0 4.4 24.7 28.6 0.1 5.6 0.0 27.1 4.7 0.3 0.0 0.0 2.6 9.8 9.1 30.0 25.3 9.6 0.0 0.9 0.2 25.9 1.0 0.0 0.0 3.9 7.2 26.6 0.0 22.0 0.0 24.5 5.2 3.8 0.0 10.6 3.4 10.1 4.7 0.0 0.2 17.6 20.9 7.4 11.0 20.0 0.5 4.0 0.2 22.9 0.0 2.9 1.1 0.2 0.4 0.4 0.1 0.2 0.2 0.2 0.2 0.1 0.2 0.2 0.2 1.2 0.3 0.1 0.3 0.1 0.0 1.8 2.3 0.9 15.2 5.7 1.8 3.6 2.1 2.6 2.4 26.8 78.1 2.4 56.1 34.7 0.9 10.0 15.3 22.7 116.0 29.6 0.0 57.9 0.0 28.0 0.0 11.7 11.2 0.0 39.8 5.0 4.0 55.8 0.0 26.0 6.1 0.0 6.9 1.3 1.0 0.0 0.6 2.0 3.3 1.8 19.7 7.4 69.4 7.0 0.0 13.5 0.3 0.0 2.3 0.0 0.6 15.6 18.2 0.0 12.7 88.5 MLH1 "COCA2, FCC2, HNPCC, HNPCC2" ENSG00000076242 "MutL homolog 1" P40692 3 36993332-37050918 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cell cycle, DNA damage, DNA repair" "Cancer-related genes, Disease mutation, Hereditary nonpolyposis colorectal cancer, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB013294, HPA052707, HPA060714, CAB070868" Supported Enhanced Nucleoplasm NA NA Nucleoplasm "CAB013294: AB_2533406, CAB070868: , HPA052707: AB_2681923, HPA060714: AB_2684348" "unprognostic (1.26e-2)" "unprognostic (3.88e-3)" "unprognostic (2.36e-2)" "unprognostic (1.82e-1)" "unprognostic (3.33e-2)" "unprognostic (1.05e-1)" "prognostic unfavorable (8.24e-5)" "unprognostic (3.36e-2)" "unprognostic (2.18e-1)" "unprognostic (1.32e-1)" "unprognostic (8.54e-2)" "unprognostic (8.63e-3)" "unprognostic (2.10e-3)" "unprognostic (4.37e-2)" "unprognostic (1.38e-1)" "unprognostic (1.02e-2)" "unprognostic (8.86e-2)" 16.3 20.7 18.2 19.4 21.4 24.4 18.7 19.7 19.6 15.3 17.3 28.8 19.6 12.4 18.7 23.6 15.1 16.2 14.4 32.0 17.3 17.7 18.8 20.5 17.8 22.8 19.9 16.0 17.6 18.1 26.0 29.4 17.3 19.2 18.5 17.7 16.7 15.6 18.1 46.4 14.2 14.1 21.1 21.6 20.7 16.5 27.6 21.5 29.0 22.2 19.5 24.5 16.9 21.4 12.0 12.9 13.2 23.2 6.7 13.4 9.0 14.2 22.5 28.1 0.0 12.5 15.7 12.6 21.3 17.0 24.8 26.4 17.0 15.9 35.3 10.6 17.3 14.0 9.8 24.2 18.0 26.6 16.0 12.5 24.7 20.8 23.8 13.9 30.3 17.2 11.7 12.7 23.1 28.8 9.8 15.3 23.9 31.6 16.9 25.1 11.5 31.6 12.4 20.6 14.5 12.4 3.1 34.4 14.9 15.7 15.5 6.0 14.2 21.6 23.0 14.2 16.4 33.2 21.6 12.1 19.5 21.0 19.1 25.0 13.4 36.6 33.1 15.1 28.7 17.5 10.9 11.7 13.2 13.4 19.5 9.7 12.0 8.4 10.7 12.9 10.3 9.6 9.7 3.4 6.7 23.2 6.1 12.5 9.0 18.2 21.4 19.7 19.6 17.3 17.7 19.9 16.0 19.2 21.5 23.8 12.0 16.0 10.7 6.4 19.2 37.1 15.3 16.0 13.6 10.4 9.8 27.1 16.6 12.5 20.3 11.2 5.3 0.0 13.0 23.0 13.4 8.0 7.0 14.5 17.5 3.2 5.2 12.3 14.3 9.5 10.3 11.4 8.5 19.8 7.2 14.3 8.6 7.0 13.1 9.2 17.9 12.9 9.5 37.0 25.4 4.8 16.7 13.1 7.6 3.4 MPL "CD110, TPOR" ENSG00000117400 "MPL proto-oncogene, thrombopoietin receptor" P40238 1 43337849-43352772 "Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" Receptor "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 8.6" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in single" "Cell type enriched" "Detected in single" 5 "neutrophil: 1.6" "Lineage enriched" "Detected in single" 5 "granulocytes: 1.6" "Cell line enriched" "Detected in single" 78 "HEL: 41.7" "Region enhanced" "Detected in single" "cerebral cortex: 1.4" "Low region specificity" "Detected in all" HPA007619 Supported "Nuclear membrane,Plasma membrane" NA NA "Plasma membrane" "Nuclear membrane" "HPA007619: AB_1854080" "unprognostic (2.74e-1)" "unprognostic (6.56e-2)" "unprognostic (2.95e-1)" "unprognostic (8.71e-2)" "unprognostic (1.37e-2)" "unprognostic (1.06e-3)" "unprognostic (1.19e-1)" "unprognostic (1.22e-2)" "unprognostic (5.83e-2)" "unprognostic (1.03e-1)" "unprognostic (5.94e-4)" "unprognostic (1.51e-1)" "unprognostic (1.19e-4)" "unprognostic (2.39e-1)" "unprognostic (3.26e-1)" "unprognostic (1.03e-4)" "unprognostic (1.42e-1)" 1.1 0.3 0.9 0.5 0.8 2.0 0.9 0.5 2.2 0.6 0.6 0.5 0.5 0.3 0.9 1.7 0.9 2.1 0.5 3.9 0.8 0.6 0.5 0.5 2.0 0.5 0.9 0.5 6.6 1.1 0.6 0.6 2.2 0.5 1.5 0.7 0.5 0.5 0.7 0.6 0.4 1.2 2.1 2.5 8.6 0.5 2.1 0.5 0.5 2.2 2.4 0.5 0.9 0.5 0.0 0.0 1.6 0.3 0.0 0.0 4.0 0.1 0.5 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.5 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.0 0.2 0.0 41.7 0.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.3 0.0 0.1 0.0 0.0 0.1 0.4 0.2 0.2 0.0 0.3 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.0 4.0 0.9 0.8 0.5 2.2 0.8 0.6 0.9 0.5 0.5 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 MSH2 "COCA1, HNPCC, HNPCC1" ENSG00000095002 "MutS homolog 2" P43246 2 47402969-47663146 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "DNA damage, DNA repair" DNA-binding "Cancer-related genes, Disease mutation, Hereditary nonpolyposis colorectal cancer, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 5 "Spermatogonia: 59.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009572, HPA066845, CAB070867" Approved Supported Nucleoplasm,Vesicles NA Yes Nucleoplasm Vesicles "CAB009572: AB_2144828, CAB070867: , HPA066845: AB_2732752" "unprognostic (2.35e-1)" "unprognostic (1.54e-2)" "unprognostic (2.89e-3)" "prognostic unfavorable (4.44e-4)" "unprognostic (2.23e-1)" "unprognostic (6.31e-3)" "prognostic unfavorable (1.72e-9)" "unprognostic (1.77e-1)" "unprognostic (7.09e-3)" "unprognostic (8.57e-2)" "prognostic unfavorable (4.63e-4)" "unprognostic (5.38e-2)" "unprognostic (3.29e-3)" "unprognostic (1.20e-3)" "unprognostic (5.74e-1)" "unprognostic (8.46e-2)" "unprognostic (1.48e-1)" 7.3 9.8 14.2 12.2 25.5 11.4 14.1 22.6 18.1 9.4 11.6 7.6 5.6 6.5 10.5 13.3 10.8 11.1 4.9 8.4 13.0 14.0 7.3 5.5 7.1 19.7 12.5 17.0 7.9 8.4 15.3 9.1 9.9 18.5 7.9 13.8 12.3 9.4 7.3 6.7 10.3 8.0 7.8 13.8 9.4 6.7 13.4 13.5 37.0 13.9 6.6 21.4 8.5 7.6 7.4 2.9 3.9 4.2 12.2 12.6 6.2 28.3 9.7 26.5 14.3 2.0 5.6 16.1 16.9 8.4 21.0 20.3 18.2 12.3 34.9 22.8 5.9 14.8 12.1 19.8 9.6 31.7 18.0 14.8 25.1 11.2 16.5 2.0 24.5 8.8 3.1 2.8 17.8 4.8 4.7 11.5 0.8 41.8 8.1 16.0 11.3 28.4 18.5 49.9 17.2 11.5 38.1 47.4 20.4 9.1 15.0 22.0 23.9 14.9 11.6 11.9 22.3 11.6 9.6 4.6 13.9 18.3 14.4 18.8 5.2 18.5 48.9 8.5 18.1 8.6 2.8 1.0 3.9 7.9 4.2 8.6 6.3 7.4 9.5 2.3 7.4 12.6 11.9 0.7 12.2 3.2 2.9 10.1 6.2 14.2 25.5 22.6 18.1 13.0 14.0 12.5 17.0 18.5 13.5 8.9 11.5 13.7 5.7 7.3 16.8 13.8 5.1 25.4 13.6 8.7 43.2 14.2 3.3 9.6 13.1 11.7 4.6 23.3 7.3 16.3 8.7 3.4 11.5 1.0 9.6 11.1 3.4 3.7 4.0 17.6 4.9 4.0 8.5 6.4 9.1 20.0 6.0 5.8 6.0 3.5 38.3 0.0 5.5 34.2 59.5 5.6 4.2 8.7 9.8 2.7 MSH6 GTBP ENSG00000116062 "MutS homolog 6" P52701 2 47695530-47810101 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "DNA damage, DNA repair, Host-virus interaction" DNA-binding "Cancer-related genes, Disease mutation, Hereditary nonpolyposis colorectal cancer" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009091, HPA028376, HPA028446, CAB070870" Enhanced Supported "Nucleoplasm,Golgi apparatus,Vesicles" NA Yes Nucleoplasm "Golgi apparatus, Vesicles" "CAB009091: AB_670083, CAB070870: AB_2144959, HPA028376: AB_10598909, HPA028446: AB_10602182" "unprognostic (5.10e-2)" "unprognostic (5.87e-3)" "unprognostic (3.29e-2)" "prognostic unfavorable (1.34e-4)" "unprognostic (1.98e-1)" "unprognostic (3.09e-2)" "prognostic unfavorable (7.86e-4)" "unprognostic (1.79e-1)" "unprognostic (2.35e-3)" "unprognostic (1.01e-1)" "unprognostic (1.74e-3)" "unprognostic (8.99e-2)" "prognostic unfavorable (1.06e-7)" "unprognostic (1.22e-1)" "unprognostic (2.31e-1)" "unprognostic (9.68e-2)" "unprognostic (3.48e-2)" 13.0 20.5 9.7 13.1 18.8 13.6 13.0 20.5 13.1 17.9 13.3 17.6 10.7 6.1 28.2 11.0 12.4 18.3 8.4 8.6 11.4 8.8 9.5 14.6 11.0 21.7 23.9 9.6 43.2 27.6 16.2 17.3 14.9 15.0 14.6 10.3 8.7 12.0 13.2 10.4 10.3 10.5 22.1 14.9 11.6 11.1 25.1 22.0 40.4 13.4 10.4 25.8 14.2 16.4 8.4 8.4 7.6 9.8 9.7 15.1 5.7 27.5 20.6 38.3 9.1 11.6 12.2 17.3 15.3 13.5 15.9 16.7 15.1 9.6 45.5 23.0 16.6 21.9 11.6 34.5 19.5 20.8 19.8 17.2 29.1 16.3 15.3 7.1 29.2 10.7 9.9 6.2 16.2 10.8 14.9 9.9 1.1 25.3 16.7 15.5 19.9 31.1 13.8 33.6 18.6 9.5 73.8 50.2 20.5 9.7 17.9 21.5 23.3 21.3 10.2 9.3 35.1 12.2 10.3 6.0 18.5 22.6 14.0 19.8 15.7 21.2 76.2 15.6 18.7 11.3 7.6 5.8 4.9 8.4 9.8 10.4 8.4 9.5 8.3 8.4 8.1 15.1 7.6 3.9 9.7 9.3 4.2 9.5 5.7 9.7 18.8 20.5 13.1 11.4 8.8 23.9 9.6 15.0 22.0 26.8 18.4 9.7 20.1 22.3 26.4 6.9 0.0 28.1 31.8 7.0 33.4 24.9 3.3 12.8 25.7 15.3 2.6 0.0 8.4 16.9 17.4 11.4 17.3 8.5 11.1 14.3 4.6 12.3 5.1 11.5 23.6 12.1 3.3 7.2 7.9 27.0 8.8 3.5 21.2 5.3 29.7 6.5 17.2 40.0 40.2 15.3 8.0 13.3 9.3 10.7 MTOR "FLJ44809, FRAP, FRAP1, FRAP2, RAFT1, RAPT1" ENSG00000198793 "Mechanistic target of rapamycin kinase" P42345 1 11106535-11262507 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Biological rhythms" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease mutation, Epilepsy, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 5 "Sertoli cells: 38.8;Spermatocytes: 48.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB069425, HPA071227" Approved Approved Vesicles,Cytosol NA NA "Vesicles, Cytosol" "CAB069425: , HPA071227: AB_2686367" "unprognostic (3.18e-1)" "unprognostic (1.50e-1)" "unprognostic (1.20e-1)" "unprognostic (2.45e-3)" "unprognostic (5.50e-2)" "unprognostic (2.55e-2)" "unprognostic (1.39e-1)" "unprognostic (1.68e-1)" "unprognostic (1.18e-1)" "unprognostic (8.24e-3)" "unprognostic (3.48e-2)" "unprognostic (1.88e-1)" "prognostic favorable (1.49e-5)" "unprognostic (1.27e-1)" "unprognostic (2.45e-1)" "unprognostic (6.60e-2)" "unprognostic (7.55e-2)" 11.3 13.9 18.7 13.0 22.5 12.3 14.9 25.2 25.2 11.3 14.5 18.2 10.4 11.2 13.8 23.6 13.1 10.5 15.7 14.2 14.5 13.6 15.8 19.4 10.8 14.3 14.0 14.4 10.7 16.6 26.5 16.0 12.5 15.5 15.2 17.1 14.4 14.2 15.2 24.6 16.5 13.6 15.2 10.4 15.4 13.1 38.6 13.1 16.6 13.2 9.9 15.7 11.7 10.2 3.9 4.0 3.0 6.4 2.6 5.6 2.3 15.2 13.9 18.7 14.2 22.7 10.8 9.4 12.9 12.4 17.3 17.0 14.2 14.1 17.0 11.1 15.2 10.7 18.2 25.3 19.8 22.4 13.5 18.5 22.6 28.7 17.9 14.2 21.9 16.8 13.8 15.1 24.7 25.1 8.2 21.8 16.4 25.2 14.6 12.0 17.4 15.1 16.8 14.2 16.0 13.1 15.2 22.1 11.4 15.3 13.9 18.9 13.9 27.6 15.0 16.9 21.5 12.2 13.0 23.3 15.1 13.7 11.5 17.3 14.4 13.4 33.4 10.9 23.8 15.9 0.7 2.9 3.0 5.2 6.4 4.3 3.9 3.0 2.7 4.0 3.4 3.6 3.1 2.0 2.6 3.3 3.1 5.6 2.3 18.7 22.5 25.2 25.2 14.5 13.6 14.0 14.4 15.5 13.1 14.9 10.2 5.2 4.5 3.1 0.0 25.7 2.5 2.7 10.3 8.7 0.0 6.5 1.7 6.3 31.2 7.8 7.9 0.0 5.4 5.9 5.1 7.5 12.7 13.0 6.1 0.0 9.9 5.5 7.3 29.3 7.2 6.0 8.5 5.4 6.8 0.0 8.6 3.5 7.8 4.3 0.0 38.8 6.9 48.4 31.3 5.0 8.2 6.5 9.5 5.5 MUTYH MYH ENSG00000132781 "MutY DNA glycosylase" Q9UIF7 1 45329163-45340470 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "DNA damage, DNA repair" "Glycosidase, Hydrolase" "Cancer-related genes, Disease mutation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 4 "Cytotrophoblasts: 33.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA008732 Uncertain Supported Nucleoplasm NA NA Nucleoplasm "HPA008732: AB_1854219" "unprognostic (6.30e-3)" "unprognostic (7.12e-2)" "unprognostic (6.29e-2)" "unprognostic (8.80e-2)" "unprognostic (3.43e-1)" "unprognostic (5.16e-3)" "prognostic unfavorable (4.76e-8)" "unprognostic (2.80e-2)" "unprognostic (7.12e-3)" "unprognostic (3.05e-2)" "unprognostic (7.80e-2)" "unprognostic (1.14e-1)" "prognostic unfavorable (7.25e-5)" "unprognostic (3.50e-3)" "unprognostic (1.62e-1)" "unprognostic (5.57e-2)" "unprognostic (5.49e-3)" 7.7 8.4 10.3 12.7 14.8 11.1 8.3 31.6 12.4 10.5 10.1 15.1 11.0 11.1 11.5 9.8 8.3 11.0 10.0 6.1 10.9 7.3 9.7 9.0 7.2 14.0 13.6 10.1 12.9 8.4 7.5 12.5 12.5 11.6 9.1 11.0 12.6 9.5 11.7 8.5 11.1 9.8 7.5 12.6 12.8 11.8 4.9 16.6 14.1 11.9 7.4 12.0 9.3 9.2 7.2 6.5 1.9 8.9 6.6 15.4 6.3 4.9 4.3 10.1 6.9 7.2 5.4 17.6 3.4 4.7 7.4 6.1 9.1 7.0 13.9 6.1 2.3 5.9 7.6 5.3 6.3 3.4 11.5 4.0 6.8 6.9 6.5 6.7 5.8 5.0 3.6 6.5 9.9 16.6 1.9 5.3 18.3 10.5 5.4 3.1 8.0 15.9 5.5 25.5 11.7 5.3 21.6 7.8 7.5 3.8 9.3 9.2 7.2 7.4 5.8 11.5 13.6 4.6 6.7 3.3 6.5 4.0 5.0 5.4 8.2 9.4 8.5 5.6 8.8 4.9 1.5 5.6 1.9 9.8 8.9 15.4 7.2 10.2 9.9 6.5 7.2 11.3 11.0 0.9 6.6 6.8 5.5 10.3 6.3 10.3 14.8 31.6 12.4 10.9 7.3 13.6 10.1 11.6 16.6 0.0 6.4 7.0 10.7 6.2 14.7 3.1 0.0 9.4 6.8 7.0 2.0 33.3 3.3 5.7 0.8 5.2 13.7 0.0 4.6 11.1 7.0 7.0 10.4 3.9 8.7 4.8 7.5 6.7 6.4 0.6 10.0 6.9 6.8 9.0 12.3 11.8 3.3 14.0 11.3 7.0 18.5 12.9 7.1 7.1 11.1 4.6 18.5 12.9 12.5 6.4 MYCN "bHLHe37, MYCNOT, N-myc, NMYC" ENSG00000134323 "MYCN proto-oncogene, bHLH transcription factor" P04198 2 15940564-15947007 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "placenta: 16.8" "Cell type enriched" "Detected in some" 8 "Extravillous trophoblasts: 75.4" "Cancer enhanced" "Detected in many" "testis cancer: 45.5" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "AF22: 12.9;BEWO: 70.2;HMC-1: 16.9;NTERA-2: 26.6;RH-30: 18.6;SuSa: 12.6" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA057420 Approved Nucleoplasm,Nucleoli NA NA Nucleoli Nucleoplasm "HPA057420: AB_2683434" "unprognostic (8.04e-2)" "unprognostic (1.96e-1)" "unprognostic (1.29e-1)" "unprognostic (2.07e-2)" "unprognostic (4.11e-1)" "unprognostic (2.46e-2)" "unprognostic (1.23e-2)" "unprognostic (3.03e-2)" "unprognostic (1.81e-1)" "unprognostic (3.35e-3)" "unprognostic (3.09e-2)" "unprognostic (2.09e-1)" "unprognostic (1.12e-3)" "unprognostic (8.89e-2)" "unprognostic (2.47e-1)" "unprognostic (4.90e-2)" "unprognostic (1.23e-1)" 0.9 1.9 5.1 1.8 5.5 1.6 1.2 1.4 8.4 3.1 1.2 12.1 0.0 3.0 1.9 0.8 1.3 1.4 2.6 2.3 7.0 4.7 6.0 1.5 1.6 2.9 6.0 2.2 10.3 0.7 0.4 0.7 16.8 6.8 0.6 1.3 1.1 6.6 0.7 1.0 2.4 1.7 0.9 8.9 0.9 8.5 6.5 4.0 5.7 5.1 2.3 3.5 2.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 12.9 0.0 0.0 0.0 70.2 0.0 0.0 0.0 0.0 1.0 0.0 0.0 1.2 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 4.7 0.0 0.0 0.0 0.0 16.9 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.2 0.1 0.0 26.6 0.6 0.0 0.0 18.6 3.5 0.0 0.9 0.2 4.7 0.0 0.0 0.0 12.6 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.1 5.5 1.4 7.0 7.0 4.7 6.0 2.2 6.8 4.0 0.0 0.0 0.0 0.1 0.5 2.6 0.7 0.0 0.0 0.0 0.0 0.0 4.4 0.0 0.0 1.2 0.2 0.0 0.0 0.0 75.4 0.6 0.0 0.0 0.5 2.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.8 0.2 0.0 0.4 2.1 0.1 0.0 0.0 0.5 3.6 0.0 9.6 0.0 0.2 0.0 MYD88 ENSG00000172936 "Myeloid differentiation primary response 88" Q99836 3 38138478-38143022 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Immunity, Inflammatory response, Innate immunity" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 68.0" "Cell type enhanced" "Detected in many" 5 "Kupffer cells: 75.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "SK-BR-3: 55.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB009104 Approved Supported Vesicles,Mitochondria,Cytosol NA NA Cytosol "Vesicles, Mitochondria" "CAB009104: AB_2146724" "prognostic favorable (8.45e-4)" "unprognostic (1.19e-1)" "unprognostic (4.31e-2)" "unprognostic (2.51e-2)" "unprognostic (4.77e-2)" "unprognostic (4.38e-3)" "unprognostic (4.37e-2)" "unprognostic (3.63e-1)" "unprognostic (1.67e-1)" "unprognostic (7.28e-2)" "unprognostic (1.01e-2)" "unprognostic (7.30e-2)" "unprognostic (2.11e-2)" "unprognostic (4.41e-1)" "unprognostic (4.17e-2)" "unprognostic (1.65e-1)" "unprognostic (2.08e-2)" 25.0 11.3 5.9 19.5 6.9 18.1 14.7 5.2 4.6 10.0 13.4 5.8 5.0 15.1 9.5 12.3 25.5 9.8 12.4 10.4 5.3 3.2 15.1 47.9 25.6 40.1 6.2 3.5 13.3 10.3 5.4 10.4 17.8 6.7 11.3 14.3 8.8 13.9 5.4 3.9 12.5 30.4 10.7 7.0 39.0 12.5 5.8 5.1 28.5 10.4 17.5 30.8 13.9 13.7 7.8 34.7 49.0 68.0 8.3 14.3 34.6 8.1 12.2 1.8 10.8 8.6 11.2 3.8 8.1 13.2 22.8 24.3 7.6 10.0 17.6 4.8 14.5 5.2 10.3 14.4 8.1 7.6 13.6 3.0 9.5 6.2 11.5 7.1 12.1 24.8 12.9 8.6 12.9 4.8 4.3 13.0 13.5 4.1 7.2 12.0 8.3 19.8 3.9 7.7 17.2 12.1 8.5 2.3 7.5 11.7 19.3 0.8 4.0 11.5 55.1 7.1 1.5 8.6 13.7 12.0 4.5 2.7 20.7 7.7 10.7 11.8 13.1 8.7 21.1 9.7 38.3 37.6 48.1 12.2 56.5 10.4 7.8 11.0 12.2 34.7 6.7 7.7 10.9 49.0 8.3 68.0 16.6 14.3 34.6 5.9 6.9 5.2 4.6 5.3 3.2 6.2 3.5 6.7 5.1 6.0 14.6 17.4 10.4 12.8 0.9 1.5 7.6 10.7 11.4 5.2 0.0 12.2 6.6 22.7 0.7 10.5 25.9 0.0 24.0 20.1 9.1 11.9 24.2 27.6 30.3 0.0 9.2 9.8 75.0 0.6 12.7 48.3 3.3 18.0 16.3 3.5 43.6 34.5 9.9 9.2 0.0 12.9 7.0 2.1 0.4 15.1 10.1 20.3 13.1 37.7 MYOD1 "bHLHc1, MYF3, MYOD, PUM" ENSG00000129152 "Myogenic differentiation 1" P15172 11 17719568-17722131 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Differentiation, Myogenesis, Transcription, Transcription regulation" "Activator, Developmental protein, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 7 "skeletal muscle: 31.8" "Cell type enriched" "Detected in single" 7 "Spermatogonia: 3.0" "Cancer enhanced" "Detected in single" "ovarian cancer: 0.7" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 15 "RH-30: 103.7" "Not detected" "Not detected" "Not detected" "Not detected" "HPA055436, HPA078647" Enhanced Nucleoplasm NA NA Nucleoplasm "HPA055436: , HPA078647: " "unprognostic (1.07e-3)" "unprognostic (2.10e-1)" "unprognostic (1.01e-1)" 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.0 0.0 0.0 0.7 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.6 0.0 0.0 0.5 0.0 31.8 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.2 4.6 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 103.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 3.0 0.0 0.0 0.0 0.0 0.0 NBN "AT-V1, AT-V2, ATV, NBS, NBS1" ENSG00000104320 Nibrin O60934 8 89933336-90003228 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cell cycle, DNA damage, DNA repair, Host-virus interaction, Meiosis" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "SK-BR-3: 78.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001429, CAB003836" Supported Approved "Nucleoplasm,Golgi apparatus" NA NA "Golgi apparatus" Nucleoplasm "CAB003836: AB_562172, HPA001429: AB_1854460" "unprognostic (1.52e-1)" "unprognostic (1.72e-1)" "unprognostic (2.32e-3)" "unprognostic (7.46e-2)" "unprognostic (2.49e-2)" "unprognostic (1.28e-1)" "unprognostic (1.05e-2)" "prognostic unfavorable (5.46e-5)" "unprognostic (5.05e-2)" "unprognostic (4.61e-2)" "prognostic unfavorable (4.20e-4)" "unprognostic (1.15e-1)" "unprognostic (6.68e-2)" "unprognostic (3.14e-2)" "unprognostic (3.28e-1)" "unprognostic (2.84e-2)" "unprognostic (1.03e-1)" 19.2 16.1 17.9 23.6 29.5 41.3 23.0 17.4 21.0 19.3 22.6 12.2 16.9 13.3 33.2 16.6 19.7 17.5 20.2 14.2 19.4 16.7 25.9 19.3 17.9 26.7 16.9 18.1 19.3 17.1 21.0 29.4 13.2 18.4 17.6 20.9 7.1 18.4 17.6 15.7 11.2 18.0 22.2 18.1 26.5 14.7 13.9 18.9 23.4 20.8 14.7 22.8 17.5 16.0 10.1 12.0 21.8 18.5 9.7 8.6 7.6 15.4 8.7 8.8 4.6 4.8 12.0 5.6 11.0 14.6 14.0 15.3 5.0 11.8 23.4 12.9 10.0 5.7 5.2 10.6 10.3 18.0 10.9 6.1 19.8 5.4 7.0 9.4 11.8 10.5 9.0 5.5 7.9 17.5 6.9 11.3 9.5 14.5 13.6 15.9 13.7 18.0 7.5 2.5 11.5 9.5 12.1 7.6 13.8 18.1 21.3 2.5 8.1 6.9 78.3 6.5 5.1 14.7 8.8 8.4 12.2 8.7 7.4 10.8 6.3 7.2 13.0 12.3 11.2 11.3 14.1 11.1 20.3 8.1 12.5 8.6 10.1 5.9 5.9 12.0 6.1 5.7 6.2 21.8 9.7 18.5 6.6 3.7 7.6 17.9 29.5 17.4 21.0 19.4 16.7 16.9 18.1 18.4 18.9 44.7 13.9 32.5 12.1 10.5 23.3 25.0 17.8 42.8 42.1 26.2 2.0 18.9 36.5 30.4 10.9 17.9 8.9 0.0 27.9 17.4 18.4 8.7 76.4 27.6 22.9 12.7 11.6 17.2 22.4 5.9 17.5 30.7 11.8 52.3 15.1 27.1 19.1 5.8 24.8 31.1 10.3 6.5 20.6 11.2 43.3 11.8 9.0 23.2 17.4 8.6 NCOR1 "hCIT529I10, hN-CoR, KIAA1047, MGC104216, N-CoR, PPP1R109, TRAC1" ENSG00000141027 "Nuclear receptor corepressor 1" O75376 17 16029157-16218185 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Biological rhythms, Transcription, Transcription regulation" "Chromatin regulator, DNA-binding, Repressor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA043246, HPA050288, HPA051168, CAB072830" Supported Enhanced Nucleoplasm,Cytosol NA NA Nucleoplasm Cytosol "CAB072830: , HPA043246: AB_2678386, HPA050288: AB_2681073, HPA051168: AB_2681370" "unprognostic (1.83e-1)" "unprognostic (3.05e-1)" "unprognostic (9.17e-2)" "unprognostic (1.10e-1)" "unprognostic (7.38e-2)" "unprognostic (3.59e-2)" "unprognostic (2.55e-2)" "unprognostic (4.27e-2)" "unprognostic (4.87e-2)" "unprognostic (4.06e-2)" "unprognostic (7.07e-2)" "unprognostic (1.52e-2)" "prognostic favorable (7.92e-5)" "unprognostic (4.40e-2)" "unprognostic (2.52e-1)" "unprognostic (1.33e-1)" "unprognostic (5.42e-2)" 19.6 21.2 25.4 24.0 30.8 27.0 25.0 41.8 31.5 24.0 30.6 19.6 18.6 33.2 29.0 19.5 25.0 20.5 21.9 17.8 22.4 17.8 25.6 33.8 20.1 19.5 25.1 19.1 25.9 24.3 39.9 39.8 19.8 21.6 20.8 29.7 17.1 20.9 29.1 43.0 23.8 36.9 29.7 26.4 23.7 29.8 22.1 26.4 38.8 25.3 15.7 23.8 29.6 27.0 43.4 29.9 78.2 24.8 30.4 35.5 19.7 20.4 34.2 24.4 20.3 20.1 15.3 12.2 15.1 17.1 16.6 15.1 18.3 9.4 21.5 10.7 26.3 12.4 15.6 30.0 18.3 24.7 28.6 22.2 21.4 29.6 21.4 19.7 13.4 25.6 15.7 19.2 25.7 30.1 14.2 23.0 30.4 18.6 8.9 16.3 13.3 23.6 8.6 12.1 36.0 9.3 23.6 24.8 10.0 17.2 23.2 8.3 13.9 24.9 10.9 11.8 65.5 10.5 15.3 20.0 17.1 10.1 12.5 20.8 6.1 7.1 12.5 16.3 16.0 14.6 78.2 24.8 52.2 31.3 19.5 25.9 40.7 35.5 34.1 17.5 43.4 34.7 34.8 48.5 30.4 24.0 29.9 31.7 19.7 25.4 30.8 41.8 31.5 22.4 17.8 25.1 19.1 21.6 26.4 74.5 98.7 86.4 91.4 60.2 144.1 78.9 66.2 61.6 72.8 50.6 149.2 79.2 29.9 80.2 53.7 68.9 164.0 93.5 85.1 85.7 74.0 70.9 83.3 105.0 67.5 122.3 84.4 59.5 70.8 35.4 94.0 84.8 35.4 184.0 101.0 81.4 89.5 133.5 114.2 37.3 152.7 90.5 89.5 82.3 75.1 59.6 73.2 110.7 125.6 110.0 NCOR2 "CTG26, SMRT, SMRTE, TNRC14, TRAC-1" ENSG00000196498 "Nuclear receptor corepressor 2" Q9Y618 12 124324415-124567589 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Repressor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 4 "Horizontal cells: 114.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "basophil: 8.1" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA001928 Approved Supported Nucleoplasm NA NA Nucleoplasm "HPA001928: AB_1079454" "unprognostic (9.51e-3)" "unprognostic (7.37e-3)" "unprognostic (4.66e-2)" "unprognostic (2.55e-3)" "unprognostic (2.14e-1)" "unprognostic (7.37e-2)" "unprognostic (3.19e-2)" "unprognostic (8.86e-2)" "unprognostic (2.21e-2)" "unprognostic (2.90e-3)" "unprognostic (6.42e-3)" "unprognostic (1.96e-1)" "unprognostic (9.86e-2)" "unprognostic (6.26e-2)" "unprognostic (1.59e-1)" "unprognostic (7.56e-2)" "unprognostic (8.90e-2)" 24.0 22.0 21.3 21.3 19.0 16.8 18.3 33.8 33.5 24.5 17.2 24.3 17.7 16.4 21.3 19.0 15.7 16.3 21.5 18.2 22.0 14.8 16.0 11.2 23.4 11.9 19.0 15.6 28.6 30.0 13.8 39.5 13.2 28.3 21.3 7.6 32.7 29.2 24.5 62.4 22.8 22.2 17.4 12.2 17.4 24.0 10.8 22.0 9.3 16.7 25.0 7.6 16.3 14.7 0.6 1.7 8.1 4.0 0.2 1.9 0.4 19.7 37.2 10.6 10.1 6.2 8.4 31.8 20.5 10.2 12.0 5.3 19.7 14.6 20.0 15.2 16.7 10.7 18.8 4.2 21.8 4.9 21.1 8.2 16.1 35.1 12.0 12.4 12.1 20.5 13.5 8.2 14.9 8.9 18.4 11.4 9.2 20.6 6.0 10.7 17.0 43.4 14.0 14.8 7.5 36.2 14.1 17.7 10.1 5.7 23.1 28.1 20.5 25.2 21.3 12.9 8.3 17.3 15.3 54.6 27.9 48.3 27.5 43.4 11.5 11.5 12.2 15.9 9.0 26.1 8.1 0.7 1.6 1.9 0.4 0.5 0.6 0.5 1.5 0.3 0.4 0.6 0.5 1.6 0.2 4.0 1.7 0.0 0.4 21.3 19.0 33.8 28.4 22.0 14.8 19.0 15.6 28.3 22.0 107.2 54.1 4.5 21.5 29.7 63.3 27.7 20.4 18.7 56.9 17.4 37.3 6.7 3.3 19.2 1.6 21.0 23.6 0.0 24.0 33.5 32.5 20.3 39.5 16.3 25.4 114.4 18.0 14.7 40.3 4.8 57.5 32.4 15.1 18.0 18.7 30.6 26.9 17.3 61.2 7.0 57.9 6.5 30.6 1.7 10.3 21.3 10.5 13.1 20.4 17.9 NF1 ENSG00000196712 "Neurofibromin 1" P21359 17 31094927-31382116 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins" "GTPase activation" "Cancer-related genes, Disease mutation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 4 "Early spermatids: 149.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Group enriched" "Detected in many" 6 "B-cells: 2.3;granulocytes: 6.5;T-cells: 8.4" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA045502 Uncertain Approved Mitochondria No No Mitochondria "HPA045502: AB_2679352" "unprognostic (6.69e-2)" "unprognostic (8.73e-2)" "unprognostic (8.26e-2)" "unprognostic (1.76e-2)" "unprognostic (2.06e-2)" "unprognostic (2.79e-2)" "unprognostic (1.38e-1)" "unprognostic (1.07e-1)" "unprognostic (1.11e-1)" "unprognostic (1.30e-2)" "unprognostic (3.14e-2)" "unprognostic (3.88e-2)" "unprognostic (1.00e-2)" "unprognostic (2.19e-1)" "unprognostic (1.53e-1)" "unprognostic (1.40e-1)" "unprognostic (3.70e-1)" 12.9 15.9 22.6 13.3 25.9 5.5 18.5 30.2 26.0 17.6 13.6 19.8 12.2 11.0 16.9 17.0 10.5 15.2 13.1 17.3 21.6 19.6 20.0 15.1 12.7 11.5 19.4 25.6 22.9 16.5 34.1 19.0 19.4 20.9 16.1 14.7 12.1 14.4 20.5 14.8 12.0 12.1 14.5 21.4 11.9 13.0 15.4 21.5 11.6 31.1 7.6 12.4 15.3 19.5 2.3 0.7 6.5 0.4 0.9 8.4 1.0 9.8 12.9 15.7 8.4 13.4 17.5 7.9 8.6 15.5 12.7 14.4 11.6 6.7 9.5 2.5 16.0 15.0 17.3 14.2 12.0 21.5 4.6 8.9 8.4 12.1 5.9 9.5 15.0 7.0 13.8 7.7 13.5 16.5 14.4 6.1 10.1 12.0 9.5 12.1 7.8 12.5 5.5 4.6 6.1 4.3 9.8 24.0 7.6 9.6 14.2 6.5 9.8 15.9 5.3 8.8 11.6 16.2 9.6 8.9 10.2 14.2 12.0 3.2 8.7 4.2 10.5 8.3 6.3 10.5 6.5 0.4 0.9 2.3 0.2 1.6 2.3 4.4 3.9 0.5 2.1 3.3 3.2 1.0 0.9 0.4 0.7 8.4 1.0 22.6 25.9 30.2 23.5 21.6 19.6 19.4 25.6 20.9 21.5 29.8 23.6 12.7 38.9 34.3 61.1 39.2 40.8 29.4 20.5 38.4 129.6 44.8 19.9 23.9 149.0 31.8 28.2 0.0 19.3 22.1 28.2 47.4 10.4 31.7 18.9 66.7 19.0 31.9 24.3 70.0 34.5 21.8 20.3 16.2 26.8 49.7 28.6 35.4 47.4 23.7 66.0 45.3 36.7 28.2 25.6 29.6 41.2 18.5 22.6 60.1 NF2 "ACN, BANF, merlin, SCH" ENSG00000186575 "Neurofibromin 2" P35240 22 29603556-29698598 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cancer-related genes, Deafness, Disease mutation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 6 "Early spermatids: 61.9;Late spermatids: 86.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003097, CAB005385" Supported Enhanced "Nucleoplasm,Plasma membrane,Cytosol" NA NA "Plasma membrane" "Nucleoplasm, Cytosol" "CAB005385: AB_2298548, HPA003097: AB_1079473" "unprognostic (3.27e-1)" "unprognostic (1.34e-2)" "unprognostic (1.34e-1)" "unprognostic (1.76e-2)" "unprognostic (3.14e-1)" "unprognostic (1.62e-1)" "unprognostic (5.76e-3)" "unprognostic (1.61e-1)" "unprognostic (3.67e-2)" "unprognostic (2.16e-2)" "unprognostic (2.01e-3)" "unprognostic (4.66e-1)" "prognostic favorable (2.89e-5)" "unprognostic (7.73e-3)" "unprognostic (1.31e-1)" "unprognostic (2.24e-1)" "unprognostic (9.62e-2)" 11.8 12.4 23.6 11.1 20.1 10.0 15.4 20.8 28.1 10.8 9.7 9.0 11.8 7.8 10.5 11.3 14.2 11.3 8.0 19.7 26.6 16.4 13.5 11.1 11.9 24.1 18.0 13.5 11.0 12.9 46.8 8.6 6.9 11.4 10.2 8.7 9.5 9.3 15.4 25.7 12.1 8.5 11.9 10.7 10.4 8.8 21.6 10.1 14.9 15.6 11.5 9.9 10.6 10.2 8.5 13.6 6.6 17.3 11.6 15.0 9.8 26.6 10.8 3.8 24.6 7.4 7.4 3.6 21.7 12.2 23.8 20.6 10.6 6.6 7.1 18.0 22.3 16.5 9.5 7.8 12.6 21.3 10.3 6.1 8.4 8.1 7.6 7.9 12.0 10.0 6.8 5.7 16.9 20.6 8.1 16.7 4.6 4.1 6.6 23.1 11.2 7.3 4.8 2.8 6.3 10.2 7.6 20.3 6.8 24.2 12.5 5.8 4.0 12.4 8.4 4.9 4.0 5.4 4.8 31.0 35.5 40.5 15.4 36.6 10.3 8.2 8.5 9.4 4.7 22.6 6.6 9.5 3.6 15.0 13.5 12.8 8.2 11.3 10.1 13.6 8.5 9.8 9.2 2.3 11.6 17.3 9.3 9.4 9.8 23.6 20.1 20.8 28.1 26.6 16.4 18.0 13.5 11.4 10.1 6.0 16.1 9.0 9.6 12.6 16.5 19.9 17.8 6.7 7.9 14.0 9.8 9.9 18.3 42.9 61.9 9.8 8.4 0.0 21.5 6.3 12.6 9.5 23.0 12.5 12.4 28.6 12.6 10.4 10.0 86.8 6.6 7.2 8.5 6.4 7.5 17.3 28.7 15.6 11.7 16.2 8.5 6.5 14.9 21.4 7.2 12.5 3.2 10.9 9.8 8.6 NFE2L2 NRF2 ENSG00000116044 "Nuclear factor, erythroid 2 like 2" Q16236 2 177227595-177392697 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Host-virus interaction, Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA002990, CAB020317, HPA043438" Supported Approved "Nucleoplasm,Plasma membrane,Cytosol" NA NA "Nucleoplasm, Plasma membrane" Cytosol "CAB020317: , HPA002990: AB_1079476, HPA043438: AB_2678482" "unprognostic (2.11e-1)" "unprognostic (3.12e-2)" "unprognostic (5.22e-2)" "unprognostic (1.41e-1)" "unprognostic (5.95e-2)" "unprognostic (3.90e-1)" "unprognostic (5.27e-2)" "unprognostic (9.58e-2)" "unprognostic (3.48e-2)" "unprognostic (9.86e-2)" "unprognostic (4.86e-2)" "unprognostic (1.83e-1)" "prognostic favorable (2.26e-4)" "unprognostic (1.97e-2)" "unprognostic (1.61e-1)" "unprognostic (1.26e-1)" "unprognostic (9.77e-3)" 30.9 24.4 25.4 19.3 34.7 15.0 24.6 36.4 29.7 31.7 28.3 25.8 22.2 28.1 27.7 30.9 82.5 27.0 28.9 32.3 28.0 16.9 44.8 49.3 29.0 19.7 49.0 18.7 53.1 16.3 21.7 52.5 29.4 33.5 39.0 25.4 21.7 34.7 28.1 25.9 48.1 29.2 42.1 42.7 26.8 45.9 21.9 41.6 21.1 49.5 35.8 25.5 43.7 47.1 23.5 41.1 42.4 35.6 25.8 43.2 22.6 10.6 12.3 11.2 12.0 37.8 40.8 12.8 18.2 25.3 16.6 18.8 16.2 20.4 10.5 19.8 20.6 31.6 19.8 13.1 27.7 23.3 8.1 8.0 13.5 21.6 31.6 48.4 8.0 12.8 28.1 65.2 23.6 35.1 39.4 16.4 8.3 14.0 20.6 22.8 10.6 8.1 21.1 12.2 55.2 11.6 6.7 9.8 10.6 25.4 40.1 14.6 9.5 41.2 13.3 43.1 33.7 10.3 21.6 24.7 17.2 11.5 19.1 11.1 14.5 8.7 8.8 17.2 8.9 33.0 42.4 35.6 21.4 23.0 34.1 26.6 23.5 26.9 23.6 41.1 19.9 43.2 28.2 39.9 25.8 31.9 15.5 25.0 22.6 25.4 34.7 36.4 29.7 28.0 16.9 49.0 18.7 33.5 41.6 145.9 85.8 49.5 216.1 262.7 59.6 57.4 96.8 143.2 127.4 146.5 15.7 88.4 333.2 126.2 58.6 116.1 96.6 0.0 147.7 27.7 204.6 118.5 212.0 76.9 78.0 54.0 72.6 97.6 100.1 19.8 266.3 164.9 91.1 213.8 57.7 176.6 122.9 89.2 201.2 56.4 47.1 38.8 169.0 50.5 33.8 275.8 155.7 62.3 90.2 201.5 NFKBIE IKBE ENSG00000146232 "NFKB inhibitor epsilon" O00221 6 44258166-44265788 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 5 "monocytes: 85.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA002692, HPA005941, CAB010272" Supported Supported "Nucleoplasm,Nucleoli fibrillar center,Cytosol" NA NA "Nucleoli fibrillar center" "Nucleoplasm, Cytosol" "CAB010272: AB_2235977, HPA002692: AB_1079479, HPA005941: AB_1079478" "prognostic favorable (1.72e-5)" "unprognostic (1.43e-1)" "unprognostic (1.39e-2)" "unprognostic (2.37e-2)" "unprognostic (6.32e-3)" "unprognostic (1.28e-1)" "prognostic unfavorable (3.50e-4)" "unprognostic (4.88e-2)" "unprognostic (1.09e-1)" "unprognostic (3.43e-2)" "unprognostic (3.36e-1)" "unprognostic (2.60e-1)" "prognostic unfavorable (1.37e-6)" "unprognostic (2.61e-2)" "unprognostic (8.83e-2)" "unprognostic (1.37e-2)" "prognostic favorable (8.07e-4)" 5.8 5.2 7.6 24.6 5.4 24.0 5.2 9.4 7.8 3.7 8.0 4.2 3.2 6.7 4.7 5.5 6.9 3.0 9.8 4.6 7.9 5.5 11.5 8.7 15.9 17.1 6.0 4.1 6.1 7.1 3.5 4.1 6.0 4.8 7.1 5.9 3.6 7.7 4.1 3.7 7.4 9.5 3.6 5.0 29.6 6.3 7.9 3.7 14.5 5.5 4.6 22.7 6.7 6.7 8.1 8.2 7.1 10.2 0.8 3.5 1.6 13.9 3.5 4.9 7.7 1.9 1.4 2.6 2.5 12.2 7.7 8.1 7.5 6.6 7.5 8.9 2.5 20.7 3.0 5.2 7.8 8.7 12.9 2.9 3.9 1.5 8.4 6.0 12.8 11.8 3.7 3.4 7.1 4.4 6.5 5.2 3.6 3.6 20.2 1.9 7.1 2.5 26.1 2.6 22.0 1.9 4.7 4.4 6.9 17.7 15.2 3.1 4.0 1.7 6.4 10.1 4.3 4.4 15.0 9.1 4.4 5.1 2.7 7.7 12.9 5.4 13.9 3.9 14.2 8.2 7.1 8.1 3.8 1.8 9.4 3.5 8.1 2.4 1.6 6.8 7.3 1.1 1.7 3.2 0.8 10.2 8.2 3.0 1.6 7.6 5.4 9.4 7.8 7.9 5.5 6.0 4.1 4.8 3.7 0.0 11.9 25.1 19.3 34.0 3.3 3.4 15.3 0.0 3.4 3.5 2.0 4.3 14.9 42.8 13.7 8.7 11.0 0.0 18.4 6.2 6.8 25.5 33.3 1.6 52.3 3.2 14.3 4.9 17.8 25.0 1.7 66.3 45.5 85.6 7.0 2.6 39.6 24.6 2.5 10.3 4.0 6.5 16.9 21.4 8.7 34.4 4.5 9.6 6.6 32.1 NOTCH1 TAN1 ENSG00000148400 "Notch 1" P46531 9 136494433-136545786 "Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters" "Angiogenesis, Differentiation, Notch signaling pathway, Transcription, Transcription regulation" "Activator, Developmental protein, Receptor" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 7 "Endothelial cells: 41.3;Ito cells: 68.2;Muller glia cells: 50.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 8.8" "Group enriched" "Detected in many" 4 "granulocytes: 8.8;NK-cells: 2.7" "Cell line enhanced" "Detected in many" "HaCaT: 25.0;HMC-1: 21.7;hTCEpi: 24.0;MOLT-4: 38.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB008112, CAB022466, HPA067168" Supported Approved Nucleoplasm NA NA 8100000 Nucleoplasm "CAB008112: AB_2153490, CAB022466: , HPA067168: AB_2685795" "unprognostic (1.77e-1)" "unprognostic (2.65e-2)" "unprognostic (2.16e-1)" "unprognostic (8.38e-3)" "unprognostic (3.04e-1)" "unprognostic (1.13e-1)" "unprognostic (7.56e-2)" "unprognostic (1.02e-1)" "unprognostic (5.74e-3)" "unprognostic (5.50e-3)" "unprognostic (8.78e-2)" "unprognostic (8.50e-2)" "prognostic unfavorable (5.45e-4)" "unprognostic (2.14e-2)" "unprognostic (1.92e-1)" "unprognostic (5.65e-2)" "unprognostic (8.84e-2)" 20.0 4.0 10.0 14.5 10.4 14.6 12.8 3.8 18.8 12.8 14.2 19.9 8.2 9.8 11.2 5.1 13.3 9.6 13.1 9.6 10.7 5.8 9.4 7.2 17.4 13.7 11.6 7.5 9.2 17.8 3.7 5.6 8.5 9.3 12.1 5.7 10.4 14.2 11.8 8.2 32.3 10.8 7.7 6.6 20.7 8.6 4.1 9.9 34.8 9.4 10.2 10.9 12.3 22.2 0.6 1.1 8.8 1.0 2.7 1.3 0.9 4.4 7.5 6.2 3.1 0.2 0.5 7.8 2.2 0.6 1.3 0.4 1.1 0.5 6.1 4.7 1.7 1.6 25.0 2.0 10.3 0.2 13.8 1.1 3.4 3.0 0.4 3.4 3.6 21.7 0.4 24.0 1.8 3.8 1.5 8.0 2.7 1.5 1.1 0.9 8.1 38.1 5.8 5.2 3.2 3.4 7.9 5.0 11.2 0.9 3.8 0.0 0.4 3.3 3.5 1.4 1.9 2.1 5.8 11.8 3.3 4.8 3.2 2.4 1.3 1.1 2.4 2.2 2.5 16.9 0.7 1.0 2.8 1.3 0.4 0.8 0.4 0.6 1.0 0.6 0.6 0.4 1.1 8.8 2.7 0.4 1.1 0.4 0.9 10.0 10.4 3.8 11.7 10.7 5.8 11.6 7.5 9.3 9.9 8.9 28.2 13.8 10.6 22.0 0.3 7.3 7.6 0.0 6.8 1.8 2.0 0.7 0.0 4.8 0.3 41.3 4.9 0.0 3.4 1.8 4.8 6.6 34.6 6.8 8.0 1.6 2.4 68.2 10.5 0.0 1.1 17.1 6.8 1.0 11.0 50.6 2.2 7.0 0.7 4.1 1.7 6.5 11.5 0.2 3.2 26.1 0.9 12.9 24.7 14.1 NOTCH2 ENSG00000134250 "Notch 2" Q04721 1 119911553-120069626 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Differentiation, Notch signaling pathway, Transcription, Transcription regulation" "Activator, Developmental protein, Receptor" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 5 "Paneth cells: 129.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA048743 Approved Supported "Nucleoplasm,Plasma membrane" NA NA 67000000 "Nucleoplasm, Plasma membrane" "HPA048743: AB_2680508" "unprognostic (1.33e-1)" "unprognostic (1.43e-2)" "unprognostic (2.66e-1)" "unprognostic (1.40e-3)" "unprognostic (7.98e-2)" "unprognostic (4.01e-2)" "unprognostic (1.22e-1)" "unprognostic (7.32e-2)" "unprognostic (1.18e-2)" "prognostic unfavorable (5.24e-4)" "prognostic unfavorable (9.48e-4)" "unprognostic (3.86e-2)" "unprognostic (6.12e-3)" "unprognostic (1.55e-2)" "unprognostic (2.65e-2)" "unprognostic (1.12e-2)" "unprognostic (7.35e-3)" 12.0 7.3 6.0 9.4 6.8 4.4 10.6 3.0 5.6 14.5 7.6 4.4 11.3 1.6 12.3 11.8 13.4 11.4 12.8 7.9 6.8 2.3 5.5 11.4 10.6 5.7 5.3 7.6 15.5 27.6 6.1 3.3 10.3 6.5 9.9 5.2 9.4 17.7 10.0 9.3 17.2 6.1 12.4 6.2 11.5 5.8 15.7 4.4 8.0 11.4 8.6 6.6 9.6 13.0 4.2 5.2 7.7 9.6 1.5 1.7 2.0 15.0 5.1 7.9 6.1 33.0 28.3 7.9 11.5 15.9 15.4 16.7 4.7 4.1 0.3 9.7 21.8 13.7 5.7 12.5 10.2 24.6 18.1 8.0 8.7 13.7 0.4 12.3 9.1 2.3 22.7 6.6 46.1 30.7 23.3 7.8 4.1 0.1 19.2 18.5 16.9 3.8 2.6 10.2 1.4 5.7 2.5 27.9 9.7 8.1 9.6 0.3 4.0 15.6 14.7 8.3 16.7 8.1 3.1 27.4 20.1 13.9 30.1 18.0 8.0 3.9 4.4 29.5 8.4 19.1 5.6 6.4 6.4 1.5 6.6 1.7 4.2 1.3 1.1 5.2 3.9 1.0 1.7 7.7 1.5 9.6 4.2 0.8 2.0 6.0 6.8 3.0 5.6 6.8 2.3 5.3 7.6 6.5 4.4 32.8 21.6 24.1 40.5 41.1 3.5 11.2 25.5 2.7 13.6 17.4 5.9 1.2 0.0 37.1 15.7 3.7 3.0 0.0 11.3 6.7 53.5 36.6 15.1 35.0 29.9 3.2 5.8 5.5 68.6 9.3 50.9 36.3 37.1 13.6 7.5 46.7 22.9 129.8 80.2 4.3 10.2 19.4 32.3 4.8 3.6 77.8 1.4 13.6 13.8 52.7 NRAS N-ras ENSG00000213281 "NRAS proto-oncogene, GTPase" P01111 1 114704469-114716894 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, RAS pathway related proteins" Hydrolase "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010157, HPA049830, CAB079912" Uncertain Supported "Plasma membrane" NA NA 4800000 "Plasma membrane" "CAB010157: AB_632073, CAB079912: AB_2784586, HPA049830: AB_2680903" "unprognostic (4.75e-2)" "unprognostic (2.81e-1)" "unprognostic (1.09e-3)" "unprognostic (2.11e-2)" "unprognostic (8.59e-3)" "unprognostic (1.14e-1)" "prognostic unfavorable (3.03e-7)" "unprognostic (7.76e-3)" "unprognostic (1.57e-2)" "unprognostic (1.01e-3)" "prognostic unfavorable (1.36e-4)" "unprognostic (6.60e-3)" "prognostic unfavorable (7.87e-4)" "unprognostic (2.68e-1)" "unprognostic (1.30e-1)" "unprognostic (1.16e-1)" "unprognostic (3.33e-2)" 18.0 9.7 13.1 16.5 14.4 33.5 12.4 9.7 16.6 10.0 18.4 15.8 3.8 14.4 9.8 6.2 19.7 8.7 11.8 7.1 11.7 13.8 24.0 23.9 13.4 18.7 15.3 9.6 10.3 14.2 8.3 7.6 27.4 19.0 9.2 18.5 8.4 12.4 5.2 7.9 16.1 23.4 9.6 20.9 19.5 14.4 9.8 9.7 45.0 11.1 14.0 19.6 13.2 10.5 11.0 9.9 23.7 15.0 12.1 11.1 10.1 24.7 6.7 18.1 6.8 7.5 16.1 12.9 11.8 13.2 22.2 25.0 13.5 9.3 18.8 15.7 15.9 15.5 7.1 24.1 19.2 31.9 25.6 9.4 12.7 10.2 16.0 14.9 31.6 19.8 14.5 15.6 25.4 18.6 7.0 28.2 14.9 20.2 21.7 19.5 66.1 21.8 12.3 30.7 8.1 4.9 16.7 32.2 11.7 19.6 13.4 11.0 16.5 12.1 10.0 28.4 22.0 8.8 25.7 21.5 12.1 23.2 22.6 24.2 38.4 26.4 22.1 24.2 17.3 43.6 23.7 10.0 9.6 9.8 15.0 8.9 11.0 8.0 9.7 9.9 8.8 8.7 11.1 2.7 12.1 12.7 7.7 10.4 10.1 13.1 14.4 9.7 16.6 11.7 13.8 15.3 9.6 19.0 9.7 14.9 13.9 22.5 24.9 27.2 4.4 4.0 25.5 18.7 12.5 21.0 7.9 18.9 11.6 31.0 2.9 23.3 32.2 0.0 27.3 39.9 16.8 25.2 31.1 24.5 43.1 4.8 23.6 40.5 41.2 4.4 7.5 27.8 21.9 41.5 29.5 7.1 39.8 29.4 6.0 27.8 2.2 6.5 10.8 6.5 14.1 31.7 26.1 20.3 24.7 34.0 NT5C2 "cN-II, GMP, NT5B, PNT5, SPG65" ENSG00000076685 "5'-nucleotidase, cytosolic II" P49902 10 103088017-103193306 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Nucleotide metabolism" "Allosteric enzyme, Hydrolase" "Cancer-related genes, Disease mutation, Hereditary spastic paraplegia, Neurodegeneration" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA003751 Approved NA NA "HPA003751: AB_1854664" "unprognostic (8.18e-2)" "unprognostic (1.98e-1)" "unprognostic (2.55e-2)" "unprognostic (2.46e-1)" "unprognostic (5.54e-2)" "unprognostic (4.87e-3)" "unprognostic (2.24e-2)" "unprognostic (1.72e-1)" "unprognostic (6.41e-2)" "unprognostic (9.59e-2)" "unprognostic (2.93e-3)" "unprognostic (6.20e-2)" "unprognostic (3.26e-2)" "unprognostic (3.70e-2)" "unprognostic (6.40e-2)" "unprognostic (3.43e-1)" "unprognostic (1.50e-1)" 15.0 17.0 17.6 18.2 21.2 31.6 19.7 22.5 19.6 17.5 20.7 25.4 24.5 10.9 24.6 19.6 38.6 14.8 17.0 16.5 16.7 20.7 19.6 15.5 18.8 16.8 21.8 17.3 24.8 19.4 18.7 29.5 16.9 29.1 22.9 17.0 26.2 67.2 21.6 41.6 11.7 13.9 20.4 19.1 20.5 15.9 21.7 14.5 29.7 39.2 16.3 31.5 21.1 31.1 6.7 9.7 23.8 14.5 10.5 8.7 7.1 50.7 20.7 14.4 32.3 12.7 14.1 8.3 25.5 24.8 12.4 12.9 15.0 40.7 24.3 19.8 17.6 10.8 26.0 9.5 13.1 14.6 14.6 8.9 17.5 8.8 14.5 22.7 25.3 8.7 21.7 14.6 10.8 17.5 30.2 11.4 11.8 11.3 17.0 21.5 30.0 22.6 32.8 13.6 15.5 25.6 36.9 12.4 7.0 17.8 29.0 4.3 10.8 13.4 10.6 20.0 20.4 16.1 19.7 11.6 9.9 10.0 14.1 18.6 14.9 24.7 32.6 10.0 29.3 2.8 19.8 11.7 23.8 8.1 11.9 8.7 6.7 7.0 6.5 9.7 4.2 6.0 6.2 21.4 10.5 14.5 7.3 6.5 7.1 17.6 21.2 22.5 18.0 16.7 20.7 21.8 17.3 29.1 14.5 77.4 27.5 10.4 26.3 6.5 19.9 2.4 20.4 32.1 67.1 26.2 43.2 16.3 10.0 27.7 82.0 15.7 21.6 0.0 22.4 10.0 11.0 32.1 8.1 14.9 17.8 44.5 11.1 12.3 30.0 49.8 23.0 20.7 25.3 13.6 16.7 78.8 41.7 14.2 12.7 13.9 53.0 32.3 12.6 23.0 21.5 6.6 29.3 16.6 13.3 73.2 PALB2 "FANCN, FLJ21816" ENSG00000083093 "Partner and localizer of BRCA2" Q86YC2 16 23603160-23641310 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "DNA damage, DNA recombination, DNA repair" DNA-binding "Cancer-related genes, Fanconi anemia, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 4 "Spermatocytes: 20.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in single" "Low region specificity" "Detected in all" "CAB014895, HPA057000" Approved Supported Nucleoplasm NA NA Nucleoplasm "CAB014895: , HPA057000: AB_2683307" "unprognostic (1.11e-1)" "unprognostic (5.67e-3)" "prognostic favorable (2.83e-5)" "unprognostic (1.43e-2)" "unprognostic (6.22e-2)" "unprognostic (1.61e-2)" "unprognostic (2.00e-3)" "unprognostic (5.18e-2)" "unprognostic (2.46e-2)" "unprognostic (2.00e-2)" "prognostic unfavorable (2.35e-5)" "unprognostic (2.05e-2)" "unprognostic (1.04e-2)" "unprognostic (2.72e-1)" "unprognostic (1.25e-1)" "unprognostic (7.20e-2)" "unprognostic (3.21e-1)" 12.4 9.9 10.7 19.6 11.9 6.8 15.2 16.5 14.1 12.4 14.0 10.8 9.1 14.8 10.9 13.5 17.6 9.6 7.8 10.5 10.0 10.6 13.7 16.1 9.2 13.4 9.7 12.5 15.3 10.6 13.7 16.1 9.1 14.9 10.9 12.7 8.6 11.0 14.7 10.3 17.0 14.1 12.8 10.8 14.1 11.0 16.9 10.5 12.9 12.1 12.0 15.3 13.6 13.3 3.7 3.9 7.2 7.7 3.9 5.5 2.0 12.0 9.3 11.3 7.9 9.4 7.4 10.1 8.7 13.4 14.4 17.5 7.9 12.6 12.7 6.4 6.1 11.1 10.8 10.0 14.7 17.2 7.5 5.8 7.8 12.9 22.4 8.7 14.3 12.7 8.4 15.0 13.6 15.5 8.0 7.6 12.3 16.0 6.9 12.6 11.9 14.7 14.9 25.1 8.8 5.5 17.1 13.8 17.4 11.0 10.8 8.3 8.3 8.9 10.2 11.4 10.3 9.4 9.8 5.5 17.3 6.6 8.5 9.3 8.1 13.1 13.0 11.3 10.5 10.3 7.2 3.3 3.0 4.4 4.2 5.3 3.7 4.9 5.3 3.9 3.1 5.5 4.3 0.2 3.9 7.7 2.8 3.1 2.0 10.7 11.9 16.5 14.1 10.0 10.6 9.7 12.5 14.9 10.5 11.9 3.4 9.4 3.5 0.8 6.2 4.2 5.1 12.0 10.3 3.5 3.9 2.3 3.3 4.3 3.0 2.3 2.6 0.0 4.4 1.7 1.4 1.5 4.7 4.7 3.2 1.6 1.2 3.1 7.0 2.9 4.4 4.0 1.7 9.0 2.6 4.7 6.9 3.4 6.0 4.6 7.1 6.5 2.1 20.2 14.4 2.4 1.0 2.5 4.3 3.7 PAX5 BSAP ENSG00000196092 "Paired box 5" Q02548 9 36833275-37034185 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Differentiation, Neurogenesis, Spermatogenesis, Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "blood: 21.6;lymphoid tissue: 33.4" "Cell type enriched" "Detected in some" 27 "B-cells: 57.6" "Low cancer specificity" "Detected in some" "Region enriched" "Detected in single" 5 "midbrain: 1.6" "Group enriched" "Detected in some" 209 "memory B-cell: 20.1;naive B-cell: 21.6" "Lineage enriched" "Detected in single" 216 "B-cells: 21.6" "Group enriched" "Detected in some" 8 "Daudi: 21.5;REH: 62.5;U-698: 28.2" "Region enriched" "Detected in single" 11 "midbrain: 4.7" "Group enriched" "Detected in some" 6 "hippocampal formation: 3.8;midbrain: 10.8;pons and medulla: 3.2" "CAB026269, CAB026869, HPA056394, HPA068498" Enhanced Supported Supported Nucleoplasm,Vesicles,Cytosol NA NA Nucleoplasm "Vesicles, Cytosol" "CAB026269: , CAB026869: , HPA056394: AB_2683116, HPA068498: AB_2685997" "unprognostic (4.69e-4)" "unprognostic (3.83e-1)" "unprognostic (9.13e-2)" "unprognostic (1.42e-1)" "unprognostic (2.65e-2)" "unprognostic (1.15e-1)" "unprognostic (2.09e-2)" "unprognostic (2.95e-2)" "unprognostic (2.48e-1)" "unprognostic (2.00e-2)" "unprognostic (1.03e-1)" "unprognostic (2.46e-2)" "unprognostic (1.11e-3)" "unprognostic (3.15e-1)" "unprognostic (8.96e-2)" "unprognostic (6.03e-2)" "unprognostic (1.01e-1)" 0.4 0.2 0.2 33.4 0.2 5.5 0.2 0.2 0.2 0.2 0.7 0.1 0.0 0.0 0.2 0.0 0.7 0.2 0.4 0.2 0.2 0.3 0.5 0.3 0.3 23.2 1.6 0.0 0.2 0.2 0.0 0.5 0.1 0.2 0.3 0.3 0.4 2.5 0.0 0.6 0.2 8.7 0.0 0.3 16.5 0.7 0.9 0.0 2.3 0.4 0.2 30.1 1.3 0.2 21.6 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.1 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 21.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.4 0.0 0.0 0.6 0.1 0.1 62.5 0.1 0.1 0.0 0.0 4.4 1.0 0.0 0.2 0.0 0.0 0.0 2.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 28.2 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 20.1 0.0 0.0 0.0 21.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.2 0.2 0.2 0.2 0.2 0.3 1.6 0.0 0.2 0.0 0.0 0.0 57.6 0.2 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.3 1.1 0.0 0.0 0.0 0.0 0.0 0.0 2.2 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.1 PBRM1 "BAF180, PB1" ENSG00000163939 "Polybromo 1" Q86U86 3 52545352-52685917 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Chromatin regulator, DNA-binding" "Cancer-related genes, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA015629, HPA059373" Uncertain Enhanced Nucleoplasm NA NA Nucleoplasm "HPA015629: AB_1855012, HPA059373: AB_2683994" "unprognostic (1.87e-1)" "unprognostic (1.73e-1)" "unprognostic (1.91e-2)" "unprognostic (2.00e-1)" "unprognostic (6.15e-2)" "unprognostic (1.34e-2)" "unprognostic (1.02e-2)" "unprognostic (9.54e-2)" "unprognostic (1.87e-2)" "unprognostic (1.43e-1)" "unprognostic (1.99e-2)" "unprognostic (4.32e-2)" "unprognostic (2.89e-3)" "unprognostic (3.06e-1)" "unprognostic (1.96e-1)" "unprognostic (1.53e-2)" "unprognostic (1.06e-1)" 24.3 14.8 13.8 20.6 15.9 17.2 24.4 19.1 13.8 18.9 18.5 14.0 22.9 12.2 25.9 13.9 19.9 18.9 13.7 15.9 11.1 10.0 11.7 14.5 14.9 16.5 16.5 8.2 25.1 15.4 14.4 30.6 28.0 14.7 16.1 15.3 12.7 17.5 16.2 21.8 17.2 14.3 21.1 15.6 19.1 14.8 13.1 13.7 51.0 22.0 10.5 17.1 22.4 23.0 6.6 10.7 11.1 8.7 4.6 7.4 1.9 12.5 8.1 29.0 14.2 14.3 14.6 20.3 17.3 11.9 20.0 17.6 9.1 8.5 30.4 2.4 20.3 16.6 8.6 25.1 13.1 24.4 32.5 13.5 28.8 15.3 7.0 20.5 24.0 21.9 13.6 15.2 22.4 14.5 15.8 19.3 24.1 16.4 16.7 20.1 4.2 39.5 7.2 17.6 8.5 13.3 20.7 18.2 15.5 8.3 24.5 19.7 21.8 20.8 5.0 16.5 18.4 9.4 13.9 22.2 18.8 14.3 16.2 21.1 12.1 19.0 28.9 11.6 19.5 18.7 10.1 5.0 11.1 4.8 3.2 4.9 3.6 4.8 5.3 4.8 6.6 7.4 4.7 2.7 4.6 8.7 10.7 4.5 1.9 13.8 15.9 19.1 13.8 11.1 10.0 16.5 8.2 14.7 13.7 38.7 54.1 19.5 31.0 35.9 42.0 48.4 28.1 53.5 38.7 22.7 45.2 31.3 16.6 31.4 28.7 40.3 25.3 23.3 40.4 28.9 31.5 35.3 27.8 37.0 45.9 28.6 33.8 35.0 63.3 14.7 31.7 46.6 45.5 50.5 30.6 28.5 42.9 28.1 54.8 13.9 43.3 25.8 45.3 41.9 32.8 45.0 42.6 34.1 34.5 33.3 PDGFRA "CD140a, GAS9, PDGFR2" ENSG00000134853 "Platelet derived growth factor receptor alpha" P16234 4 54229097-54298247 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins" "Chemotaxis, Host-virus interaction" "Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "ovary: 81.5" "Group enriched" "Detected in many" 9 "Fibroblasts: 171.4;Leydig cells: 416.6;Peritubular cells: 384.4" "Cancer enhanced" "Detected in all" "glioma: 30.8" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in single" "Cell line enhanced" "Detected in some" "ASC diff: 82.8;ASC TERT1: 38.8;BJ hTERT+: 48.0;fHDF/TERT166: 33.4;HHSteC: 28.0;HSkMC: 70.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA004947, CAB018143" Supported Approved "Nucleoplasm,Plasma membrane,Cell Junctions" "Intracellular and membrane" NA NA 150000 "Nucleoplasm, Plasma membrane, Cell Junctions" "CAB018143: AB_2162351, HPA004947: AB_2732399" "unprognostic (1.67e-1)" "unprognostic (9.35e-2)" "unprognostic (4.59e-3)" "unprognostic (1.60e-1)" "unprognostic (8.92e-2)" "prognostic favorable (9.33e-4)" "unprognostic (1.24e-1)" "unprognostic (2.00e-2)" "unprognostic (1.46e-1)" "unprognostic (2.18e-2)" "unprognostic (2.18e-1)" "unprognostic (7.01e-2)" "prognostic unfavorable (9.79e-6)" "unprognostic (9.58e-3)" "unprognostic (9.87e-2)" "unprognostic (2.16e-2)" "unprognostic (1.72e-3)" 35.0 12.4 12.6 16.1 7.6 0.9 17.2 2.4 20.1 33.2 19.1 9.2 6.4 9.6 27.6 14.6 21.9 22.5 16.2 15.3 8.9 7.4 22.8 8.4 24.1 26.9 9.2 4.0 81.5 6.8 1.6 2.1 25.1 7.2 18.6 15.2 19.2 8.5 8.3 11.9 7.0 17.4 19.7 8.8 51.6 13.6 19.0 9.3 0.5 11.3 12.8 4.3 35.9 24.6 0.9 0.4 2.5 0.4 0.3 0.8 0.3 0.0 0.0 0.2 0.1 82.8 38.8 0.1 4.3 48.0 0.0 0.1 11.5 0.0 0.1 0.1 33.4 0.1 0.1 3.3 0.0 0.0 0.4 0.1 0.1 0.1 0.2 28.0 0.0 0.0 70.4 0.0 5.5 0.0 0.9 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.2 0.6 0.0 0.1 0.1 0.0 0.0 0.0 0.3 0.1 6.7 0.0 0.1 0.0 0.3 0.1 0.0 0.1 15.2 0.5 16.6 0.0 0.0 0.0 0.1 0.4 0.0 0.3 2.5 0.4 0.2 0.5 0.2 0.2 0.6 0.8 0.4 0.0 0.9 0.7 0.4 2.3 0.3 0.3 0.4 0.2 0.3 12.6 7.6 2.4 7.3 8.9 7.4 9.2 4.0 7.2 9.3 0.0 0.3 0.9 0.3 15.1 0.7 4.0 0.0 0.0 0.0 0.0 0.0 1.3 1.7 2.9 1.6 3.3 0.0 0.0 5.8 1.2 171.4 0.4 0.0 0.8 2.8 0.0 0.0 38.1 0.6 3.7 416.6 1.6 21.9 8.2 0.0 18.3 12.2 0.0 384.4 0.0 0.4 0.0 13.2 1.1 3.5 13.8 1.1 0.0 0.0 0.8 PHF6 "BFLS, BORJ, CENP-31, KIAA1823, MGC14797" ENSG00000156531 "PHD finger protein 6" Q8IWS0 X 134373253-134428791 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" DNA-binding "Cancer-related genes, Disease mutation, Epilepsy, Hypotrichosis, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA001023 Enhanced Supported Nucleoplasm,Nucleoli NA NA "Nucleoplasm, Nucleoli" "HPA001023: AB_1079606" "unprognostic (2.38e-3)" "unprognostic (8.21e-2)" "unprognostic (1.99e-1)" "unprognostic (3.04e-3)" "unprognostic (6.03e-3)" "unprognostic (5.20e-3)" "prognostic unfavorable (3.38e-4)" "unprognostic (1.81e-1)" "unprognostic (4.85e-2)" "unprognostic (1.08e-1)" "prognostic unfavorable (9.96e-4)" "unprognostic (1.09e-1)" "unprognostic (5.96e-2)" "unprognostic (4.84e-2)" "unprognostic (7.45e-2)" "unprognostic (1.28e-1)" "unprognostic (1.29e-2)" 7.4 19.3 10.2 14.1 12.2 6.5 9.7 18.2 13.5 8.7 8.0 11.6 20.3 7.8 9.0 30.1 11.5 7.3 6.1 7.2 11.0 11.1 9.9 7.5 8.4 20.4 12.5 9.3 30.7 10.4 24.1 18.1 8.2 13.3 8.6 9.5 5.4 11.3 16.8 6.2 7.4 10.2 8.1 17.1 17.8 8.1 8.3 14.4 30.2 11.8 6.0 25.0 8.9 9.8 18.4 11.0 5.3 7.4 9.6 9.9 5.0 11.5 9.6 42.3 17.3 7.9 10.1 8.0 11.6 9.3 12.5 15.5 5.7 12.0 18.6 26.7 7.0 12.2 10.4 29.5 13.1 21.1 15.1 13.7 18.0 16.5 6.6 8.4 17.9 10.0 6.7 10.0 13.6 17.0 12.6 17.4 18.2 13.2 9.2 15.3 7.6 28.9 8.9 12.9 15.8 13.0 28.5 15.4 14.1 13.3 14.0 14.7 17.2 8.9 8.2 12.2 13.1 7.7 9.9 13.2 11.7 8.4 14.6 17.8 4.7 10.9 25.1 7.6 21.4 14.5 5.3 6.1 3.7 7.9 6.0 8.5 18.4 8.2 7.1 8.8 12.8 9.9 8.2 2.5 9.6 7.4 11.0 8.3 5.0 10.2 12.2 18.2 13.5 11.0 11.1 12.5 9.3 13.3 14.4 20.8 17.3 24.1 12.5 11.6 21.9 13.7 7.6 16.0 13.6 15.7 17.7 9.9 19.9 12.5 2.6 14.3 7.9 0.0 11.8 6.8 11.3 10.2 23.2 12.7 13.2 17.5 10.9 19.6 12.6 2.1 19.2 15.3 6.8 19.0 13.4 25.6 12.4 15.0 14.5 16.5 18.2 25.8 9.2 4.6 17.9 10.0 3.9 22.0 16.6 11.0 PHOX2B "NBPhox, Phox2b, PMX2B" ENSG00000109132 "Paired like homeobox 2b" Q99453 4 41744082-41748970 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, Developmental protein, DNA-binding" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "adrenal gland: 14.5;brain: 24.8" "Not detected" "Not detected" "Not detected" "Not detected" "Region enriched" "Detected in single" 99 "pons and medulla: 24.8" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in single" 91 "SH-SY5Y: 53.6" "Region enriched" "Detected in single" 17 "pons and medulla: 5.9" "Region enriched" "Detected in single" 27 "pons and medulla: 2.0" "HPA074325, HPA074941" Enhanced Enhanced Nucleoplasm NA NA Nucleoplasm "HPA074325: AB_2686678, HPA074941: AB_2732272" "unprognostic (1.01e-1)" "unprognostic (2.47e-1)" "unprognostic (5.27e-2)" 0.0 14.5 0.0 2.1 0.0 0.0 0.0 0.0 0.0 0.0 5.6 0.2 0.0 0.8 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 1.4 0.0 0.0 0.0 24.8 0.2 1.4 0.8 0.0 0.0 0.0 0.0 3.2 0.5 0.4 0.0 0.9 0.1 0.0 0.1 0.0 0.0 0.0 0.6 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 53.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 24.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 PIK3CA PI3K ENSG00000121879 "Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha" P42336 3 179148114-179240093 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins" "Angiogenesis, Phagocytosis" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA009985, CAB017804" Approved Supported Mitochondria,Cytosol NA NA Cytosol Mitochondria "CAB017804: , HPA009985: AB_1079610" "unprognostic (1.81e-1)" "unprognostic (2.77e-1)" "unprognostic (2.18e-1)" "unprognostic (2.69e-3)" "unprognostic (6.49e-3)" "unprognostic (1.43e-1)" "unprognostic (2.65e-2)" "unprognostic (1.00e-2)" "unprognostic (1.03e-1)" "unprognostic (2.37e-1)" "unprognostic (2.57e-3)" "unprognostic (5.21e-2)" "unprognostic (4.50e-2)" "unprognostic (1.16e-2)" "unprognostic (2.48e-1)" "unprognostic (9.74e-2)" "unprognostic (3.82e-2)" 20.1 12.3 13.7 11.5 13.4 25.7 22.4 17.1 24.5 12.9 14.0 5.2 5.7 6.5 15.3 7.9 11.6 11.1 13.2 14.2 18.4 9.7 11.7 10.8 13.2 13.8 9.8 15.7 15.4 9.2 24.7 11.6 16.5 16.3 10.7 8.9 7.2 10.9 10.9 15.2 12.0 10.5 12.8 14.4 16.2 10.6 9.3 9.8 29.6 11.0 7.3 13.9 15.1 15.7 6.2 2.6 7.8 3.8 2.4 5.0 1.1 14.6 5.0 8.0 7.4 19.0 22.2 5.9 9.4 12.7 9.3 14.7 4.3 10.9 13.4 16.1 11.2 13.2 6.0 6.6 8.1 13.5 22.4 5.8 18.4 5.5 3.8 9.1 10.3 10.5 14.0 8.6 10.2 11.7 10.4 13.3 9.7 9.1 15.0 13.3 5.8 7.9 9.3 6.4 7.3 6.8 12.0 8.1 16.1 7.3 9.0 4.5 7.7 10.2 9.1 12.2 7.3 15.2 8.9 14.0 8.7 5.7 13.7 9.3 7.3 10.3 24.1 7.9 7.8 5.1 2.1 3.8 1.6 5.0 2.9 3.9 5.8 4.2 2.8 2.2 6.2 4.6 3.8 7.8 2.4 3.0 2.6 4.1 1.1 13.7 13.4 17.1 24.5 18.4 9.7 9.8 15.7 16.3 9.8 29.8 23.2 13.7 15.2 13.1 26.3 15.4 7.6 18.7 17.0 7.0 29.5 8.1 1.7 9.8 1.7 21.4 4.9 0.0 11.9 5.0 18.3 27.3 30.1 17.4 9.5 36.5 2.4 29.4 21.2 1.6 30.2 16.4 13.5 16.2 9.6 15.6 13.1 12.7 37.1 11.2 26.2 25.8 22.1 9.6 7.6 13.0 7.3 14.0 9.2 27.6 PIK3CB PIK3C1 ENSG00000051382 "Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta" P42338 3 138652699-138834938 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins" "Autophagy, Cell adhesion, Endocytosis" "Kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "HEL: 42.0;HMC-1: 66.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB031938, HPA042288, HPA064207" Approved Supported Nucleoplasm,Nucleoli,Vesicles,Midbody Yes No Nucleoplasm "Nucleoli, Vesicles, Midbody" "CAB031938: AB_2165408, HPA042288: , HPA064207: AB_2685212" "unprognostic (4.89e-2)" "unprognostic (1.42e-2)" "unprognostic (5.97e-2)" "unprognostic (7.85e-2)" "unprognostic (4.89e-2)" "unprognostic (6.01e-2)" "prognostic unfavorable (6.42e-4)" "unprognostic (3.98e-2)" "unprognostic (1.35e-1)" "unprognostic (2.28e-1)" "prognostic unfavorable (3.99e-5)" "unprognostic (2.15e-1)" "unprognostic (6.18e-3)" "unprognostic (9.33e-2)" "unprognostic (7.82e-2)" "unprognostic (2.79e-1)" "unprognostic (4.59e-2)" 12.5 9.9 10.6 9.7 20.6 17.4 11.5 29.9 25.0 12.4 14.6 11.9 11.7 13.7 9.6 6.9 15.2 10.9 8.7 12.7 12.2 14.2 22.6 9.3 9.5 9.1 11.9 15.2 8.8 20.3 20.2 10.9 18.1 24.1 13.4 15.7 12.2 14.9 15.9 33.4 19.6 16.4 8.3 12.5 9.9 11.0 6.4 10.7 14.4 37.4 7.1 11.9 13.4 11.0 4.6 9.1 11.3 7.8 1.3 6.5 2.6 23.0 10.0 4.3 3.6 3.9 5.3 29.3 5.4 5.2 5.5 5.9 10.7 8.8 9.3 14.8 5.3 10.6 9.9 5.6 8.6 9.9 11.8 6.3 42.0 6.8 6.4 4.0 10.2 66.6 4.5 6.6 3.8 7.8 9.8 8.3 4.5 16.0 6.9 6.9 10.6 5.9 7.2 6.2 17.0 9.4 4.3 4.5 6.6 8.5 12.8 3.7 2.7 15.0 6.5 19.3 13.2 16.3 24.4 8.7 3.5 4.5 7.7 7.6 11.7 7.6 8.5 8.6 9.9 4.9 7.0 7.8 11.3 4.0 4.5 2.7 4.6 5.2 3.0 9.1 4.1 6.5 4.4 10.0 1.3 4.3 1.4 2.2 2.6 10.6 20.6 29.9 25.0 12.2 14.2 11.9 15.2 24.1 10.7 8.9 14.7 4.7 12.9 16.9 15.4 30.2 12.7 14.7 21.6 17.4 23.6 29.1 5.0 9.4 0.9 8.5 21.3 0.0 16.5 46.3 6.5 23.0 13.9 15.8 13.4 20.6 15.6 11.6 28.8 1.1 3.4 19.7 6.8 14.4 14.9 8.2 15.2 21.8 6.3 18.9 17.9 6.5 6.1 10.7 14.9 20.5 40.0 6.1 12.7 15.3 PIK3R1 "GRB1, p85, p85-ALPHA" ENSG00000145675 "Phosphoinositide-3-kinase regulatory subunit 1" P27986 5 68215720-68301821 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins" "Host-virus interaction, Protein transport, Stress response, Transport" "Cancer-related genes, Disease mutation, Dwarfism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 6 "Cardiomyocytes: 241.2;Leydig cells: 159.3;Muller glia cells: 180.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "ASC diff: 73.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001216, CAB004268" Approved Supported Cytosol NA NA Cytosol "CAB004268: AB_628126, HPA001216: AB_1079612" "unprognostic (5.74e-2)" "unprognostic (6.58e-2)" "unprognostic (2.01e-1)" "unprognostic (1.31e-2)" "unprognostic (1.18e-1)" "unprognostic (1.33e-2)" "prognostic favorable (8.09e-4)" "unprognostic (3.78e-3)" "unprognostic (1.78e-1)" "unprognostic (2.71e-1)" "unprognostic (6.10e-2)" "unprognostic (1.32e-1)" "unprognostic (4.59e-3)" "unprognostic (5.66e-3)" "unprognostic (1.27e-1)" "unprognostic (5.92e-2)" "unprognostic (1.54e-1)" 26.2 13.4 26.0 13.0 24.3 51.6 42.3 15.3 50.3 27.1 20.3 12.8 12.8 8.1 41.3 22.1 20.8 33.0 18.1 33.9 24.0 13.4 17.9 46.5 16.3 12.0 22.0 40.8 25.8 6.8 22.3 9.4 15.0 18.2 15.2 10.8 8.7 54.6 16.2 48.9 19.1 16.1 36.3 17.6 18.8 13.1 7.6 23.6 16.2 12.8 8.5 10.8 25.2 24.4 2.2 2.1 10.6 4.1 8.2 14.8 4.0 1.1 2.1 6.4 19.1 73.1 21.4 2.8 6.1 2.8 2.3 2.5 5.3 1.9 5.6 10.5 8.4 1.1 2.6 1.8 12.4 3.0 23.5 2.3 6.7 1.8 4.3 24.6 6.9 5.4 22.6 28.2 4.3 22.9 1.1 3.1 6.6 1.0 4.3 2.1 2.9 16.7 2.7 1.8 3.8 1.1 15.8 3.0 4.4 3.1 12.6 1.2 5.8 1.0 1.6 4.0 3.9 9.2 4.9 3.7 2.8 2.8 4.6 3.8 4.8 7.1 6.5 3.0 8.6 2.0 10.6 1.2 5.9 9.2 1.7 12.7 1.2 11.5 8.4 2.1 2.2 14.8 10.8 1.5 8.2 4.1 0.9 8.5 4.0 26.0 24.3 15.3 50.3 24.0 13.4 22.0 40.8 18.2 23.6 47.6 25.6 14.3 14.9 12.8 45.1 241.2 28.1 12.0 27.3 5.2 23.6 12.3 61.3 13.7 9.4 23.1 20.0 0.0 8.1 13.0 36.6 8.2 66.0 142.1 25.9 46.1 9.2 39.9 52.0 6.8 159.3 29.5 32.1 21.6 24.8 180.6 9.7 19.3 114.9 31.6 85.9 19.4 26.7 0.9 2.6 8.9 8.4 132.3 21.7 6.0 PLCG1 "NCKAP3, PLC-II, PLC1, PLC148, PLCgamma1" ENSG00000124181 "Phospholipase C gamma 1" P19174 20 41136960-41196801 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins" "Host-virus interaction, Lipid degradation, Lipid metabolism" "Hydrolase, Transducer" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 7 "gdT-cell: 5.9;MAIT T-cell: 8.0;memory CD4 T-cell: 5.2;memory CD8 T-cell: 4.9;naive CD4 T-cell: 5.7;naive CD8 T-cell: 5.4;NK-cell: 4.0;T-reg: 4.4" "Group enriched" "Detected in many" 8 "NK-cells: 4.0;T-cells: 8.0" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004277, HPA036681, HPA036682" Approved Enhanced Cytosol NA NA Cytosol "CAB004277: AB_628119, HPA036681: AB_2675245, HPA036682: AB_2675246" "unprognostic (2.77e-1)" "unprognostic (1.35e-1)" "unprognostic (1.65e-1)" "unprognostic (4.31e-2)" "unprognostic (5.82e-2)" "unprognostic (2.09e-2)" "unprognostic (4.45e-3)" "unprognostic (1.25e-2)" "unprognostic (2.29e-2)" "unprognostic (1.16e-1)" "prognostic favorable (4.72e-4)" "unprognostic (3.32e-1)" "unprognostic (2.73e-3)" "unprognostic (1.82e-1)" "unprognostic (2.65e-1)" "unprognostic (9.27e-2)" "unprognostic (2.79e-2)" 20.2 15.1 25.1 20.9 22.1 8.3 34.9 52.6 26.8 19.9 13.9 23.4 12.5 16.5 27.6 13.9 13.5 17.0 18.7 20.9 25.4 13.6 15.3 6.8 19.3 30.7 18.5 20.5 28.7 9.1 16.9 14.2 22.2 18.7 18.4 13.2 20.0 13.2 20.6 13.4 22.3 17.1 22.2 15.4 20.1 12.4 19.9 23.9 48.1 28.5 11.9 21.9 17.1 21.1 0.7 0.0 0.0 0.0 4.0 8.0 3.3 5.4 6.9 33.2 24.3 13.3 9.3 10.6 8.9 11.5 18.0 15.3 16.6 1.8 12.1 11.0 9.7 18.9 10.1 14.4 16.0 10.5 3.4 7.7 0.8 11.5 19.5 10.1 4.7 3.3 11.9 9.0 13.3 10.4 16.3 20.0 26.0 9.0 8.0 16.2 40.4 29.2 3.7 12.3 7.0 12.7 23.3 24.2 5.9 9.9 10.0 11.8 22.5 16.0 7.5 16.0 19.4 8.7 5.6 21.6 43.1 14.0 13.7 10.8 8.9 3.9 10.0 10.2 5.2 17.8 0.0 0.0 0.0 5.9 0.0 8.0 0.3 5.2 4.9 0.0 0.7 5.7 5.4 0.0 4.0 0.0 0.0 4.4 3.3 25.1 22.1 52.6 26.8 25.4 13.6 18.5 20.5 18.7 23.9 14.9 6.5 0.8 1.8 4.9 3.7 9.2 0.0 1.4 3.4 3.5 9.8 1.3 0.0 2.7 5.1 15.8 6.4 0.0 1.4 1.6 6.1 1.9 1.1 2.5 3.2 3.2 1.7 13.5 2.2 5.3 14.1 1.7 3.3 1.0 9.8 7.2 2.8 3.7 17.3 2.4 4.6 12.9 5.1 11.6 11.5 6.0 0.7 6.9 5.1 0.9 PMS2 "H_DJ0042M02.9, HNPCC4, MLH4, PMSL2" ENSG00000122512 "PMS1 homolog 2, mismatch repair system component" P54278 7 5973239-6009125 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "DNA damage, DNA repair" "Endonuclease, Hydrolase, Nuclease" "Cancer-related genes, Disease mutation, Hereditary nonpolyposis colorectal cancer, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010235, HPA066490, HPA070310" Approved Enhanced Nucleoplasm NA NA Nucleoplasm "CAB010235: AB_2167281, HPA066490: AB_2685677, HPA070310: AB_2686250" "unprognostic (5.13e-2)" "unprognostic (6.55e-3)" "unprognostic (1.54e-1)" "unprognostic (1.43e-3)" "unprognostic (5.14e-2)" "unprognostic (1.29e-1)" "unprognostic (7.36e-2)" "unprognostic (1.02e-1)" "unprognostic (7.43e-2)" "unprognostic (2.35e-1)" "unprognostic (1.86e-1)" "unprognostic (7.38e-2)" "prognostic favorable (1.23e-5)" "unprognostic (5.31e-2)" "unprognostic (2.01e-2)" "unprognostic (3.67e-2)" "unprognostic (2.81e-2)" 6.3 7.4 8.7 6.0 19.8 3.6 8.1 15.5 21.2 6.2 6.0 11.5 6.9 6.4 6.4 6.3 7.5 7.5 5.0 5.3 9.0 10.3 14.2 5.8 5.5 9.1 8.4 9.5 7.5 7.1 16.6 7.1 5.9 16.2 7.0 6.2 8.0 7.1 7.8 5.7 14.8 6.8 7.1 7.5 6.9 6.1 4.8 5.8 7.5 12.4 5.7 10.7 7.7 6.5 6.2 5.8 7.2 7.9 4.0 9.3 6.3 9.7 10.6 8.5 21.2 6.7 9.9 7.3 5.2 4.0 5.1 4.1 9.2 7.0 18.3 6.2 7.5 11.5 13.4 12.7 3.4 5.5 7.2 5.2 8.0 8.6 6.6 11.4 9.8 5.5 10.4 9.7 4.0 15.2 7.3 9.4 8.7 14.9 8.9 8.4 9.0 2.9 7.0 8.6 4.4 6.5 10.0 10.3 9.3 10.7 7.3 7.8 16.8 10.2 14.9 11.2 13.2 18.5 6.9 8.0 6.5 14.5 9.5 9.4 12.0 20.0 18.5 4.5 9.7 14.8 7.2 5.4 3.1 8.4 7.9 9.3 6.2 6.6 7.2 5.8 5.6 8.8 6.2 2.4 4.0 3.2 5.3 6.4 6.3 8.7 19.8 15.5 21.2 9.0 10.3 8.4 9.5 16.2 5.8 11.9 5.1 17.2 8.2 4.4 12.6 2.8 5.1 6.7 7.9 10.4 21.6 7.8 29.9 4.7 6.9 7.4 2.0 0.0 2.9 5.4 5.5 8.4 4.7 9.6 4.5 28.6 5.2 7.4 7.3 5.6 11.8 4.9 6.8 5.4 2.3 5.2 3.5 2.9 9.6 32.0 14.2 25.8 6.6 24.2 10.2 7.0 10.6 8.5 2.6 10.2 POLD1 "CDC2, POLD" ENSG00000062822 "DNA polymerase delta 1, catalytic subunit" P28340 19 50384204-50418016 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "DNA damage, DNA excision, DNA repair, DNA replication" "DNA-binding, DNA-directed DNA polymerase, Exonuclease, Hydrolase, Nuclease, Nucleotidyltransferase, Transferase" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 8 "Paneth cells: 38.7;Spermatogonia: 26.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004375, HPA046524" Supported Supported Nucleoplasm NA NA Nucleoplasm "CAB004375: AB_675487, HPA046524: AB_2679684" "unprognostic (2.45e-1)" "unprognostic (7.02e-3)" "unprognostic (1.59e-1)" "unprognostic (4.35e-2)" "unprognostic (2.55e-1)" "unprognostic (1.85e-2)" "prognostic unfavorable (2.87e-6)" "unprognostic (4.12e-2)" "unprognostic (1.16e-2)" "unprognostic (2.83e-1)" "unprognostic (5.08e-1)" "unprognostic (3.92e-3)" "unprognostic (4.01e-3)" "unprognostic (1.28e-2)" "unprognostic (1.61e-1)" "unprognostic (2.89e-1)" "unprognostic (3.70e-2)" 7.9 5.7 5.4 18.3 9.9 31.6 6.6 9.4 5.4 8.2 10.0 6.1 5.9 6.8 9.5 7.2 11.3 6.9 5.2 5.5 4.4 3.2 7.6 9.3 10.9 15.7 7.0 3.6 8.2 8.4 5.2 5.1 10.9 6.7 6.3 5.2 4.9 8.1 5.4 7.2 13.1 9.9 6.2 7.7 14.1 6.5 13.2 6.5 27.4 12.1 8.1 14.2 5.9 7.8 9.3 10.5 2.1 8.5 5.4 7.3 5.6 18.2 25.2 13.8 7.9 1.8 1.5 14.2 11.4 5.0 14.1 17.9 13.7 14.5 26.2 6.4 3.4 6.3 15.0 16.3 12.4 4.8 22.1 43.8 22.8 24.4 18.0 1.6 21.7 20.1 2.9 3.8 12.7 3.8 3.0 7.2 22.0 24.5 20.4 5.8 12.3 33.5 33.9 16.3 11.8 18.3 33.3 23.2 23.0 4.5 17.5 14.4 13.0 11.3 13.9 2.6 5.2 7.6 20.6 5.6 7.1 23.2 7.7 20.0 19.2 31.6 28.0 7.8 24.5 7.0 1.6 6.2 2.1 7.3 7.8 6.2 7.8 6.5 5.9 5.7 9.3 6.5 5.9 1.1 5.4 8.5 10.5 4.5 5.6 5.4 9.9 9.4 5.4 4.4 3.2 7.0 3.6 6.7 6.5 3.0 3.8 3.7 1.7 5.7 3.3 2.8 2.5 2.7 3.4 3.5 5.9 12.2 0.0 4.4 1.7 2.6 4.6 0.0 3.4 11.7 4.1 1.3 0.0 2.1 13.6 0.0 6.9 1.8 6.3 1.1 2.8 5.0 5.0 3.6 5.3 1.2 3.9 38.7 4.9 2.2 4.1 0.0 2.1 10.9 26.7 4.5 6.4 4.3 10.0 0.6 POLE POLE1 ENSG00000177084 "DNA polymerase epsilon, catalytic subunit" Q07864 12 132623753-132687365 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "DNA damage, DNA repair, DNA replication" "DNA-binding, DNA-directed DNA polymerase, Hydrolase, Nucleotidyltransferase, Transferase" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 5 "Sertoli cells: 25.8;Spermatocytes: 25.4" "Low cancer specificity" "Detected in all" "Region enhanced" "Detected in all" "cerebellum: 34.8" "Cell type enhanced" "Detected in some" "NK-cell: 4.8" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in many" "Not detected" "Not detected" "HPA058210, HPA067385" Supported "Nucleoplasm,Plasma membrane" NA NA Nucleoplasm "Plasma membrane" "HPA058210: AB_2683639, HPA067385: AB_2685830" "unprognostic (1.60e-1)" "unprognostic (1.77e-3)" "unprognostic (2.00e-1)" "unprognostic (9.17e-2)" "unprognostic (1.68e-1)" "unprognostic (2.01e-2)" "unprognostic (3.96e-3)" "unprognostic (2.23e-1)" "prognostic unfavorable (1.44e-4)" "unprognostic (7.12e-2)" "unprognostic (2.21e-1)" "unprognostic (1.67e-1)" "prognostic unfavorable (3.19e-8)" "unprognostic (8.60e-2)" "unprognostic (3.18e-1)" "unprognostic (1.28e-1)" "unprognostic (9.95e-2)" 6.1 3.4 6.7 10.2 4.4 29.3 6.2 34.8 14.4 7.0 6.6 2.0 7.6 7.3 6.1 4.4 7.5 6.2 6.5 4.7 5.6 1.6 3.8 8.6 5.4 8.2 3.3 4.3 8.7 6.8 3.6 3.1 6.5 5.1 6.8 7.7 4.3 8.7 7.4 8.9 17.9 8.5 6.8 3.7 16.7 7.8 25.6 4.4 29.8 5.1 6.0 10.3 6.7 8.7 0.5 1.7 0.8 0.8 4.8 0.7 0.5 11.2 15.0 22.3 10.6 4.7 3.7 19.9 11.5 5.2 13.8 10.1 18.2 6.7 12.9 4.9 6.2 5.3 15.7 15.5 7.8 8.4 6.0 19.6 20.4 19.4 8.9 0.9 15.9 11.7 2.8 3.1 14.4 4.7 3.8 4.8 16.6 22.8 7.3 6.8 18.2 26.1 29.2 17.3 5.3 9.0 21.7 12.6 5.8 4.4 18.4 18.6 10.7 13.4 11.0 2.5 11.2 16.2 9.9 4.4 12.6 12.9 9.5 11.6 9.7 6.5 20.3 6.9 22.0 8.9 0.0 0.3 0.8 0.5 0.1 0.7 0.5 0.3 0.4 0.7 0.3 0.5 0.3 0.1 4.8 0.8 1.7 0.6 0.5 6.7 4.4 34.8 14.4 5.6 1.6 3.3 4.3 5.1 4.4 0.0 7.9 4.5 3.5 5.0 8.1 5.6 0.0 2.7 0.0 1.8 0.0 6.2 0.0 2.1 6.5 3.0 4.7 0.0 2.7 9.0 4.7 3.7 2.3 8.9 10.4 0.0 6.9 12.9 7.9 7.0 6.4 3.2 5.0 1.0 6.7 3.7 2.4 5.8 3.2 0.8 5.0 25.8 3.3 25.4 7.9 6.8 3.3 5.7 9.8 2.5 POLQ POLH ENSG00000051341 "DNA polymerase theta" O75417 3 121431427-121546641 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "DNA damage, DNA repair" "DNA-directed DNA polymerase, Nucleotidyltransferase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 9.5;lymphoid tissue: 21.4" "Cell type enhanced" "Detected in some" 10 "Club cells: 3.4;Extravillous trophoblasts: 2.8;Spermatocytes: 7.0;Spermatogonia: 3.3" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "basophil: 1.6" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in many" "Not detected" "Not detected" "Region enhanced" "Detected in many" "cerebellum: 5.2" HPA053359 Supported "Nucleoplasm,Golgi apparatus,Cytosol" NA Yes Nucleoplasm "Golgi apparatus, Cytosol" "HPA053359: " "unprognostic (1.59e-1)" "unprognostic (4.18e-2)" "unprognostic (2.66e-2)" "prognostic unfavorable (5.46e-5)" "unprognostic (2.70e-1)" "unprognostic (6.23e-3)" "unprognostic (3.09e-5)" "unprognostic (8.55e-3)" "unprognostic (1.09e-4)" "unprognostic (2.86e-1)" "unprognostic (5.59e-5)" "unprognostic (2.06e-3)" "unprognostic (0.00e+0)" "prognostic favorable (1.04e-4)" "unprognostic (1.76e-1)" "unprognostic (6.01e-2)" "unprognostic (5.76e-2)" 0.5 0.8 0.2 8.2 0.7 9.5 0.6 0.6 0.4 0.9 3.5 0.2 0.8 2.0 0.9 0.6 6.0 0.3 0.4 0.8 0.3 0.2 0.4 0.6 0.9 4.7 0.3 0.0 0.4 0.4 0.0 0.2 2.8 0.3 0.4 3.7 0.1 1.1 0.8 1.2 2.4 3.9 0.5 0.4 2.6 1.1 5.8 0.6 21.4 0.3 5.6 7.5 0.6 1.7 0.5 1.1 1.6 0.4 0.0 0.4 0.0 13.5 9.2 7.9 5.6 0.7 0.9 7.2 6.4 2.5 7.6 10.2 7.3 5.0 16.1 2.9 3.5 9.2 10.7 9.3 4.1 12.9 4.7 5.1 10.3 5.7 4.5 0.0 11.1 9.5 0.1 0.3 6.9 4.3 1.3 3.7 6.0 6.8 12.3 7.9 5.2 10.0 6.5 7.5 4.1 4.5 8.5 9.5 5.7 2.4 7.8 4.3 3.9 7.4 4.0 2.6 7.2 3.7 11.1 2.9 6.7 8.8 2.6 8.3 6.2 5.0 16.7 3.2 8.3 4.9 1.6 0.2 0.0 0.3 0.2 0.0 0.3 0.4 0.3 0.4 0.5 0.0 0.2 0.0 0.0 0.4 1.1 0.1 0.0 0.2 0.7 0.6 0.4 0.3 0.2 0.3 0.0 0.3 0.6 0.0 0.3 0.0 0.4 0.8 0.3 1.4 0.0 1.4 3.4 0.0 0.0 0.9 0.0 0.1 0.3 0.0 0.4 0.0 0.0 2.8 0.7 0.3 0.0 0.0 1.9 0.0 0.0 0.0 0.6 0.2 0.3 1.5 0.0 1.0 0.4 0.5 0.3 0.3 0.0 0.1 0.1 0.0 0.5 7.0 3.3 0.1 0.2 0.9 0.9 0.9 POT1 "DKFZp586D211, hPot1" ENSG00000128513 "Protection of telomeres 1" Q9NUX5 7 124822386-124929983 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" DNA-binding "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 4 "Spermatocytes: 27.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" HPA068538 Supported Nucleoplasm NA NA Nucleoplasm "HPA068538: AB_2686001" "unprognostic (1.39e-3)" "unprognostic (1.34e-1)" "unprognostic (2.04e-1)" "unprognostic (5.71e-2)" "unprognostic (1.69e-1)" "unprognostic (1.49e-1)" "unprognostic (1.38e-3)" "unprognostic (7.88e-2)" "unprognostic (2.26e-2)" "unprognostic (1.51e-1)" "unprognostic (2.48e-2)" "unprognostic (9.89e-2)" "unprognostic (1.42e-1)" "unprognostic (2.92e-1)" "unprognostic (1.75e-2)" "unprognostic (4.77e-3)" "unprognostic (7.42e-2)" 12.0 13.2 11.1 8.3 14.3 6.2 15.8 13.0 16.6 13.4 10.1 16.0 12.0 7.8 17.0 13.4 10.1 12.6 11.3 11.2 15.5 11.3 16.6 14.7 9.9 14.0 15.0 12.4 15.7 9.4 15.5 29.6 11.1 16.4 12.0 9.7 12.2 8.7 10.1 9.5 8.0 8.8 13.1 16.4 13.6 9.5 15.8 14.8 17.9 21.5 9.3 12.9 13.6 9.8 4.8 3.6 2.7 3.3 5.2 7.4 2.7 12.9 5.5 8.2 6.3 5.5 10.3 5.8 7.3 8.6 8.3 12.6 4.5 13.1 11.7 5.9 5.5 11.6 5.1 9.0 7.4 13.2 15.1 13.1 11.4 5.5 4.8 12.4 11.0 6.8 7.3 8.9 7.7 12.1 9.6 10.5 4.8 20.2 28.1 9.3 2.5 14.6 11.6 9.3 8.4 9.1 8.7 8.6 16.7 7.2 7.2 8.8 11.7 7.4 9.9 10.3 13.2 4.4 10.6 3.4 10.0 4.4 12.1 9.6 15.6 15.9 16.6 10.1 12.6 12.4 0.9 3.1 2.7 4.3 3.3 6.3 4.8 4.5 5.0 3.1 3.4 7.4 5.5 0.7 5.2 3.0 3.6 4.4 2.7 11.1 14.3 13.0 16.6 15.5 11.3 15.0 12.4 16.4 14.8 6.0 5.5 4.2 5.9 4.0 7.0 8.2 7.6 2.7 2.3 12.2 9.8 5.8 16.6 4.2 13.5 4.3 0.8 0.0 3.9 6.8 6.0 3.8 3.5 10.4 5.6 7.9 8.6 6.2 10.0 6.8 8.1 6.1 15.1 4.6 3.2 12.6 3.0 0.0 4.2 8.6 9.3 0.0 8.2 27.5 12.0 2.3 3.8 6.2 4.0 1.8 PPM1D "PP2C-DELTA, Wip1" ENSG00000170836 "Protein phosphatase, Mg2+/Mn2+ dependent 1D" O15297 17 60600183-60666280 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Cell cycle" "Hydrolase, Protein phosphatase" "Autism spectrum disorder, Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 5 "Early spermatids: 51.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "MCF7: 26.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA022277, HPA061848" Approved Supported Nucleoplasm,Nucleoli NA NA Nucleoplasm Nucleoli "HPA022277: AB_1858839, HPA061848: " "unprognostic (1.48e-1)" "unprognostic (1.36e-2)" "prognostic favorable (3.52e-4)" "unprognostic (1.76e-1)" "unprognostic (1.02e-1)" "unprognostic (5.12e-2)" "prognostic unfavorable (4.27e-4)" "unprognostic (5.50e-2)" "unprognostic (1.70e-2)" "unprognostic (6.07e-2)" "unprognostic (2.52e-3)" "unprognostic (3.46e-2)" "unprognostic (1.95e-3)" "unprognostic (7.33e-2)" "unprognostic (1.58e-1)" "unprognostic (1.71e-2)" "unprognostic (1.98e-1)" 12.2 7.0 6.1 5.7 9.2 13.6 11.9 30.8 6.6 11.1 10.0 10.6 7.8 7.6 12.0 8.3 8.6 11.1 8.3 5.8 7.7 4.4 7.4 7.4 9.2 7.9 10.3 4.6 17.3 12.3 8.1 8.9 18.5 8.8 9.3 9.4 8.2 8.1 6.8 9.7 8.1 8.1 8.2 7.3 9.2 7.3 16.2 12.5 15.5 8.7 6.9 7.0 7.8 11.3 7.3 13.1 20.5 13.2 6.8 8.3 6.8 2.7 5.5 6.2 5.3 4.2 2.6 8.0 4.3 2.9 2.8 4.0 5.6 1.6 7.9 3.6 3.0 1.1 3.0 4.0 1.8 3.8 1.4 8.8 5.7 5.4 6.5 3.5 2.3 4.4 2.3 2.9 4.2 2.5 2.3 6.4 3.4 4.1 3.3 3.0 26.9 6.2 3.4 2.7 2.6 4.3 7.6 7.9 4.7 2.5 3.4 8.5 6.2 5.7 1.9 1.3 6.9 2.3 3.1 4.7 3.7 10.1 2.8 2.3 5.4 5.7 6.0 1.5 2.3 2.8 8.2 13.2 14.1 6.7 10.2 5.9 7.3 5.6 6.1 13.1 5.9 6.1 6.2 20.5 6.8 6.1 5.8 8.3 6.8 6.1 9.2 30.8 6.6 7.7 4.4 10.3 4.6 8.8 12.5 29.8 7.7 13.7 4.0 18.7 12.0 5.6 5.1 2.7 4.5 5.2 3.9 13.6 3.3 6.0 51.4 15.8 10.1 0.0 6.0 5.1 11.2 6.9 1.1 2.8 7.5 3.2 13.8 20.3 23.0 8.1 12.7 9.8 3.3 6.4 9.0 6.4 5.1 8.6 7.1 4.2 10.1 0.0 12.0 24.5 13.9 15.7 32.3 7.5 10.5 5.5 PPP2R1A "PP2A-Aalpha, PP2AA, PR65A" ENSG00000105568 "Protein phosphatase 2 scaffold subunit Aalpha" P30153 19 52190039-52229533 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Chromosome partition" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB018599 Approved Cytosol NA NA 3400000 Cytosol "CAB018599: AB_628178" "unprognostic (1.78e-1)" "unprognostic (2.31e-2)" "unprognostic (4.52e-2)" "unprognostic (2.87e-1)" "unprognostic (6.67e-2)" "unprognostic (7.82e-2)" "prognostic unfavorable (1.76e-4)" "prognostic unfavorable (2.50e-4)" "unprognostic (4.30e-2)" "unprognostic (3.06e-1)" "unprognostic (6.48e-3)" "unprognostic (8.28e-2)" "prognostic favorable (1.20e-4)" "unprognostic (1.97e-1)" "unprognostic (3.57e-2)" "unprognostic (1.70e-2)" "unprognostic (9.19e-2)" 25.3 57.3 60.7 20.5 71.0 18.0 21.4 47.5 82.1 29.6 31.2 26.6 21.5 33.4 26.4 37.9 37.7 47.0 39.9 74.7 70.2 44.8 31.0 29.3 20.0 27.5 44.0 50.9 45.8 24.3 37.8 29.5 24.6 51.0 31.0 29.8 31.0 24.3 35.6 50.6 33.5 25.3 34.5 25.2 20.5 19.8 21.7 18.1 29.0 28.9 35.9 30.6 27.3 23.1 52.8 62.8 51.9 67.2 69.8 56.3 67.8 30.9 52.6 42.0 37.3 34.2 35.8 22.1 26.1 34.2 34.9 30.6 26.4 24.5 27.1 18.8 41.5 19.2 22.4 45.0 39.4 20.3 20.0 121.9 19.9 29.0 29.7 31.3 21.5 19.0 48.0 32.6 32.7 30.1 32.8 33.1 18.2 23.1 19.1 38.7 35.8 30.0 41.0 41.5 31.2 46.5 29.5 24.4 30.3 56.1 51.0 31.7 33.9 32.0 32.0 19.5 28.6 28.9 38.0 31.4 27.7 25.1 13.5 29.8 19.8 29.0 31.8 29.8 21.8 34.9 45.0 55.3 51.9 50.4 67.2 45.8 48.4 45.1 47.1 62.8 52.8 37.7 43.0 33.7 69.8 59.8 39.0 56.3 67.8 60.7 71.0 47.5 82.1 70.2 44.8 44.0 50.9 51.0 18.1 41.7 30.7 69.2 78.9 62.5 111.3 81.8 68.8 52.2 36.4 113.4 23.6 183.6 99.5 195.0 3.8 51.7 133.3 0.0 136.1 214.1 70.0 78.9 68.0 44.8 127.2 136.7 102.6 66.9 55.1 6.8 67.0 47.0 50.6 131.7 108.9 97.9 137.7 175.6 80.2 103.3 48.5 77.6 81.4 14.8 54.1 55.3 152.2 70.3 147.4 93.1 PPP6C PP6 ENSG00000119414 "Protein phosphatase 6 catalytic subunit" O00743 9 125146573-125189939 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Cell cycle, Immunity, Innate immunity" "Hydrolase, Protein phosphatase" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" HPA050940 Uncertain NA NA "HPA050940: AB_2681283" "unprognostic (6.45e-2)" "unprognostic (4.01e-3)" "unprognostic (7.12e-2)" "unprognostic (5.36e-2)" "unprognostic (2.78e-2)" "unprognostic (2.92e-2)" "unprognostic (2.57e-3)" "unprognostic (1.53e-1)" "unprognostic (2.14e-1)" "unprognostic (2.44e-1)" "unprognostic (1.71e-2)" "unprognostic (2.28e-2)" "prognostic favorable (4.50e-6)" "unprognostic (1.54e-2)" "unprognostic (3.51e-1)" "unprognostic (1.12e-2)" "unprognostic (1.12e-1)" 21.7 20.1 20.1 15.7 24.5 24.8 21.2 20.8 26.2 17.0 19.1 25.9 15.1 13.9 15.6 17.2 21.2 14.0 12.9 15.3 19.8 16.6 22.8 17.8 16.3 21.5 20.1 16.1 17.5 27.7 21.3 17.3 17.6 17.8 14.5 21.8 16.8 26.9 14.6 50.5 19.3 17.3 16.3 22.6 19.4 16.5 22.8 23.7 34.1 22.2 20.5 24.0 13.8 15.6 17.3 14.8 32.2 19.5 13.9 23.3 13.8 14.1 10.3 18.8 17.8 20.2 16.9 19.0 15.0 16.3 22.2 18.6 16.5 15.0 20.4 11.7 20.1 18.9 28.9 25.4 16.3 25.8 18.2 12.3 16.7 16.2 14.6 16.6 29.1 23.2 13.9 22.4 18.2 17.4 17.1 20.7 23.4 19.5 23.7 23.9 21.0 27.4 18.4 17.5 39.6 19.2 22.4 28.5 27.2 18.8 14.3 19.5 19.3 26.8 21.6 17.4 16.7 33.4 18.4 20.0 13.7 13.1 26.5 19.9 26.2 47.2 27.0 18.4 19.1 22.2 27.2 13.2 21.4 14.7 17.4 18.0 17.3 18.9 16.6 14.8 13.3 18.9 17.5 32.2 13.9 19.5 10.7 23.3 13.8 20.1 24.5 20.8 26.2 19.8 16.6 20.1 16.1 17.8 23.7 38.7 27.8 41.7 45.6 68.7 15.2 30.8 35.7 21.4 23.9 26.2 7.9 40.2 48.0 40.6 102.7 41.4 34.6 23.3 47.6 45.3 30.1 41.0 43.9 36.1 46.7 14.3 46.0 46.6 52.3 56.7 27.6 48.9 42.2 46.9 41.6 28.7 41.6 38.6 33.9 54.9 12.9 51.8 44.8 93.3 43.0 76.5 72.9 49.0 37.9 48.2 PRDM1 "BLIMP1, PRDI-BF1" ENSG00000057657 "PR/SET domain 1" O75626 6 106086320-106109939 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Adaptive immunity, Immunity, Innate immunity, Transcription, Transcription regulation" "DNA-binding, Methyltransferase, Repressor, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 49.9" "Cell type enhanced" "Detected in many" 8 "Cone photoreceptor cells: 49.1;T-cells: 100.2;Urothelial cells: 77.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Group enriched" "Detected in many" 4 "eosinophil: 5.6;gdT-cell: 12.6;MAIT T-cell: 19.3;memory CD4 T-cell: 12.0;memory CD8 T-cell: 11.6;naive CD8 T-cell: 6.8;neutrophil: 6.8;T-reg: 15.4" "Group enriched" "Detected in many" 5 "granulocytes: 6.8;T-cells: 19.3" "Cell line enhanced" "Detected in some" "Karpas-707: 68.5;RPMI-8226: 12.8;U-266/70: 25.7;U-266/84: 16.6" "Region enriched" "Detected in single" 6 "olfactory region: 4.4" "Low region specificity" "Detected in all" "HPA030033, HPA075427" Approved Approved Nucleoplasm,Nucleoli NA NA Nucleoli Nucleoplasm "HPA030033: AB_10601050, HPA075427: " "unprognostic (9.60e-2)" "unprognostic (3.28e-2)" "unprognostic (1.71e-1)" "unprognostic (1.98e-2)" "unprognostic (4.03e-1)" "unprognostic (3.77e-2)" "unprognostic (1.04e-1)" "unprognostic (1.49e-1)" "unprognostic (2.42e-1)" "unprognostic (1.81e-1)" "unprognostic (3.50e-2)" "unprognostic (7.56e-2)" "prognostic unfavorable (9.81e-5)" "unprognostic (1.52e-1)" "unprognostic (3.51e-1)" "unprognostic (2.45e-3)" "unprognostic (7.90e-2)" 11.6 1.5 1.6 26.3 3.2 10.4 7.0 5.3 1.6 14.0 16.5 1.9 1.4 5.4 11.6 2.2 33.4 3.8 8.1 2.3 1.9 2.0 3.1 2.4 18.8 33.3 2.1 0.5 4.2 1.8 1.2 2.1 9.0 4.9 3.6 11.0 4.3 10.6 3.0 2.0 8.9 18.2 3.4 7.4 24.2 8.6 3.0 1.5 3.1 7.7 35.7 49.9 12.8 18.0 1.5 0.2 6.8 0.6 2.5 19.3 1.3 0.4 0.1 0.3 0.0 0.5 0.7 0.0 2.3 7.2 0.7 1.3 0.4 2.8 0.6 0.1 4.6 0.1 0.1 0.0 1.1 0.8 6.4 0.0 0.1 1.4 0.0 1.1 0.2 0.5 0.7 3.6 1.0 3.0 0.2 0.9 0.3 0.4 68.5 0.1 0.0 0.0 0.1 0.2 0.4 0.0 0.1 0.0 12.8 0.6 0.1 0.0 0.0 0.3 0.3 0.0 0.5 0.3 0.7 0.4 1.1 0.6 0.6 2.1 25.7 16.6 1.5 1.6 0.4 0.6 1.2 0.4 5.6 12.6 0.6 19.3 1.5 12.0 11.6 0.2 0.5 1.1 6.8 6.8 2.5 0.1 0.2 15.4 1.3 1.6 3.2 5.3 1.6 1.9 2.0 2.1 0.5 4.9 1.5 0.0 9.0 19.7 8.0 17.3 0.8 1.4 0.0 2.7 7.9 3.5 49.1 0.4 0.0 0.3 0.8 20.4 7.3 23.3 0.2 0.5 5.1 3.1 3.5 1.5 19.3 0.0 1.7 8.0 24.7 0.0 0.0 38.5 35.4 47.7 3.1 0.5 4.8 4.3 1.1 0.1 0.4 0.0 16.4 0.3 1.3 36.3 0.6 100.2 2.5 77.0 PREX2 "DEP.2, DEPDC2, FLJ12987, P-REX2, PPP1R129" ENSG00000046889 "Phosphatidylinositol-3,4,5-trisphosphate dependent Rac exchange factor 2" Q70Z35 8 67952118-68237030 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Guanine-nucleotide releasing factor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 11 "Early spermatids: 31.5;Endothelial cells: 35.0;Ito cells: 52.8;Muller glia cells: 74.9" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in single" "Low lineage specificity" "Detected in single" "Cell line enhanced" "Detected in some" "AF22: 12.8;HUVEC TERT2: 17.4;JURKAT: 7.5;NTERA-2: 11.1;RH-30: 5.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA015234, HPA075956" Enhanced Approved "Endoplasmic reticulum" NA NA "Endoplasmic reticulum" "HPA015234: AB_1847604, HPA075956: AB_2686769" "unprognostic (2.25e-1)" "unprognostic (3.32e-2)" "unprognostic (1.30e-2)" "unprognostic (3.39e-2)" "unprognostic (1.79e-1)" "unprognostic (2.37e-2)" "unprognostic (4.19e-1)" "unprognostic (8.27e-2)" "unprognostic (2.00e-1)" "unprognostic (1.98e-2)" "unprognostic (2.53e-2)" "unprognostic (8.77e-2)" "prognostic unfavorable (1.61e-7)" "unprognostic (8.30e-3)" "unprognostic (2.79e-1)" "unprognostic (3.67e-2)" "unprognostic (6.64e-2)" 18.8 3.0 14.1 3.3 17.9 1.0 8.5 11.4 16.4 10.8 4.4 13.1 3.0 4.3 6.2 4.5 4.4 12.4 7.6 7.6 15.5 8.1 4.1 3.2 9.1 2.4 12.4 10.0 5.2 3.1 3.7 4.4 17.5 17.2 6.3 4.4 2.6 3.0 5.7 4.9 4.4 4.0 6.1 12.7 3.5 4.1 2.7 16.2 0.0 12.1 3.9 2.9 5.9 15.8 1.1 0.3 0.8 0.1 0.2 0.4 0.0 0.0 0.0 12.8 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 3.4 0.0 0.0 0.0 3.6 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 17.4 7.5 0.0 0.0 0.0 0.0 2.6 0.0 11.1 0.0 0.0 0.0 5.0 0.0 0.6 0.0 3.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 1.2 0.1 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.8 0.1 0.1 0.4 0.1 0.2 0.5 0.2 0.2 0.0 1.1 0.2 0.3 0.5 0.2 0.1 0.3 0.0 0.0 14.1 17.9 11.4 13.6 15.5 8.1 12.4 10.0 17.2 16.2 3.0 5.3 0.0 3.2 3.5 24.6 4.4 0.0 1.4 5.7 1.8 2.0 0.0 0.0 0.0 31.5 35.0 0.0 0.0 0.0 0.0 5.5 0.5 1.1 0.4 0.1 4.8 0.0 52.8 3.1 4.9 10.3 0.2 8.5 0.0 0.0 74.9 0.0 0.0 9.9 0.0 3.0 25.8 3.4 0.7 0.7 2.3 0.0 0.0 0.0 1.4 PRKACA PKACa ENSG00000072062 "Protein kinase cAMP-activated catalytic subunit alpha" P17612 19 14091688-14118084 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Cushing syndrome, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 6 "Cardiomyocytes: 110.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010361, HPA071185" Approved Approved "Cytokinetic bridge,Cytosol" NA NA 1300000 Cytosol "Cytokinetic bridge" "CAB010361: AB_2268772, HPA071185: AB_2686356" "unprognostic (1.08e-1)" "prognostic favorable (6.28e-6)" "unprognostic (2.09e-2)" "prognostic unfavorable (6.26e-5)" "unprognostic (1.38e-2)" "unprognostic (2.95e-1)" "unprognostic (1.64e-1)" "unprognostic (9.36e-3)" "unprognostic (7.01e-2)" "unprognostic (3.41e-1)" "prognostic favorable (6.47e-4)" "unprognostic (2.86e-1)" "unprognostic (1.17e-1)" "unprognostic (4.68e-2)" "unprognostic (1.87e-1)" "unprognostic (3.66e-2)" "unprognostic (6.14e-3)" 25.6 43.4 19.6 17.8 22.7 9.1 34.1 29.1 39.6 20.6 17.5 16.0 16.2 13.4 19.8 15.6 20.9 18.8 16.4 91.6 20.7 29.4 14.7 34.5 16.5 28.2 21.6 27.5 47.0 15.6 20.8 24.6 15.4 26.9 16.6 16.2 18.4 15.5 24.9 92.4 13.4 14.4 29.0 16.2 28.1 13.9 24.4 11.1 15.2 15.7 26.2 14.8 21.1 17.3 1.7 2.4 8.6 5.3 0.7 1.7 1.2 26.2 15.3 34.7 41.3 30.7 32.7 6.3 28.0 25.9 39.8 36.5 18.6 9.4 11.4 22.7 44.3 19.4 17.2 24.4 26.5 37.8 20.7 12.3 20.9 28.9 18.0 26.3 12.9 22.2 31.1 12.8 31.6 11.0 24.6 33.5 18.7 19.6 29.8 40.6 38.9 29.0 9.7 12.4 26.6 34.1 26.2 32.0 26.3 19.4 16.7 27.4 17.5 25.3 15.5 11.5 17.5 22.1 12.5 25.9 47.0 13.1 62.9 26.1 20.6 21.1 16.8 31.5 19.6 17.6 0.3 3.4 0.4 1.7 5.3 0.8 1.7 0.9 1.1 2.4 1.3 1.2 1.7 8.6 0.7 4.6 1.6 0.8 1.2 19.6 22.7 29.1 39.6 20.7 29.4 21.6 27.5 26.9 11.1 6.0 4.3 11.5 6.1 7.8 40.4 110.4 28.1 4.0 2.3 14.0 25.5 5.8 6.6 10.7 25.7 21.6 16.0 0.0 16.2 4.8 14.3 7.3 0.0 30.1 29.0 3.2 16.8 31.9 44.8 12.8 45.5 32.4 13.5 7.2 14.3 24.1 13.5 7.0 48.8 9.6 23.0 19.4 17.3 25.7 6.4 9.8 6.8 7.2 11.4 6.4 PRKAR1A "CNC1, PRKAR1, TSE1" ENSG00000108946 "Protein kinase cAMP-dependent type I regulatory subunit alpha" P10644 17 68511780-68551319 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cancer-related genes, Cushing syndrome, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" 5 "Cardiomyocytes: 608.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB019378, HPA049979" Approved Approved Cytosol NA NA 11000000 Cytosol "CAB019378: , HPA049979: AB_2680980" "unprognostic (8.69e-2)" "unprognostic (6.97e-2)" "unprognostic (5.34e-2)" "unprognostic (2.04e-1)" "unprognostic (1.68e-1)" "unprognostic (4.39e-2)" "unprognostic (2.61e-1)" "unprognostic (6.42e-2)" "unprognostic (2.27e-1)" "unprognostic (2.30e-1)" "unprognostic (1.19e-2)" "unprognostic (5.55e-2)" "unprognostic (8.56e-3)" "unprognostic (6.26e-2)" "unprognostic (6.92e-2)" "unprognostic (3.29e-2)" "unprognostic (1.11e-1)" 47.1 48.0 41.7 34.5 54.8 14.6 38.7 40.4 57.4 48.2 23.8 44.9 31.4 15.1 43.6 37.7 29.6 43.2 37.4 122.7 42.5 52.3 49.2 43.4 47.3 29.5 50.1 43.6 62.5 19.1 107.8 41.9 47.3 57.7 35.6 24.2 32.2 47.5 43.6 99.8 22.8 19.3 39.4 52.8 35.3 25.1 36.9 40.1 28.2 51.8 23.6 29.2 33.8 33.4 11.3 26.9 52.6 28.7 18.5 13.0 22.9 16.6 32.1 41.2 24.6 55.0 62.5 6.2 22.5 46.5 35.2 31.2 12.5 22.5 16.9 15.5 49.1 36.1 13.8 30.4 36.5 50.6 11.4 10.9 26.2 27.9 40.8 39.9 20.0 29.4 44.6 38.0 40.6 34.3 39.6 58.4 14.5 11.8 26.7 42.6 31.6 22.0 10.7 15.2 17.2 21.9 15.4 68.2 18.7 53.4 36.3 15.0 20.3 20.6 37.7 86.7 40.0 29.5 28.3 41.4 49.7 23.7 22.4 20.9 22.3 15.8 25.2 30.1 19.1 30.9 31.1 26.1 46.3 13.0 25.5 13.0 11.3 9.8 11.6 26.9 8.5 8.9 9.8 52.6 18.5 28.7 8.8 12.3 22.9 41.7 54.8 40.4 57.4 42.5 52.3 50.1 43.6 57.7 40.1 137.0 210.8 75.1 77.8 126.8 93.4 608.0 89.2 258.3 168.4 239.0 62.8 66.4 150.9 74.2 287.1 138.4 34.9 23.3 45.5 74.3 135.4 82.7 180.2 101.7 123.8 131.9 131.3 160.2 157.1 53.4 123.7 102.2 182.2 93.8 51.5 115.8 62.1 52.9 179.3 150.9 56.6 84.1 208.1 100.7 40.5 115.2 69.0 106.6 36.6 95.0 PTCH1 "BCNS, NBCCS, PTCH" ENSG00000185920 "Patched 1" Q13635 9 95442980-95517057 "Cancer-related genes, Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" Receptor "Cancer-related genes, Disease mutation, Holoprosencephaly, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" 17 "Late spermatids: 165.3;Leydig cells: 176.9;Peritubular cells: 417.9" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "gdT-cell: 8.9" "Lineage enriched" "Detected in many" 8 "T-cells: 8.9" "Cell line enhanced" "Detected in many" "NTERA-2: 15.8;WM-115: 37.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB013717, HPA075072" Uncertain Approved "Golgi apparatus" NA NA "Golgi apparatus" "CAB013717: , HPA075072: AB_2686733" "unprognostic (1.46e-1)" "unprognostic (1.06e-1)" "unprognostic (3.16e-1)" "unprognostic (1.79e-2)" "unprognostic (3.22e-2)" "unprognostic (9.01e-2)" "unprognostic (2.13e-1)" "unprognostic (3.54e-3)" "unprognostic (2.63e-1)" "unprognostic (8.66e-3)" "unprognostic (1.52e-2)" "unprognostic (2.82e-1)" "unprognostic (1.13e-6)" "unprognostic (8.63e-2)" "unprognostic (4.40e-2)" "unprognostic (2.76e-1)" "unprognostic (2.82e-1)" 4.1 3.8 6.7 6.0 9.5 0.7 7.9 21.0 6.4 28.5 12.5 6.1 8.0 7.8 16.2 4.2 3.0 7.4 13.2 2.8 7.0 6.6 4.9 2.2 7.1 4.5 9.5 3.2 5.2 10.8 3.4 4.0 3.7 6.9 6.9 12.3 11.2 6.9 9.5 2.7 4.3 10.9 8.5 5.1 3.8 12.1 14.3 7.9 1.0 6.3 1.9 3.2 11.3 6.9 1.0 0.0 0.0 0.0 0.3 8.9 1.8 5.1 2.5 10.9 6.8 1.6 2.7 6.2 1.0 0.9 1.2 0.7 2.5 2.5 4.1 1.8 1.9 2.3 11.8 6.2 0.8 0.7 4.0 4.1 0.0 2.5 1.1 1.5 0.1 2.3 2.5 1.3 1.1 0.8 2.3 2.2 1.8 3.6 4.8 0.5 1.0 0.0 1.6 15.8 3.7 1.0 0.0 8.3 2.1 0.8 0.7 7.5 3.7 3.7 3.6 1.6 10.6 0.9 1.1 0.5 1.4 7.2 7.3 0.7 9.7 8.4 2.7 2.0 2.0 37.6 0.0 0.0 0.0 8.9 0.0 5.3 1.0 1.7 3.8 0.0 0.3 2.8 3.2 0.0 0.3 0.0 0.0 1.4 1.8 6.7 9.5 21.0 6.4 7.0 6.6 9.5 3.2 6.9 7.9 0.0 5.4 0.9 2.8 3.5 17.4 5.1 10.2 1.4 2.3 0.0 39.3 2.0 5.0 2.5 80.9 3.7 1.3 0.0 3.5 1.6 6.9 5.8 1.1 1.0 0.7 19.1 20.8 3.1 0.8 165.3 176.9 0.8 11.8 0.0 11.2 71.0 2.6 3.5 417.9 1.1 13.5 38.8 4.2 3.3 33.2 3.9 1.1 4.3 5.0 1.1 PTEN "BZS, MHAM, MMAC1, PTEN1, TEP1" ENSG00000171862 "Phosphatase and tensin homolog" P60484 10 87863113-87971930 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins" "Apoptosis, Lipid metabolism, Neurogenesis" "Hydrolase, Protein phosphatase" "Autism spectrum disorder, Cancer-related genes, Disease mutation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "neutrophil: 29.6" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB004076, HPA031335" Approved Supported Nucleoplasm,Cytosol "Secreted - unknown location" NA NA Nucleoplasm Cytosol "CAB004076: AB_390810, HPA031335: AB_2797221" "unprognostic (8.72e-2)" "unprognostic (2.45e-1)" "unprognostic (5.43e-1)" "unprognostic (1.50e-2)" "unprognostic (3.71e-2)" "unprognostic (1.30e-1)" "unprognostic (2.18e-1)" "unprognostic (2.08e-1)" "unprognostic (2.07e-1)" "unprognostic (6.87e-2)" "unprognostic (9.77e-2)" "unprognostic (2.71e-1)" "prognostic unfavorable (7.35e-4)" "unprognostic (1.57e-1)" "unprognostic (2.73e-1)" "unprognostic (6.54e-3)" "unprognostic (2.41e-1)" 42.4 24.1 17.7 20.9 17.7 13.5 32.8 39.9 19.7 43.1 26.7 9.9 19.0 15.1 29.8 22.8 26.8 30.3 21.0 19.1 16.0 17.4 19.6 32.4 27.2 30.4 15.7 19.5 29.1 21.3 16.4 23.6 36.4 14.2 35.3 17.7 21.6 16.8 20.8 16.8 20.4 25.4 26.0 11.7 40.9 17.8 18.7 12.5 49.7 25.2 13.3 18.6 29.6 30.9 4.3 5.1 29.6 11.0 4.3 4.7 2.0 10.2 4.8 5.5 5.0 12.8 8.8 5.0 5.5 12.2 6.5 9.1 4.9 12.6 12.1 3.7 9.0 3.8 6.2 7.4 6.3 10.3 6.0 2.1 4.0 12.5 6.0 13.7 13.5 6.9 6.0 17.6 8.2 10.6 27.6 9.1 7.7 3.0 32.9 5.9 7.8 7.6 24.6 2.0 8.9 0.0 11.8 2.9 8.9 10.1 5.8 2.0 9.0 7.3 3.5 9.2 4.6 9.7 19.6 7.9 21.4 5.0 8.3 4.4 10.8 14.0 13.8 6.6 12.8 1.2 8.3 7.9 12.2 3.6 11.0 3.9 4.3 4.0 3.5 5.1 3.7 4.7 4.5 29.6 4.3 7.2 4.2 3.5 2.0 17.7 17.7 39.9 19.7 16.0 17.4 15.7 19.5 14.2 12.5 32.8 55.3 40.2 50.0 49.8 113.3 39.2 40.8 25.4 28.4 27.9 37.3 22.6 28.2 23.2 57.0 44.4 33.9 0.0 25.8 44.5 52.3 36.9 25.3 58.6 31.3 42.9 30.0 47.9 167.4 70.7 52.6 69.1 59.1 27.9 44.1 54.1 30.2 24.6 51.2 30.8 55.8 90.5 118.8 24.9 24.0 52.6 47.9 35.7 39.2 51.2 PTK6 BRK ENSG00000101213 "Protein tyrosine kinase 6" Q13882 20 63528001-63537370 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "esophagus: 44.0;intestine: 24.2;skin 1: 24.2" "Cell type enhanced" "Detected in many" 12 "Alveolar cells type 2: 34.1;Enterocytes: 90.1;Mucus-secreting cells: 39.1;Paneth cells: 65.1" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in some" "A-431: 10.6;CAPAN-2: 20.4;HaCaT: 16.6;hTCEpi: 22.5;OE19: 27.4;RT4: 13.0;T-47d: 12.5" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB032952, HPA036070, HPA036071" Approved Supported "Nucleoplasm,Nuclear bodies,Plasma membrane,Cytosol" NA NA Nucleoplasm "Nuclear bodies, Plasma membrane, Cytosol" "CAB032952: AB_634461, HPA036070: AB_10602292, HPA036071: AB_10669982" "unprognostic (2.32e-2)" "unprognostic (1.36e-1)" "unprognostic (1.05e-1)" "unprognostic (2.42e-2)" "unprognostic (1.41e-1)" "unprognostic (1.35e-1)" "unprognostic (1.04e-1)" "unprognostic (2.29e-1)" "unprognostic (3.03e-1)" "unprognostic (3.72e-2)" "prognostic unfavorable (1.96e-4)" "unprognostic (1.28e-1)" "prognostic unfavorable (1.26e-9)" "unprognostic (4.19e-2)" "unprognostic (1.74e-1)" "unprognostic (1.73e-1)" "unprognostic (4.24e-2)" 0.7 0.0 0.4 5.3 0.4 0.0 1.7 0.4 0.4 7.6 18.1 0.5 0.8 13.6 0.6 0.5 44.0 0.0 11.7 0.4 0.4 0.0 0.8 1.7 1.1 0.4 0.4 0.4 0.4 1.4 0.0 0.4 0.6 0.4 2.2 7.4 0.4 7.6 0.4 0.4 24.2 24.2 0.9 0.4 0.4 12.5 0.4 0.4 0.4 0.4 18.9 17.2 6.5 15.0 1.3 4.5 1.2 2.4 0.3 1.9 0.9 10.6 1.2 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 20.4 0.0 3.6 0.0 0.0 16.6 0.0 0.0 0.0 2.6 0.2 0.0 4.3 0.0 0.0 0.0 3.4 0.0 22.5 0.0 0.1 0.1 0.0 0.0 0.1 1.2 0.1 5.9 0.0 0.1 0.1 27.4 7.7 0.0 0.6 0.2 0.0 13.0 0.1 1.1 1.2 4.0 0.0 0.0 12.5 0.8 0.1 0.1 0.2 0.4 0.1 0.2 0.0 0.0 0.2 0.2 0.5 1.2 2.4 0.4 0.5 1.7 1.9 1.2 0.4 0.1 4.5 1.3 0.4 0.6 1.2 0.3 1.3 0.3 0.5 0.9 0.4 0.4 0.4 0.4 0.4 0.0 0.4 0.4 0.4 0.4 11.9 34.1 0.0 2.8 5.3 2.0 0.4 12.7 9.4 17.0 0.0 2.0 0.2 0.0 1.4 0.0 0.3 90.1 0.0 1.4 0.1 0.4 1.3 9.2 1.5 0.7 0.0 5.2 0.6 4.1 0.0 0.3 2.8 0.0 0.0 39.1 2.4 10.3 65.1 0.0 0.1 3.9 0.0 0.4 0.2 0.2 13.6 0.1 0.0 18.8 13.8 PTPN11 "BPTP3, NS1, PTP2C, SH-PTP2, SHP-2, SHP2" ENSG00000179295 "Protein tyrosine phosphatase, non-receptor type 11" Q06124 12 112418351-112509913 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins" "Hydrolase, Protein phosphatase" "Cancer-related genes, Deafness, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 4 "Cardiomyocytes: 136.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB005377 Approved Supported "Nucleoplasm,Nucleoli rim,Actin filaments,Cytosol" NA NA 160000 "Nucleoli rim" "Nucleoplasm, Actin filaments, Cytosol" "CAB005377: AB_632401" "unprognostic (2.18e-3)" "unprognostic (1.73e-3)" "unprognostic (5.62e-2)" "unprognostic (1.19e-1)" "unprognostic (1.63e-2)" "unprognostic (2.27e-1)" "unprognostic (6.05e-2)" "unprognostic (4.25e-2)" "unprognostic (3.55e-2)" "unprognostic (1.88e-1)" "unprognostic (2.22e-2)" "unprognostic (8.85e-2)" "unprognostic (3.75e-3)" "unprognostic (1.66e-1)" "unprognostic (2.46e-1)" "unprognostic (3.62e-2)" "unprognostic (1.80e-2)" 25.4 16.8 38.6 14.4 39.0 17.7 30.8 17.5 39.5 18.3 14.7 26.9 9.9 11.9 19.1 13.3 17.6 11.1 13.1 30.1 38.0 32.2 18.0 23.1 15.1 14.5 45.3 22.5 13.1 14.0 29.3 12.9 16.6 26.2 16.2 13.9 9.4 12.0 20.0 34.0 14.1 11.1 28.0 45.7 10.9 12.8 7.6 32.1 10.9 21.2 8.2 13.7 17.4 15.4 17.3 17.1 22.0 11.8 11.3 15.4 6.3 35.4 33.8 24.7 23.4 36.0 35.2 29.2 43.1 47.0 34.0 25.6 33.7 13.7 37.5 22.5 39.8 21.5 21.2 31.7 38.2 56.5 28.4 26.1 54.5 31.5 18.4 35.9 43.7 34.8 28.4 38.5 36.5 51.9 32.8 28.0 29.0 41.4 13.2 32.8 25.6 30.7 21.3 29.9 34.7 22.2 31.6 36.4 21.5 31.3 39.9 17.2 21.1 41.5 31.8 26.5 26.1 36.6 30.3 34.1 40.0 35.9 23.7 37.6 25.6 42.2 37.5 33.3 30.7 37.3 22.0 11.0 15.0 14.8 9.5 14.1 15.5 13.4 12.1 12.6 17.3 15.4 11.8 10.3 11.3 11.8 17.1 9.8 6.3 38.6 39.0 17.5 39.5 38.0 32.2 45.3 22.5 26.2 32.1 56.6 53.2 13.4 22.8 22.8 27.6 136.3 30.6 20.1 50.0 34.9 15.7 20.0 28.2 34.0 65.9 35.8 17.2 0.0 36.7 21.0 25.9 57.9 26.7 93.6 22.8 12.7 12.6 27.0 32.4 19.0 47.8 23.7 13.5 16.2 19.6 59.0 45.4 20.4 75.0 29.8 21.4 32.3 31.9 7.7 5.3 24.0 29.4 19.8 18.7 65.6 PTPN13 "PTP-BAS, PTP-BL, PTP1E, PTPL1" ENSG00000163629 "Protein tyrosine phosphatase, non-receptor type 13" Q12923 4 86594315-86815171 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Hydrolase, Protein phosphatase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" 7 "Alveolar cells type 2: 152.9;Basal keratinocytes: 97.1;Rod photoreceptor cells: 171.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 6 "intermediate monocyte: 3.0;MAIT T-cell: 2.3;memory CD4 T-cell: 2.2;non-classical monocyte: 4.9" "Group enriched" "Detected in many" 7 "monocytes: 4.9;T-cells: 2.3" "Cell line enhanced" "Detected in many" "AF22: 45.2;RT4: 21.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002213, HPA063119" Approved Supported "Nucleoplasm,Nucleoli fibrillar center,Cytosol" NA NA Nucleoplasm "Nucleoli fibrillar center, Cytosol" "CAB002213: AB_564089, HPA063119: " "unprognostic (5.36e-2)" "unprognostic (4.46e-1)" "unprognostic (1.11e-1)" "unprognostic (2.54e-3)" "unprognostic (4.02e-1)" "unprognostic (9.03e-3)" "unprognostic (4.43e-2)" "unprognostic (4.38e-2)" "unprognostic (2.46e-1)" "unprognostic (7.05e-2)" "unprognostic (3.69e-2)" "unprognostic (1.46e-1)" "unprognostic (1.28e-3)" "unprognostic (3.95e-3)" "unprognostic (2.26e-1)" "unprognostic (2.66e-1)" "unprognostic (2.85e-2)" 10.3 5.9 10.8 2.7 16.9 0.7 9.9 5.7 11.6 15.9 4.1 13.0 7.6 1.2 10.8 21.2 18.7 11.4 6.5 5.3 10.4 5.7 22.1 1.6 18.0 4.3 16.9 7.9 24.1 4.3 26.6 38.3 3.0 14.2 12.0 2.4 39.0 5.9 9.4 1.0 43.0 2.3 8.7 10.3 3.5 3.6 12.2 17.6 1.9 16.9 12.4 11.8 15.7 17.6 0.0 0.5 0.1 4.9 0.1 2.3 0.1 5.1 2.6 45.2 4.4 19.1 16.7 0.0 9.5 19.4 3.6 4.6 0.0 2.6 0.0 2.1 10.5 1.3 17.0 7.8 14.3 7.0 0.1 5.8 4.3 5.6 0.0 2.3 7.5 0.0 10.7 4.6 2.6 8.7 7.6 0.0 0.0 0.0 7.4 0.0 2.3 0.6 2.7 10.3 0.0 1.9 1.5 0.0 0.0 13.8 21.5 2.6 3.8 2.8 6.3 5.2 7.6 3.7 0.2 0.0 3.5 2.7 0.0 1.2 7.7 0.0 0.0 3.7 0.0 1.5 0.0 0.2 0.0 0.2 3.0 2.3 0.0 2.2 0.3 0.5 0.0 0.0 0.0 0.1 0.1 4.9 0.0 0.1 0.1 10.8 16.9 5.7 11.6 10.4 5.7 16.9 7.9 14.2 17.6 44.7 152.9 0.0 21.0 97.1 9.8 1.7 10.2 32.1 75.1 45.4 86.4 0.2 3.3 4.3 20.2 2.2 0.0 0.0 3.0 0.1 20.2 12.1 4.7 0.0 0.2 1.6 4.6 1.8 2.2 14.8 42.3 5.7 18.6 0.0 0.5 14.1 4.3 3.5 30.8 9.2 171.6 12.9 12.5 24.4 21.6 86.9 0.2 4.4 0.2 45.5 PTPRB PTPB ENSG00000127329 "Protein tyrosine phosphatase, receptor type B" P23467 12 70515866-70637440 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" Angiogenesis "Hydrolase, Protein phosphatase" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Group enriched" "Detected in many" 6 "Endothelial cells: 113.4;Ito cells: 448.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 7 "memory B-cell: 3.5" "Lineage enriched" "Detected in single" 7 "B-cells: 3.5" "Cell line enhanced" "Detected in some" "EFO-21: 11.3;hTERT-RPE1: 9.1;HUVEC TERT2: 28.0;TIME: 40.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004782, HPA067868" Uncertain Approved "Vesicles,Plasma membrane,Cell Junctions" NA NA 6700000 "Plasma membrane" "Vesicles, Cell Junctions" "CAB004782: , HPA067868: AB_2685911" "unprognostic (3.18e-1)" "unprognostic (2.99e-6)" "unprognostic (1.56e-1)" "unprognostic (1.80e-1)" "unprognostic (3.55e-2)" "unprognostic (1.77e-2)" "prognostic favorable (6.05e-4)" "unprognostic (4.59e-1)" "unprognostic (2.22e-2)" "unprognostic (1.85e-1)" "unprognostic (2.28e-2)" "unprognostic (1.40e-1)" "prognostic favorable (1.02e-4)" "unprognostic (2.91e-2)" "unprognostic (7.18e-2)" "unprognostic (1.31e-1)" "unprognostic (1.38e-1)" 23.5 7.0 4.5 5.5 7.0 0.1 22.9 3.6 6.1 11.3 8.0 4.3 7.1 5.3 17.1 8.5 5.8 8.2 11.4 17.6 6.2 5.1 18.7 12.0 39.9 3.3 6.9 4.6 5.5 4.4 4.9 5.7 23.3 7.8 6.1 8.2 16.0 3.6 7.1 11.8 4.7 7.4 13.3 7.3 22.9 5.2 3.7 4.3 0.7 14.0 12.2 2.6 6.5 14.7 3.5 0.1 0.2 0.0 0.4 0.3 0.2 1.9 0.1 0.8 0.1 0.0 0.0 0.4 0.4 1.9 1.0 2.4 0.0 1.5 0.7 11.3 0.3 0.1 6.9 0.1 0.3 3.6 0.6 0.3 0.1 0.8 0.5 0.1 0.3 0.0 0.0 0.3 2.8 0.0 9.1 28.0 0.0 1.5 0.5 0.6 0.0 0.0 0.0 1.0 1.9 0.4 0.0 0.7 0.4 5.2 0.8 0.0 0.4 0.7 0.0 1.6 0.2 0.0 0.6 40.9 0.4 0.4 0.1 2.4 0.5 0.4 0.3 0.2 0.5 0.0 0.2 0.0 0.0 0.2 0.0 0.0 3.5 0.0 0.3 0.0 0.3 0.1 0.0 0.1 0.4 0.0 0.1 0.0 0.2 4.5 7.0 3.6 6.1 6.2 5.1 6.9 4.6 7.8 4.3 0.0 19.9 13.7 0.8 3.3 5.4 9.2 17.8 0.0 1.2 3.5 0.0 0.0 0.0 1.4 4.3 113.4 4.3 46.7 0.8 0.0 1.9 0.6 23.3 2.0 0.3 4.8 0.0 448.7 26.3 2.5 1.1 2.0 5.0 0.0 4.8 0.3 7.2 14.4 0.0 0.0 0.8 0.0 0.9 0.7 0.5 1.4 0.0 1.7 5.2 0.6 PTPRC "CD45, GP180, LCA, T200" ENSG00000081237 "Protein tyrosine phosphatase, receptor type C" 1 198638457-198757476 "Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "blood: 116.9;lymphoid tissue: 172.5" "Cell type enhanced" "Detected in many" 12 "B-cells: 266.4;granulocytes: 232.9;Kupffer cells: 338.8;Macrophages: 290.3;T-cells: 539.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in some" "Daudi: 47.1;HEL: 26.6;HL-60: 24.0;JURKAT: 61.5;MOLT-4: 35.5;THP-1: 19.7;U-266/70: 22.0;U-266/84: 20.0;U-698: 28.2;U-937: 21.5" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "CAB000052, HPA000440, CAB002800, CAB056154, CAB068221" Enhanced Uncertain Nucleoplasm,Vesicles "Intracellular and membrane" NA NA "Nucleoplasm, Vesicles" "CAB000052: AB_2314143, CAB002800: AB_2237910, CAB056154: AB_2665572, CAB068221: AB_2665571, HPA000440: AB_611377" "unprognostic (1.51e-2)" "unprognostic (1.24e-2)" "unprognostic (5.10e-3)" "unprognostic (2.33e-3)" "unprognostic (1.30e-1)" "unprognostic (2.40e-3)" "unprognostic (1.62e-1)" "unprognostic (3.17e-2)" "unprognostic (1.25e-1)" "unprognostic (3.18e-2)" "unprognostic (8.08e-2)" "unprognostic (3.95e-1)" "prognostic unfavorable (2.42e-4)" "unprognostic (2.31e-1)" "unprognostic (3.43e-2)" "unprognostic (6.41e-2)" "unprognostic (7.06e-2)" 9.8 2.9 3.4 48.0 6.2 36.1 4.3 1.3 3.5 3.1 5.6 2.8 0.5 4.9 2.9 3.9 4.8 5.6 8.8 4.9 3.9 4.5 4.4 5.2 27.5 93.2 7.9 1.3 2.9 2.1 0.3 2.5 4.5 5.3 4.2 5.8 3.3 10.7 1.0 1.7 2.5 22.2 4.5 13.2 89.3 6.5 2.3 5.3 172.5 4.6 3.9 53.2 13.1 3.7 28.5 42.8 94.7 103.8 53.7 76.1 116.9 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 47.1 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.0 26.6 0.0 0.0 0.0 24.0 0.1 0.0 0.0 0.0 0.0 0.1 0.1 61.5 0.5 0.7 0.0 0.0 35.5 14.5 0.1 0.0 0.0 1.0 0.1 0.0 0.0 0.0 0.3 0.4 0.0 0.1 0.1 0.0 0.0 19.7 0.3 0.0 0.2 0.1 0.1 22.0 20.0 28.2 0.0 21.5 0.1 20.8 52.0 56.3 76.1 99.7 64.5 28.5 52.9 72.7 42.8 26.8 60.2 60.3 94.7 53.7 103.8 6.4 54.6 116.9 3.4 6.2 1.3 3.5 3.9 4.5 7.9 1.3 5.3 5.3 41.7 86.9 266.4 0.7 14.1 0.0 4.1 7.6 21.4 26.1 1.8 0.0 0.4 0.0 0.0 2.0 11.9 0.1 23.3 0.0 0.5 8.9 0.9 232.9 3.0 90.3 0.0 1.2 14.1 338.8 1.5 1.1 290.3 20.3 120.0 0.2 0.0 0.1 0.0 0.0 1.7 0.2 6.5 4.3 0.2 0.2 13.2 0.7 539.1 0.5 0.9 PTPRT "KIAA0283, RPTPrho" ENSG00000196090 "Protein tyrosine phosphatase, receptor type T" O14522 20 42072752-43189970 "Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins" "Hydrolase, Protein phosphatase, Receptor" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "brain: 23.5;fallopian tube: 17.0" "Cell type enhanced" "Detected in some" 17 "Bipolar cells: 40.8;Ciliated cells: 33.5;Early spermatids: 10.0;Late spermatids: 9.9" "Cancer enhanced" "Detected in many" "breast cancer: 5.1" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "BEWO: 4.6;RPMI-8226: 1.2;SCLC-21H: 2.9;U-266/70: 1.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA017336, CAB069423" Approved NA NA "CAB069423: AB_1622602, HPA017336: AB_1855943" "unprognostic (7.17e-3)" "unprognostic (1.02e-1)" "unprognostic (5.61e-3)" "unprognostic (1.08e-2)" "unprognostic (5.95e-2)" "unprognostic (3.71e-2)" "unprognostic (1.97e-1)" "unprognostic (1.31e-2)" "unprognostic (6.93e-2)" "unprognostic (2.00e-1)" "unprognostic (1.37e-6)" "unprognostic (3.16e-1)" "unprognostic (1.13e-2)" "unprognostic (1.81e-1)" "unprognostic (3.17e-1)" "unprognostic (1.10e-1)" "unprognostic (1.17e-1)" 0.6 0.8 5.0 0.6 11.1 0.5 4.6 1.6 23.5 1.6 0.7 0.9 0.0 1.2 0.5 1.8 0.5 17.0 0.7 0.8 4.7 6.5 0.6 0.9 2.1 1.0 2.2 12.6 0.5 0.9 0.5 4.1 4.6 5.1 0.8 0.6 0.5 2.0 4.6 0.5 0.8 1.0 0.5 1.4 0.7 1.8 2.8 0.9 4.9 0.5 0.0 1.1 0.5 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.4 0.0 0.0 0.3 0.0 0.0 0.0 0.0 1.2 0.0 0.0 2.9 0.1 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.1 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.0 11.1 1.6 22.6 4.7 6.5 2.2 12.6 5.1 0.9 0.0 0.6 0.0 0.0 0.8 40.8 1.1 0.0 33.5 1.2 0.0 0.0 0.0 0.0 0.0 10.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.2 4.8 0.0 7.4 0.3 9.9 0.0 0.0 0.0 0.0 0.0 9.1 0.0 0.0 0.0 0.0 2.2 0.0 0.0 0.0 0.4 0.1 0.0 0.0 0.0 0.1 QKI QK3 ENSG00000112531 "QKI, KH domain containing RNA binding" Q96PU8 6 163414000-163578596 "Cancer-related genes, Predicted intracellular proteins" "Differentiation, mRNA processing, mRNA splicing, mRNA transport, Translation regulation, Transport" "Developmental protein, RNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 100.3" "Cell type enhanced" "Detected in many" 5 "Cardiomyocytes: 308.9" "Cancer enriched" "Detected in all" 6 "glioma: 42.0" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "AF22: 64.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA019123, CAB022602" Enhanced Supported Supported Nucleoplasm NA NA Nucleoplasm "CAB022602: , HPA019123: AB_1855980" "unprognostic (2.42e-1)" "unprognostic (5.81e-2)" "unprognostic (1.31e-1)" "unprognostic (1.06e-2)" "unprognostic (8.57e-2)" "unprognostic (1.65e-1)" "prognostic unfavorable (1.27e-4)" "unprognostic (1.34e-1)" "unprognostic (7.06e-2)" "unprognostic (1.76e-3)" "unprognostic (1.08e-1)" "unprognostic (5.15e-2)" "prognostic unfavorable (2.31e-5)" "prognostic unfavorable (3.69e-4)" "unprognostic (1.16e-1)" "unprognostic (3.86e-1)" "unprognostic (4.09e-2)" 32.4 12.4 37.5 16.2 63.5 27.1 14.6 15.1 100.3 14.9 12.2 83.9 3.7 4.0 14.7 4.9 16.0 12.3 15.7 64.0 43.7 18.1 11.1 18.4 24.9 11.4 72.5 31.9 18.4 7.6 7.8 4.7 23.4 46.5 7.9 8.4 7.1 10.2 11.1 59.9 12.4 7.1 21.1 68.8 16.9 8.9 20.5 74.3 5.0 10.4 10.8 11.4 15.8 17.7 1.7 7.3 10.8 8.4 7.4 3.8 1.3 4.3 18.2 64.8 21.5 19.6 21.9 15.1 11.8 27.9 19.3 23.4 12.3 4.0 5.2 9.9 29.5 13.2 6.5 34.3 12.2 31.4 10.5 11.1 20.6 10.1 13.8 24.0 11.0 6.3 25.6 5.0 20.7 32.9 18.9 26.6 7.8 30.2 12.4 12.4 8.2 7.3 2.3 8.3 4.3 9.2 11.3 40.4 10.5 10.6 13.7 1.3 7.5 12.6 6.8 5.2 27.5 2.6 18.0 27.0 13.4 11.3 14.4 21.6 7.9 9.6 6.4 11.5 9.7 31.4 3.4 8.4 3.8 2.3 5.4 3.8 1.4 1.6 2.0 4.3 1.7 1.5 2.5 10.8 7.4 5.5 7.3 1.1 1.3 37.5 63.5 15.1 41.4 43.7 18.1 72.5 31.9 46.5 74.3 140.0 54.6 32.8 29.3 136.6 56.8 308.9 40.8 21.4 36.4 19.2 55.0 41.8 18.3 21.6 45.5 100.3 0.0 46.7 10.3 40.7 66.9 33.8 60.0 61.0 75.9 30.2 0.0 146.1 189.4 77.1 80.3 114.7 108.0 31.5 0.0 113.1 17.4 0.0 92.6 25.9 30.1 45.3 91.7 34.4 14.6 118.9 46.1 25.8 0.0 35.3 RAC1 "p21-Rac1, Rac-1, TC-25" ENSG00000136238 "Rac family small GTPase 1" P63000 7 6374523-6403977 "Cancer-related genes, Predicted intracellular proteins, RAS pathway related proteins" Hydrolase "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB035994, HPA047820" Approved Approved Nucleoplasm,Nucleoli,Cytosol NA NA 44000000 "Nucleoplasm, Cytosol" Nucleoli "CAB035994: , HPA047820: AB_2680167" "unprognostic (8.66e-3)" "unprognostic (2.47e-1)" "unprognostic (4.00e-1)" "unprognostic (2.40e-2)" "unprognostic (1.88e-3)" "unprognostic (4.06e-2)" "prognostic unfavorable (1.74e-5)" "prognostic unfavorable (4.59e-4)" "unprognostic (1.59e-1)" "unprognostic (2.04e-1)" "prognostic unfavorable (4.57e-5)" "unprognostic (3.63e-1)" "prognostic unfavorable (2.11e-4)" "unprognostic (1.95e-1)" "unprognostic (2.11e-2)" "unprognostic (4.13e-2)" "unprognostic (8.72e-3)" 45.2 35.0 71.0 28.4 64.0 24.4 46.5 42.1 93.0 48.7 58.9 75.5 22.5 51.6 48.7 49.5 93.4 47.2 40.0 48.4 73.8 59.8 47.8 42.9 45.6 38.3 76.7 60.9 45.1 29.2 51.0 25.2 55.8 54.9 40.5 64.0 37.2 43.3 48.9 57.4 58.6 49.8 57.3 88.2 35.0 49.7 28.1 47.1 41.3 40.9 42.8 50.7 52.2 54.0 11.0 32.0 49.1 31.9 7.3 11.8 10.7 75.1 34.1 35.3 38.3 41.9 53.5 21.1 42.4 52.1 56.6 57.7 33.5 71.1 21.2 27.5 59.1 58.6 53.6 37.6 51.4 72.5 9.9 31.2 21.3 27.6 24.1 50.4 19.2 17.4 35.6 46.0 40.7 45.7 43.1 49.8 21.0 38.0 16.8 60.9 54.8 10.5 45.2 63.2 38.3 40.9 18.7 35.9 31.1 72.7 47.7 26.8 45.1 29.9 109.6 34.0 42.1 61.8 57.8 52.2 37.2 56.0 45.5 48.9 12.8 14.0 20.0 34.3 36.7 70.4 7.6 31.9 16.4 7.2 22.2 4.5 11.0 8.1 9.2 32.0 11.0 9.8 6.5 49.1 7.3 22.1 18.2 11.8 10.7 71.0 64.0 42.1 93.0 73.8 59.8 76.7 60.9 54.9 47.1 137.0 112.5 192.8 745.4 829.8 84.3 183.1 481.6 92.3 104.6 338.5 23.6 691.3 454.3 121.1 58.5 522.9 706.2 303.7 149.3 914.8 466.9 1152.5 132.3 288.4 738.1 138.2 323.2 535.2 736.9 43.7 441.0 745.3 435.3 408.4 531.5 280.9 231.2 471.0 444.5 611.5 54.4 472.1 495.6 210.1 328.6 1004.1 707.0 194.1 436.1 1582.5 RAD21 "hHR21, KIAA0078, SCC1" ENSG00000164754 "RAD21 cohesin complex component" O60216 8 116845935-116874866 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Apoptosis, Cell cycle, Cell division, Chromosome partition, DNA damage, DNA repair, Mitosis, Transcription, Transcription regulation" "Activator, Developmental protein, Repressor" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA020044, CAB022065" Supported Enhanced Nucleoplasm NA Yes Nucleoplasm "CAB022065: , HPA020044: AB_1856035" "unprognostic (7.85e-2)" "unprognostic (4.92e-1)" "unprognostic (3.05e-1)" "unprognostic (5.43e-3)" "unprognostic (9.56e-2)" "unprognostic (3.50e-1)" "prognostic unfavorable (1.71e-4)" "unprognostic (1.86e-3)" "unprognostic (8.99e-2)" "unprognostic (8.80e-2)" "unprognostic (5.58e-3)" "unprognostic (3.56e-2)" "unprognostic (4.40e-2)" "unprognostic (2.00e-1)" "unprognostic (1.82e-1)" "unprognostic (1.39e-1)" "unprognostic (1.95e-1)" 31.6 40.9 48.2 30.5 52.2 78.5 37.7 58.8 55.3 24.2 36.3 37.5 21.5 24.8 30.5 25.3 32.1 23.1 22.0 37.8 45.6 44.1 30.5 27.9 29.6 49.2 54.3 35.4 33.5 18.2 29.1 30.0 38.9 45.5 26.5 37.3 19.0 25.3 31.0 37.8 24.0 26.0 33.4 49.7 31.2 31.5 37.6 56.2 58.3 41.9 20.9 50.4 37.1 36.0 8.7 5.4 17.9 7.1 8.0 25.4 6.2 41.6 20.5 40.2 22.5 20.2 17.5 18.0 29.0 27.5 32.2 29.8 16.8 39.3 61.6 16.0 20.6 17.2 23.3 34.2 18.7 37.8 81.7 21.9 62.8 25.2 21.3 12.7 20.1 37.0 14.9 15.4 18.8 22.8 21.3 25.1 89.9 25.2 86.3 27.7 25.1 92.1 11.9 23.6 53.8 25.9 33.8 29.2 30.9 19.2 24.5 50.8 26.2 30.4 82.1 19.6 22.0 34.4 24.9 18.4 22.8 33.4 23.8 30.3 45.7 52.5 55.5 19.5 29.0 27.2 17.2 4.5 15.5 11.0 5.3 11.2 8.7 12.9 13.0 5.4 8.3 13.5 13.0 17.9 8.0 7.1 4.5 25.4 6.2 48.2 52.2 58.8 55.3 45.6 44.1 54.3 35.4 45.5 56.2 238.2 123.7 70.9 67.0 84.9 73.4 149.3 48.4 87.0 138.8 52.4 29.5 106.6 36.5 47.5 247.8 88.8 56.4 70.0 38.8 119.7 73.7 80.6 143.9 61.8 58.9 63.5 81.0 64.4 91.5 303.2 107.9 82.3 65.8 97.4 62.9 99.6 49.1 57.5 100.0 50.1 60.7 71.1 54.7 31.6 81.6 87.8 95.1 93.8 69.2 65.3 RB1 "OSRC, PPP1R130, RB" ENSG00000139687 "RB transcriptional corepressor 1" P06400 13 48303726-48599436 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cell cycle, Host-virus interaction, Transcription, Transcription regulation" "Chromatin regulator, DNA-binding, Repressor" "Cancer-related genes, Disease mutation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 4 "monocytes: 107.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "MOLT-4: 58.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000095, CAB016687, HPA050082" Supported Supported Nucleoplasm NA NA Nucleoplasm "CAB000095: , CAB016687: AB_1622010, HPA050082: AB_2681008" "unprognostic (4.24e-3)" "unprognostic (1.00e-1)" "unprognostic (3.62e-2)" "unprognostic (4.67e-2)" "unprognostic (2.04e-2)" "unprognostic (3.86e-1)" "unprognostic (4.69e-2)" "unprognostic (7.08e-2)" "unprognostic (1.59e-1)" "prognostic unfavorable (6.92e-4)" "unprognostic (4.06e-2)" "unprognostic (9.40e-2)" "unprognostic (4.67e-2)" "unprognostic (1.79e-1)" "unprognostic (9.99e-2)" "unprognostic (2.31e-1)" "unprognostic (1.70e-1)" 19.6 21.5 14.9 23.2 18.4 14.7 28.1 25.6 19.4 18.0 13.2 11.5 19.0 12.3 16.8 19.5 27.9 12.7 15.3 19.5 15.4 15.3 18.1 12.1 25.4 30.1 17.0 11.8 15.2 11.6 12.8 17.2 21.5 16.0 15.5 15.3 11.6 20.0 17.4 27.9 20.3 14.3 16.8 23.6 29.4 13.7 14.4 15.3 39.1 19.9 15.8 25.3 17.4 23.6 20.5 10.3 13.2 12.2 3.6 4.6 4.0 9.1 4.9 13.5 14.5 6.7 7.8 6.1 18.0 15.0 19.0 16.2 4.2 16.2 11.8 4.2 12.0 10.5 12.7 17.5 14.5 29.0 16.5 6.7 21.7 10.2 7.2 7.1 18.6 20.6 4.3 8.9 12.3 15.8 15.9 13.1 29.2 7.2 9.7 21.7 4.3 58.2 9.4 6.6 20.8 5.4 25.0 13.5 13.5 19.7 8.9 0.6 13.8 17.8 8.9 14.7 12.5 9.7 24.3 10.1 11.8 7.7 14.3 16.2 4.3 1.2 0.1 6.2 11.7 15.9 11.0 9.7 5.0 4.6 12.2 3.7 17.4 3.8 4.6 9.3 20.5 3.2 3.8 13.2 3.6 12.1 10.3 4.5 4.0 14.9 18.4 25.6 19.4 15.4 15.3 17.0 11.8 16.0 15.3 3.0 18.7 56.5 18.3 25.2 14.4 15.9 17.8 20.1 14.8 29.6 27.5 5.9 13.3 15.8 20.6 33.6 15.9 0.0 10.4 8.0 15.4 21.4 11.5 14.7 64.6 17.5 16.8 38.6 83.9 10.6 24.2 88.8 25.3 107.4 18.5 21.8 13.3 9.9 26.9 21.1 18.5 19.4 20.6 27.9 14.3 33.4 3.7 20.8 15.0 14.4 RBM10 "DXS8237E, GPATC9, GPATCH9, KIAA0122, ZRANB5" ENSG00000182872 "RNA binding motif protein 10" P98175 X 47144869-47186813 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "mRNA processing, mRNA splicing" RNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA034972, HPA057372" Approved Enhanced "Nuclear speckles" NA NA "Nuclear speckles" "HPA034972: AB_10602919, HPA057372: AB_2683421" "unprognostic (9.07e-2)" "prognostic favorable (6.71e-4)" "unprognostic (7.83e-2)" "unprognostic (1.61e-2)" "unprognostic (1.86e-1)" "unprognostic (3.04e-2)" "unprognostic (4.47e-3)" "unprognostic (8.11e-2)" "unprognostic (9.86e-3)" "unprognostic (1.76e-1)" "prognostic favorable (2.86e-6)" "unprognostic (1.18e-1)" "unprognostic (6.23e-3)" "unprognostic (3.33e-2)" "unprognostic (1.09e-1)" "unprognostic (4.40e-2)" "unprognostic (1.20e-3)" 18.1 22.2 19.8 38.0 21.9 34.0 17.1 41.2 22.9 19.9 20.5 25.7 22.7 21.8 22.1 17.3 23.7 26.2 29.1 21.7 19.8 18.3 18.4 21.6 17.1 27.2 20.1 19.2 36.4 27.4 20.1 28.3 24.9 17.9 23.5 14.2 18.5 25.1 28.8 20.6 23.8 23.7 18.9 17.2 24.7 20.5 8.7 21.4 32.9 26.8 18.0 22.7 17.6 20.9 15.9 14.6 14.4 19.2 12.3 18.3 11.5 20.9 22.7 21.8 25.8 11.7 9.6 25.3 16.0 9.4 16.5 16.1 19.8 17.2 25.6 9.8 11.0 21.1 20.5 28.4 20.1 9.1 26.0 25.7 19.1 27.6 20.7 17.1 19.3 23.1 12.6 9.7 27.3 22.2 11.9 17.7 24.8 15.9 20.6 10.0 32.0 35.4 32.8 35.9 15.8 25.5 31.3 18.2 26.4 12.2 18.6 25.9 19.7 24.1 18.1 15.3 13.5 22.2 19.3 15.4 19.5 24.8 21.0 16.7 21.7 17.5 21.1 17.3 14.0 27.2 14.0 10.8 14.4 18.3 14.5 17.0 15.9 14.7 15.3 12.3 15.6 14.8 14.1 10.1 12.3 19.2 14.6 16.6 11.5 19.8 21.9 41.2 21.9 19.8 18.3 20.1 19.2 17.9 21.4 38.7 44.1 14.3 20.3 9.8 26.5 30.9 25.5 30.8 36.4 8.7 13.7 27.7 10.0 17.2 0.6 18.8 24.8 0.0 15.2 23.9 18.1 14.5 23.1 19.8 16.9 20.6 34.3 14.7 12.9 1.6 16.7 11.8 15.1 18.0 24.9 14.0 16.8 18.6 24.1 11.5 25.3 0.0 16.9 5.7 6.1 9.3 38.6 17.5 23.4 16.5 RET "CDHF12, CDHR16, HSCR1, MEN2A, MEN2B, MTC1, PTC, RET51" ENSG00000165731 "Ret proto-oncogene" P07949 10 43077027-43130351 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Hirschsprung disease, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "parathyroid gland: 63.9" "Cell type enriched" "Detected in some" 44 "Horizontal cells: 74.7" "Cancer enhanced" "Detected in many" "breast cancer: 11.0" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in some" "non-classical monocyte: 6.7" "Group enriched" "Detected in many" 13 "dendritic cells: 2.1;monocytes: 6.7" "Cell line enhanced" "Detected in some" "MCF7: 18.0;NB-4: 11.8;SH-SY5Y: 91.8;THP-1: 27.4" "Low region specificity" "Detected in many" "Region enriched" "Detected in all" 6 "midbrain: 95.5" "CAB002581, HPA008356, HPA008495" Approved Supported Approved "Golgi apparatus,Plasma membrane,Cytosol" No NA 260000 "Golgi apparatus, Cytosol" "Plasma membrane" "CAB002581: AB_563673, HPA008356: AB_1847232, HPA008495: " "unprognostic (7.94e-2)" "unprognostic (3.68e-2)" "unprognostic (4.49e-1)" "prognostic unfavorable (5.02e-4)" "unprognostic (1.15e-1)" "unprognostic (9.13e-4)" "unprognostic (1.27e-2)" "unprognostic (3.62e-2)" "unprognostic (2.86e-1)" "unprognostic (2.01e-1)" "unprognostic (1.54e-3)" "unprognostic (4.43e-1)" "unprognostic (9.35e-5)" "unprognostic (1.64e-3)" "unprognostic (8.28e-2)" "unprognostic (3.67e-3)" "unprognostic (2.02e-2)" 1.8 15.2 1.1 1.8 1.3 0.7 1.2 4.1 9.0 1.9 3.1 0.9 1.1 1.5 0.9 0.6 1.2 0.7 1.0 1.2 1.5 5.8 1.0 11.7 0.7 0.8 17.5 1.2 0.8 1.3 63.9 6.3 0.8 16.8 2.2 1.5 2.8 13.6 2.0 4.5 1.1 2.6 1.1 2.8 0.6 2.1 2.0 0.0 0.1 0.8 5.1 0.6 1.9 1.4 0.2 2.1 0.0 6.7 0.0 0.3 0.4 0.0 0.1 0.0 0.5 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.4 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 18.0 0.0 11.8 2.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 91.8 0.0 0.0 0.0 0.1 1.3 27.4 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 1.8 0.0 0.2 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 6.7 2.1 0.3 0.4 1.1 1.3 4.1 9.0 1.5 5.8 17.5 1.2 16.8 0.0 0.0 0.3 0.0 0.5 0.2 0.1 1.6 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.1 0.0 0.0 0.2 1.7 1.0 1.2 1.1 0.8 0.1 74.7 0.0 0.0 0.0 1.4 0.3 0.0 0.0 0.0 0.8 0.3 0.0 0.0 0.0 0.0 0.4 0.0 1.4 0.4 1.1 0.5 0.0 0.0 0.0 0.1 RHOA "ARH12, ARHA, Rho12, RhoA, RHOH12" ENSG00000067560 "Ras homolog family member A" P61586 3 49359145-49412998 "Cancer-related genes, Predicted intracellular proteins, RAS pathway related proteins" "Cell cycle, Cell division, Host-virus interaction" Hydrolase "Cancer-related genes, Disease mutation, Ectodermal dysplasia, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB005052 Approved Supported "Plasma membrane,Cytosol" NA NA 65000000 "Plasma membrane, Cytosol" "CAB005052: AB_562216" "unprognostic (1.50e-1)" "unprognostic (3.38e-1)" "prognostic favorable (3.08e-4)" "unprognostic (8.75e-2)" "unprognostic (1.63e-1)" "unprognostic (1.24e-1)" "prognostic unfavorable (9.15e-4)" "unprognostic (1.39e-1)" "unprognostic (8.83e-2)" "unprognostic (9.44e-3)" "unprognostic (2.21e-2)" "unprognostic (4.29e-2)" "prognostic favorable (3.21e-6)" "unprognostic (5.14e-2)" "unprognostic (7.50e-2)" "unprognostic (1.57e-1)" "unprognostic (4.52e-2)" 141.1 89.5 63.0 79.8 60.6 91.4 93.1 34.3 77.3 80.3 79.1 100.4 48.9 63.6 84.4 66.4 116.7 67.8 74.2 72.5 57.6 54.8 104.0 80.7 104.6 102.4 74.0 43.8 102.7 64.9 45.8 48.2 105.3 68.8 76.0 80.3 81.6 66.5 72.0 86.0 73.9 90.8 88.9 97.3 116.0 73.4 57.3 60.3 127.1 108.1 80.1 99.8 103.4 75.7 42.6 78.4 124.2 125.7 38.3 50.5 151.5 55.7 43.0 54.0 57.9 62.0 94.0 42.2 121.4 77.8 84.9 78.3 36.4 58.5 81.8 34.9 145.8 49.3 31.8 59.3 66.2 87.2 63.1 35.3 78.1 57.9 42.7 66.5 77.0 58.6 73.4 47.1 69.4 55.9 85.8 108.6 43.5 41.6 51.5 100.6 26.6 83.8 75.1 51.6 56.0 54.8 38.8 54.3 64.3 73.4 63.7 19.8 45.1 72.9 52.8 54.7 55.8 34.2 86.8 117.2 68.2 61.8 89.9 87.2 51.2 103.7 93.9 66.4 75.8 77.8 52.5 99.7 106.8 49.1 125.7 41.6 42.6 41.4 47.6 78.4 37.5 32.2 40.1 124.2 38.3 120.4 58.7 50.5 151.5 63.0 60.6 34.3 77.3 57.6 54.8 74.0 43.8 68.8 60.3 360.3 233.2 266.1 228.8 240.6 42.2 113.5 155.4 182.0 182.0 171.0 5.9 328.4 288.5 303.4 30.3 372.7 339.7 93.5 302.0 572.5 345.6 260.3 251.7 153.0 691.2 77.9 225.0 312.5 712.8 42.2 310.4 490.6 310.4 582.5 261.8 172.7 313.0 270.7 383.3 255.4 33.0 271.7 354.1 227.5 221.8 244.4 439.3 304.1 267.8 270.4 RNF43 "DKFZp781H0392, FLJ20315, URCC" ENSG00000108375 "Ring finger protein 43" Q68DV7 17 58352500-58417595 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins" "Ubl conjugation pathway, Wnt signaling pathway" "Developmental protein, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" 7 "Enterocytes: 33.4;Mucus-secreting cells: 39.0;Undifferentiated cells: 47.8" "Cancer enhanced" "Detected in many" "colorectal cancer: 41.7" "Region enriched" "Detected in many" 7 "cerebellum: 30.6" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "CACO-2: 13.4;Hep G2: 26.2;OE19: 29.2" "Low region specificity" "Detected in many" "Not detected" "Not detected" HPA008079 Uncertain NA NA "HPA008079: AB_1856371" "unprognostic (2.53e-1)" "unprognostic (1.09e-1)" "unprognostic (7.46e-2)" "unprognostic (2.56e-1)" "unprognostic (1.10e-1)" "unprognostic (4.33e-2)" "unprognostic (1.39e-1)" "unprognostic (3.62e-1)" "unprognostic (2.93e-1)" "unprognostic (1.05e-1)" "unprognostic (5.69e-2)" "unprognostic (3.79e-1)" "prognostic favorable (6.04e-9)" "unprognostic (3.61e-3)" "unprognostic (2.56e-1)" "unprognostic (3.58e-1)" "unprognostic (1.04e-2)" 0.4 9.4 2.2 6.2 3.5 1.9 4.5 30.6 4.3 3.4 26.4 0.9 21.3 18.5 1.7 9.1 10.0 3.9 8.1 3.3 1.9 1.3 8.0 7.0 6.1 2.7 0.8 1.1 1.6 13.2 3.0 13.3 8.7 4.1 8.0 16.3 3.8 13.7 19.0 0.5 8.9 29.0 0.9 0.8 0.9 4.9 3.1 0.7 3.0 1.8 5.7 6.6 4.0 4.4 0.9 1.1 1.7 1.8 5.6 3.6 1.2 0.6 9.3 1.7 0.0 0.0 0.0 5.2 0.0 0.0 0.0 0.0 13.4 4.5 3.8 4.8 0.0 1.1 2.6 0.3 3.6 0.0 7.9 6.5 3.0 0.4 26.2 0.0 3.7 2.7 0.0 7.4 0.0 1.1 0.5 0.0 1.2 0.2 3.3 0.0 0.1 2.0 3.5 0.2 29.2 0.6 6.2 0.0 2.0 3.3 5.1 1.0 0.3 0.8 0.4 0.3 3.2 1.1 1.0 0.0 0.1 1.1 0.0 0.0 3.4 1.6 2.9 0.3 0.4 2.2 1.7 0.2 1.6 3.1 0.8 3.2 0.9 2.5 3.6 0.4 0.9 2.3 3.0 0.8 5.6 1.8 1.1 1.2 1.2 2.2 3.5 30.6 4.3 1.9 1.3 0.8 1.1 4.1 0.7 3.0 6.2 0.5 15.7 8.5 2.4 3.5 10.2 4.0 3.4 17.4 2.0 19.4 13.3 5.6 1.2 0.7 33.4 0.0 2.4 2.2 0.6 8.7 0.0 8.7 2.3 4.8 14.9 0.6 0.6 1.3 0.3 0.7 13.5 2.8 39.0 11.7 4.5 24.6 0.4 2.2 2.8 0.0 0.4 1.1 0.5 5.4 4.9 3.9 47.8 5.4 RPL10 "DXS648, DXS648E, FLJ23544, L10, NOV, QM" ENSG00000147403 "Ribosomal protein L10" P27635 X 154389955-154409168 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins" "Translation regulation" "Developmental protein, Ribonucleoprotein, Ribosomal protein" "Autism, Autism spectrum disorder, Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "CAB010339, HPA011311" Enhanced Enhanced "Endoplasmic reticulum,Cytosol" NA NA 130000 "Endoplasmic reticulum, Cytosol" "CAB010339: AB_2181277, HPA011311: AB_1856431" "unprognostic (2.46e-3)" "unprognostic (3.57e-2)" "unprognostic (1.72e-1)" "unprognostic (2.14e-2)" "unprognostic (1.25e-2)" "unprognostic (2.06e-1)" "unprognostic (6.11e-2)" "unprognostic (9.01e-3)" "unprognostic (1.91e-1)" "unprognostic (2.21e-1)" "unprognostic (5.39e-2)" "unprognostic (3.37e-1)" "prognostic unfavorable (7.67e-6)" "unprognostic (6.84e-2)" "unprognostic (1.86e-1)" "unprognostic (1.65e-2)" "unprognostic (5.68e-2)" 103.6 65.3 41.4 108.0 48.5 103.7 152.6 82.4 70.7 118.2 80.6 44.6 107.8 51.3 100.4 75.5 105.2 122.3 52.6 82.5 38.2 31.9 112.1 155.0 97.6 190.2 48.2 37.4 223.5 242.3 35.0 51.9 87.4 53.1 83.6 77.1 66.7 109.9 101.5 125.9 121.8 108.9 78.7 51.4 93.9 90.5 33.9 47.2 158.9 198.9 137.9 134.4 86.9 119.3 252.9 168.6 64.4 124.1 149.1 304.9 445.3 190.6 88.4 88.6 67.9 201.2 381.1 78.4 73.4 170.1 141.3 179.7 78.4 85.8 378.1 177.6 122.3 139.8 74.1 173.4 175.7 121.4 83.0 137.5 51.0 63.4 85.9 236.7 109.5 75.5 287.6 278.2 84.9 265.3 244.2 221.6 161.8 71.8 120.9 137.9 95.7 119.3 106.6 69.8 188.1 152.9 143.1 84.0 210.1 154.1 68.1 71.1 118.8 17.7 156.2 216.7 89.4 56.8 153.2 106.6 49.4 94.0 111.2 162.3 287.9 207.9 376.0 75.1 158.2 61.7 64.4 124.1 18.1 149.9 107.7 256.2 252.9 251.6 186.2 151.2 243.2 304.9 231.1 13.0 149.1 94.9 168.6 178.0 445.3 41.4 48.5 82.4 70.7 38.2 31.9 48.2 37.4 53.1 47.2 1664.5 2043.1 10322.4 11239.3 10721.6 451.7 309.0 3949.0 1271.5 2545.5 1934.9 233.7 5960.7 5721.4 3854.4 49.9 6113.6 2058.8 1915.6 11641.3 8484.3 6948.0 9869.1 2815.7 3204.1 6194.0 254.3 2785.1 5085.5 7653.2 131.8 7835.9 9465.3 7747.1 9437.5 6244.9 793.3 8332.0 5018.5 3353.3 5769.1 609.3 2942.7 9122.3 99.1 315.1 12724.6 6324.6 8194.7 7230.3 10693.0 RPL5 "L5, PPP1R135" ENSG00000122406 "Ribosomal protein L5" P46777 1 92831983-92841924 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins" "Ribonucleoprotein, Ribosomal protein, RNA-binding, rRNA-binding" "Cancer-related genes, Diamond-Blackfan anemia, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "HPA043717, HPA054444" Approved Supported "Nucleoli,Nucleoli rim,Endoplasmic reticulum,Cytosol" NA NA 130000 "Endoplasmic reticulum, Cytosol" "Nucleoli, Nucleoli rim" "HPA043717: AB_10964719, HPA054444: AB_2732584" "unprognostic (5.81e-3)" "unprognostic (3.96e-1)" "unprognostic (1.04e-1)" "unprognostic (1.52e-1)" "unprognostic (9.44e-3)" "unprognostic (1.96e-1)" "unprognostic (1.03e-3)" "unprognostic (9.95e-2)" "unprognostic (8.68e-2)" "unprognostic (1.23e-1)" "unprognostic (3.98e-2)" "unprognostic (3.48e-1)" "prognostic unfavorable (6.81e-5)" "unprognostic (2.26e-2)" "unprognostic (3.12e-2)" "unprognostic (1.09e-1)" "unprognostic (3.97e-1)" 119.4 80.3 50.0 70.0 50.1 113.8 140.5 46.9 46.8 158.6 111.4 45.0 75.1 61.7 135.2 114.6 159.4 100.5 73.1 73.0 43.5 43.1 99.7 114.9 89.9 148.2 54.5 36.2 296.8 306.5 40.8 90.3 90.2 44.3 175.4 78.8 64.3 121.5 73.2 109.1 97.8 95.3 153.4 61.9 130.1 90.0 68.8 45.7 156.6 210.0 97.7 118.9 191.2 146.6 104.5 85.2 12.8 45.9 72.4 143.0 142.1 118.8 51.1 91.0 76.7 118.4 239.2 146.0 71.1 95.2 88.5 63.5 135.2 52.0 224.2 114.2 79.8 84.0 76.0 104.3 133.2 113.2 71.0 142.8 116.3 85.0 124.4 142.0 178.1 49.1 195.6 210.2 78.6 173.1 160.6 122.3 118.5 144.0 118.2 101.4 67.4 141.8 201.9 140.6 90.4 96.5 130.3 176.3 144.8 107.4 99.0 77.6 92.9 46.3 129.2 206.7 78.2 71.2 245.0 74.2 44.7 81.8 84.6 128.1 73.2 69.5 151.7 30.3 153.6 30.3 12.8 45.9 7.2 60.9 44.8 122.1 104.5 111.5 91.6 85.2 88.4 143.0 123.9 4.4 72.4 38.3 71.1 83.2 142.1 50.0 50.1 46.9 46.8 43.5 43.1 54.5 36.2 44.3 45.7 607.4 848.7 2690.4 3540.6 2525.4 316.8 352.2 1200.0 674.6 1189.7 390.8 84.4 2237.8 1689.4 1278.7 1159.8 1643.6 564.1 537.3 2338.5 3530.6 1572.9 2535.7 1002.7 856.3 1297.7 138.2 1189.1 1198.2 1468.3 888.7 2620.2 1565.9 1334.5 1646.5 1585.6 343.0 1936.2 1164.3 2027.0 1766.3 226.7 1034.8 1885.9 531.9 457.4 2528.9 2185.2 1965.9 2487.8 3230.9 SALL4 "dJ1112F19.1, ZNF797" ENSG00000101115 "Spalt like transcription factor 4" Q9UJQ4 20 51782331-51802520 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" DNA-binding "Cancer-related genes, Disease mutation, Oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "parathyroid gland: 8.8;testis: 11.7;thyroid gland: 8.6" "Cell type enriched" "Detected in some" 7 "Horizontal cells: 25.4" "Cancer enriched" "Detected in many" 11 "testis cancer: 22.7" "Not detected" "Not detected" "Cell type enriched" "Detected in single" 9 "NK-cell: 6.3" "Lineage enriched" "Detected in single" 9 "NK-cells: 6.3" "Cell line enhanced" "Detected in some" "AF22: 13.1;AN3-CA: 9.1;BEWO: 17.5;NTERA-2: 31.5;SiHa: 8.0;SuSa: 22.0" "Not detected" "Not detected" "Low region specificity" "Detected in all" "HPA015291, HPA015791" Enhanced Enhanced Nucleoplasm Yes No Nucleoplasm "HPA015291: AB_1856548, HPA015791: AB_1856547" "unprognostic (1.30e-1)" "unprognostic (2.35e-2)" "unprognostic (1.11e-1)" "unprognostic (1.09e-3)" "unprognostic (3.55e-2)" "unprognostic (7.43e-2)" "unprognostic (3.63e-2)" "unprognostic (1.47e-1)" "unprognostic (1.20e-1)" "unprognostic (9.23e-2)" "unprognostic (2.50e-2)" "unprognostic (2.39e-2)" "unprognostic (2.42e-8)" "unprognostic (5.90e-3)" "unprognostic (1.82e-1)" "unprognostic (5.00e-5)" "unprognostic (7.41e-2)" 0.3 0.4 0.3 0.3 0.9 1.2 0.3 0.8 0.9 0.4 0.7 0.3 2.2 0.1 0.3 0.8 0.3 0.2 0.3 0.3 0.3 0.1 0.5 1.9 0.3 0.3 0.3 0.3 0.3 4.6 8.8 0.6 0.3 0.9 3.1 0.2 4.5 2.2 0.4 0.3 0.3 0.7 0.3 0.3 0.8 0.3 11.7 0.3 0.3 8.6 0.3 0.3 0.9 0.3 0.1 0.1 0.6 0.1 6.3 0.2 0.0 0.0 0.8 13.1 9.1 0.0 0.0 17.5 0.0 0.1 0.0 0.1 4.5 0.1 0.0 0.1 0.1 0.1 2.2 0.1 0.0 0.1 0.2 0.0 0.0 3.0 0.2 0.1 0.0 1.0 0.4 0.2 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.9 0.0 0.0 31.5 0.1 0.2 1.2 0.0 0.0 0.0 0.2 3.0 1.6 8.0 0.0 0.7 22.0 0.0 0.5 0.0 0.5 1.8 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.2 0.0 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.6 6.3 0.1 0.1 0.0 0.0 0.3 0.9 0.8 0.9 0.3 0.1 0.3 0.3 0.9 0.3 0.0 1.3 0.0 0.7 0.0 0.1 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.5 0.0 0.0 0.0 0.0 0.2 0.0 0.4 1.1 0.0 0.0 0.2 25.4 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.4 0.0 0.0 0.5 1.7 0.0 0.0 0.0 0.0 1.0 SDHA "FP, SDH2, SDHF" ENSG00000073578 "Succinate dehydrogenase complex flavoprotein subunit A" P31040 5 218241-256700 "Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Electron transport, Transport, Tricarboxylic acid cycle" Oxidoreductase "Cancer-related genes, Cardiomyopathy, Disease mutation, FDA approved drug targets, Leigh syndrome, Primary mitochondrial disease, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "heart muscle: 100.1;skeletal muscle: 114.0" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB034929, HPA041981, HPA064582" Enhanced Supported Nucleoli,Mitochondria No No 780000 Mitochondria Nucleoli "CAB034929: AB_2183443, HPA041981: AB_2677779, HPA064582: AB_2685293" "prognostic unfavorable (6.00e-4)" "unprognostic (1.93e-1)" "unprognostic (5.97e-2)" "unprognostic (1.36e-1)" "unprognostic (1.89e-1)" "unprognostic (1.62e-1)" "unprognostic (2.80e-1)" "unprognostic (3.14e-2)" "unprognostic (2.88e-1)" "unprognostic (1.67e-2)" "unprognostic (1.97e-1)" "unprognostic (1.24e-1)" "prognostic favorable (9.53e-8)" "unprognostic (1.11e-2)" "unprognostic (2.62e-1)" "unprognostic (3.57e-1)" "unprognostic (1.79e-1)" 17.6 31.4 15.3 11.5 20.3 10.6 12.8 18.8 29.0 10.2 29.4 17.3 10.0 44.3 11.3 12.1 15.3 12.6 14.8 100.1 15.8 14.5 36.5 55.4 10.7 11.7 19.6 19.3 14.5 14.7 23.2 9.5 9.2 29.7 10.7 24.6 14.5 17.3 12.0 114.0 11.5 39.9 16.5 13.2 13.9 21.2 14.6 14.8 15.7 12.5 39.6 12.5 13.2 11.1 28.3 31.9 29.1 29.2 27.1 48.9 32.4 18.7 30.4 12.5 20.4 21.6 16.2 34.0 14.5 18.4 25.0 25.5 32.9 25.6 23.2 45.8 16.5 18.9 24.3 22.1 29.6 14.8 49.4 20.2 11.8 84.1 42.8 13.4 14.7 15.4 16.1 19.0 18.6 9.9 19.9 27.0 16.6 19.0 19.3 11.7 28.7 19.4 39.7 4.3 20.5 38.6 25.1 18.2 45.0 53.1 24.9 13.8 7.9 68.2 44.1 17.9 8.1 26.7 18.6 19.5 18.5 18.2 11.0 11.9 20.6 8.8 17.1 17.9 21.2 11.7 17.8 24.4 29.1 36.4 29.2 32.1 28.3 34.8 35.1 31.9 24.5 34.5 31.7 5.9 27.1 24.1 20.5 48.9 32.4 15.3 20.3 18.8 29.0 15.8 14.5 19.6 19.3 29.7 14.8 32.8 63.8 52.9 58.0 54.4 45.7 238.2 76.5 58.9 40.9 71.5 96.2 94.1 121.0 78.8 32.8 37.6 207.8 0.0 39.4 87.2 53.2 29.4 42.7 135.6 60.4 95.3 45.6 43.0 39.1 20.2 63.3 43.9 86.0 78.5 75.8 40.3 44.9 92.8 52.3 129.8 77.8 77.6 45.0 66.5 55.1 31.5 129.4 59.9 128.8 78.3 SDHB "SDH, SDH1" ENSG00000117118 "Succinate dehydrogenase complex iron sulfur subunit B" P21912 1 17018722-17054170 "Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Electron transport, Transport, Tricarboxylic acid cycle" Oxidoreductase "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" 4 "Cardiomyocytes: 395.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA002868, CAB009822, CAB068233, CAB068234, CAB068235" Enhanced Supported "Nucleoplasm,Plasma membrane,Mitochondria" "Intracellular and membrane" NA NA Mitochondria "Nucleoplasm, Plasma membrane" "CAB009822: AB_2183458, CAB068233: AB_2665638, CAB068234: AB_2665639, CAB068235: AB_2665640, HPA002868: AB_1079889" "unprognostic (1.06e-1)" "unprognostic (2.86e-2)" "unprognostic (2.19e-2)" "unprognostic (2.93e-2)" "unprognostic (1.88e-1)" "unprognostic (2.79e-3)" "unprognostic (1.58e-1)" "unprognostic (3.02e-1)" "unprognostic (1.19e-1)" "unprognostic (8.45e-2)" "unprognostic (5.51e-2)" "unprognostic (3.93e-2)" "prognostic favorable (2.93e-7)" "unprognostic (1.46e-1)" "unprognostic (2.75e-1)" "unprognostic (7.82e-2)" "unprognostic (3.82e-2)" 17.8 25.6 19.8 16.6 21.7 17.0 26.4 18.0 29.1 13.9 30.8 12.3 15.1 34.0 14.2 15.7 19.8 13.6 15.1 86.9 18.2 16.4 51.0 75.1 16.8 24.6 20.1 18.9 10.5 30.7 20.0 11.3 15.6 16.7 13.0 31.5 11.7 15.9 19.5 96.2 13.2 31.4 21.3 16.5 17.2 21.7 18.7 15.7 14.2 15.5 52.2 18.0 15.4 17.1 22.2 45.9 48.5 48.7 18.9 26.7 25.0 26.0 25.8 14.7 18.8 28.7 28.5 16.8 22.8 29.3 52.3 47.2 36.3 31.3 35.7 28.5 30.7 33.8 30.7 58.7 45.4 59.0 20.9 48.1 32.1 26.9 27.8 35.1 50.2 23.9 29.3 30.0 45.2 76.6 27.8 36.9 31.4 26.8 41.4 36.3 21.5 33.3 28.7 12.2 41.9 51.9 24.0 28.4 44.2 48.1 14.8 27.8 15.2 30.9 38.7 64.9 16.3 22.7 28.4 18.3 20.1 22.7 36.9 30.0 17.3 21.3 36.5 30.8 76.6 22.2 16.6 38.4 37.4 18.3 48.7 18.3 22.2 21.2 19.5 45.9 18.3 19.3 19.5 48.5 18.9 42.2 21.5 26.7 25.0 19.8 21.7 18.0 29.1 18.2 16.4 20.1 18.9 16.7 15.7 59.6 39.6 77.3 79.1 46.2 28.1 395.8 109.5 78.9 40.9 45.4 13.7 93.2 300.1 104.4 146.0 54.0 212.4 116.8 130.5 121.6 58.6 70.1 65.7 198.8 162.9 35.0 46.7 41.7 81.2 13.8 53.5 90.6 60.8 125.4 89.5 52.1 97.2 192.9 63.6 355.3 35.5 38.8 60.4 85.9 68.4 47.7 101.8 52.3 135.8 97.0 SDHC "CYB560, cybL, PGL3" ENSG00000143252 "Succinate dehydrogenase complex subunit C" Q99643 1 161314257-161375340 "Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "Electron transport, Transport, Tricarboxylic acid cycle" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" 6 "Distal tubular cells: 658.2;Proximal tubular cells: 706.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" NA NA "unprognostic (1.48e-2)" "unprognostic (6.88e-2)" "unprognostic (6.38e-3)" "unprognostic (1.86e-2)" "unprognostic (1.90e-2)" "unprognostic (5.02e-2)" "unprognostic (7.08e-2)" "unprognostic (2.33e-1)" "unprognostic (7.38e-2)" "unprognostic (1.35e-1)" "unprognostic (2.43e-2)" "unprognostic (1.29e-1)" "prognostic favorable (2.20e-4)" "unprognostic (9.14e-2)" "unprognostic (1.52e-1)" "unprognostic (4.19e-3)" "unprognostic (3.77e-1)" 36.8 49.7 25.6 17.1 27.3 14.1 24.1 14.4 36.2 20.6 29.1 31.2 17.0 34.3 22.1 19.7 35.2 21.4 19.3 35.5 21.5 21.8 65.9 75.3 17.8 20.9 28.6 20.1 20.1 17.2 28.8 17.0 19.2 28.0 20.8 28.4 23.9 28.5 21.9 98.0 21.6 33.4 23.2 24.9 21.2 24.3 17.0 16.2 25.7 35.9 45.4 22.4 20.6 19.2 31.3 60.4 28.3 48.2 29.0 38.6 47.9 29.6 21.7 30.6 26.4 40.4 32.3 33.8 32.9 26.2 25.5 19.8 32.1 36.9 8.8 42.8 33.2 22.9 34.7 40.8 34.6 29.7 31.5 40.0 20.4 20.8 32.9 23.0 37.7 21.9 34.1 28.5 29.7 20.0 31.6 26.6 31.4 28.7 8.3 41.1 28.6 26.8 21.8 30.1 66.8 23.0 28.1 29.9 37.4 53.8 29.5 21.4 36.4 39.6 74.6 47.0 38.0 60.9 47.3 23.4 17.8 27.2 25.1 28.4 43.4 53.0 52.2 26.0 24.7 34.4 27.7 48.2 28.3 36.0 44.9 38.6 31.3 32.3 35.5 60.4 30.6 36.3 35.7 23.9 29.0 38.8 44.8 35.2 47.9 25.6 27.3 14.4 36.2 21.5 21.8 28.6 20.1 28.0 16.2 41.7 50.7 84.8 120.9 55.0 71.4 87.7 163.1 97.7 59.1 143.1 60.9 207.5 658.2 185.1 14.4 65.2 106.6 23.3 127.6 211.0 62.7 94.7 56.6 206.9 208.7 68.3 64.2 75.5 101.7 25.9 95.3 83.6 123.2 205.6 95.6 90.0 123.2 105.2 102.6 706.4 61.9 51.8 92.0 89.9 105.2 66.9 257.2 81.0 139.7 129.5 SDHD "cybS, PGL, PGL1" ENSG00000204370 "Succinate dehydrogenase complex subunit D" O14521 11 112086773-112120013 "Cancer-related genes, Citric acid cycle related proteins, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Electron transport, Transport, Tricarboxylic acid cycle" "Cancer-related genes, Disease mutation, FDA approved drug targets, Primary mitochondrial disease" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" 5 "Distal tubular cells: 449.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" HPA045727 Approved "Intracellular and membrane" NA NA "HPA045727: AB_10963114" "unprognostic (9.13e-2)" "unprognostic (3.51e-2)" "unprognostic (4.47e-3)" "unprognostic (4.21e-2)" "unprognostic (1.93e-1)" "unprognostic (4.98e-2)" "unprognostic (5.69e-2)" "unprognostic (2.50e-1)" "unprognostic (1.83e-3)" "unprognostic (7.10e-2)" "unprognostic (3.03e-2)" "unprognostic (1.80e-1)" "prognostic favorable (1.99e-10)" "unprognostic (5.14e-2)" "unprognostic (1.58e-2)" "unprognostic (1.56e-2)" "unprognostic (7.51e-2)" 20.9 23.1 17.1 21.7 19.4 10.9 19.6 14.1 18.4 18.1 33.6 14.2 23.9 36.0 22.7 17.5 35.2 17.3 17.9 42.5 15.1 13.7 66.6 75.4 19.1 23.3 17.1 15.1 18.6 23.2 22.5 16.1 20.1 18.0 23.7 33.9 15.7 32.6 21.7 65.4 15.5 61.2 24.0 15.3 22.8 22.2 8.8 14.8 21.7 46.2 33.9 24.6 23.5 20.3 55.5 74.7 62.1 91.7 46.1 53.7 68.9 16.7 17.2 11.7 17.7 43.8 35.2 19.7 20.4 29.0 21.4 26.9 59.4 43.9 30.4 63.1 27.5 31.7 42.0 36.5 28.9 26.3 27.0 18.3 28.9 12.8 31.5 34.1 45.5 22.0 38.8 32.0 25.5 40.8 25.6 30.1 22.0 29.8 42.0 26.5 21.0 27.3 41.2 15.8 64.5 42.6 25.3 31.1 56.7 43.8 40.9 16.9 11.2 28.6 38.7 20.3 17.7 39.8 32.8 23.5 20.9 27.4 23.2 18.7 12.5 16.0 55.7 11.9 59.6 19.9 46.1 73.0 48.7 41.4 91.7 44.1 55.5 44.5 43.1 74.7 45.6 53.7 49.8 62.1 46.1 70.7 36.8 44.2 68.9 17.1 19.4 14.1 18.4 15.1 13.7 17.1 15.1 18.0 14.8 74.5 39.0 90.1 83.6 72.5 10.9 198.1 91.7 68.3 63.7 85.5 7.9 134.7 449.3 67.9 8.3 67.1 194.1 46.7 51.2 94.9 111.1 52.7 63.6 160.7 147.1 11.1 48.5 66.9 103.7 21.8 96.4 98.5 72.6 129.8 105.1 39.2 45.9 122.4 93.7 350.8 18.5 90.5 100.9 53.9 50.7 65.1 149.7 72.6 141.2 82.2 SETBP1 "KIAA0437, SEB" ENSG00000152217 "SET binding protein 1" Q9Y6X0 18 44680173-45068510 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" DNA-binding "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 7 "Leydig cells: 58.1;Peritubular cells: 37.4" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "memory B-cell: 4.9;naive B-cell: 7.5" "Low lineage specificity" "Detected in many" "Group enriched" "Detected in many" 4 "AF22: 9.5;Karpas-707: 37.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA049022, HPA057259" Uncertain Supported "Nucleoplasm,Nuclear bodies,Cytosol" NA NA Nucleoplasm "Nuclear bodies, Cytosol" "HPA049022: AB_2680602, HPA057259: AB_2683384" "unprognostic (1.25e-1)" "unprognostic (1.57e-1)" "unprognostic (1.11e-1)" "unprognostic (1.97e-2)" "unprognostic (4.63e-2)" "unprognostic (1.80e-1)" "unprognostic (1.91e-1)" "unprognostic (3.57e-2)" "unprognostic (3.49e-1)" "unprognostic (2.01e-2)" "unprognostic (2.71e-3)" "unprognostic (6.52e-2)" "prognostic favorable (6.34e-8)" "unprognostic (2.18e-2)" "unprognostic (2.29e-1)" "unprognostic (6.06e-2)" "unprognostic (7.81e-5)" 10.6 2.9 3.8 13.2 8.7 2.1 9.8 16.0 12.6 16.9 14.6 4.2 19.9 2.5 14.0 17.5 6.6 11.0 7.9 6.8 3.6 3.5 15.0 7.2 9.8 7.0 2.9 7.4 12.8 8.2 9.1 5.1 10.2 3.2 12.2 5.3 14.0 6.9 21.3 14.5 6.6 6.9 19.9 3.7 5.9 9.1 5.5 1.2 3.4 8.4 8.7 8.8 11.9 13.3 7.5 4.3 0.2 1.6 0.0 0.6 0.2 0.0 1.7 9.5 0.0 2.7 0.7 0.6 0.8 1.7 0.9 0.7 0.1 0.0 0.5 0.3 1.0 0.5 2.8 1.0 3.0 0.6 0.8 0.5 0.0 1.0 0.6 0.0 0.0 0.0 2.3 1.1 0.0 1.8 1.6 0.3 0.0 0.0 37.9 0.2 0.5 0.0 0.0 1.3 0.0 0.6 3.1 0.0 3.3 3.2 2.2 4.8 2.5 0.0 0.0 0.5 4.5 1.3 0.0 0.0 5.6 2.1 0.0 4.4 5.0 0.3 0.0 3.4 0.1 3.2 0.2 0.0 0.0 0.6 1.1 0.0 4.9 0.1 0.5 0.1 7.5 0.0 0.2 0.0 0.0 1.6 4.3 0.0 0.2 3.8 8.7 16.0 12.6 3.6 3.5 2.9 7.4 3.2 1.2 0.0 2.6 26.0 8.5 13.7 11.5 3.6 10.2 2.7 3.4 15.7 17.7 1.3 3.3 4.1 0.9 9.5 0.4 0.0 2.9 1.2 27.4 6.4 0.0 13.5 1.6 3.2 11.5 12.3 1.6 1.8 58.1 2.7 3.3 0.0 2.5 9.1 3.3 8.4 37.4 6.8 19.3 6.5 30.7 0.0 0.1 13.2 0.7 4.9 4.6 1.0 SETD2 "FLJ23184, HIF-1, HYPB, KIAA1732, KMT3A" ENSG00000181555 "SET domain containing 2" Q9BYW2 3 47016429-47163967 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Antiviral defense, Differentiation, DNA damage, DNA repair, Host-virus interaction, Immunity, Innate immunity, Transcription, Transcription regulation" "Activator, Chromatin regulator, Developmental protein, Methyltransferase, Transferase" "Autism spectrum disorder, Cancer-related genes, Disease mutation, Mental retardation, Tumor suppressor" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA042451 Approved Approved "Nuclear speckles,Cytosol" NA NA "Nuclear speckles" Cytosol "HPA042451: AB_10806239" "unprognostic (2.78e-1)" "unprognostic (1.01e-1)" "unprognostic (6.08e-2)" "unprognostic (1.01e-1)" "unprognostic (3.37e-2)" "unprognostic (1.37e-2)" "unprognostic (1.40e-2)" "unprognostic (1.01e-2)" "prognostic unfavorable (8.19e-4)" "unprognostic (6.19e-2)" "unprognostic (2.45e-1)" "unprognostic (7.84e-2)" "prognostic favorable (7.99e-6)" "unprognostic (1.03e-1)" "unprognostic (1.91e-1)" "unprognostic (8.79e-2)" "unprognostic (5.43e-2)" 13.2 10.5 12.2 15.2 15.4 20.0 11.7 22.4 16.4 13.4 14.0 9.1 12.9 9.5 15.8 7.5 10.8 11.4 8.7 8.8 10.6 6.8 11.4 10.3 10.4 11.8 11.7 9.5 16.0 13.4 21.4 16.3 10.7 11.3 12.4 10.9 7.7 12.7 14.8 27.6 12.5 11.5 11.9 9.8 13.8 10.4 12.8 12.8 23.2 15.8 5.5 12.8 16.1 15.5 4.8 2.6 6.0 2.3 7.1 3.9 1.0 11.6 9.2 15.4 7.9 9.3 10.7 6.5 10.7 10.4 12.6 11.5 9.7 7.6 25.7 6.7 14.8 12.3 7.1 16.7 10.2 17.1 14.7 6.6 26.4 15.3 7.5 7.0 19.7 15.3 9.2 9.9 12.4 15.4 10.2 11.6 13.3 16.9 9.7 10.3 6.1 14.5 2.6 11.7 5.6 7.7 9.6 15.0 13.3 6.4 15.3 6.7 10.6 18.1 7.1 6.7 11.5 7.5 14.7 14.8 13.9 10.4 11.8 17.1 12.5 13.9 26.0 8.0 11.3 8.1 2.4 2.2 5.2 3.9 2.3 2.4 3.7 2.4 3.0 2.5 4.8 3.5 3.0 6.0 7.1 1.9 2.6 1.0 1.0 12.2 15.4 22.4 16.4 10.6 6.8 11.7 9.5 11.3 12.8 44.7 53.3 20.6 20.5 29.7 33.4 58.5 22.9 66.9 80.8 10.4 39.3 16.3 10.0 17.4 24.0 29.3 26.5 0.0 19.3 10.1 20.8 25.9 55.6 26.7 14.3 25.4 21.2 23.4 27.2 20.8 28.1 21.6 16.9 20.8 27.8 21.7 20.0 17.5 31.1 9.3 37.0 12.9 21.7 78.1 18.9 31.1 15.4 27.7 24.8 34.2 SF3B1 "Hsh155, Prp10, PRPF10, SAP155, SF3b155" ENSG00000115524 "Splicing factor 3b subunit 1" O75533 2 197389784-197435091 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "mRNA processing, mRNA splicing" RNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA050275 Approved Enhanced "Nuclear speckles" NA NA 840000 "Nuclear speckles" "HPA050275: AB_2681071" "unprognostic (6.86e-2)" "unprognostic (2.78e-1)" "unprognostic (2.14e-1)" "unprognostic (3.51e-1)" "unprognostic (4.42e-2)" "unprognostic (1.25e-3)" "unprognostic (2.44e-3)" "unprognostic (3.31e-3)" "unprognostic (1.25e-2)" "unprognostic (2.20e-1)" "unprognostic (6.79e-2)" "unprognostic (1.78e-2)" "unprognostic (2.57e-2)" "unprognostic (9.15e-2)" "unprognostic (1.16e-1)" "unprognostic (1.79e-1)" "unprognostic (3.41e-2)" 53.9 49.9 36.5 54.5 44.9 88.0 57.9 60.8 47.3 72.3 54.2 44.3 45.6 36.8 64.6 72.0 50.5 53.3 43.1 39.6 34.7 26.0 49.7 50.7 53.1 65.3 56.5 27.7 73.6 60.5 66.2 81.4 64.6 46.7 50.0 51.0 37.0 54.4 45.4 49.3 48.5 67.8 41.2 50.2 88.1 48.8 33.3 53.5 113.0 53.3 38.0 65.7 62.4 56.0 32.7 41.9 41.1 37.8 39.6 45.9 29.4 30.2 27.8 62.7 34.2 48.6 49.7 52.6 42.4 43.4 37.0 45.5 53.0 32.7 57.9 28.6 43.1 38.4 29.4 62.6 34.4 58.0 44.3 38.9 61.2 68.0 62.3 36.7 65.0 44.7 51.9 33.7 38.6 47.5 63.1 43.1 38.6 43.8 40.0 41.0 26.6 59.7 62.6 49.3 34.3 44.0 52.7 53.6 38.4 51.5 77.0 35.2 43.6 40.5 24.8 29.0 81.0 24.5 49.8 43.4 29.1 25.0 29.3 30.1 36.4 59.2 83.1 27.9 39.3 32.1 27.7 33.1 39.1 37.5 37.8 40.6 32.7 32.5 35.3 41.9 30.8 33.9 33.9 41.1 39.6 36.1 23.8 45.9 29.4 36.5 44.9 60.8 47.3 34.7 26.0 56.5 27.7 46.7 53.5 166.7 222.4 88.0 131.1 105.8 96.4 104.9 73.9 257.0 221.8 87.2 68.7 93.6 48.0 91.8 6.7 106.2 77.2 46.7 82.1 86.2 104.2 87.4 231.0 63.5 87.0 89.0 106.0 112.3 145.9 14.9 111.4 119.2 72.6 130.8 98.8 119.0 91.7 60.4 98.3 63.2 88.9 116.4 99.9 81.4 93.6 103.8 119.3 119.3 74.2 125.4 SFRP4 "FRP-4, frpHE, FRZB-2" ENSG00000106483 "Secreted frizzled related protein 4" Q6FHJ7 7 37905932-38025695 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins" "Differentiation, Wnt signaling pathway" "Developmental protein" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "cervix, uterine: 144.9;endometrium 1: 100.7;retina: 123.0" "Cell type enriched" "Detected in some" 5 "Peritubular cells: 177.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in single" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "ASC diff: 14.1;HSkMC: 5.5;U-937: 5.3" "Low region specificity" "Detected in many" "Low region specificity" "Detected in some" "HPA009712, HPA050585" Enhanced "Secreted in female reproductive system" NA NA 1500000 "HPA009712: AB_1856778, HPA050585: AB_2681183" "unprognostic (5.93e-2)" "unprognostic (5.84e-3)" "unprognostic (2.75e-2)" "unprognostic (1.58e-3)" "unprognostic (2.61e-1)" "unprognostic (2.35e-2)" "unprognostic (4.02e-2)" "unprognostic (2.60e-1)" "unprognostic (1.21e-1)" "unprognostic (3.76e-2)" "unprognostic (2.12e-1)" "unprognostic (1.18e-1)" "prognostic unfavorable (1.36e-5)" "unprognostic (7.37e-3)" "unprognostic (1.61e-1)" "unprognostic (4.35e-3)" "unprognostic (1.89e-3)" 4.6 2.3 0.5 0.9 0.9 0.0 12.5 0.3 0.4 144.9 0.8 1.7 5.4 0.0 100.7 11.5 3.2 35.1 2.5 5.5 0.4 0.4 1.2 0.2 3.9 0.8 0.8 0.7 42.7 1.4 0.1 4.0 0.4 1.3 4.9 0.2 123.0 2.3 7.1 1.4 0.3 0.5 14.5 3.3 4.1 0.5 5.8 0.3 0.4 3.3 2.5 0.5 8.8 14.8 0.4 0.8 0.4 0.6 0.1 0.1 0.0 0.0 2.6 2.9 0.0 14.1 0.6 0.1 0.0 0.1 0.0 0.0 0.4 0.0 0.1 0.1 3.0 0.4 0.1 0.0 0.3 0.3 0.0 0.0 0.2 0.2 2.0 0.1 0.4 0.0 5.5 0.7 0.6 0.0 1.0 0.2 0.2 0.0 0.3 0.2 0.4 0.0 1.7 0.1 0.0 0.0 0.2 1.7 0.0 0.1 0.3 0.1 0.3 0.0 0.0 0.3 0.6 0.0 0.0 0.9 0.0 1.2 1.7 0.2 0.5 0.1 0.2 0.3 5.3 0.9 0.0 0.1 0.0 0.0 0.6 0.0 0.4 0.0 0.0 0.1 0.1 0.1 0.0 0.4 0.1 0.0 0.8 0.0 0.0 0.5 0.9 0.3 0.4 0.4 0.4 0.8 0.7 1.3 0.3 0.0 2.6 0.0 1.7 0.9 0.0 0.4 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.8 0.5 0.0 0.0 0.4 0.1 8.6 1.6 0.0 0.0 0.2 0.0 0.0 4.3 0.0 0.9 38.6 0.8 0.0 0.0 0.0 2.7 0.1 0.0 177.1 2.1 0.1 0.0 3.1 0.2 0.5 1.4 0.2 0.0 0.0 0.0 SH2B3 "IDDM20, LNK" ENSG00000111252 "SH2B adaptor protein 3" Q9UQQ2 12 111405948-111451623 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes, Diabetes mellitus" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 10 "Ito cells: 49.7;Kupffer cells: 110.0;Macrophages: 49.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HMC-1: 32.3;hTEC/SVTERT24-B: 37.0;U-87 MG: 56.2;WM-115: 42.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA005483 Approved Approved Nucleoplasm NA NA Nucleoplasm "HPA005483: AB_1079260" "unprognostic (2.77e-1)" "unprognostic (1.74e-1)" "unprognostic (1.20e-1)" "unprognostic (1.12e-1)" "unprognostic (1.18e-1)" "unprognostic (9.09e-2)" "unprognostic (1.23e-1)" "unprognostic (2.42e-1)" "unprognostic (1.18e-1)" "unprognostic (4.65e-2)" "unprognostic (8.17e-3)" "unprognostic (9.08e-2)" "prognostic unfavorable (6.20e-4)" "unprognostic (2.86e-1)" "unprognostic (3.89e-3)" "unprognostic (1.11e-1)" "unprognostic (2.24e-2)" 17.6 9.0 7.9 13.7 7.9 34.4 19.8 3.8 9.3 8.9 7.5 7.2 3.1 5.3 8.0 7.1 5.6 7.5 12.7 15.3 5.8 5.5 9.2 12.5 17.6 27.8 6.6 4.0 8.2 11.0 4.7 7.6 16.1 5.2 8.4 9.3 8.7 5.0 4.2 10.2 3.6 10.3 9.1 7.8 31.7 5.5 13.3 6.8 9.5 10.2 3.2 11.8 10.0 5.8 1.8 6.1 3.8 10.3 2.3 1.7 1.9 2.3 1.4 1.8 1.9 6.4 9.6 1.2 7.5 20.6 5.7 6.2 2.1 1.3 3.9 5.4 11.4 19.5 0.4 1.4 4.3 9.4 3.3 0.7 13.4 0.6 1.5 6.3 5.8 32.3 5.7 1.0 37.0 3.3 12.8 30.9 3.3 9.6 1.6 20.9 0.8 2.4 11.7 2.8 0.6 5.4 2.4 4.2 2.5 2.7 0.9 1.2 1.3 1.3 0.1 10.7 1.7 0.9 8.4 23.9 5.3 3.0 4.5 12.1 3.6 3.8 4.5 56.2 4.2 42.8 1.1 4.3 1.5 1.6 10.3 1.4 1.8 1.4 1.7 5.9 0.7 1.0 1.3 3.8 2.3 7.6 6.1 0.5 1.9 7.9 7.9 3.8 9.3 5.8 5.5 6.6 4.0 5.2 6.8 3.0 31.9 11.5 1.3 6.1 4.1 14.9 5.1 0.0 2.3 1.8 2.0 0.4 1.7 3.1 9.6 32.1 3.8 0.0 7.5 1.1 9.8 2.4 37.0 9.4 35.5 3.2 3.4 49.7 110.0 4.0 2.6 49.7 15.1 34.3 2.6 0.9 6.9 7.0 3.9 1.4 3.1 0.0 17.6 9.4 4.0 3.6 0.8 11.8 1.7 0.8 SIX1 DFNA23 ENSG00000126778 "SIX homeobox 1" Q15475 14 60643415-60658259 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Apoptosis, Transcription, Transcription regulation" "Activator, Developmental protein, DNA-binding, Repressor" "Cancer-related genes, Deafness, Disease mutation, Non-syndromic deafness" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "pituitary gland: 39.1;salivary gland: 55.1;skeletal muscle: 59.0" "Cell type enhanced" "Detected in some" 19 "Basal glandular cells: 23.3;Ciliated cells: 65.6;Club cells: 33.0;Glandular cells: 24.0;Urothelial cells: 14.9" "Low cancer specificity" "Detected in many" "Group enriched" "Detected in some" 5 "olfactory region: 1.2;pons and medulla: 4.5" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "hTERT-RPE1: 14.3;LHCN-M2: 53.4;RH-30: 29.2" "Not detected" "Not detected" "Not detected" "Not detected" "HPA001893, CAB058690" Enhanced Supported Nucleoplasm,Nucleoli No No Nucleoplasm Nucleoli "CAB058690: AB_2665581, HPA001893: AB_1079991" "unprognostic (3.62e-1)" "unprognostic (5.44e-2)" "unprognostic (5.09e-2)" "prognostic unfavorable (8.92e-6)" "unprognostic (1.33e-2)" "unprognostic (1.44e-2)" "unprognostic (2.04e-3)" "prognostic favorable (3.94e-4)" "unprognostic (1.40e-1)" "unprognostic (9.15e-2)" "unprognostic (6.45e-2)" "unprognostic (1.89e-1)" "unprognostic (3.06e-8)" "unprognostic (8.61e-2)" "unprognostic (2.13e-1)" "unprognostic (1.94e-1)" "unprognostic (3.86e-1)" 7.1 0.4 0.3 0.1 0.5 0.1 4.7 0.3 0.6 7.4 0.2 0.2 0.0 0.1 0.2 2.1 1.3 0.5 0.4 0.4 0.3 0.3 0.3 0.2 1.8 0.3 0.4 1.2 0.3 0.3 16.8 39.1 0.1 4.5 8.7 0.1 2.0 55.1 0.2 59.0 0.4 0.2 0.7 0.5 0.2 0.5 1.6 0.0 6.5 2.4 22.5 3.0 1.4 9.7 0.6 0.0 0.0 0.0 0.0 0.0 0.0 8.3 1.9 0.2 11.9 6.9 8.1 0.1 2.0 4.5 2.3 2.0 0.0 3.8 0.0 1.1 0.4 1.1 2.7 3.9 3.6 0.8 0.0 9.5 0.9 0.8 2.7 0.0 0.0 0.1 6.0 1.8 1.6 0.3 14.3 0.1 0.7 2.6 0.0 53.4 1.3 0.0 0.2 0.0 0.0 4.8 0.0 29.2 0.0 2.3 6.5 1.1 0.1 2.3 0.1 2.4 0.2 1.4 0.2 6.8 3.2 3.2 3.7 3.0 0.2 0.0 0.0 0.8 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.5 0.3 0.5 0.3 0.3 0.4 1.2 4.5 0.0 3.0 1.0 0.0 23.3 0.1 0.0 0.8 0.0 65.6 33.0 1.8 0.0 0.0 1.7 0.0 0.2 0.0 0.0 0.0 0.7 0.4 0.8 24.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.8 0.2 0.0 1.1 0.0 0.3 0.0 0.2 0.0 2.5 0.1 0.2 0.0 0.0 14.9 SMAD2 "JV18-1, MADH2, MADR2" ENSG00000175387 "SMAD family member 2" Q15796 18 47808957-47931146 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors" "Transcription, Transcription regulation" DNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" 4 "Cone photoreceptor cells: 200.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB025507, HPA067203, CAB073546" Approved Supported Nucleoplasm,Nucleoli,Cytosol NA NA "Nucleoplasm, Nucleoli, Cytosol" "CAB025507: , CAB073546: , HPA067203: AB_2685803" "unprognostic (1.55e-1)" "unprognostic (2.49e-1)" "unprognostic (1.43e-2)" "unprognostic (9.82e-3)" "unprognostic (9.88e-2)" "unprognostic (1.06e-1)" "prognostic unfavorable (9.44e-5)" "unprognostic (1.91e-2)" "unprognostic (7.59e-2)" "unprognostic (1.41e-3)" "unprognostic (6.46e-2)" "unprognostic (4.91e-2)" "unprognostic (9.20e-3)" "unprognostic (2.68e-1)" "unprognostic (6.13e-2)" "unprognostic (3.20e-2)" "unprognostic (6.28e-2)" 38.5 39.2 29.0 26.2 25.9 19.6 31.4 19.5 28.9 28.8 34.2 29.4 28.9 21.5 26.6 26.3 33.5 28.8 25.7 31.1 26.1 27.1 26.4 20.9 28.3 23.8 30.9 24.3 36.6 28.1 25.7 24.4 34.8 28.6 27.8 29.8 31.7 29.7 28.7 33.9 28.0 26.4 34.6 35.4 34.1 26.3 29.2 26.2 60.7 46.1 23.6 31.5 35.1 35.7 12.0 21.8 28.9 24.7 24.5 25.9 19.7 22.2 32.0 19.5 18.9 31.2 38.2 22.3 24.3 29.2 25.4 29.7 12.2 21.4 34.6 17.5 30.8 35.6 24.6 21.9 27.1 34.1 37.6 11.2 29.4 48.3 19.8 36.4 40.8 30.1 28.2 35.0 21.7 50.3 29.6 28.0 28.2 13.6 29.0 31.2 14.5 28.0 19.6 9.6 1.1 7.6 20.5 28.5 23.6 57.0 38.4 18.1 21.2 29.2 20.1 23.8 19.9 15.2 27.2 31.3 37.7 21.8 10.2 17.6 28.5 27.3 30.2 26.1 27.9 27.5 28.9 22.6 25.0 16.9 24.7 21.2 12.0 23.1 20.9 21.8 9.4 25.8 19.8 22.7 24.5 20.8 15.5 25.9 19.7 29.0 25.9 19.5 28.9 26.1 27.1 30.9 24.3 28.6 26.2 41.7 29.7 22.0 39.2 48.3 44.4 40.0 40.8 30.8 45.5 73.3 200.3 37.8 33.2 31.7 53.8 44.7 32.0 46.7 38.2 33.2 34.3 51.4 20.8 22.6 38.9 33.4 49.0 57.7 52.1 97.0 38.6 38.2 49.0 44.1 42.5 37.9 37.5 24.6 50.2 32.1 82.1 32.3 35.9 26.3 39.6 54.1 58.1 38.1 35.7 55.8 SMAD3 "HsT17436, JV15-2, MADH3" ENSG00000166949 "SMAD family member 3" P84022 15 67063763-67195195 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Host-virus interaction, Transcription, Transcription regulation" DNA-binding "Aortic aneurysm, Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 10 "Glandular cells: 111.1;Urothelial cells: 247.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB008094, HPA046386, HPA067203, CAB069409" Approved Supported Nucleoplasm,Cytosol NA NA Nucleoplasm Cytosol "CAB008094: AB_2302271, CAB069409: AB_1622941, HPA046386: AB_2679647, HPA067203: AB_2685803" "unprognostic (1.04e-1)" "unprognostic (1.83e-1)" "unprognostic (1.06e-1)" "unprognostic (1.99e-2)" "unprognostic (1.61e-1)" "unprognostic (1.98e-2)" "unprognostic (8.40e-3)" "unprognostic (1.80e-2)" "unprognostic (7.62e-2)" "unprognostic (6.82e-2)" "prognostic unfavorable (2.48e-4)" "unprognostic (2.93e-1)" "unprognostic (2.14e-2)" "unprognostic (3.10e-1)" "unprognostic (1.79e-1)" "unprognostic (1.15e-1)" "unprognostic (5.97e-2)" 25.3 4.6 12.2 18.5 12.4 12.4 21.6 5.0 12.7 20.9 17.9 7.6 9.5 12.7 19.9 16.6 35.3 14.3 27.7 19.7 7.5 4.8 15.6 13.6 13.9 14.0 6.0 7.5 23.0 12.6 7.0 10.8 11.5 8.2 20.5 9.2 30.8 12.5 10.8 37.3 19.6 19.0 23.2 5.5 11.2 15.8 7.0 7.7 10.5 21.8 23.4 29.7 31.4 24.6 4.8 2.5 3.2 1.9 0.4 6.3 1.8 12.2 41.2 7.7 3.7 13.6 31.4 6.1 7.1 29.3 9.9 8.0 8.5 32.9 4.1 9.6 20.2 44.6 29.1 8.0 30.0 9.9 3.2 3.0 0.4 11.6 6.4 10.2 1.6 0.7 28.4 7.0 8.7 7.4 22.0 33.3 1.3 9.9 11.5 12.3 6.3 0.3 6.2 4.5 6.5 12.9 0.4 2.3 1.5 6.6 39.5 0.2 2.6 9.4 5.2 8.1 15.7 1.4 7.6 28.0 13.4 12.6 9.6 8.0 4.4 1.2 5.1 12.1 1.7 12.0 0.0 1.9 3.2 5.5 1.5 5.7 2.1 6.2 6.3 1.8 4.8 2.8 2.4 0.1 0.4 1.5 2.5 3.1 1.8 12.2 12.4 5.0 12.7 7.5 4.8 6.0 7.5 8.2 7.7 44.7 14.5 13.6 67.6 79.0 8.3 9.5 15.3 24.1 30.7 34.9 5.9 0.8 3.3 53.0 0.9 20.1 34.4 0.0 44.0 4.0 34.3 111.1 24.2 11.3 8.4 0.0 3.4 9.8 4.8 3.7 24.7 13.8 20.3 3.6 11.9 9.7 71.0 21.0 19.4 12.2 0.4 25.8 14.6 0.3 0.7 42.8 1.4 12.5 15.7 247.9 SMAD4 "DPC4, MADH4" ENSG00000141646 "SMAD family member 4" Q13485 18 51028394-51085045 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" DNA-binding "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA019154 Approved Supported Nucleoplasm,Centrosome,Cytosol NA NA "Nucleoplasm, Cytosol" Centrosome "HPA019154: AB_1853480" "unprognostic (1.58e-1)" "unprognostic (1.75e-1)" "unprognostic (1.25e-2)" "unprognostic (4.83e-2)" "unprognostic (1.17e-2)" "unprognostic (4.05e-1)" "unprognostic (7.29e-3)" "unprognostic (9.00e-2)" "unprognostic (4.01e-2)" "unprognostic (2.51e-2)" "unprognostic (1.03e-3)" "unprognostic (4.40e-2)" "prognostic favorable (1.92e-5)" "unprognostic (2.62e-2)" "unprognostic (4.23e-1)" "unprognostic (1.36e-1)" "unprognostic (1.44e-1)" 25.6 17.5 16.0 14.0 16.7 11.4 24.9 29.7 16.0 27.9 22.6 17.9 21.3 15.1 28.2 18.8 21.7 20.5 17.5 19.6 15.3 11.5 21.0 22.0 20.1 16.0 17.2 13.3 30.5 25.0 30.0 28.9 30.6 14.2 27.8 17.4 18.4 23.1 22.8 39.7 18.2 23.4 27.6 13.9 21.7 19.3 17.6 18.4 38.8 35.0 13.9 18.1 29.0 24.1 3.6 3.6 3.4 1.8 2.9 4.7 1.3 8.5 11.4 30.9 8.9 12.8 19.8 17.4 15.1 16.6 20.3 25.5 7.0 2.0 14.3 4.5 13.0 10.4 14.2 17.3 6.8 21.6 12.4 9.8 9.9 11.4 8.0 12.7 17.2 7.8 8.9 11.5 10.0 14.7 19.6 14.7 7.3 11.1 13.2 12.0 4.5 10.2 5.0 16.1 4.6 7.1 13.3 15.7 14.0 9.7 3.7 19.1 11.3 14.1 2.6 9.4 13.7 7.0 10.0 11.0 17.2 8.0 4.3 10.0 19.9 13.8 12.4 11.2 6.7 11.3 0.8 1.8 1.8 3.2 1.1 3.7 2.2 3.3 2.6 3.6 3.6 4.0 4.7 3.4 2.9 1.3 2.9 4.3 1.3 16.0 16.7 29.7 16.0 15.3 11.5 17.2 13.3 14.2 18.4 20.8 23.2 11.8 18.4 22.8 13.2 33.5 40.8 16.0 19.4 21.0 19.6 15.5 10.0 16.2 7.3 23.2 15.6 0.0 10.8 16.8 23.8 31.7 4.6 40.0 13.2 14.3 38.1 23.9 26.1 11.4 30.8 16.7 27.0 5.4 33.8 18.9 18.1 24.3 28.7 18.5 20.8 25.8 29.2 13.9 16.2 23.8 10.5 13.8 26.2 22.5 SMARCA4 "BAF190, BRG1, FLJ39786, hSNF2b, SNF2, SNF2-BETA, SNF2L4, SNF2LB, SWI2" ENSG00000127616 "SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4" P51532 19 10960825-11079426 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Neurogenesis, Transcription, Transcription regulation" "Activator, Chromatin regulator, Helicase, Hydrolase, Repressor, RNA-binding" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" 5 "Cardiomyocytes: 219.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB004208 Supported Supported Nucleoplasm NA NA 260000 Nucleoplasm "CAB004208: AB_626762" "unprognostic (2.68e-1)" "unprognostic (4.85e-2)" "unprognostic (1.71e-1)" "unprognostic (3.43e-3)" "unprognostic (1.40e-1)" "unprognostic (6.33e-3)" "prognostic unfavorable (1.11e-4)" "unprognostic (7.19e-2)" "unprognostic (7.29e-2)" "unprognostic (1.73e-2)" "unprognostic (1.97e-1)" "unprognostic (1.15e-2)" "unprognostic (6.80e-3)" "unprognostic (6.83e-3)" "unprognostic (5.44e-2)" "unprognostic (1.01e-1)" "unprognostic (1.29e-1)" 10.3 12.4 15.5 18.0 21.3 20.5 10.9 29.1 28.0 13.2 12.8 16.6 9.7 14.3 16.6 9.4 24.7 15.7 12.8 11.6 14.4 17.7 13.0 9.9 13.0 18.1 17.1 16.8 13.6 13.4 18.1 11.5 14.6 16.1 13.3 9.4 17.3 18.2 12.5 21.9 20.4 12.0 10.6 16.1 13.2 14.5 22.2 12.4 58.2 15.5 10.1 21.5 15.2 12.6 9.8 11.2 8.6 13.5 11.4 13.7 5.9 20.5 1.1 36.7 34.7 7.2 6.1 16.1 14.3 8.6 17.5 13.0 28.7 0.9 48.3 22.2 12.5 0.7 15.1 28.6 17.7 9.7 19.8 21.4 38.4 18.2 33.3 10.9 27.8 19.2 10.2 8.6 14.7 15.2 7.8 15.6 21.1 34.4 18.2 13.7 41.9 46.2 23.9 37.2 10.0 31.1 49.2 23.2 25.0 11.2 26.1 41.8 37.9 15.2 19.6 16.3 12.3 16.6 20.9 20.6 26.1 13.6 23.8 23.6 37.7 41.8 47.9 14.8 26.7 22.1 8.1 8.3 8.6 13.7 9.5 12.2 7.4 10.4 11.6 8.5 9.8 11.4 11.2 5.2 11.4 13.5 11.2 8.8 5.9 15.5 21.3 29.1 28.0 14.4 17.7 17.1 16.8 16.1 12.4 62.5 67.7 32.7 32.8 32.7 82.3 219.1 43.3 46.8 51.2 41.8 66.8 57.1 34.9 75.0 39.4 30.8 34.6 23.3 53.1 46.8 38.0 38.3 29.0 19.2 36.4 95.3 60.6 22.7 21.0 29.3 24.2 23.3 15.1 57.7 37.3 37.2 60.6 38.6 12.7 19.3 63.8 12.9 30.3 93.0 96.0 45.2 51.0 28.4 50.9 40.7 SMARCE1 BAF57 ENSG00000073584 "SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily e, member 1" Q969G3 17 40624962-40648864 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" Neurogenesis "Chromatin regulator, DNA-binding" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003916, CAB037318" Supported Supported Nucleoplasm NA NA Nucleoplasm "CAB037318: AB_476780, HPA003916: AB_1857279" "unprognostic (7.91e-2)" "unprognostic (2.68e-2)" "unprognostic (2.09e-2)" "unprognostic (8.06e-3)" "unprognostic (1.87e-1)" "unprognostic (2.55e-2)" "unprognostic (4.48e-1)" "unprognostic (1.25e-2)" "unprognostic (2.20e-2)" "unprognostic (1.05e-1)" "unprognostic (2.53e-2)" "unprognostic (2.04e-1)" "unprognostic (9.80e-2)" "unprognostic (5.93e-2)" "unprognostic (7.63e-2)" "unprognostic (1.09e-1)" "unprognostic (1.27e-2)" 25.1 20.2 14.4 17.2 18.8 18.4 20.2 17.0 16.7 37.6 25.1 18.0 12.6 18.4 42.8 19.5 31.0 21.1 20.6 19.6 13.3 12.0 23.0 22.6 20.1 22.3 16.5 14.3 39.5 16.9 13.3 20.4 34.8 15.2 32.4 19.2 17.9 20.6 21.9 32.0 21.3 22.6 33.4 15.8 30.3 19.1 22.0 17.5 53.9 23.8 18.9 25.1 31.2 21.0 40.3 32.0 34.0 30.3 47.2 44.0 39.2 20.7 34.5 42.3 31.5 22.4 32.3 20.8 26.1 36.0 30.7 23.1 22.6 18.0 32.9 37.7 35.2 20.5 28.3 26.2 27.6 36.9 30.8 34.0 23.5 18.6 39.6 22.6 42.9 23.9 28.0 21.8 24.5 35.7 31.0 33.0 26.6 34.2 13.1 29.3 23.3 78.5 8.9 23.6 17.1 17.1 44.0 47.7 25.0 37.0 35.6 33.9 32.8 23.2 67.3 21.7 48.0 40.3 26.9 27.0 25.0 27.5 22.5 32.1 24.6 28.6 49.2 25.4 19.7 38.4 31.8 26.0 34.0 39.1 26.8 40.5 38.4 35.8 40.9 31.3 40.3 30.2 34.9 11.0 47.2 30.3 32.0 44.0 39.2 14.4 18.8 17.0 16.7 13.3 12.0 16.5 14.3 15.2 17.5 44.7 30.1 53.5 36.0 33.9 46.7 46.8 38.2 73.6 60.3 19.2 15.7 85.1 13.3 34.9 18.3 60.7 37.1 23.3 27.8 65.4 59.9 34.1 70.6 38.4 44.7 77.9 92.7 48.5 34.8 7.7 83.7 37.7 23.6 49.5 51.9 65.5 27.8 51.0 77.4 21.6 34.7 38.8 52.6 40.8 46.0 35.0 96.0 60.9 54.8 33.5 SMO "FZD11, SMOH" ENSG00000128602 "Smoothened, frizzled class receptor" Q99835 7 129188872-129213545 "Cancer-related genes, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Transporters" "Developmental protein, G-protein coupled receptor, Receptor, Transducer" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" 8 "Collecting duct cells: 10.4;Leydig cells: 19.2;Muller glia cells: 15.1;Peritubular cells: 20.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "AF22: 20.3;AN3-CA: 37.6;NTERA-2: 28.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB011446 Approved NA NA "CAB011446: " "unprognostic (2.48e-2)" "unprognostic (2.69e-2)" "unprognostic (7.09e-2)" "unprognostic (1.10e-1)" "unprognostic (8.16e-2)" "unprognostic (2.02e-1)" "unprognostic (3.63e-1)" "unprognostic (5.89e-2)" "unprognostic (5.38e-3)" "unprognostic (1.59e-1)" "unprognostic (1.17e-2)" "unprognostic (8.74e-3)" "unprognostic (1.62e-1)" "unprognostic (5.15e-3)" "unprognostic (2.09e-1)" "unprognostic (2.25e-1)" "unprognostic (2.61e-2)" 4.0 4.1 4.2 3.8 4.8 0.5 7.4 5.3 4.6 18.2 5.8 5.1 9.2 2.5 20.9 18.7 10.3 11.4 10.0 5.2 8.4 3.7 10.6 13.7 2.4 2.0 4.3 4.5 23.0 7.1 14.4 13.5 2.6 9.0 18.4 2.2 17.2 9.4 12.8 3.5 16.6 3.5 9.8 7.0 2.0 4.2 7.9 3.4 5.3 9.2 6.8 4.6 6.3 17.6 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.6 8.0 20.3 37.6 0.5 0.1 6.4 2.2 2.9 4.5 2.6 6.1 0.1 0.0 6.2 4.5 10.2 12.4 12.2 0.7 1.7 0.0 9.9 3.9 0.0 9.8 2.5 0.1 0.0 7.4 5.0 1.4 0.0 9.0 2.6 11.2 0.6 0.0 1.4 0.0 10.3 0.0 28.8 0.0 2.3 15.0 8.7 0.0 2.3 0.0 0.6 13.6 0.0 0.0 5.3 8.1 4.9 2.6 0.0 0.3 6.5 7.8 4.3 0.4 0.0 0.0 0.0 0.0 7.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.2 4.8 5.3 4.6 8.4 3.7 4.3 4.5 9.0 3.4 0.0 0.0 0.0 2.3 1.6 0.6 1.2 2.5 0.0 4.5 10.4 0.0 0.3 1.7 3.2 0.3 0.4 0.0 0.0 1.0 0.3 4.4 2.8 0.0 5.1 3.3 0.0 0.0 1.3 1.3 0.9 19.2 0.4 0.0 1.0 0.0 15.1 1.9 0.0 20.5 3.7 0.3 6.5 2.1 0.0 0.4 2.5 0.5 0.0 0.0 0.4 SPEN "KIAA0929, MINT, RBM15C, SHARP" ENSG00000065526 "Spen family transcriptional repressor" Q96T58 1 15847864-15940460 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Host-virus interaction, Notch signaling pathway, Transcription, Transcription regulation" "Activator, DNA-binding, Repressor, RNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA015825, HPA050257" Supported Enhanced Nucleoplasm NA NA Nucleoplasm "HPA015825: AB_1856823, HPA050257: AB_2681065" "unprognostic (3.91e-1)" "unprognostic (1.74e-1)" "unprognostic (3.76e-1)" "unprognostic (2.04e-1)" "unprognostic (1.48e-1)" "unprognostic (3.06e-2)" "unprognostic (6.93e-3)" "unprognostic (2.26e-1)" "unprognostic (4.26e-2)" "unprognostic (4.88e-3)" "unprognostic (1.71e-1)" "unprognostic (5.98e-2)" "unprognostic (1.06e-3)" "unprognostic (1.49e-1)" "unprognostic (1.66e-1)" "unprognostic (2.26e-1)" "unprognostic (1.83e-1)" 18.2 11.2 18.2 18.2 22.2 27.2 17.3 38.2 25.9 18.5 13.4 20.7 17.7 11.9 19.0 12.7 16.7 19.4 11.8 13.5 17.6 11.5 14.4 13.2 17.8 16.6 23.4 17.5 31.2 23.9 35.1 17.5 16.2 19.0 14.9 13.3 11.6 16.2 16.2 24.0 22.8 16.0 15.1 22.0 16.5 13.7 13.6 23.3 18.3 20.1 8.7 18.0 17.1 41.9 5.0 2.7 7.7 2.4 1.3 1.7 0.6 12.7 10.8 13.5 10.1 13.6 8.3 7.3 6.6 8.7 7.2 6.1 9.8 10.0 18.0 7.9 13.0 8.5 18.5 12.7 11.8 11.6 16.2 35.2 22.6 9.6 6.2 6.1 18.5 10.8 6.1 8.5 10.7 15.6 6.8 8.2 13.8 23.5 18.6 5.8 7.1 15.3 7.3 6.1 7.4 8.3 14.8 13.2 11.1 4.0 11.5 10.5 10.6 18.6 9.1 7.9 6.4 3.2 9.1 14.7 6.6 8.2 12.8 9.4 11.2 7.3 20.6 6.5 15.0 9.2 7.7 1.5 0.9 1.6 2.4 1.3 1.8 1.7 1.4 0.7 5.0 0.9 1.3 4.2 1.3 1.2 2.7 1.1 0.6 18.2 22.2 38.2 25.9 17.6 11.5 23.4 17.5 19.0 23.3 74.5 74.0 31.3 47.9 93.0 64.6 48.1 20.4 38.8 66.0 5.2 49.1 10.9 3.3 16.9 3.4 55.5 30.7 23.3 15.0 12.0 46.5 43.4 59.1 26.3 13.3 90.6 30.4 13.5 30.8 3.6 25.3 30.1 20.3 25.2 24.4 29.6 18.0 23.2 33.6 6.5 54.5 19.4 54.6 34.9 51.9 88.8 13.2 20.2 18.7 49.2 SPOP "BTBD32, TEF2" ENSG00000121067 "Speckle type BTB/POZ protein" O43791 17 49598884-49678234 "Cancer-related genes, Predicted intracellular proteins" "Ubl conjugation pathway" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" NA NA "unprognostic (1.96e-2)" "unprognostic (1.43e-2)" "unprognostic (8.83e-2)" "unprognostic (3.23e-1)" "unprognostic (2.15e-2)" "unprognostic (4.51e-2)" "prognostic unfavorable (6.88e-4)" "unprognostic (1.89e-2)" "unprognostic (7.20e-2)" "unprognostic (1.17e-2)" "unprognostic (1.51e-2)" "unprognostic (1.24e-3)" "unprognostic (7.67e-2)" "unprognostic (2.81e-1)" "unprognostic (3.45e-2)" "unprognostic (1.10e-2)" "unprognostic (3.29e-1)" 22.0 16.5 22.5 16.9 24.9 7.9 18.6 39.8 26.9 27.5 59.5 25.0 25.1 15.2 36.2 21.2 35.4 25.2 17.2 22.7 22.7 18.8 17.0 20.2 19.1 19.6 20.9 21.4 26.0 18.5 15.1 28.5 18.2 23.2 38.8 23.5 21.8 22.8 49.5 29.2 15.2 24.1 45.1 18.4 18.8 28.4 10.5 26.8 28.6 26.4 14.3 23.3 35.6 22.3 43.2 55.6 59.6 43.1 40.7 58.4 50.8 14.2 16.1 18.6 7.0 20.9 22.3 12.6 18.8 19.4 24.9 25.9 32.8 15.7 23.6 36.0 17.0 17.2 11.5 21.1 13.7 29.8 43.7 23.3 27.4 16.4 18.7 24.0 17.9 22.4 16.7 17.6 19.4 21.1 18.1 25.3 17.6 28.3 24.3 16.7 13.9 32.9 16.5 4.9 33.7 19.7 18.7 27.1 30.5 13.5 8.5 28.0 13.0 11.8 6.0 15.4 10.5 23.2 18.7 22.2 27.0 18.7 21.1 15.4 24.4 20.3 20.6 15.8 16.1 13.5 57.0 41.8 50.6 36.2 37.1 36.1 42.4 40.6 39.2 55.6 43.2 58.4 45.3 59.6 40.7 43.1 37.2 36.0 50.8 22.5 24.9 39.8 26.9 22.7 18.8 20.9 21.4 23.2 26.8 44.7 34.5 45.7 39.5 38.0 59.7 46.4 22.9 33.5 30.7 27.9 41.2 19.1 24.9 30.3 13.7 56.0 23.9 0.0 24.6 19.6 43.7 25.3 30.1 39.9 33.5 71.5 49.4 54.6 50.5 4.5 52.0 43.8 37.1 65.9 43.6 94.4 23.0 36.5 68.9 22.7 54.6 71.1 58.6 30.9 46.6 38.3 30.2 43.7 32.2 18.0 SRC "ASV, c-src, SRC1" ENSG00000197122 "SRC proto-oncogene, non-receptor tyrosine kinase" P12931 20 37344685-37406050 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transporters" "Cell adhesion, Cell cycle, Host-virus interaction, Immunity" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "intermediate monocyte: 5.3;non-classical monocyte: 4.4" "Group enriched" "Detected in many" 6 "dendritic cells: 3.0;monocytes: 5.3" "Cell line enhanced" "Detected in many" "A549: 35.9;HBEC3-KT: 33.4;RT4: 34.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004023, HPA030875" Approved Supported "Nucleoplasm,Plasma membrane,Cell Junctions,Cytosol" NA NA 20000000 "Plasma membrane, Cell Junctions" "Nucleoplasm, Cytosol" "CAB004023: AB_2106059, HPA030875: AB_2673640" "unprognostic (5.58e-2)" "unprognostic (9.83e-2)" "unprognostic (3.56e-1)" "unprognostic (4.54e-3)" "unprognostic (1.52e-1)" "unprognostic (1.54e-2)" "prognostic unfavorable (4.90e-5)" "unprognostic (3.89e-2)" "unprognostic (7.04e-2)" "unprognostic (8.13e-2)" "unprognostic (1.54e-2)" "prognostic unfavorable (1.63e-4)" "prognostic unfavorable (1.22e-4)" "unprognostic (2.33e-2)" "unprognostic (4.72e-2)" "unprognostic (3.65e-2)" "prognostic favorable (5.22e-5)" 6.9 17.5 12.8 11.1 12.0 5.4 9.9 6.4 16.0 16.0 16.4 3.5 15.1 29.5 20.3 9.7 16.2 14.2 42.1 5.8 11.3 6.6 13.4 2.9 10.4 7.0 3.3 9.9 15.8 19.1 6.6 11.3 6.3 5.1 19.9 13.1 13.1 7.5 22.5 3.4 7.7 28.1 27.2 3.6 12.2 29.8 27.3 4.8 4.0 6.6 10.5 10.4 26.4 20.0 0.3 3.0 0.1 5.3 0.6 0.1 1.6 7.7 35.9 8.3 7.4 3.1 5.0 17.2 7.2 6.2 8.8 5.6 13.5 7.0 0.2 4.5 13.0 10.0 14.2 4.9 33.4 3.4 0.0 4.5 2.0 1.3 20.9 7.5 0.1 3.1 5.3 11.4 5.7 7.7 9.8 8.0 4.6 0.2 0.0 1.4 5.3 1.9 0.2 3.9 21.5 32.6 8.4 2.2 0.2 3.7 34.4 7.7 27.9 8.1 11.4 8.9 6.6 10.2 2.8 11.6 10.5 7.1 3.8 6.4 0.1 0.2 0.1 7.4 0.0 7.8 0.0 2.6 0.0 0.0 5.3 0.0 0.3 0.0 0.1 1.1 0.3 0.0 0.0 0.1 0.6 4.4 3.0 0.1 1.6 12.8 12.0 6.4 16.0 11.3 6.6 3.3 9.9 5.1 4.8 3.0 1.7 4.4 10.8 7.2 5.4 1.6 15.3 1.4 0.0 12.2 2.0 1.6 1.7 9.7 1.3 1.4 30.0 0.0 16.2 7.0 8.2 11.2 0.0 0.9 5.8 3.2 16.1 1.3 6.9 1.5 10.0 12.1 1.7 7.2 25.9 4.1 29.0 18.1 16.3 9.5 4.7 12.9 6.4 0.2 0.7 8.0 1.9 0.0 14.9 27.7 SRSF2 "PR264, SC-35, SC35, SFRS2, SFRS2A" ENSG00000161547 "Serine and arginine rich splicing factor 2" Q01130 17 76734115-76737374 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "mRNA processing, mRNA splicing" RNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA049905 Supported Approved Nucleoplasm,Cytosol NA NA 140000 Nucleoplasm Cytosol "HPA049905: AB_2680945" "unprognostic (2.50e-1)" "unprognostic (2.16e-3)" "unprognostic (2.73e-3)" "prognostic unfavorable (8.73e-4)" "unprognostic (1.75e-2)" "unprognostic (4.19e-2)" "prognostic unfavorable (3.53e-8)" "unprognostic (1.19e-1)" "unprognostic (7.79e-3)" "unprognostic (7.03e-3)" "unprognostic (1.92e-1)" "unprognostic (1.07e-3)" "prognostic unfavorable (1.05e-7)" "unprognostic (3.85e-2)" "unprognostic (8.05e-2)" "unprognostic (1.95e-1)" "prognostic favorable (9.87e-4)" 35.4 40.2 20.6 56.6 30.3 73.1 35.3 33.3 36.2 42.1 37.7 34.0 19.5 41.8 37.0 33.6 51.1 35.1 34.8 32.4 19.9 22.6 36.9 66.7 37.3 64.3 21.6 24.0 47.1 34.2 29.1 33.8 51.2 29.5 31.3 36.5 35.5 35.6 40.5 44.9 41.1 46.6 25.5 23.9 52.5 35.6 29.2 18.9 105.3 41.1 41.3 64.5 30.6 35.7 11.1 30.2 4.2 23.5 15.6 12.7 12.2 48.2 38.9 46.2 32.2 11.3 9.6 48.0 31.2 23.1 36.2 33.6 40.8 33.8 74.4 22.8 29.3 26.1 43.7 45.8 36.0 36.5 31.1 79.8 55.8 37.7 47.4 12.9 61.6 33.4 10.6 8.2 30.0 8.7 14.7 28.2 33.3 56.7 32.9 28.3 38.6 67.6 67.3 54.1 28.1 55.5 68.5 49.7 54.9 24.2 34.8 39.4 56.3 35.6 30.6 16.8 25.4 37.5 45.0 29.5 33.5 43.1 22.2 50.4 43.3 32.5 86.0 30.1 49.0 27.6 1.0 17.5 4.2 12.3 23.5 12.6 11.1 8.5 12.7 30.2 9.8 9.8 9.0 2.1 15.6 14.7 22.4 10.6 12.2 20.6 30.3 33.3 36.2 19.9 22.6 21.6 24.0 29.5 18.9 110.2 104.2 263.7 359.4 409.3 143.7 75.1 117.2 84.3 119.4 83.7 86.4 268.2 132.6 175.8 190.8 186.2 246.5 140.2 136.4 478.7 232.5 241.3 217.7 110.3 220.7 93.8 255.6 111.1 135.5 118.5 147.3 197.1 268.2 218.2 170.4 153.0 146.8 241.8 119.9 87.2 188.9 116.4 279.5 292.6 343.6 387.6 264.3 196.1 264.9 438.8 STAG2 "SA-2, SA2, SCC3B" ENSG00000101972 "Stromal antigen 2" Q8N3U4 X 123960212-124422664 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Cell cycle, Cell division, Chromosome partition, Meiosis, Mitosis" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA002857 Supported NA NA "HPA002857: AB_1079861" "unprognostic (1.62e-1)" "unprognostic (1.01e-2)" "unprognostic (6.75e-2)" "unprognostic (2.16e-2)" "unprognostic (1.37e-2)" "unprognostic (2.70e-2)" "unprognostic (3.77e-2)" "unprognostic (9.67e-3)" "unprognostic (4.68e-2)" "unprognostic (1.86e-1)" "unprognostic (1.24e-1)" "unprognostic (3.38e-1)" "unprognostic (1.59e-3)" "unprognostic (2.81e-1)" "unprognostic (2.77e-2)" "unprognostic (1.63e-1)" "unprognostic (3.97e-1)" 24.0 18.8 21.5 23.9 23.7 39.7 30.1 35.4 23.5 28.1 25.1 16.4 25.2 14.9 24.3 21.0 24.3 20.0 16.3 15.7 21.4 17.9 22.2 18.1 23.4 26.2 24.9 17.5 31.1 19.7 46.1 27.6 25.5 20.6 25.9 18.3 14.2 20.7 27.8 27.6 18.9 21.9 25.9 30.6 26.7 17.6 9.3 26.4 69.3 32.0 19.7 27.1 37.7 37.8 12.8 12.5 30.3 14.4 12.1 15.5 6.7 17.5 16.5 24.9 15.7 10.7 16.2 16.1 16.6 17.9 17.3 21.8 15.4 18.8 32.4 23.6 14.9 19.4 16.0 50.9 14.1 24.5 23.0 21.7 29.9 33.1 10.1 11.1 39.1 23.6 12.7 14.0 20.5 33.1 15.0 14.5 33.1 29.2 34.6 12.7 19.1 50.0 17.6 13.0 16.1 24.6 35.5 32.9 27.1 13.4 33.5 22.5 17.9 37.5 14.0 19.7 18.6 8.4 18.0 17.6 0.1 9.3 20.3 18.9 14.9 22.5 40.7 10.9 24.1 17.4 16.8 10.2 18.1 10.8 13.1 12.6 10.0 11.2 10.1 12.5 12.8 15.5 12.4 30.3 12.1 14.4 11.2 8.7 6.7 21.5 23.7 35.4 23.5 21.4 17.9 24.9 17.5 20.6 26.4 59.6 44.6 53.3 44.3 49.9 49.3 38.4 28.1 60.2 64.8 41.8 56.9 28.0 18.3 37.3 0.9 53.4 25.6 46.7 33.1 27.7 48.0 69.8 54.5 35.8 31.4 42.9 55.8 46.6 58.6 1.6 60.9 61.9 32.1 38.7 36.8 54.0 42.5 20.1 65.0 27.0 60.0 64.7 43.2 7.0 11.3 49.1 59.7 50.7 37.9 72.3 STAT3 APRF ENSG00000168610 "Signal transducer and activator of transcription 3" P40763 17 42313324-42388568 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Host-virus interaction, Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Diabetes mellitus, Disease mutation, Dwarfism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001671, CAB003859, HPA058603, CAB068241, CAB068242" Supported Supported Nucleoplasm,Cytosol NA NA 220000 "Nucleoplasm, Cytosol" "CAB003859: AB_347629, CAB068241: AB_2665663, CAB068242: AB_2665662, HPA001671: AB_1080102, HPA058603: AB_2683772" "unprognostic (1.83e-2)" "unprognostic (2.42e-1)" "unprognostic (9.23e-3)" "unprognostic (2.91e-1)" "unprognostic (5.59e-3)" "unprognostic (1.78e-2)" "unprognostic (8.26e-2)" "unprognostic (1.51e-1)" "unprognostic (1.32e-1)" "unprognostic (1.77e-1)" "unprognostic (2.21e-1)" "unprognostic (1.26e-1)" "unprognostic (6.47e-3)" "unprognostic (7.75e-3)" "unprognostic (2.21e-2)" "unprognostic (7.63e-2)" "unprognostic (1.61e-1)" 44.6 30.7 23.2 34.4 27.5 35.3 49.3 15.7 23.5 25.1 31.5 18.4 21.7 20.5 33.2 27.4 36.4 32.7 34.0 82.9 20.1 14.7 34.5 90.0 45.7 45.5 26.0 11.1 40.6 32.1 18.6 27.9 24.6 27.6 28.9 21.8 24.3 29.3 22.9 53.4 28.4 28.6 49.7 25.1 41.4 29.4 15.4 25.7 16.8 38.0 31.2 28.8 40.4 53.1 10.8 13.7 69.7 20.2 13.9 21.7 26.7 17.0 32.3 14.3 14.1 30.5 29.2 10.4 20.0 25.4 17.3 16.9 8.5 16.5 5.3 19.8 19.8 26.2 26.0 12.9 20.4 14.2 43.9 8.9 36.9 19.6 17.4 22.6 9.0 24.1 45.5 20.1 13.8 20.0 18.2 23.5 9.8 22.6 17.0 11.4 12.0 33.3 9.0 8.3 17.4 0.0 7.4 38.2 7.8 27.4 22.1 13.1 8.5 23.0 54.6 8.2 17.9 28.7 13.5 19.7 26.9 13.7 15.9 16.3 26.2 20.4 4.5 16.6 9.5 11.9 26.2 19.4 24.9 21.7 20.2 17.3 10.8 16.0 16.8 13.7 10.4 16.6 15.8 69.7 13.9 18.7 7.5 12.0 26.7 23.2 27.5 15.7 23.5 20.1 14.7 26.0 11.1 27.6 25.7 86.4 150.9 56.2 91.3 115.1 87.1 46.2 43.3 85.6 108.1 127.4 265.1 21.1 14.9 68.7 27.3 107.9 156.0 0.0 83.8 34.3 140.9 148.0 138.6 102.5 60.4 23.8 119.1 104.3 64.9 11.1 66.4 84.8 69.2 88.4 68.1 108.0 75.8 94.7 57.3 38.3 352.3 64.7 221.4 32.2 15.1 139.9 26.1 86.3 72.7 78.8 STAT5B ENSG00000173757 "Signal transducer and activator of transcription 5B" P51692 17 42199168-42276707 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Disease mutation, Dwarfism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" 7 "Early spermatids: 85.5;Late spermatids: 113.5;Peritubular cells: 70.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HDLM-2: 43.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004298, CAB005418, HPA042128, HPA049883, HPA051156" Approved Approved Cytosol NA NA 170000 Cytosol "CAB004298: AB_2197067, CAB005418: AB_632445, HPA042128: AB_2677864, HPA049883: AB_2680931, HPA051156: AB_2681366" "unprognostic (1.49e-1)" "unprognostic (3.60e-2)" "unprognostic (4.06e-2)" "prognostic favorable (9.37e-4)" "unprognostic (2.68e-1)" "unprognostic (4.29e-1)" "unprognostic (2.23e-1)" "unprognostic (1.03e-1)" "unprognostic (3.06e-2)" "unprognostic (7.98e-2)" "prognostic favorable (1.63e-4)" "unprognostic (1.36e-1)" "prognostic favorable (2.39e-5)" "unprognostic (9.19e-2)" "unprognostic (2.95e-1)" "unprognostic (1.54e-1)" "unprognostic (2.13e-1)" 25.7 24.0 13.5 19.5 16.3 21.8 26.2 32.1 15.9 21.6 21.0 13.7 16.3 8.6 31.9 12.0 11.6 24.5 18.1 12.8 11.9 20.1 12.4 13.5 15.8 24.6 16.0 13.9 34.4 12.1 12.0 22.6 55.4 17.2 20.8 10.3 16.4 12.9 21.7 38.3 12.2 14.8 33.1 10.6 22.1 14.4 13.2 15.7 21.7 15.4 9.6 19.8 21.5 33.1 2.5 2.4 18.8 2.8 3.5 8.3 3.8 5.3 8.4 12.5 3.3 15.6 7.9 6.0 5.5 9.8 7.9 6.9 3.6 4.5 17.4 8.3 6.3 15.7 6.9 7.4 4.8 6.3 43.9 8.6 17.0 15.8 5.6 8.6 7.5 27.5 9.7 7.4 5.9 7.6 6.8 12.5 11.8 30.6 3.8 3.2 5.2 35.1 19.7 3.1 12.4 0.0 15.1 7.8 6.0 5.0 8.6 9.2 5.4 10.1 12.9 7.7 2.9 9.1 8.8 9.5 11.1 3.9 5.7 7.6 7.5 3.4 8.7 4.4 7.9 5.7 8.8 2.8 4.6 5.9 2.5 6.4 2.5 8.3 6.7 2.4 2.5 5.9 5.0 18.8 3.5 2.8 1.8 6.9 3.8 13.5 16.3 32.1 15.9 11.9 20.1 16.0 13.9 17.2 15.7 6.0 17.9 3.7 4.7 7.9 18.0 17.3 10.2 5.3 9.1 3.5 19.6 5.9 5.0 7.2 85.5 23.3 6.2 23.3 10.1 5.7 10.8 8.0 15.1 10.2 8.1 9.5 9.8 16.0 14.2 113.5 43.7 11.1 10.1 10.0 7.2 8.4 10.7 7.8 70.0 8.1 13.8 38.8 22.8 4.2 4.1 8.5 10.6 24.5 7.5 5.4 STK11 "LKB1, PJS" ENSG00000118046 "Serine/threonine kinase 11" Q15831 19 1177558-1228435 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Apoptosis, Autophagy, Cell cycle, Differentiation, DNA damage, Spermatogenesis" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease mutation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 11 "Early spermatids: 124.0;Late spermatids: 234.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 11.7" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB016231, HPA017254, CAB022105, HPA067481" Approved Supported Nucleoplasm,Cytosol NA NA Nucleoplasm Cytosol "CAB016231: AB_627890, CAB022105: , HPA017254: AB_1852924, HPA067481: AB_2685847" "unprognostic (8.60e-2)" "unprognostic (1.68e-1)" "unprognostic (5.00e-2)" "prognostic favorable (3.69e-5)" "unprognostic (2.04e-2)" "prognostic favorable (1.96e-4)" "unprognostic (9.11e-3)" "unprognostic (3.19e-1)" "unprognostic (9.08e-2)" "unprognostic (1.26e-1)" "unprognostic (1.95e-3)" "unprognostic (7.70e-3)" "unprognostic (3.54e-2)" "unprognostic (3.16e-2)" "unprognostic (1.60e-1)" "unprognostic (3.31e-1)" "unprognostic (3.12e-3)" 13.4 13.7 13.5 11.8 12.4 19.3 16.7 17.8 16.0 12.2 16.1 8.3 19.8 18.1 10.8 8.7 15.1 10.0 11.8 15.3 12.6 9.8 10.7 22.1 9.4 12.5 9.7 10.4 11.0 16.8 10.7 11.6 12.2 9.9 12.2 5.3 11.9 16.0 12.2 49.2 16.8 18.0 7.7 7.6 16.9 15.5 59.8 7.5 11.8 12.4 14.5 19.0 11.4 9.8 2.7 1.9 11.7 6.3 1.9 1.8 0.5 21.2 10.3 7.8 14.8 7.4 6.7 16.5 10.4 10.9 9.8 10.4 8.4 14.9 13.9 11.5 10.8 4.4 13.8 7.7 16.0 3.0 26.0 18.8 14.2 0.6 10.5 16.0 14.3 23.9 12.2 11.7 7.5 11.2 8.9 9.8 11.1 26.6 19.2 5.5 15.9 13.7 14.5 15.0 7.3 12.7 21.8 8.4 15.6 8.8 15.6 18.1 13.1 0.0 7.7 11.2 4.7 12.1 23.5 13.2 10.1 11.5 19.8 16.5 37.8 15.9 10.4 10.1 19.1 10.4 2.0 4.2 4.5 0.6 6.0 0.4 2.7 1.0 1.8 1.9 1.0 1.0 0.9 11.7 1.9 6.3 1.0 0.7 0.5 13.5 12.4 17.8 16.0 12.6 9.8 9.7 10.4 9.9 7.5 6.0 13.6 11.1 6.4 14.8 23.6 11.8 17.8 2.7 6.8 22.7 17.7 6.7 6.6 8.1 124.0 14.7 29.5 0.0 11.9 4.5 10.4 14.2 2.3 25.2 12.9 17.5 14.5 16.0 22.2 234.7 22.7 10.4 15.1 17.2 29.2 19.3 13.0 25.9 19.4 8.6 19.8 12.9 20.8 49.9 19.4 13.6 7.3 8.6 33.0 10.9 TBL1XR1 "C21, DC42, FLJ12894, IRA1, TBLR1" ENSG00000177565 "Transducin beta like 1 X-linked receptor 1" Q9BZK7 3 177019340-177228000 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Transcription, Transcription regulation, Ubl conjugation pathway" "Activator, Chromatin regulator, Repressor" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "U-698: 71.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA019182 Supported Approved Nucleoplasm NA NA Nucleoplasm "HPA019182: AB_1857800" "unprognostic (4.11e-2)" "unprognostic (3.00e-1)" "unprognostic (1.33e-2)" "unprognostic (1.27e-3)" "prognostic favorable (5.16e-5)" "unprognostic (4.44e-2)" "prognostic unfavorable (1.08e-7)" "unprognostic (3.75e-1)" "unprognostic (4.84e-2)" "unprognostic (3.04e-1)" "unprognostic (3.13e-3)" "unprognostic (2.50e-1)" "prognostic unfavorable (4.25e-5)" "unprognostic (5.83e-2)" "unprognostic (1.69e-1)" "unprognostic (1.50e-1)" "unprognostic (1.17e-1)" 20.7 26.0 27.4 24.3 26.8 27.3 20.3 27.5 28.1 28.9 29.9 22.6 15.4 24.0 23.9 20.5 23.8 21.9 22.7 30.3 26.2 20.7 19.9 21.8 30.8 27.8 21.4 25.9 26.5 19.9 30.6 11.3 24.0 19.7 24.4 23.2 24.7 21.3 17.7 21.1 17.8 24.3 21.9 19.6 24.7 21.3 17.4 22.3 28.4 45.6 14.9 32.1 29.1 25.5 7.4 13.3 12.9 4.6 6.8 8.3 4.1 23.9 12.3 16.0 9.0 13.6 14.8 9.6 7.6 11.8 6.6 9.1 14.1 19.9 24.6 35.9 10.9 17.5 14.8 11.9 15.8 13.3 25.8 3.7 13.8 21.0 8.4 11.7 21.9 8.2 21.8 8.2 9.7 24.1 13.0 10.3 17.3 10.3 43.6 8.5 8.6 20.4 3.0 10.1 15.4 8.3 11.7 20.4 26.2 5.9 34.0 5.8 9.2 10.2 8.0 9.5 10.5 29.3 16.8 15.7 10.8 9.1 6.0 16.4 23.8 30.5 71.1 7.3 16.4 12.3 11.4 3.0 3.8 5.8 4.6 5.1 7.3 5.7 6.6 4.0 7.4 5.0 6.4 12.9 6.8 3.9 13.3 8.3 4.1 27.4 26.8 27.5 28.1 26.2 20.7 21.4 25.9 19.7 22.3 68.5 47.1 43.4 46.9 81.4 116.0 84.2 48.4 61.6 62.6 99.5 117.8 22.3 24.9 43.8 5.7 62.9 42.8 23.3 37.3 28.5 65.8 123.0 24.3 58.7 32.8 109.7 81.9 55.9 85.4 5.2 59.2 54.6 62.4 31.5 74.5 41.8 53.4 23.0 68.6 46.2 81.2 45.3 41.5 8.4 53.9 97.7 23.0 49.8 75.7 61.8 TBX3 "TBX3-ISO, UMS, XHL" ENSG00000135111 "T-box 3" O15119 12 114670254-114684164 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Developmental protein, DNA-binding, Repressor" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "seminal vesicle: 117.7" "Cell type enriched" "Detected in many" 6 "Syncytiotrophoblasts: 513.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "BJ: 34.0;BJ hTERT+: 32.4;RT4: 42.4" "Low region specificity" "Detected in single" "Not detected" "Not detected" "HPA005799, HPA075876" Supported Nucleoplasm,Cytosol NA NA Nucleoplasm Cytosol "HPA005799: AB_1857817, HPA075876: " "unprognostic (3.27e-1)" "unprognostic (2.64e-1)" "unprognostic (2.84e-1)" "unprognostic (1.11e-1)" "unprognostic (3.40e-2)" "unprognostic (5.97e-3)" "unprognostic (1.56e-1)" "unprognostic (2.99e-2)" "unprognostic (9.43e-2)" "unprognostic (1.15e-1)" "unprognostic (3.35e-1)" "unprognostic (3.06e-1)" "unprognostic (3.64e-3)" "unprognostic (1.09e-3)" "unprognostic (1.43e-1)" "unprognostic (1.01e-1)" "prognostic favorable (3.28e-4)" 4.3 60.5 0.9 3.3 1.9 0.0 19.9 0.7 2.3 18.2 12.2 1.7 69.6 14.2 13.1 18.7 1.9 7.5 5.0 6.2 1.2 1.5 4.1 15.1 12.6 0.8 1.2 0.5 15.6 1.1 0.3 5.3 67.8 1.6 32.3 1.5 2.6 7.3 117.7 4.2 4.8 19.4 9.7 1.4 2.6 2.2 3.5 1.2 0.5 36.3 7.3 3.5 24.6 25.2 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.7 6.0 0.0 0.0 9.0 12.4 13.5 34.0 32.4 13.2 13.1 5.3 1.4 0.0 0.5 5.9 0.8 1.5 2.8 1.2 16.3 0.0 4.1 0.0 1.5 15.5 2.9 0.0 0.0 5.5 0.8 4.4 9.1 0.0 0.1 0.0 1.2 0.0 1.1 0.5 0.0 0.1 0.0 17.2 1.8 0.0 0.0 0.8 0.0 42.4 2.2 6.6 4.8 2.2 1.1 15.8 1.7 0.0 0.0 4.0 2.6 2.3 11.0 0.0 0.0 0.0 8.5 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 1.9 0.7 2.3 1.2 1.5 1.2 0.5 1.6 1.2 0.0 3.4 0.9 88.0 8.8 6.3 9.8 0.0 0.0 0.0 33.2 3.9 39.8 0.0 0.4 1.3 26.5 25.4 0.0 0.0 5.9 9.5 74.0 0.0 31.0 5.4 1.6 4.7 0.6 1.6 1.8 4.9 0.8 3.3 0.0 13.8 1.5 0.5 23.0 5.6 0.0 2.0 38.8 34.1 0.1 4.7 8.5 513.4 0.7 4.5 62.6 TERT "EST2, hEST2, TCS1, TP2, TRT" ENSG00000164362 "Telomerase reverse transcriptase" O14746 5 1253147-1295069 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins" "DNA-binding, Nucleotidyltransferase, Ribonucleoprotein, RNA-directed DNA polymerase, Transferase" "Cancer-related genes, Disease mutation, Dyskeratosis congenita" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 6 "bone marrow: 3.4;lymphoid tissue: 12.0;testis: 5.0" "Cell type enhanced" "Detected in some" 24 "Cardiomyocytes: 1.2;Spermatogonia: 1.9" "Low cancer specificity" "Detected in some" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "ASC TERT1: 62.6;fHDF/TERT166: 59.4;HBEC3-KT: 120.8;hTEC/SVTERT24-B: 76.3;LHCN-M2: 34.4;TIME: 98.2" "Low region specificity" "Detected in single" "Low region specificity" "Detected in all" "HPA054641, HPA065897" Supported Supported "Nucleoplasm,Nuclear speckles,Cytosol" NA NA Nucleoplasm "Nuclear speckles, Cytosol" "HPA054641: AB_2682554, HPA065897: AB_2685576" "unprognostic (1.21e-2)" "unprognostic (2.88e-2)" "unprognostic (1.24e-3)" "unprognostic (1.53e-1)" "unprognostic (1.43e-3)" "unprognostic (6.42e-3)" "unprognostic (1.85e-2)" "unprognostic (2.21e-1)" "unprognostic (6.91e-2)" "unprognostic (1.89e-1)" "unprognostic (3.59e-1)" "unprognostic (9.16e-4)" "unprognostic (8.84e-11)" "unprognostic (1.92e-1)" "unprognostic (2.15e-1)" "unprognostic (3.35e-1)" 0.0 0.0 0.0 7.1 0.9 3.4 0.0 0.0 0.2 0.1 1.1 0.0 0.0 1.0 0.1 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 1.0 2.4 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.9 0.0 0.0 1.0 0.4 5.0 0.0 12.0 0.0 0.0 2.8 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 31.3 62.6 0.5 0.0 23.8 4.3 8.0 0.1 0.1 0.7 0.0 59.4 0.0 0.0 0.2 120.8 5.1 0.0 0.3 0.0 0.0 0.1 0.0 0.3 0.3 0.0 3.1 76.3 0.8 0.1 0.2 0.5 0.6 0.1 34.4 0.0 0.2 1.7 0.4 0.0 0.2 0.9 0.0 0.8 3.5 0.2 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.2 98.2 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.2 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 1.9 0.0 0.0 0.0 0.2 0.0 TET2 "FLJ20032, KIAA1546" ENSG00000168769 "Tet methylcytosine dioxygenase 2" Q6N021 4 105145875-105279816 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Cell cycle" "Chromatin regulator, Dioxygenase, DNA-binding, Oxidoreductase" "Cancer-related genes, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 29.0" "Lineage enriched" "Detected in all" 4 "granulocytes: 29.0" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA043135 Supported Approved Nucleoplasm NA NA Nucleoplasm "HPA043135: AB_10794177" "unprognostic (6.83e-2)" "unprognostic (3.52e-2)" "unprognostic (1.69e-2)" "unprognostic (9.42e-2)" "unprognostic (4.15e-2)" "unprognostic (5.88e-2)" "unprognostic (6.12e-2)" "unprognostic (1.19e-3)" "unprognostic (1.15e-2)" "unprognostic (1.57e-2)" "unprognostic (5.77e-2)" "unprognostic (7.29e-2)" "unprognostic (2.70e-3)" "unprognostic (6.10e-2)" "unprognostic (1.89e-1)" "unprognostic (9.15e-2)" "unprognostic (7.84e-2)" 9.9 6.1 8.7 11.9 11.4 26.3 8.0 4.1 10.0 9.6 7.4 10.1 5.8 8.2 10.1 7.4 16.2 9.2 6.6 6.8 9.0 4.2 6.7 5.5 9.9 9.8 13.7 5.7 8.5 7.0 7.4 29.0 12.4 9.1 6.5 8.0 4.7 13.5 8.2 9.8 16.0 10.2 7.8 15.5 12.9 6.8 3.2 14.6 9.3 7.2 6.9 8.7 9.8 12.3 2.8 5.1 29.0 7.0 2.6 2.1 1.4 4.8 3.1 10.6 10.8 1.9 4.3 4.3 3.5 4.7 5.0 4.9 3.1 6.5 0.5 4.0 4.3 2.4 4.6 10.2 6.1 5.7 6.2 2.7 6.8 6.0 1.1 5.4 15.4 11.3 3.7 8.3 4.8 6.2 8.1 6.6 3.7 7.2 12.7 4.3 3.6 2.5 4.2 2.3 6.4 1.9 7.9 5.3 1.0 4.6 10.2 7.6 6.2 3.8 9.9 0.6 6.0 4.5 11.1 8.5 7.6 6.9 2.2 5.9 8.5 6.1 6.4 4.6 3.8 7.4 10.8 7.0 7.2 2.1 5.5 0.8 2.6 1.2 1.2 5.1 2.8 1.0 1.6 29.0 2.6 6.4 4.5 1.5 1.4 8.7 11.4 4.1 10.0 9.0 4.2 13.7 5.7 9.1 14.6 23.8 26.1 5.6 9.4 12.8 21.1 21.6 7.6 21.4 20.5 8.7 15.7 16.9 6.6 5.6 0.2 12.9 15.8 0.0 6.6 4.8 7.5 10.8 26.6 6.6 13.0 33.4 22.3 9.2 49.2 0.4 7.5 43.4 5.0 11.8 15.9 5.6 6.6 17.3 6.7 2.4 23.8 12.9 8.2 0.2 0.6 31.5 28.6 17.5 12.7 22.5 TGFBR2 "MFS2, TBR-ii, TBRII" ENSG00000163513 "Transforming growth factor beta receptor 2" P37173 3 30606502-30694142 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins" "Apoptosis, Differentiation, Growth regulation" "Kinase, Receptor, Serine/threonine-protein kinase, Transferase" "Aortic aneurysm, Cancer-related genes, Craniosynostosis, Disease mutation, Hereditary nonpolyposis colorectal cancer" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 14 "Endothelial cells: 188.8;Ito cells: 564.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "ASC diff: 54.5;ASC TERT1: 82.2;HSkMC: 70.9;LHCN-M2: 67.2;TIME: 61.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB073537 Supported "Plasma membrane" NA NA 560000 "Plasma membrane" "CAB073537: " "unprognostic (1.74e-1)" "unprognostic (1.84e-2)" "unprognostic (3.70e-1)" "unprognostic (3.02e-2)" "unprognostic (1.92e-1)" "unprognostic (2.26e-1)" "unprognostic (1.96e-1)" "unprognostic (1.62e-1)" "unprognostic (1.40e-1)" "unprognostic (2.24e-2)" "unprognostic (7.36e-2)" "unprognostic (1.12e-1)" "unprognostic (1.65e-2)" "unprognostic (4.72e-2)" "unprognostic (1.81e-2)" "unprognostic (8.81e-2)" "unprognostic (8.02e-2)" 91.8 24.6 6.7 24.6 10.3 7.3 88.3 3.6 7.3 36.5 42.6 9.8 18.6 13.2 42.6 23.3 36.2 28.4 42.6 73.5 6.9 5.2 32.6 21.9 52.6 75.7 12.6 3.7 22.2 26.0 17.4 10.3 24.2 9.9 35.2 17.5 27.9 22.5 19.5 34.9 17.0 31.3 37.2 12.0 68.7 26.8 15.4 8.2 19.3 40.9 16.8 26.9 48.0 82.0 5.3 6.8 20.0 6.6 1.4 19.7 3.9 2.5 14.7 0.9 0.0 54.5 82.2 2.5 12.8 18.0 4.4 4.4 3.3 13.6 0.3 46.2 17.1 5.2 5.1 0.6 18.7 7.3 1.0 1.3 1.4 1.7 16.5 23.3 2.3 12.1 70.9 16.6 19.0 18.4 20.2 47.6 1.7 0.3 0.0 67.2 0.2 2.3 1.7 0.4 12.8 5.9 2.1 5.9 0.3 23.6 6.0 0.0 0.9 3.8 1.0 3.6 1.2 0.0 2.5 61.6 21.7 5.4 9.8 4.8 0.5 0.0 2.0 13.0 2.5 8.7 6.9 2.9 20.0 3.5 3.0 3.2 4.0 5.4 4.2 2.6 5.3 19.7 9.1 12.6 1.4 6.6 6.8 1.2 3.9 6.7 10.3 3.6 7.3 6.9 5.2 12.6 3.7 9.9 8.2 134.0 83.8 41.5 14.2 33.2 1.9 64.1 48.4 12.0 53.4 26.2 0.0 5.3 3.3 11.4 2.0 188.8 9.7 0.0 13.8 4.3 48.1 7.3 28.9 45.3 27.1 0.0 8.1 564.1 139.2 2.0 30.5 46.1 28.7 1.8 11.9 0.2 25.3 10.8 44.6 5.6 0.9 32.3 36.0 0.3 1.1 26.7 3.1 39.4 13.0 9.0 TNFRSF14 "ATAR, CD270, HVEA, HVEM, LIGHTR, TR2" ENSG00000157873 "TNF receptor superfamily member 14" Q92956 1 2555639-2565382 "Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins" "Adaptive immunity, Host-virus interaction, Immunity, Innate immunity" "Host cell receptor for virus entry, Receptor" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "CAPAN-2: 14.6;HDLM-2: 14.8;HHSteC: 17.3;Karpas-707: 13.6;SK-MEL-30: 28.5" "HPA006404, CAB026150, CAB030007" Approved NA NA "CAB026150: , CAB030007: AB_2303380, HPA006404: AB_1851348" "prognostic favorable (4.39e-5)" "unprognostic (3.48e-2)" "unprognostic (1.53e-2)" "prognostic favorable (8.01e-6)" "unprognostic (1.11e-2)" "unprognostic (6.83e-3)" "unprognostic (9.62e-3)" "unprognostic (2.32e-1)" "unprognostic (3.25e-1)" "unprognostic (1.62e-1)" "unprognostic (2.31e-1)" "unprognostic (1.64e-1)" "unprognostic (1.86e-2)" "unprognostic (1.16e-2)" "unprognostic (2.72e-2)" "unprognostic (1.58e-1)" "prognostic favorable (7.79e-6)" 15.9 24.9 4.9 38.9 2.8 11.0 21.9 2.0 4.5 16.8 36.3 3.2 18.5 36.3 15.2 20.5 13.7 12.3 36.7 12.7 4.9 2.5 19.3 20.5 30.3 33.2 3.6 5.7 12.8 7.3 3.5 9.3 8.3 3.9 21.5 8.2 44.1 20.9 22.6 5.2 8.4 41.9 14.6 4.1 36.7 16.7 5.9 2.7 23.5 10.8 10.6 25.0 15.4 17.2 18.2 9.7 30.2 25.8 8.1 25.1 14.2 1.3 0.1 0.1 2.4 5.2 2.8 0.8 0.7 2.4 1.4 1.9 0.2 14.6 0.8 0.1 2.2 1.4 1.3 0.0 0.9 0.2 14.8 0.0 8.5 0.4 2.7 17.3 1.1 10.6 2.7 1.4 0.7 0.1 2.1 3.8 0.8 1.2 13.6 1.3 0.0 4.7 1.3 0.0 4.6 1.3 3.8 0.0 4.2 0.2 2.1 0.4 0.0 0.6 0.1 28.5 0.0 0.4 0.3 9.6 0.2 0.6 0.3 0.1 11.1 2.7 0.4 2.4 1.2 1.0 3.0 15.1 8.2 17.2 25.8 14.9 16.6 18.0 14.8 9.7 18.2 17.3 14.9 30.2 8.1 24.1 8.7 25.1 14.2 4.9 2.8 2.0 4.5 4.9 2.5 3.6 5.7 3.9 2.7 17.9 38.9 54.7 30.5 14.5 1.5 6.7 56.0 26.8 31.8 33.2 0.0 1.0 3.3 16.7 0.3 48.4 116.5 0.0 29.0 0.8 16.0 32.4 50.9 18.3 78.8 0.0 34.7 35.0 60.9 1.3 19.2 62.9 43.9 111.0 60.4 15.8 19.7 86.3 13.1 30.9 0.5 19.4 17.5 0.0 0.3 11.7 1.0 77.3 72.2 38.8 TP53 "LFS1, p53" ENSG00000141510 "Tumor protein p53" P04637 17 7661779-7687550 "Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transcription factors, Transporters" "Apoptosis, Biological rhythms, Cell cycle, Host-virus interaction, Necrosis, Transcription, Transcription regulation" "Activator, DNA-binding, Repressor" "Cancer-related genes, Disease mutation, Li-Fraumeni syndrome, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 102.6" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002973, CAB039238, CAB039239, HPA051244, HPA063532, CAB072876" Enhanced Enhanced Nucleoplasm Yes No Nucleoplasm "CAB002973: AB_2206626, CAB039238: , CAB039239: , CAB072876: AB_2665731, HPA051244: AB_2681403, HPA063532: " "unprognostic (2.29e-2)" "unprognostic (8.83e-3)" "unprognostic (1.26e-2)" "prognostic favorable (1.35e-4)" "unprognostic (9.95e-2)" "unprognostic (4.00e-2)" "unprognostic (2.79e-3)" "unprognostic (4.99e-2)" "unprognostic (2.75e-2)" "unprognostic (2.55e-1)" "unprognostic (1.30e-1)" "prognostic unfavorable (5.01e-4)" "unprognostic (1.86e-3)" "unprognostic (7.89e-3)" "unprognostic (8.05e-2)" "unprognostic (2.74e-1)" "unprognostic (1.08e-1)" 18.5 11.1 6.0 28.6 6.8 9.0 17.5 2.5 7.3 18.5 14.6 6.8 8.3 9.7 20.3 15.0 25.3 16.7 22.6 8.1 5.0 3.8 10.6 20.8 11.2 26.0 6.6 3.1 33.8 13.8 4.9 6.0 22.8 6.9 16.5 14.5 9.9 15.3 16.1 12.5 24.6 14.0 12.8 6.2 24.2 12.0 14.1 6.9 102.6 13.2 23.5 31.2 16.9 15.0 15.2 19.6 2.2 14.1 11.0 11.3 8.2 19.4 36.0 19.7 14.2 9.2 11.0 20.8 7.0 15.8 19.4 24.6 1.0 10.0 45.8 31.9 13.8 18.9 43.0 28.5 19.3 18.2 10.2 19.1 18.5 20.2 17.1 27.7 0.4 9.6 13.9 22.5 9.4 26.1 11.2 19.0 6.2 0.9 1.8 9.9 34.6 31.1 22.7 19.8 2.5 0.7 60.4 13.9 15.9 14.5 21.6 11.7 20.3 23.1 15.6 5.9 10.2 27.0 1.7 24.6 23.3 7.7 0.3 11.8 12.1 8.8 19.7 6.0 2.4 19.6 0.8 13.3 2.2 9.1 14.1 11.1 15.2 9.4 10.2 19.6 14.5 9.9 10.8 1.7 11.0 11.9 17.9 11.3 8.2 6.0 6.8 2.5 6.4 5.0 3.8 6.6 3.1 6.9 6.9 8.9 10.9 24.4 8.9 25.4 2.3 2.0 22.9 8.1 12.5 19.2 0.0 30.5 8.3 19.1 7.8 19.6 10.2 0.0 15.7 35.3 17.1 11.3 1.1 16.1 21.7 0.0 29.6 20.3 27.8 2.1 21.3 14.4 11.8 15.4 37.2 6.1 19.5 0.0 15.9 6.5 2.2 12.9 20.1 0.5 4.2 28.7 18.8 15.7 50.6 7.4 TP63 "EEC3, KET, NBP, OFC8, p51, p53CP, p63, p73H, p73L, SHFM4, TP53CP, TP53L, TP73L" ENSG00000073282 "Tumor protein p63" Q9H3D4 3 189631416-189897279 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Apoptosis, Notch signaling pathway, Transcription, Transcription regulation" "Activator, Developmental protein, DNA-binding" "Cancer-related genes, Disease mutation, Ectodermal dysplasia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "skeletal muscle: 83.2;skin 1: 54.2" "Group enriched" "Detected in many" 12 "Basal keratinocytes: 244.6;Suprabasal keratinocytes: 247.4" "Group enriched" "Detected in many" 11 "cervical cancer: 37.9;head and neck cancer: 73.3;lung cancer: 37.3;urothelial cancer: 21.2" "Not detected" "Not detected" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Group enriched" "Detected in some" 5 "HaCaT: 23.8;HBEC3-KT: 45.6;hTCEpi: 34.6;hTERT-HME1: 33.1;RT4: 50.1" "Low region specificity" "Detected in many" "Not detected" "Not detected" "CAB000083, HPA006288, HPA006289, HPA007009, HPA007010" Enhanced Enhanced Nucleoplasm NA NA Nucleoplasm "CAB000083: AB_2207187, HPA006288: AB_1080334, HPA006289: , HPA007009: , HPA007010: AB_1080336" "prognostic favorable (1.07e-4)" "unprognostic (1.30e-1)" "unprognostic (1.44e-1)" "unprognostic (3.02e-1)" "unprognostic (4.38e-2)" "unprognostic (3.50e-1)" "unprognostic (1.29e-1)" "unprognostic (5.17e-2)" "unprognostic (2.78e-1)" "unprognostic (5.37e-2)" "unprognostic (2.09e-3)" "unprognostic (1.54e-1)" "unprognostic (1.87e-5)" "unprognostic (1.86e-1)" "unprognostic (1.05e-1)" "unprognostic (1.62e-1)" "unprognostic (2.74e-3)" 2.9 0.1 0.2 0.7 0.1 0.0 7.2 0.1 0.2 9.5 0.1 0.1 5.7 0.0 0.3 8.0 33.7 0.3 0.0 0.2 0.1 0.1 0.4 0.1 1.2 0.2 0.1 0.2 0.1 0.1 0.0 0.3 7.8 0.8 9.6 0.0 0.3 9.0 7.8 83.2 54.2 0.1 2.7 0.6 0.1 0.1 1.2 0.0 9.0 0.4 36.7 26.1 9.6 19.2 3.7 1.3 3.0 0.9 1.2 1.2 0.2 0.6 1.2 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 4.4 0.1 0.0 0.0 23.8 0.0 45.6 0.0 0.3 0.0 0.5 0.3 0.1 0.0 0.0 0.1 0.0 34.6 0.0 33.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 50.1 0.0 0.0 0.0 0.0 0.0 0.7 0.2 0.0 0.0 0.0 0.0 0.0 0.0 7.0 0.1 0.3 0.1 0.0 0.2 2.0 0.4 1.1 0.9 0.5 0.7 3.7 1.2 1.0 0.4 1.7 0.8 0.7 3.0 1.2 0.9 1.3 0.8 0.2 0.2 0.1 0.1 0.2 0.1 0.1 0.1 0.2 0.8 0.0 0.0 4.0 0.0 20.4 244.6 0.0 0.6 0.0 1.4 5.7 0.0 0.0 18.7 0.0 0.2 0.7 0.3 0.0 0.0 0.2 1.8 1.0 2.6 0.0 0.0 2.2 0.0 0.0 0.0 0.0 0.0 0.3 0.0 8.5 1.0 0.0 0.0 1.2 0.0 1.1 0.0 0.0 0.0 0.5 0.3 2.6 247.4 7.4 0.0 0.0 10.1 TRAF7 "DKFZp586I021, MGC7807, RFWD1, RNF119" ENSG00000131653 "TNF receptor associated factor 7" Q6Q0C0 16 2155698-2178129 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Apoptosis, Transcription, Transcription regulation, Ubl conjugation pathway" Transferase "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA041229 Approved Supported "Vesicles,Plasma membrane" NA NA Vesicles "Plasma membrane" "HPA041229: AB_10794194" "unprognostic (1.94e-1)" "unprognostic (5.97e-2)" "unprognostic (1.13e-1)" "unprognostic (4.23e-2)" "unprognostic (1.09e-1)" "unprognostic (1.03e-1)" "unprognostic (1.65e-2)" "unprognostic (2.77e-3)" "unprognostic (7.08e-2)" "unprognostic (3.52e-2)" "unprognostic (1.52e-2)" "unprognostic (1.08e-1)" "unprognostic (9.23e-2)" "unprognostic (6.07e-2)" "unprognostic (2.99e-2)" "unprognostic (2.43e-1)" "unprognostic (8.48e-2)" 16.0 18.2 18.3 22.3 20.6 28.5 39.1 28.7 25.6 22.1 29.4 9.1 21.1 37.3 20.4 18.3 32.9 21.9 36.9 21.0 18.3 14.8 21.3 47.3 18.3 40.9 13.4 14.7 19.3 41.6 17.7 20.3 19.5 12.8 16.2 16.9 13.0 24.4 23.1 25.5 32.2 37.8 28.8 14.1 21.4 25.1 13.2 10.6 26.1 20.3 30.9 21.9 21.9 28.9 6.7 12.3 7.7 13.9 3.0 7.1 5.2 20.7 26.6 15.2 27.2 15.8 29.8 17.9 16.0 20.2 18.9 17.1 32.3 26.8 13.3 19.0 20.4 12.1 24.4 14.2 28.4 7.2 21.0 18.2 19.0 35.4 24.7 20.9 20.2 27.6 29.5 23.8 18.2 23.9 15.6 36.5 26.4 20.3 18.0 18.0 47.5 20.7 23.5 29.9 28.7 13.0 38.7 25.3 26.7 15.2 11.2 30.7 25.5 13.4 25.8 17.5 8.3 29.3 24.9 27.5 23.0 32.4 21.4 17.4 26.1 19.3 17.6 13.1 13.1 17.8 3.7 10.0 7.7 5.4 13.9 5.0 6.7 5.3 5.7 12.3 4.9 3.8 4.5 6.9 3.0 9.4 6.0 7.1 5.2 18.3 20.6 28.7 25.6 18.3 14.8 13.4 14.7 12.8 10.6 0.0 8.6 11.9 15.5 25.5 14.6 3.4 17.8 4.0 4.5 14.0 5.9 20.5 14.9 35.4 3.8 23.9 60.0 0.0 51.6 30.1 20.0 27.8 9.2 26.1 37.6 35.0 32.6 23.4 38.3 9.1 23.0 18.8 10.1 35.1 35.9 10.5 45.1 40.3 20.8 18.9 8.9 6.5 16.0 4.8 21.5 28.4 22.3 12.9 33.8 29.6 TRRAP "PAF400, TR-AP, Tra1" ENSG00000196367 "Transformation/transcription domain associated protein" Q9Y4A5 7 98877933-99050831 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Transcription, Transcription regulation" "Activator, Chromatin regulator" "Autism spectrum disorder, Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA054376 Supported "Nucleoplasm,Golgi apparatus" NA NA Nucleoplasm "Golgi apparatus" "HPA054376: AB_2682467" "unprognostic (2.10e-1)" "unprognostic (7.79e-2)" "unprognostic (2.21e-1)" "unprognostic (4.35e-2)" "unprognostic (2.02e-1)" "unprognostic (2.02e-1)" "prognostic unfavorable (8.77e-4)" "unprognostic (1.40e-2)" "unprognostic (2.39e-2)" "unprognostic (3.99e-2)" "unprognostic (9.45e-2)" "unprognostic (7.02e-2)" "unprognostic (2.21e-3)" "unprognostic (1.59e-1)" "unprognostic (1.98e-1)" "unprognostic (1.04e-1)" "unprognostic (2.96e-1)" 9.6 14.2 10.7 18.4 13.4 18.8 14.9 22.8 14.4 14.1 11.3 15.4 10.0 10.6 15.1 10.1 11.3 17.1 11.4 11.4 10.7 9.5 10.8 11.0 13.1 17.1 12.4 9.4 22.4 16.2 26.7 29.9 12.2 9.6 11.8 10.2 13.7 11.8 16.7 11.7 16.9 13.3 16.9 14.2 14.5 11.5 19.3 12.1 37.1 16.6 7.7 19.3 12.8 11.5 2.7 3.1 5.7 0.9 1.3 2.7 0.3 12.3 14.4 15.0 12.7 7.4 7.6 7.5 5.4 7.3 8.6 8.3 11.2 5.5 17.2 8.7 10.1 16.6 6.4 15.5 7.5 9.5 9.9 15.2 10.5 10.5 6.5 5.5 18.8 7.8 7.1 4.4 14.0 12.0 6.0 11.0 15.6 17.9 32.7 8.0 23.8 23.0 7.5 11.4 7.5 8.9 17.0 8.6 13.1 4.5 13.8 11.9 14.8 13.8 9.1 4.6 12.8 4.6 8.5 11.5 11.6 16.9 15.3 12.7 13.5 15.3 25.5 8.2 9.7 11.4 5.7 0.9 0.6 1.5 0.6 2.7 2.0 2.7 1.3 0.9 2.7 1.9 1.8 2.9 1.3 0.9 3.1 2.0 0.3 10.7 13.4 22.8 14.4 10.7 9.5 12.4 9.4 9.6 12.1 14.9 13.9 4.5 3.7 14.1 13.1 9.2 5.1 4.0 10.3 14.0 25.5 7.7 0.0 6.7 3.0 9.0 6.1 0.0 5.7 4.3 8.0 6.5 5.7 10.9 7.0 20.6 12.1 9.2 8.7 4.0 8.1 8.4 8.5 5.4 10.6 5.8 7.9 3.5 8.1 4.3 8.5 0.0 6.1 14.4 8.0 18.6 9.2 9.2 9.5 6.0 TSC1 "hamartin, KIAA0243, LAM, TSC" ENSG00000165699 "TSC complex subunit 1" Q92574 9 132891348-132946874 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" Chaperone "Cancer-related genes, Disease mutation, Epilepsy, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 7 "Late spermatids: 99.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB011568, CAB012481, HPA074132" Supported Enhanced Cytosol NA NA Cytosol "CAB011568: AB_732752, CAB012481: , HPA074132: AB_2686666" "unprognostic (1.88e-1)" "unprognostic (1.51e-1)" "unprognostic (1.40e-2)" "unprognostic (2.56e-1)" "unprognostic (6.67e-2)" "unprognostic (4.23e-3)" "prognostic unfavorable (6.03e-6)" "unprognostic (1.96e-2)" "unprognostic (3.48e-2)" "unprognostic (1.24e-1)" "prognostic favorable (8.01e-4)" "unprognostic (1.84e-2)" "prognostic favorable (7.91e-4)" "unprognostic (9.49e-2)" "unprognostic (1.46e-1)" "unprognostic (2.35e-1)" "unprognostic (1.16e-1)" 10.4 13.6 15.8 8.8 26.8 13.6 11.4 32.1 28.3 12.7 10.8 22.6 7.9 9.1 14.6 12.3 10.9 12.4 9.7 17.6 13.0 12.1 13.1 9.4 11.6 10.2 12.5 15.1 21.2 12.1 15.9 19.5 15.8 21.1 11.8 12.6 13.1 11.6 10.4 20.0 13.8 11.2 14.2 12.4 13.7 10.6 36.2 14.9 10.5 16.2 8.6 14.2 10.9 11.1 2.8 3.1 4.8 7.0 4.9 7.1 2.6 6.2 7.4 10.1 8.3 10.4 9.9 19.0 8.4 13.6 8.8 8.7 12.5 7.3 14.6 3.7 16.0 13.4 16.2 11.9 8.5 9.0 7.0 6.3 4.6 14.7 10.2 12.4 6.8 6.3 10.7 6.4 11.2 13.8 8.8 10.1 13.0 8.1 8.0 10.0 11.5 6.1 5.8 13.9 9.2 6.2 7.4 19.1 8.2 3.9 8.2 5.1 7.8 9.8 6.1 4.8 12.5 11.1 4.0 10.4 14.4 8.7 8.6 5.7 4.5 10.0 14.2 8.2 4.0 6.4 4.1 4.4 4.8 6.5 7.0 7.1 1.9 3.6 5.7 3.1 2.8 5.9 5.3 1.7 4.9 3.2 1.8 5.7 2.6 15.8 26.8 32.1 28.3 13.0 12.1 12.5 15.1 21.1 14.9 20.8 25.6 10.8 4.8 6.6 26.0 26.6 7.6 21.4 12.5 10.4 35.3 12.8 11.6 9.5 39.6 8.7 6.3 0.0 6.2 19.5 9.1 6.5 8.1 5.0 7.8 23.8 16.1 12.3 8.7 99.6 14.4 7.4 11.8 8.2 7.9 10.4 10.9 8.4 10.6 7.5 25.2 19.4 8.0 18.9 17.8 7.5 17.6 7.1 9.9 6.5 TSC2 "LAM, PPP1R160, TSC4, tuberin" ENSG00000103197 "TSC complex subunit 2" P49815 16 2047465-2089487 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Host-virus interaction" "GTPase activation" "Cancer-related genes, Disease mutation, Epilepsy, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 4 "Cone photoreceptor cells: 88.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002225, HPA030409, HPA049679" Approved Enhanced Cytosol NA NA Cytosol "CAB002225: AB_564043, HPA030409: AB_10602483, HPA049679: AB_2680848" "unprognostic (2.80e-1)" "unprognostic (1.01e-1)" "unprognostic (1.60e-2)" "unprognostic (2.24e-1)" "unprognostic (1.02e-1)" "unprognostic (1.03e-3)" "unprognostic (2.04e-2)" "unprognostic (6.05e-3)" "unprognostic (3.43e-1)" "unprognostic (8.94e-2)" "prognostic favorable (5.06e-4)" "unprognostic (4.32e-2)" "unprognostic (3.91e-2)" "unprognostic (2.14e-2)" "unprognostic (2.54e-1)" "unprognostic (1.51e-2)" "unprognostic (8.96e-2)" 13.9 11.9 16.9 12.4 20.0 10.9 13.2 35.1 26.9 20.5 17.0 19.4 17.9 14.0 20.1 12.2 13.0 18.6 15.0 14.0 13.3 8.8 11.8 9.8 12.7 10.1 13.8 14.7 21.1 16.1 20.0 18.1 10.6 14.6 13.8 10.8 16.7 22.9 19.6 31.7 14.5 13.2 13.5 11.4 12.9 16.6 21.4 12.9 14.1 20.1 11.3 10.9 18.0 14.0 4.7 5.6 7.7 4.9 3.6 7.0 3.7 7.2 11.6 16.1 18.2 19.2 16.2 13.6 17.4 11.9 13.1 11.2 13.9 13.8 10.9 15.5 14.3 6.1 12.0 9.6 12.6 9.8 8.3 15.8 10.3 22.5 5.7 13.2 12.8 12.5 19.1 8.0 10.6 7.9 15.8 12.3 7.9 10.0 9.8 11.6 14.4 15.2 3.7 16.7 5.4 11.4 24.2 17.6 13.9 5.3 6.5 12.2 23.1 24.8 16.4 8.8 16.7 15.0 9.5 19.4 13.8 9.4 12.3 8.8 21.9 21.8 21.8 5.7 5.2 16.3 6.2 4.9 5.4 7.0 4.7 6.7 4.4 4.4 4.1 5.6 4.7 3.1 4.8 7.7 3.6 3.7 1.5 3.2 3.7 16.9 20.0 35.1 26.9 13.3 8.8 13.8 14.7 14.6 12.9 23.8 17.6 14.9 7.2 8.1 44.2 38.9 20.4 9.4 10.3 19.2 88.4 10.1 3.3 12.8 11.0 19.5 25.8 0.0 12.2 6.5 14.6 9.4 8.1 29.2 9.8 42.9 31.2 34.4 10.5 22.4 26.2 16.6 8.5 7.2 23.8 24.1 15.9 17.5 24.4 6.7 69.1 12.9 11.8 19.4 39.6 8.5 7.8 20.0 24.7 9.2 TSHR LGR3 ENSG00000165409 "Thyroid stimulating hormone receptor" P16473 14 80954989-81146302 "Cancer-related genes, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "Cancer-related genes, Congenital hypothyroidism, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 6 "thyroid gland: 158.0" "Cell type enhanced" "Detected in some" 15 "Club cells: 2.3;Intestinal endocrine cells: 1.7" "Cancer enriched" "Detected in some" 116 "thyroid cancer: 100.4" "Not detected" "Not detected" "Cell type enriched" "Detected in some" 5 "T-reg: 9.9" "Lineage enriched" "Detected in many" 5 "T-cells: 9.9" "Cell line enhanced" "Detected in some" "JURKAT: 34.0;MOLT-4: 13.3;SCLC-21H: 13.7;U-266/70: 6.7" "Low region specificity" "Detected in single" "Low region specificity" "Detected in all" CAB000473 Approved "Intracellular and membrane" NA NA "CAB000473: AB_2303782" "unprognostic (3.36e-3)" "unprognostic (1.31e-3)" "unprognostic (1.02e-2)" "unprognostic (4.17e-6)" "unprognostic (3.01e-3)" "unprognostic (1.85e-3)" "unprognostic (1.83e-1)" "unprognostic (2.66e-2)" "unprognostic (3.39e-2)" "unprognostic (2.60e-2)" "unprognostic (1.70e-1)" "unprognostic (7.11e-3)" "unprognostic (5.08e-7)" "unprognostic (1.32e-1)" "unprognostic (7.40e-2)" "unprognostic (1.19e-1)" "unprognostic (1.66e-1)" 0.1 0.2 0.1 0.2 0.4 0.3 0.2 0.1 0.3 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.0 0.3 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.4 0.1 0.0 0.1 0.1 0.1 0.3 0.3 0.5 0.1 0.0 0.8 0.2 0.0 0.1 0.3 0.1 0.0 0.2 0.2 0.1 0.1 0.1 27.3 158.0 0.2 0.4 0.1 0.1 1.8 0.8 1.3 0.3 0.1 9.9 0.1 0.2 0.1 0.4 0.3 0.0 0.0 0.2 0.1 0.0 0.0 0.1 0.2 0.3 0.4 0.1 0.1 0.2 0.1 0.5 0.0 0.1 0.2 0.1 0.2 0.4 0.2 0.0 0.1 0.2 0.2 0.0 0.1 0.2 0.1 0.0 34.0 0.2 0.4 0.1 0.3 13.3 0.3 0.3 0.1 0.1 0.5 0.1 0.5 0.0 0.3 13.7 0.2 0.1 0.1 0.1 0.3 0.2 0.0 0.1 0.4 0.3 0.3 0.2 6.7 3.5 0.3 0.2 0.1 0.2 0.6 0.2 0.2 0.2 0.1 0.2 1.0 0.8 0.5 0.1 1.8 0.3 0.2 1.3 0.1 0.3 0.8 9.9 0.1 0.1 0.4 0.1 0.1 0.1 0.1 0.1 0.0 0.5 0.1 0.0 0.3 0.0 0.0 0.0 0.0 0.5 0.0 0.0 2.3 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.5 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 U2AF1 "RN, RNU2AF1, U2AF35, U2AFBP" ENSG00000160201 "U2 small nuclear RNA auxiliary factor 1" Q01081 21 43092956-43107587 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "mRNA processing, mRNA splicing" RNA-binding "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Group enriched" "Detected in many" 6 "Basal keratinocytes: 437.9;Melanocytes: 192.3;Suprabasal keratinocytes: 379.0" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "HPA044833, HPA052083" Supported Enhanced Nucleoplasm NA NA Nucleoplasm "HPA044833: AB_10960990, HPA052083: AB_2681720" "unprognostic (1.10e-1)" "unprognostic (1.28e-1)" "unprognostic (5.98e-2)" "unprognostic (2.87e-2)" "unprognostic (1.36e-1)" "unprognostic (8.06e-2)" "unprognostic (2.76e-2)" "unprognostic (4.29e-4)" "unprognostic (4.81e-4)" "unprognostic (3.42e-2)" "unprognostic (2.31e-3)" "unprognostic (8.85e-2)" "unprognostic (2.14e-6)" "unprognostic (1.08e-1)" "unprognostic (1.40e-2)" "unprognostic (1.72e-1)" "unprognostic (1.26e-2)" 20.0 15.1 20.8 19.2 21.1 48.5 61.0 25.6 20.8 16.1 21.5 9.7 12.3 17.6 28.8 26.5 19.3 27.6 17.1 19.5 19.7 15.8 14.6 17.1 35.2 33.5 25.7 2.9 22.1 48.3 15.3 27.8 21.2 20.8 23.9 13.7 9.6 44.5 19.8 33.0 16.6 20.4 38.7 23.9 21.0 17.5 33.9 22.7 20.6 27.3 26.5 20.0 22.9 31.7 58.4 82.8 81.2 54.1 33.1 55.5 53.8 25.3 27.8 15.1 11.4 8.9 6.4 35.5 22.0 15.3 18.0 16.1 64.6 9.3 43.4 12.0 14.3 24.7 12.4 31.6 23.4 9.3 34.0 71.5 70.2 14.2 24.3 21.7 30.2 17.3 8.8 14.4 29.1 18.6 6.5 14.8 26.6 38.5 19.6 12.5 47.7 24.9 33.5 32.1 21.7 32.1 41.2 14.6 21.8 12.0 10.7 23.0 17.6 23.6 14.3 11.7 4.3 17.4 17.6 18.5 15.0 20.4 13.5 23.0 26.3 30.9 35.9 14.4 55.6 23.1 48.4 52.6 50.9 42.2 52.5 41.4 55.9 46.4 42.1 54.1 58.4 46.4 44.8 81.2 33.1 54.1 82.8 55.5 53.8 20.8 21.1 25.6 20.8 19.7 15.8 25.7 2.9 20.8 22.7 17.9 17.8 8.9 29.0 437.9 21.8 2.8 7.6 21.4 27.3 1.8 41.2 16.3 1.7 4.5 1.9 22.2 22.9 0.0 5.1 15.6 26.8 31.7 26.7 17.8 19.6 17.5 17.5 28.8 21.4 2.0 17.0 27.1 192.3 2.8 16.7 13.0 4.0 17.5 21.2 2.8 59.6 6.5 29.2 14.4 17.7 379.0 19.9 20.0 22.2 30.1 UBR5 "DD5, EDD, EDD1, HYD, KIAA0896" ENSG00000104517 "Ubiquitin protein ligase E3 component n-recognin 5" O95071 8 102253012-102412841 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "DNA damage, DNA repair, Host-virus interaction, Ubl conjugation pathway" Transferase "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA053688 Supported Nucleoplasm,Cytosol NA NA Nucleoplasm Cytosol "HPA053688: AB_2682230" "unprognostic (3.79e-3)" "unprognostic (7.44e-3)" "unprognostic (1.25e-1)" "unprognostic (2.10e-2)" "unprognostic (2.44e-2)" "unprognostic (1.41e-1)" "prognostic unfavorable (1.26e-4)" "unprognostic (2.50e-1)" "unprognostic (1.75e-2)" "unprognostic (7.54e-3)" "unprognostic (8.29e-3)" "unprognostic (3.84e-2)" "unprognostic (6.64e-2)" "unprognostic (3.16e-1)" "unprognostic (1.94e-1)" "unprognostic (1.69e-2)" "unprognostic (2.45e-1)" 27.0 16.7 27.1 29.5 31.7 30.3 29.2 40.8 32.8 24.9 25.0 19.1 21.1 14.4 26.8 24.0 23.8 22.0 17.6 22.7 25.5 15.3 17.9 17.0 24.2 29.6 21.9 20.6 29.7 22.2 32.4 25.5 25.0 23.6 20.2 17.1 19.7 22.9 21.8 39.9 29.7 22.4 29.3 17.5 21.9 21.1 39.7 28.3 37.9 20.3 15.9 27.0 27.5 28.6 5.0 4.0 6.3 5.5 2.4 7.1 2.1 23.6 10.6 20.5 10.4 20.2 20.6 18.9 17.9 15.8 14.0 12.3 10.6 15.9 47.1 15.5 16.7 9.2 14.4 17.5 15.5 19.7 20.4 8.6 39.3 14.5 19.0 18.0 12.2 21.7 23.6 15.5 14.4 25.2 16.0 16.8 13.5 18.9 26.8 13.7 21.4 31.0 14.6 15.4 22.9 12.0 18.1 12.1 22.3 12.8 23.2 15.1 12.6 12.5 12.1 12.4 18.6 19.6 13.0 16.8 15.0 17.5 13.4 12.4 14.4 13.8 48.5 14.8 19.1 12.1 3.1 3.4 5.0 5.6 3.4 5.6 5.0 6.0 5.9 4.0 3.9 4.8 7.1 6.3 2.4 5.5 3.6 7.1 2.1 27.1 31.7 40.8 32.8 25.5 15.3 21.9 20.6 23.6 28.3 23.8 27.7 29.8 38.5 46.4 48.4 35.8 5.1 40.2 63.7 29.6 64.8 19.1 8.3 15.1 25.0 38.3 17.3 0.0 13.1 14.9 48.2 37.7 28.9 15.8 15.4 54.0 32.0 23.4 29.4 20.2 36.8 28.9 42.2 27.1 17.9 31.5 16.2 17.3 34.3 6.7 44.0 12.9 38.7 64.7 30.4 53.3 58.2 30.5 17.7 46.9 USP8 "HumORF8, KIAA0055, SPG59, UBPY" ENSG00000138592 "Ubiquitin specific peptidase 8" P40818 15 50424380-50514419 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Cell cycle, Ubl conjugation pathway" "Hydrolase, Protease, Thiol protease" "Cancer-related genes, Cushing syndrome, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA050215 Approved Supported "Golgi apparatus,Cytosol" NA NA "Golgi apparatus" Cytosol "HPA050215: AB_2681054" "unprognostic (5.81e-2)" "unprognostic (1.34e-1)" "unprognostic (1.46e-1)" "unprognostic (9.58e-2)" "unprognostic (2.35e-2)" "unprognostic (2.91e-1)" "unprognostic (1.42e-1)" "unprognostic (3.96e-1)" "unprognostic (1.68e-2)" "unprognostic (5.08e-2)" "unprognostic (2.94e-1)" "unprognostic (3.99e-2)" "prognostic favorable (1.29e-5)" "unprognostic (4.89e-2)" "unprognostic (1.13e-1)" "unprognostic (3.79e-1)" "unprognostic (1.58e-1)" 19.4 21.9 21.0 20.6 20.6 21.6 18.1 27.3 21.6 21.4 23.9 13.8 19.5 20.2 22.1 17.4 22.3 17.4 15.5 17.4 19.7 18.2 28.2 26.4 17.0 25.4 21.8 15.2 21.9 16.7 42.6 43.2 29.1 29.7 16.7 18.9 10.7 19.9 17.9 24.3 17.8 32.1 19.2 29.3 30.3 17.7 27.5 26.1 28.9 24.1 12.7 20.9 22.3 18.4 16.7 10.6 38.1 15.1 9.5 11.9 6.9 11.2 16.2 9.1 16.0 16.6 18.7 12.6 16.2 19.2 15.8 18.7 10.8 7.5 11.9 12.5 18.5 17.8 21.8 12.4 12.1 18.7 10.4 8.2 21.9 15.1 11.0 17.1 14.7 14.9 14.4 14.6 13.9 23.6 14.7 15.3 8.5 12.5 14.5 14.8 23.1 9.4 5.8 10.4 12.9 7.5 8.5 16.9 17.8 15.0 26.5 11.6 10.6 17.0 25.5 21.2 20.1 14.0 18.0 17.3 16.4 9.2 50.5 21.3 11.3 23.4 13.1 13.1 29.7 15.8 38.1 13.3 22.4 11.1 12.4 10.7 16.5 11.4 11.1 10.6 16.7 11.9 10.7 22.7 9.5 15.1 9.9 8.5 6.9 21.0 20.6 27.3 21.6 19.7 18.2 21.8 15.2 29.7 26.1 89.3 104.5 61.4 35.4 25.6 51.6 61.8 48.4 147.2 88.7 45.4 64.8 49.9 21.6 44.4 53.0 44.9 70.6 23.3 44.6 38.3 35.3 38.8 83.3 45.5 40.2 31.8 51.2 53.4 59.1 12.4 49.8 49.2 38.8 52.3 54.2 53.3 45.7 54.3 58.0 40.7 75.6 45.3 42.6 86.1 47.1 36.3 88.0 47.9 55.0 52.6 VHL VHL1 ENSG00000134086 "Von Hippel-Lindau tumor suppressor" P40337 3 10141008-10152220 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Ubl conjugation pathway" "Cancer-related genes, Congenital erythrocytosis, Disease mutation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "BEWO: 54.7" "CAB005430, HPA031631, HPA031632" Uncertain Enhanced Nucleoplasm,Cytosol NA NA Nucleoplasm Cytosol "CAB005430: AB_2241850, HPA031631: AB_2673968, HPA031632: AB_2673969" "prognostic unfavorable (9.02e-5)" "unprognostic (1.10e-1)" "unprognostic (4.46e-3)" "unprognostic (1.52e-1)" "unprognostic (1.10e-1)" "unprognostic (1.33e-1)" "prognostic unfavorable (1.32e-5)" "unprognostic (3.55e-1)" "unprognostic (3.03e-2)" "unprognostic (4.36e-2)" "unprognostic (5.82e-3)" "unprognostic (1.81e-2)" "unprognostic (2.51e-1)" "prognostic favorable (7.84e-4)" "unprognostic (1.46e-1)" "unprognostic (2.92e-2)" "unprognostic (1.28e-3)" 13.8 17.4 18.1 29.2 18.4 24.3 15.4 25.8 21.4 13.3 19.8 19.3 14.5 15.9 15.1 13.6 16.4 14.3 18.9 10.5 17.1 18.5 13.7 16.3 14.6 27.9 13.5 12.3 15.2 22.5 13.8 14.6 18.8 12.8 15.1 16.6 12.5 21.8 13.7 14.8 14.0 22.3 13.4 17.0 22.6 16.2 17.9 11.2 39.2 16.9 11.5 29.3 15.4 19.1 5.4 3.9 8.0 4.1 4.4 4.3 1.7 6.8 6.6 14.6 8.9 13.6 10.5 54.7 6.1 8.7 7.8 9.2 7.8 8.6 24.3 8.3 8.2 11.0 5.9 13.5 8.5 9.6 11.6 12.2 18.9 10.8 10.7 12.9 16.6 15.2 10.6 9.7 10.3 13.0 10.4 8.9 15.3 16.8 18.5 7.6 12.4 15.8 12.2 9.8 7.4 8.5 20.1 12.9 12.2 9.5 17.8 5.5 18.3 12.8 6.8 7.3 9.2 13.4 21.1 7.7 7.7 10.4 7.2 9.5 13.2 26.9 38.8 8.6 20.0 7.0 2.6 4.1 3.3 3.8 2.5 3.6 4.1 2.9 4.3 3.9 5.4 2.5 2.7 8.0 4.4 3.2 2.4 3.1 1.7 18.1 18.4 25.8 21.4 17.1 18.5 13.5 12.3 12.8 11.2 11.9 12.2 25.5 15.5 13.1 15.6 5.0 20.4 5.3 5.7 15.7 17.7 13.9 6.6 9.9 7.6 12.1 10.5 0.0 4.5 15.8 9.5 19.0 4.7 12.3 12.9 17.5 13.8 17.2 20.2 6.1 13.0 18.5 11.8 15.4 9.3 10.4 8.5 9.3 10.6 7.3 13.9 6.5 6.2 14.4 25.6 17.9 14.4 17.5 10.7 19.5 WAS "IMD2, THC, WASP, WASPA" ENSG00000015285 "Wiskott-Aldrich syndrome" P42768 X 48676596-48691427 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 30.7;lymphoid tissue: 55.9" "Cell type enhanced" "Detected in many" 8 "B-cells: 72.2;Hofbauer cells: 95.2;Kupffer cells: 94.9;Macrophages: 70.0;T-cells: 87.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "eosinophil: 20.3" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in some" "Daudi: 21.7;HEL: 19.1;HMC-1: 46.5;MOLT-4: 19.7;NB-4: 21.5;RPMI-8226: 26.5;THP-1: 19.5;U-266/70: 24.6;U-937: 24.8" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA002022, CAB004290" Enhanced Approved "Plasma membrane,Cytosol" NA NA 320000 "Plasma membrane" Cytosol "CAB004290: AB_628445, HPA002022: AB_1080581" "unprognostic (1.43e-3)" "unprognostic (2.09e-3)" "unprognostic (2.36e-2)" "prognostic favorable (4.95e-4)" "unprognostic (9.89e-2)" "prognostic favorable (3.78e-4)" "unprognostic (5.12e-3)" "unprognostic (7.60e-2)" "unprognostic (1.54e-2)" "unprognostic (2.86e-1)" "unprognostic (7.40e-2)" "unprognostic (3.60e-1)" "prognostic unfavorable (5.58e-6)" "unprognostic (2.24e-1)" "unprognostic (2.37e-2)" "unprognostic (3.55e-2)" "unprognostic (1.71e-1)" 7.6 4.0 4.9 28.9 7.8 30.7 3.3 2.0 5.1 2.7 4.4 5.9 0.5 4.8 2.4 5.6 3.7 4.5 4.4 3.0 4.6 4.1 4.1 5.0 12.6 29.9 7.6 1.3 2.6 2.2 0.7 2.6 5.4 6.0 3.2 3.2 3.5 5.4 1.9 1.4 2.2 14.3 3.7 12.8 55.9 4.1 1.7 7.3 53.2 2.8 1.4 33.2 5.8 2.5 2.1 3.5 20.3 5.3 2.1 3.2 2.0 0.2 0.0 0.1 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.3 21.7 0.1 0.0 0.1 0.7 0.0 0.0 0.0 12.5 0.1 19.1 0.2 0.0 0.2 9.8 46.5 0.0 0.0 0.0 0.0 0.0 0.0 11.7 0.2 13.4 0.0 2.2 19.7 21.5 0.1 0.3 0.1 17.3 0.0 26.5 0.0 0.0 0.1 0.2 0.3 0.2 0.2 0.1 0.1 19.5 0.1 0.0 0.1 0.3 0.0 24.6 12.0 15.2 0.1 24.8 0.0 1.8 4.6 20.3 3.0 5.0 2.2 1.8 2.3 2.5 3.5 2.1 2.1 2.3 18.1 2.1 5.3 1.8 3.2 2.0 4.9 7.8 2.0 5.1 4.6 4.1 7.6 1.3 6.0 7.3 3.0 21.3 72.2 0.1 2.2 0.0 0.8 0.0 2.7 0.0 0.0 0.0 0.8 1.7 0.1 0.5 0.5 0.0 23.3 0.3 0.9 1.5 0.2 46.2 0.9 95.2 0.0 1.2 5.5 94.9 0.8 0.0 70.0 3.3 45.9 0.0 0.2 0.1 0.0 0.0 1.5 0.0 0.0 0.6 1.4 1.1 1.3 1.1 87.0 0.0 0.1 WRN "RECQ3, RECQL2" ENSG00000165392 "Werner syndrome RecQ like helicase" Q14191 8 31033801-31173769 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "DNA damage, DNA repair" "DNA-binding, Exonuclease, Helicase, Hydrolase, Multifunctional enzyme, Nuclease" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA028661 Approved Supported "Nuclear speckles" NA NA "Nuclear speckles" "HPA028661: AB_10602255" "unprognostic (8.73e-2)" "unprognostic (9.33e-2)" "unprognostic (1.51e-3)" "unprognostic (3.85e-2)" "unprognostic (1.41e-1)" "unprognostic (1.85e-2)" "unprognostic (2.21e-3)" "unprognostic (1.25e-1)" "unprognostic (1.07e-1)" "unprognostic (1.16e-2)" "unprognostic (1.27e-2)" "unprognostic (6.63e-2)" "unprognostic (1.53e-2)" "unprognostic (6.51e-2)" "unprognostic (2.49e-1)" "unprognostic (1.00e-2)" "unprognostic (2.66e-1)" 10.1 9.2 5.6 8.5 6.6 15.6 11.1 10.7 7.3 14.2 8.0 7.7 7.7 5.5 24.4 8.8 7.6 9.7 6.9 7.0 5.9 4.0 5.1 7.7 7.2 6.7 8.2 5.3 12.0 9.9 7.8 28.1 8.5 7.0 8.6 7.8 8.3 10.8 7.8 7.7 10.2 7.0 12.1 14.9 8.9 8.3 10.4 7.3 11.8 7.9 6.3 9.3 10.8 8.7 3.9 2.7 1.3 1.9 2.9 6.2 1.6 6.5 6.4 13.3 8.4 8.0 12.8 8.4 7.4 7.3 9.1 9.5 4.1 4.0 15.4 6.8 7.5 6.9 3.4 8.2 5.3 13.6 4.3 7.0 15.7 6.1 3.4 10.0 9.3 5.8 9.3 5.9 8.6 10.4 4.5 8.7 10.8 24.8 9.7 8.3 4.2 19.3 4.5 11.4 7.1 4.6 11.1 10.1 6.2 3.8 7.2 2.9 7.7 9.0 5.1 7.0 7.8 3.5 4.6 13.9 9.9 6.1 5.0 6.2 2.6 2.8 19.3 7.3 7.3 6.8 1.2 1.9 1.3 3.3 1.9 6.2 3.9 3.8 3.3 2.7 3.5 2.5 3.2 0.5 2.9 0.8 2.0 2.8 1.6 5.6 6.6 10.7 7.3 5.9 4.0 8.2 5.3 7.0 7.3 8.9 8.8 10.8 8.0 11.9 14.2 6.5 12.7 9.4 11.4 15.7 21.6 5.9 1.7 5.1 37.8 8.5 3.2 23.3 8.4 4.7 10.8 8.1 2.3 8.9 4.5 14.3 2.4 6.2 5.1 8.1 17.5 4.9 10.1 5.4 12.1 21.9 7.1 2.9 13.4 2.1 22.1 6.5 9.5 8.7 18.6 8.9 4.7 5.1 7.6 9.8 WT1 "AWT1, GUD, NPHS4, WAGR, WIT-2" ENSG00000184937 "Wilms tumor 1" P19544 11 32387775-32435630 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, RNA-binding" "Cancer-related genes, Disease mutation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "endometrium 1: 69.0;fallopian tube: 34.5;ovary: 53.4" "Cell type enhanced" "Detected in some" 18 "Collecting duct cells: 19.2;Late spermatids: 5.9;Leydig cells: 7.8;Sertoli cells: 6.5" "Cancer enriched" "Detected in many" 14 "ovarian cancer: 55.2" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "HEL: 13.5;HMC-1: 17.4;K-562: 12.2;NB-4: 32.6;THP-1: 15.6" "Region enhanced" "Detected in single" "pons and medulla: 0.5" "Not detected" "Not detected" "CAB000327, HPA035717, HPA053848" Enhanced Enhanced Nucleoplasm NA NA Nucleoplasm "CAB000327: AB_2304486, HPA035717: AB_2674748, HPA053848: AB_2682279" "unprognostic (3.09e-3)" "unprognostic (9.97e-4)" "unprognostic (3.32e-1)" "unprognostic (8.24e-3)" "unprognostic (5.20e-2)" "unprognostic (1.98e-3)" "unprognostic (2.94e-2)" "unprognostic (1.59e-2)" "unprognostic (1.23e-2)" "unprognostic (4.15e-2)" "unprognostic (1.86e-2)" "unprognostic (1.36e-1)" "unprognostic (1.31e-10)" "unprognostic (2.65e-3)" "unprognostic (1.87e-1)" "unprognostic (1.96e-3)" "unprognostic (1.30e-2)" 10.3 0.0 0.2 1.8 0.6 0.0 0.2 0.2 0.5 20.3 1.5 0.2 3.7 0.0 69.0 9.3 0.4 34.5 0.8 2.1 0.9 0.0 5.3 0.2 0.8 0.5 0.2 0.2 53.4 0.2 0.0 0.2 6.9 0.3 0.9 0.0 0.2 0.2 4.2 0.2 0.0 0.4 23.7 0.2 14.6 0.0 24.5 0.2 0.2 0.3 0.2 0.2 1.3 4.1 0.1 0.0 0.0 0.4 0.0 0.0 0.0 0.0 2.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.4 0.0 0.1 0.1 0.0 0.0 0.0 6.3 0.0 0.0 0.0 4.7 13.5 0.0 1.2 3.8 9.0 17.4 0.0 0.0 2.8 0.0 0.0 0.0 2.8 12.2 0.1 2.7 0.0 7.9 32.6 0.7 0.0 3.8 1.2 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.6 1.8 15.6 0.1 0.0 2.4 0.0 0.3 0.0 0.0 0.0 0.1 2.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.2 0.6 0.2 0.5 0.9 0.0 0.2 0.2 0.3 0.2 0.0 0.0 0.0 0.2 0.0 0.0 1.4 0.0 0.0 0.0 19.2 0.0 0.9 0.0 0.0 2.5 0.0 0.0 0.0 0.0 0.7 0.2 0.1 0.0 0.0 0.3 0.0 0.0 2.5 0.0 5.9 7.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 1.2 0.0 6.5 0.0 1.9 0.9 0.0 0.7 0.0 0.0 0.1 XPA "XP1, XPAC" ENSG00000136936 "XPA, DNA damage recognition and repair factor" P23025 9 97674909-97697357 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "DNA damage, DNA repair" DNA-binding "Cancer-related genes, Disease mutation, Xeroderma pigmentosum" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000155, HPA056856" Supported Approved "Nucleoplasm,Cytokinetic bridge" Yes No Nucleoplasm "Cytokinetic bridge" "CAB000155: , HPA056856: AB_2683258" "unprognostic (8.76e-2)" "unprognostic (1.05e-3)" "unprognostic (1.60e-1)" "unprognostic (2.30e-2)" "unprognostic (4.17e-1)" "unprognostic (1.84e-1)" "unprognostic (5.26e-2)" "unprognostic (2.38e-1)" "unprognostic (3.90e-2)" "unprognostic (1.28e-1)" "unprognostic (1.97e-3)" "unprognostic (9.55e-3)" "prognostic favorable (4.28e-5)" "unprognostic (2.19e-2)" "unprognostic (1.56e-1)" "unprognostic (3.03e-2)" "unprognostic (1.17e-1)" 18.7 17.5 20.1 17.1 21.0 10.6 17.4 26.8 20.8 20.3 25.2 17.2 11.7 20.6 25.5 15.4 18.9 15.0 19.5 12.9 17.2 15.3 24.9 24.2 14.8 16.7 18.6 17.5 17.2 14.5 23.0 23.1 12.8 17.7 20.3 13.6 16.4 16.1 21.7 43.3 16.3 22.2 27.5 17.1 16.2 25.1 6.4 15.8 15.7 31.5 11.9 21.6 22.0 16.4 22.2 23.4 12.7 15.8 19.7 21.6 11.3 23.0 5.4 8.1 10.0 9.9 9.7 5.6 6.3 10.0 11.5 7.8 14.1 19.4 13.0 6.1 6.9 7.7 11.6 6.4 7.6 9.8 8.9 12.9 10.2 11.8 7.8 10.8 12.1 12.4 8.4 8.2 5.3 5.5 7.8 12.8 10.8 14.1 10.2 6.3 7.2 15.7 14.6 5.5 22.0 9.0 16.0 17.3 11.0 18.3 9.0 11.4 11.5 9.0 6.9 8.1 6.4 10.1 7.3 8.0 4.0 10.1 15.9 13.6 18.1 14.5 8.2 10.0 8.7 7.9 6.0 13.3 12.7 16.2 13.1 18.7 19.5 17.7 15.6 13.5 22.2 21.6 18.6 1.5 19.7 15.8 23.4 18.3 11.3 20.1 21.0 26.8 20.8 17.2 15.3 18.6 17.5 17.7 15.8 23.8 31.5 27.5 17.4 15.3 99.5 29.1 50.9 34.8 40.9 21.0 76.6 27.4 102.8 31.2 1.2 29.2 16.9 0.0 33.5 8.3 24.2 16.3 29.0 40.6 30.4 79.4 21.5 17.8 17.5 2.6 40.9 29.8 13.5 49.5 21.3 71.6 24.5 21.0 44.6 38.3 99.8 32.3 31.9 12.8 16.4 16.4 11.7 25.3 26.3 20.2 XPC "RAD4, XPCC" ENSG00000154767 "XPC complex subunit, DNA damage recognition and repair factor" Q01831 3 14145147-14178783 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "DNA damage, DNA repair, Transcription, Transcription regulation" DNA-binding "Cancer-related genes, Disease mutation, Xeroderma pigmentosum" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009932, HPA035707, HPA069673" Supported Enhanced "Nucleoplasm,Plasma membrane" NA NA Nucleoplasm "Plasma membrane" "CAB009932: AB_2241587, HPA035707: AB_2674743, HPA069673: AB_2686167" "unprognostic (7.46e-2)" "unprognostic (2.52e-2)" "unprognostic (4.50e-2)" "unprognostic (3.01e-1)" "unprognostic (6.63e-2)" "unprognostic (2.54e-2)" "unprognostic (1.97e-1)" "unprognostic (5.65e-2)" "unprognostic (1.50e-1)" "unprognostic (7.13e-3)" "unprognostic (4.39e-2)" "unprognostic (2.07e-1)" "prognostic favorable (4.14e-7)" "unprognostic (1.59e-1)" "unprognostic (7.88e-2)" "unprognostic (7.62e-2)" "prognostic favorable (2.46e-4)" 20.2 17.1 14.2 24.0 30.2 8.4 21.4 16.1 19.3 22.3 18.9 20.8 27.5 18.0 24.6 18.3 16.9 24.9 25.1 12.4 16.2 14.4 24.6 23.4 19.9 21.1 33.4 15.2 35.0 20.9 35.4 26.7 28.0 22.1 20.9 15.9 16.7 17.6 30.3 22.4 30.5 23.6 17.7 22.6 23.3 15.9 12.9 30.6 18.5 25.7 12.4 20.8 22.4 22.3 10.9 7.0 34.6 8.8 8.8 12.2 6.1 4.5 11.6 13.1 8.4 19.7 13.6 44.5 11.3 32.3 10.9 8.5 4.2 5.4 15.1 5.0 13.7 5.1 5.7 8.6 18.0 9.0 6.1 7.4 8.0 12.3 7.8 17.5 6.0 15.3 19.3 21.4 14.5 29.1 12.8 12.9 6.9 11.0 8.2 12.1 9.5 4.9 5.7 7.8 7.4 7.9 6.3 5.9 12.1 13.8 13.5 2.8 10.2 12.3 10.2 8.1 21.5 10.7 4.9 20.2 4.2 11.5 6.4 5.2 18.9 13.7 8.9 10.1 7.0 15.2 12.0 8.2 9.4 9.8 6.3 9.6 10.7 11.2 9.6 7.0 10.9 12.2 8.7 34.6 8.8 8.8 6.7 9.2 6.1 14.2 30.2 16.1 19.3 16.2 14.4 33.4 15.2 22.1 30.6 56.6 54.6 22.2 18.7 12.2 33.8 11.2 33.1 84.3 73.9 15.7 37.3 34.0 29.9 16.3 1.9 24.9 12.3 46.7 16.9 17.1 16.4 15.5 44.1 30.4 16.2 25.4 15.6 22.1 24.3 1.8 28.4 28.4 8.5 38.7 12.2 29.9 15.2 14.8 26.5 34.1 50.6 25.8 18.0 22.7 57.3 9.7 26.8 34.6 13.3 8.7 XPO1 "CRM1, emb" ENSG00000082898 "Exportin 1" O14980 2 61477849-61538626 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters" "Host-virus interaction, mRNA transport, Protein transport, Transport" RNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010184, HPA042933" Supported Enhanced "Nucleoplasm,Nuclear membrane,Vesicles,Cytosol" NA NA 170000 "Nucleoplasm, Nuclear membrane" "Vesicles, Cytosol" "CAB010184: AB_2215817, HPA042933: AB_2678229" "unprognostic (7.34e-2)" "unprognostic (7.04e-2)" "unprognostic (6.37e-2)" "unprognostic (1.67e-2)" "unprognostic (5.61e-2)" "unprognostic (1.28e-1)" "prognostic unfavorable (1.84e-5)" "unprognostic (1.84e-1)" "unprognostic (1.99e-3)" "unprognostic (4.43e-1)" "unprognostic (3.53e-3)" "unprognostic (4.90e-2)" "prognostic unfavorable (3.74e-4)" "unprognostic (5.69e-2)" "unprognostic (2.08e-1)" "unprognostic (2.43e-1)" "unprognostic (5.55e-2)" 20.7 27.9 36.1 28.1 39.6 21.6 35.1 41.5 36.3 28.2 23.2 19.5 26.0 16.5 35.7 35.3 26.1 36.0 20.3 20.1 33.0 19.2 19.5 22.2 22.0 34.5 42.0 19.5 45.0 34.6 33.4 27.6 30.8 33.6 25.8 24.5 18.0 20.2 29.9 34.9 29.8 25.0 28.4 32.1 24.5 21.9 32.1 39.3 51.1 28.2 16.4 35.7 26.0 57.8 6.1 5.4 12.6 5.1 6.2 5.1 2.5 39.4 35.3 47.9 35.9 21.7 29.2 35.3 43.7 28.2 46.0 39.4 46.9 29.7 57.9 30.6 29.9 46.8 33.5 73.0 30.3 67.7 35.3 26.9 57.0 36.3 29.3 15.7 57.4 39.0 16.4 22.7 36.3 39.6 34.9 37.5 29.2 65.7 33.8 42.3 20.8 47.7 25.2 55.7 47.2 27.1 42.8 54.7 35.2 20.9 30.0 38.3 20.4 42.5 35.9 21.3 50.4 29.4 28.4 25.0 43.2 49.1 35.1 42.9 27.5 45.3 84.0 26.8 49.3 38.9 12.6 5.1 5.8 5.1 5.0 4.7 4.3 3.6 4.5 3.9 6.1 4.3 3.7 12.4 6.2 3.2 5.4 3.2 2.5 36.1 39.6 41.5 36.3 33.0 19.2 42.0 19.5 33.6 39.3 38.7 36.3 31.8 27.6 46.2 69.7 57.0 43.3 46.8 28.4 29.6 90.3 46.3 11.6 24.4 3.2 40.7 19.3 70.0 22.5 42.3 40.9 34.4 40.5 48.0 49.4 68.3 43.4 42.4 46.3 8.0 31.1 53.2 35.4 49.5 31.2 34.0 26.3 17.5 29.0 20.8 102.5 19.4 43.7 64.6 88.2 49.7 25.2 42.9 37.6 38.3 ZFHX3 "ATBF1, ZNF927" ENSG00000140836 "Zinc finger homeobox 3" Q15911 16 72782885-73891871 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Myogenesis, Transcription, Transcription regulation" "Activator, DNA-binding, Repressor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 6 "Smooth muscle cells: 198.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "NK-cell: 2.5" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA059353 Uncertain Supported Nucleoplasm NA NA Nucleoplasm "HPA059353: AB_2683987" "prognostic unfavorable (1.55e-4)" "unprognostic (3.57e-2)" "unprognostic (1.68e-1)" "unprognostic (2.03e-2)" "unprognostic (2.81e-2)" "unprognostic (3.12e-1)" "unprognostic (4.24e-2)" "unprognostic (6.36e-2)" "unprognostic (9.94e-3)" "unprognostic (2.85e-1)" "unprognostic (1.06e-1)" "unprognostic (4.16e-2)" "prognostic favorable (1.37e-5)" "unprognostic (6.76e-2)" "unprognostic (1.10e-1)" "unprognostic (2.11e-1)" "unprognostic (2.15e-2)" 7.9 6.0 2.5 2.3 4.6 1.1 11.3 1.5 4.1 7.5 7.7 5.4 14.5 2.0 7.4 7.3 4.5 4.9 18.2 4.9 4.3 4.8 4.4 6.5 6.1 1.4 4.0 2.6 4.4 5.7 23.8 6.3 8.1 5.5 12.0 3.5 10.5 5.0 19.5 16.9 3.6 3.6 15.5 9.7 3.9 5.0 2.3 5.2 0.5 10.8 4.0 1.0 16.7 14.7 0.8 1.0 0.2 1.6 2.5 0.1 0.2 4.4 7.9 12.9 10.7 4.8 6.1 13.3 3.4 3.7 2.2 2.5 9.0 2.5 1.9 6.0 6.4 3.0 3.1 8.1 4.0 3.0 7.8 2.0 0.3 10.8 12.8 4.4 1.3 3.2 2.2 2.4 6.4 5.8 2.0 4.1 0.9 0.9 0.5 5.4 9.2 0.4 2.6 2.3 2.3 1.3 5.9 3.5 0.6 3.5 7.5 9.6 3.4 6.0 1.9 4.3 6.2 2.6 0.6 8.8 5.4 6.4 5.7 4.5 4.9 1.6 1.4 2.6 1.2 4.1 0.2 1.6 0.2 0.1 0.9 0.1 0.5 0.0 0.0 0.7 0.8 0.0 0.1 0.2 2.5 1.1 1.0 0.1 0.2 2.5 4.6 1.5 4.1 4.3 4.8 4.0 2.6 5.5 5.2 65.5 26.1 8.1 52.4 15.0 87.0 16.5 43.3 32.1 48.9 45.4 21.6 35.9 5.0 23.2 1.9 28.2 6.0 0.0 20.2 18.1 50.1 96.3 20.7 30.0 55.1 22.3 25.8 42.4 67.6 1.3 9.8 55.4 20.3 24.4 18.0 18.0 20.8 21.0 18.7 6.1 31.2 122.9 198.8 3.4 17.7 15.1 51.9 3.2 29.3 41.2 ZRSR2 "U2AF1-RS2, U2AF1L2, URP, ZC3H22" ENSG00000169249 "Zinc finger CCCH-type, RNA binding motif and serine/arginine rich 2" Q15696 X 15790472-15823260 "Cancer-related genes, Predicted intracellular proteins" "mRNA processing, mRNA splicing" "Ribonucleoprotein, RNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" NA NA "prognostic favorable (7.96e-4)" "unprognostic (1.54e-2)" "unprognostic (7.31e-2)" "prognostic favorable (8.50e-5)" "unprognostic (8.08e-2)" "unprognostic (1.69e-1)" "unprognostic (6.14e-3)" "unprognostic (5.72e-3)" "unprognostic (8.46e-2)" "unprognostic (3.47e-3)" "unprognostic (6.90e-2)" "unprognostic (2.85e-2)" "prognostic unfavorable (4.87e-5)" "unprognostic (8.14e-2)" "unprognostic (3.04e-1)" "unprognostic (1.65e-2)" "prognostic favorable (2.97e-4)" 11.4 9.7 16.7 13.4 21.7 32.5 14.2 22.5 22.1 20.7 13.6 7.6 11.2 9.1 17.1 17.7 10.9 11.8 8.8 12.8 16.1 14.4 11.5 8.2 13.9 21.7 18.1 11.6 16.7 9.2 15.7 31.1 9.8 16.0 11.8 10.9 9.4 10.6 10.6 31.7 12.3 12.4 14.5 20.1 21.1 9.5 4.8 17.5 7.9 12.8 5.6 16.5 21.8 16.7 23.8 17.8 22.0 18.8 10.2 20.3 7.6 9.5 6.4 11.0 10.3 15.6 13.5 4.4 7.9 7.4 7.7 7.8 7.5 7.9 10.9 13.6 7.3 19.7 9.4 10.6 13.7 8.0 8.1 14.0 7.2 15.1 7.0 10.7 16.4 16.9 6.7 12.6 14.1 23.0 15.1 13.3 10.5 11.3 10.8 9.2 11.7 8.7 17.3 14.0 5.0 8.9 10.1 15.4 11.1 9.1 7.6 7.7 8.4 18.5 16.5 11.5 15.7 13.0 9.5 9.3 7.7 5.5 20.2 7.4 9.2 7.7 10.4 5.9 11.9 9.9 22.0 18.8 16.6 13.5 16.6 13.1 21.6 17.1 18.0 10.9 23.8 20.3 14.8 21.0 10.2 15.6 17.8 16.0 7.6 16.7 21.7 22.5 22.1 16.1 14.4 18.1 11.6 16.0 17.5 8.9 19.5 19.6 9.7 10.1 13.0 20.2 5.1 25.4 17.0 15.7 13.7 6.1 19.9 11.9 1.0 13.5 12.1 0.0 12.9 6.7 11.0 6.3 31.2 12.5 17.3 7.9 16.1 8.6 25.9 1.1 12.7 29.4 11.8 22.6 11.2 9.0 11.1 9.1 15.6 11.0 18.4 19.4 17.9 3.8 3.8 9.3 6.1 30.8 11.5 6.5